#setwd('/afs/inf.ed.ac.uk/user/s17/s1725186/Documents/PhD-Models/FirstPUModel/RMarkdowns')
library(tidyverse) ; library(reshape2) ; library(glue) ; library(plotly) ; library(dendextend)
library(RColorBrewer) ; library(viridis) ; require(gridExtra) ; library(GGally)
library(knitr)
library(biomaRt)
library(clusterProfiler) ; library(ReactomePA) ; library(DOSE)
Load preprocessed dataset (preprocessing code in 19_10_14_data_preprocessing.Rmd) and clustering (pipeline in 19_10_21_WGCNA.Rmd)
# Gandal dataset
load('./../Data/preprocessed_data.RData')
datExpr = datExpr %>% data.frame
DE_info = DE_info %>% data.frame
# GO Neuronal annotations: regex 'neuron' in GO functional annotations and label the genes that make a match as neuronal
GO_annotations = read.csv('./../Data/genes_GO_annotations.csv')
GO_neuronal = GO_annotations %>% filter(grepl('neuron', go_term)) %>%
mutate('ID'=as.character(ensembl_gene_id)) %>%
dplyr::select(-ensembl_gene_id) %>% distinct(ID) %>%
mutate('Neuronal'=1)
# SFARI Genes
SFARI_genes = read_csv('./../../../SFARI/Data/SFARI_genes_01-03-2020_w_ensembl_IDs.csv')
SFARI_genes = SFARI_genes[!duplicated(SFARI_genes$ID) & !is.na(SFARI_genes$ID),]
# Clusterings
clusterings = read_csv('./../Data/clusters.csv')
# Update DE_info with SFARI and Neuronal information
genes_info = DE_info %>% mutate('ID'=rownames(.)) %>% left_join(SFARI_genes, by='ID') %>%
mutate(`gene-score`=ifelse(is.na(`gene-score`), 'None', `gene-score`)) %>%
left_join(GO_neuronal, by='ID') %>% left_join(clusterings, by='ID') %>%
mutate(Neuronal=ifelse(is.na(Neuronal), 0, Neuronal)) %>%
mutate(gene.score=ifelse(`gene-score`=='None' & Neuronal==1, 'Neuronal', `gene-score`),
significant=padj<0.05 & !is.na(padj))
clustering_selected = 'DynamicHybrid'
genes_info$Module = genes_info[,clustering_selected]
dataset = read.csv(paste0('./../Data/dataset_', clustering_selected, '.csv'))
dataset$Module = dataset[,clustering_selected]
# Correct SFARI Scores
dataset$gene.score = genes_info$gene.score
# GSEA Results
load('./../Data/GSEA.RData')
SFARI_colour_hue = function(r) {
pal = c('#FF7631','#FFB100','#E8E328','#8CC83F','#62CCA6','#59B9C9','#b3b3b3','#808080','gray','#d9d9d9')[r]
}
rm(DE_info, GO_annotations, clusterings, getinfo, mart, dds, GO_neuronal)
plot_data = dataset %>% dplyr::select(Module, MTcor) %>% distinct
ggplotly(plot_data %>% ggplot(aes(reorder(Module, -MTcor), MTcor)) + geom_bar(stat='identity', fill = plot_data$Module) + theme_minimal() +
xlab('Modules')+ ylab('Module-Diagnosis Correlation') + geom_hline(yintercept =c(0.9, -0.9), color = 'gray', linetype = 'dashed') +
theme(axis.text.x = element_text(angle = 90, hjust = 1)))
top_modules = plot_data$Module[abs(plot_data$MTcor)>0.9]
cat(paste0('Top modules selected: ', paste(top_modules, collapse=', '),'\n'))
## Top modules selected: #00B9E3, #73B000, #EE8045, #84AD00
for(module in top_modules){
df = enrichment_KEGG[[module]] %>% dplyr::select(ID, Description, setSize, NES, p.adjust, qvalues) %>% arrange(desc(NES)) %>% filter(NES>0)
if(nrow(df)>0){
print(kable(df, caption = paste0('Enriched terms for module ', module, ' (MTcor = ', round(dataset$MTcor[dataset$Module==module][1],2),')')))
cat('\n')
} else cat(paste0('\nNo enrichment found for module ',module,'\n'))
}
| ID | Description | setSize | NES | p.adjust | qvalues |
|---|---|---|---|---|---|
| hsa00190 | Oxidative phosphorylation | 127 | 2.725585 | 0.0142895 | 0.0090437 |
| hsa05016 | Huntington disease | 289 | 2.590995 | 0.0142895 | 0.0090437 |
| hsa05012 | Parkinson disease | 235 | 2.558477 | 0.0142895 | 0.0090437 |
| hsa04721 | Synaptic vesicle cycle | 70 | 2.390995 | 0.0142895 | 0.0090437 |
| hsa04723 | Retrograde endocannabinoid signaling | 142 | 2.372331 | 0.0142895 | 0.0090437 |
| hsa05010 | Alzheimer disease | 348 | 2.329095 | 0.0142895 | 0.0090437 |
| hsa04260 | Cardiac muscle contraction | 79 | 2.291035 | 0.0142895 | 0.0090437 |
| hsa04970 | Salivary secretion | 72 | 2.282914 | 0.0142895 | 0.0090437 |
| hsa05033 | Nicotine addiction | 35 | 2.266381 | 0.0142895 | 0.0090437 |
| hsa04720 | Long-term potentiation | 65 | 2.227201 | 0.0142895 | 0.0090437 |
| hsa00020 | Citrate cycle (TCA cycle) | 29 | 2.222275 | 0.0142895 | 0.0090437 |
| hsa04114 | Oocyte meiosis | 108 | 2.220302 | 0.0142895 | 0.0090437 |
| hsa04728 | Dopaminergic synapse | 125 | 2.187980 | 0.0142895 | 0.0090437 |
| hsa03050 | Proteasome | 43 | 2.178270 | 0.0142895 | 0.0090437 |
| hsa04727 | GABAergic synapse | 82 | 2.167709 | 0.0142895 | 0.0090437 |
| hsa05017 | Spinocerebellar ataxia | 124 | 2.147446 | 0.0142895 | 0.0090437 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD) | 139 | 2.146858 | 0.0142895 | 0.0090437 |
| hsa04714 | Thermogenesis | 220 | 2.133993 | 0.0142895 | 0.0090437 |
| hsa04713 | Circadian entrainment | 93 | 2.128740 | 0.0142895 | 0.0090437 |
| hsa04961 | Endocrine and other factor-regulated calcium reabsorption | 48 | 2.127776 | 0.0142895 | 0.0090437 |
| hsa04724 | Glutamatergic synapse | 108 | 2.091530 | 0.0142895 | 0.0090437 |
| hsa05031 | Amphetamine addiction | 63 | 2.059674 | 0.0142895 | 0.0090437 |
| hsa04740 | Olfactory transduction | 76 | 2.055744 | 0.0142895 | 0.0090437 |
| hsa05032 | Morphine addiction | 85 | 2.031618 | 0.0142895 | 0.0090437 |
| hsa01210 | 2-Oxocarboxylic acid metabolism | 16 | 2.003497 | 0.0185904 | 0.0117657 |
| hsa04020 | Calcium signaling pathway | 184 | 1.966258 | 0.0142895 | 0.0090437 |
| hsa04070 | Phosphatidylinositol signaling system | 95 | 1.950537 | 0.0142895 | 0.0090437 |
| hsa04929 | GnRH secretion | 60 | 1.939168 | 0.0142895 | 0.0090437 |
| hsa04925 | Aldosterone synthesis and secretion | 91 | 1.937756 | 0.0142895 | 0.0090437 |
| hsa04261 | Adrenergic signaling in cardiomyocytes | 141 | 1.909070 | 0.0142895 | 0.0090437 |
| hsa04921 | Oxytocin signaling pathway | 149 | 1.894214 | 0.0142895 | 0.0090437 |
| hsa04136 | Autophagy - other | 31 | 1.881438 | 0.0182086 | 0.0115241 |
| hsa04750 | Inflammatory mediator regulation of TRP channels | 94 | 1.880734 | 0.0142895 | 0.0090437 |
| hsa00430 | Taurine and hypotaurine metabolism | 10 | 1.868491 | 0.0333333 | 0.0210964 |
| hsa04725 | Cholinergic synapse | 106 | 1.867310 | 0.0142895 | 0.0090437 |
| hsa04971 | Gastric acid secretion | 70 | 1.847689 | 0.0177466 | 0.0112316 |
| hsa04911 | Insulin secretion | 77 | 1.814558 | 0.0177466 | 0.0112316 |
| hsa01230 | Biosynthesis of amino acids | 68 | 1.779597 | 0.0177466 | 0.0112316 |
| hsa04910 | Insulin signaling pathway | 130 | 1.773621 | 0.0142895 | 0.0090437 |
| hsa04962 | Vasopressin-regulated water reabsorption | 40 | 1.772690 | 0.0142895 | 0.0090437 |
| hsa04966 | Collecting duct acid secretion | 23 | 1.769597 | 0.0281783 | 0.0178338 |
| hsa01200 | Carbon metabolism | 109 | 1.762592 | 0.0142895 | 0.0090437 |
| hsa04973 | Carbohydrate digestion and absorption | 34 | 1.729121 | 0.0276165 | 0.0174782 |
| hsa04914 | Progesterone-mediated oocyte maturation | 82 | 1.708799 | 0.0261934 | 0.0165776 |
| hsa05110 | Vibrio cholerae infection | 47 | 1.704891 | 0.0266368 | 0.0168582 |
| hsa04930 | Type II diabetes mellitus | 40 | 1.693712 | 0.0275011 | 0.0174052 |
| hsa04924 | Renin secretion | 64 | 1.675302 | 0.0264688 | 0.0167518 |
| hsa05214 | Glioma | 72 | 1.662962 | 0.0287805 | 0.0182149 |
| hsa00650 | Butanoate metabolism | 23 | 1.660218 | 0.0281783 | 0.0178338 |
| hsa05014 | Amyotrophic lateral sclerosis (ALS) | 52 | 1.656965 | 0.0293698 | 0.0185879 |
| hsa04912 | GnRH signaling pathway | 86 | 1.650970 | 0.0287805 | 0.0182149 |
| hsa04972 | Pancreatic secretion | 72 | 1.646154 | 0.0287805 | 0.0182149 |
| hsa00970 | Aminoacyl-tRNA biosynthesis | 44 | 1.644861 | 0.0231068 | 0.0146241 |
| hsa04012 | ErbB signaling pathway | 82 | 1.640908 | 0.0287805 | 0.0182149 |
| hsa04360 | Axon guidance | 179 | 1.625791 | 0.0142895 | 0.0090437 |
| hsa04024 | cAMP signaling pathway | 192 | 1.618113 | 0.0142895 | 0.0090437 |
| hsa04922 | Glucagon signaling pathway | 93 | 1.614376 | 0.0215552 | 0.0136421 |
| hsa00250 | Alanine, aspartate and glutamate metabolism | 34 | 1.612569 | 0.0357580 | 0.0226309 |
| hsa00620 | Pyruvate metabolism | 36 | 1.610817 | 0.0357514 | 0.0226267 |
| hsa04960 | Aldosterone-regulated sodium reabsorption | 32 | 1.590688 | 0.0357580 | 0.0226309 |
| hsa04150 | mTOR signaling pathway | 147 | 1.587515 | 0.0142895 | 0.0090437 |
| hsa04120 | Ubiquitin mediated proteolysis | 135 | 1.578271 | 0.0177466 | 0.0112316 |
| hsa04140 | Autophagy - animal | 131 | 1.546534 | 0.0142895 | 0.0090437 |
| hsa04978 | Mineral absorption | 48 | 1.540175 | 0.0383349 | 0.0242618 |
| hsa04726 | Serotonergic synapse | 102 | 1.532754 | 0.0215552 | 0.0136421 |
| hsa04014 | Ras signaling pathway | 209 | 1.514586 | 0.0213190 | 0.0134926 |
| hsa04371 | Apelin signaling pathway | 127 | 1.510024 | 0.0256672 | 0.0162445 |
| hsa04660 | T cell receptor signaling pathway | 87 | 1.469408 | 0.0444462 | 0.0281296 |
| hsa04071 | Sphingolipid signaling pathway | 113 | 1.457265 | 0.0357580 | 0.0226309 |
| hsa04022 | cGMP-PKG signaling pathway | 157 | 1.435193 | 0.0427310 | 0.0270440 |
| hsa04080 | Neuroactive ligand-receptor interaction | 254 | 1.385600 | 0.0439353 | 0.0278062 |
| ID | Description | setSize | NES | p.adjust | qvalues |
|---|---|---|---|---|---|
| hsa05322 | Systemic lupus erythematosus | 108 | 3.169288 | 0.0117509 | 0.0072829 |
| hsa05034 | Alcoholism | 165 | 2.474094 | 0.0117509 | 0.0072829 |
| hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 52 | 2.309397 | 0.0117509 | 0.0072829 |
| hsa05202 | Transcriptional misregulation in cancer | 163 | 2.223024 | 0.0117509 | 0.0072829 |
| hsa05144 | Malaria | 39 | 2.172061 | 0.0117509 | 0.0072829 |
| hsa04392 | Hippo signaling pathway - multiple species | 26 | 2.149780 | 0.0117509 | 0.0072829 |
| hsa05150 | Staphylococcus aureus infection | 49 | 2.132591 | 0.0117509 | 0.0072829 |
| hsa05321 | Inflammatory bowel disease (IBD) | 47 | 2.125786 | 0.0117509 | 0.0072829 |
| hsa04064 | NF-kappa B signaling pathway | 89 | 2.090723 | 0.0117509 | 0.0072829 |
| hsa04060 | Cytokine-cytokine receptor interaction | 170 | 2.053668 | 0.0117509 | 0.0072829 |
| hsa05134 | Legionellosis | 52 | 1.967451 | 0.0117509 | 0.0072829 |
| hsa04612 | Antigen processing and presentation | 59 | 1.964714 | 0.0117509 | 0.0072829 |
| hsa05203 | Viral carcinogenesis | 188 | 1.955215 | 0.0117509 | 0.0072829 |
| hsa04977 | Vitamin digestion and absorption | 18 | 1.947716 | 0.0190273 | 0.0117926 |
| hsa04610 | Complement and coagulation cascades | 61 | 1.879219 | 0.0190273 | 0.0117926 |
| hsa05416 | Viral myocarditis | 52 | 1.858729 | 0.0117509 | 0.0072829 |
| hsa00532 | Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate | 19 | 1.858662 | 0.0190273 | 0.0117926 |
| hsa04520 | Adherens junction | 70 | 1.853247 | 0.0117509 | 0.0072829 |
| hsa05145 | Toxoplasmosis | 104 | 1.817225 | 0.0117509 | 0.0072829 |
| hsa04330 | Notch signaling pathway | 51 | 1.813349 | 0.0117509 | 0.0072829 |
| hsa04512 | ECM-receptor interaction | 80 | 1.781208 | 0.0117509 | 0.0072829 |
| hsa05206 | MicroRNAs in cancer | 155 | 1.775663 | 0.0117509 | 0.0072829 |
| hsa05205 | Proteoglycans in cancer | 190 | 1.775018 | 0.0117509 | 0.0072829 |
| hsa05131 | Shigellosis | 226 | 1.749792 | 0.0117509 | 0.0072829 |
| hsa04510 | Focal adhesion | 192 | 1.737613 | 0.0117509 | 0.0072829 |
| hsa04350 | TGF-beta signaling pathway | 86 | 1.714838 | 0.0190273 | 0.0117926 |
| hsa05332 | Graft-versus-host disease | 26 | 1.709331 | 0.0241808 | 0.0149866 |
| hsa05340 | Primary immunodeficiency | 25 | 1.705382 | 0.0301940 | 0.0187135 |
| hsa05330 | Allograft rejection | 24 | 1.700455 | 0.0190273 | 0.0117926 |
| hsa05168 | Herpes simplex virus 1 infection | 446 | 1.673237 | 0.0117509 | 0.0072829 |
| hsa05320 | Autoimmune thyroid disease | 28 | 1.669109 | 0.0455375 | 0.0282229 |
| hsa04672 | Intestinal immune network for IgA production | 32 | 1.666816 | 0.0241808 | 0.0149866 |
| hsa04621 | NOD-like receptor signaling pathway | 148 | 1.636858 | 0.0117509 | 0.0072829 |
| hsa04514 | Cell adhesion molecules (CAMs) | 123 | 1.565910 | 0.0117509 | 0.0072829 |
| hsa04659 | Th17 cell differentiation | 88 | 1.564444 | 0.0302873 | 0.0187713 |
| hsa04670 | Leukocyte transendothelial migration | 97 | 1.561877 | 0.0243206 | 0.0150733 |
| hsa04810 | Regulation of actin cytoskeleton | 197 | 1.561233 | 0.0190273 | 0.0117926 |
| hsa04668 | TNF signaling pathway | 103 | 1.545790 | 0.0190273 | 0.0117926 |
| hsa00514 | Other types of O-glycan biosynthesis | 46 | 1.532010 | 0.0455375 | 0.0282229 |
| hsa04151 | PI3K-Akt signaling pathway | 308 | 1.497327 | 0.0241808 | 0.0149866 |
| hsa05222 | Small cell lung cancer | 89 | 1.472050 | 0.0455375 | 0.0282229 |
| hsa04630 | JAK-STAT signaling pathway | 113 | 1.458875 | 0.0455375 | 0.0282229 |
| hsa05130 | Pathogenic Escherichia coli infection | 176 | 1.454159 | 0.0245707 | 0.0152283 |
| hsa04390 | Hippo signaling pathway | 148 | 1.444705 | 0.0359616 | 0.0222880 |
| hsa04217 | Necroptosis | 134 | 1.439714 | 0.0412331 | 0.0255552 |
| hsa05200 | Pathways in cancer | 479 | 1.417741 | 0.0117509 | 0.0072829 |
| hsa05165 | Human papillomavirus infection | 300 | 1.416952 | 0.0348186 | 0.0215797 |
| hsa05163 | Human cytomegalovirus infection | 199 | 1.370276 | 0.0455375 | 0.0282229 |
| hsa05166 | Human T-cell leukemia virus 1 infection | 197 | 1.344666 | 0.0496712 | 0.0307849 |
| ID | Description | setSize | NES | p.adjust | qvalues |
|---|---|---|---|---|---|
| hsa05322 | Systemic lupus erythematosus | 108 | 3.121824 | 0.0140101 | 0.0083156 |
| hsa05168 | Herpes simplex virus 1 infection | 446 | 2.543998 | 0.0140101 | 0.0083156 |
| hsa05202 | Transcriptional misregulation in cancer | 163 | 2.476173 | 0.0140101 | 0.0083156 |
| hsa05150 | Staphylococcus aureus infection | 49 | 2.471518 | 0.0140101 | 0.0083156 |
| hsa05034 | Alcoholism | 165 | 2.465300 | 0.0140101 | 0.0083156 |
| hsa04064 | NF-kappa B signaling pathway | 89 | 2.305115 | 0.0140101 | 0.0083156 |
| hsa04610 | Complement and coagulation cascades | 61 | 2.192555 | 0.0140101 | 0.0083156 |
| hsa05321 | Inflammatory bowel disease (IBD) | 47 | 2.156191 | 0.0140101 | 0.0083156 |
| hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 52 | 2.120471 | 0.0140101 | 0.0083156 |
| hsa05320 | Autoimmune thyroid disease | 28 | 2.092993 | 0.0140101 | 0.0083156 |
| hsa04392 | Hippo signaling pathway - multiple species | 26 | 2.086178 | 0.0140101 | 0.0083156 |
| hsa05416 | Viral myocarditis | 52 | 2.083955 | 0.0140101 | 0.0083156 |
| hsa05134 | Legionellosis | 52 | 2.079065 | 0.0140101 | 0.0083156 |
| hsa05330 | Allograft rejection | 24 | 2.036625 | 0.0140101 | 0.0083156 |
| hsa05203 | Viral carcinogenesis | 188 | 2.002009 | 0.0140101 | 0.0083156 |
| hsa05332 | Graft-versus-host disease | 26 | 1.983489 | 0.0140101 | 0.0083156 |
| hsa04672 | Intestinal immune network for IgA production | 32 | 1.982276 | 0.0140101 | 0.0083156 |
| hsa04060 | Cytokine-cytokine receptor interaction | 170 | 1.974136 | 0.0140101 | 0.0083156 |
| hsa04640 | Hematopoietic cell lineage | 66 | 1.926270 | 0.0140101 | 0.0083156 |
| hsa05140 | Leishmaniasis | 67 | 1.923574 | 0.0140101 | 0.0083156 |
| hsa05340 | Primary immunodeficiency | 25 | 1.902833 | 0.0140101 | 0.0083156 |
| hsa04612 | Antigen processing and presentation | 59 | 1.873119 | 0.0140101 | 0.0083156 |
| hsa05310 | Asthma | 14 | 1.863082 | 0.0140101 | 0.0083156 |
| hsa04658 | Th1 and Th2 cell differentiation | 75 | 1.819414 | 0.0140101 | 0.0083156 |
| hsa05144 | Malaria | 39 | 1.814599 | 0.0203551 | 0.0120816 |
| hsa04621 | NOD-like receptor signaling pathway | 148 | 1.808902 | 0.0140101 | 0.0083156 |
| hsa04670 | Leukocyte transendothelial migration | 97 | 1.807719 | 0.0140101 | 0.0083156 |
| hsa05145 | Toxoplasmosis | 104 | 1.790727 | 0.0140101 | 0.0083156 |
| hsa00310 | Lysine degradation | 58 | 1.773076 | 0.0238857 | 0.0141771 |
| hsa04611 | Platelet activation | 114 | 1.747916 | 0.0140101 | 0.0083156 |
| hsa05130 | Pathogenic Escherichia coli infection | 176 | 1.688804 | 0.0140101 | 0.0083156 |
| hsa04520 | Adherens junction | 70 | 1.674426 | 0.0238857 | 0.0141771 |
| hsa04380 | Osteoclast differentiation | 114 | 1.661062 | 0.0151515 | 0.0089930 |
| hsa04659 | Th17 cell differentiation | 88 | 1.659774 | 0.0140101 | 0.0083156 |
| hsa04512 | ECM-receptor interaction | 80 | 1.658362 | 0.0151594 | 0.0089977 |
| hsa04350 | TGF-beta signaling pathway | 86 | 1.654834 | 0.0151594 | 0.0089977 |
| hsa05205 | Proteoglycans in cancer | 190 | 1.621493 | 0.0140101 | 0.0083156 |
| hsa04510 | Focal adhesion | 192 | 1.620985 | 0.0140101 | 0.0083156 |
| hsa05206 | MicroRNAs in cancer | 155 | 1.603931 | 0.0140101 | 0.0083156 |
| hsa05131 | Shigellosis | 226 | 1.594731 | 0.0140101 | 0.0083156 |
| hsa04810 | Regulation of actin cytoskeleton | 197 | 1.572728 | 0.0140101 | 0.0083156 |
| hsa04668 | TNF signaling pathway | 103 | 1.524116 | 0.0321654 | 0.0190915 |
| hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 166 | 1.495412 | 0.0221601 | 0.0131529 |
| hsa05222 | Small cell lung cancer | 89 | 1.478848 | 0.0497166 | 0.0295088 |
| hsa04151 | PI3K-Akt signaling pathway | 308 | 1.448583 | 0.0186492 | 0.0110691 |
| hsa03040 | Spliceosome | 130 | 1.447219 | 0.0360264 | 0.0213831 |
| hsa05200 | Pathways in cancer | 479 | 1.441772 | 0.0140101 | 0.0083156 |
| hsa05135 | Yersinia infection | 114 | 1.439091 | 0.0450000 | 0.0267093 |
| ID | Description | setSize | NES | p.adjust | qvalues |
|---|---|---|---|---|---|
| hsa00190 | Oxidative phosphorylation | 127 | 2.984700 | 0.0149748 | 0.0097229 |
| hsa05016 | Huntington disease | 289 | 2.681127 | 0.0149748 | 0.0097229 |
| hsa00020 | Citrate cycle (TCA cycle) | 29 | 2.617023 | 0.0149748 | 0.0097229 |
| hsa05012 | Parkinson disease | 235 | 2.586621 | 0.0149748 | 0.0097229 |
| hsa04260 | Cardiac muscle contraction | 79 | 2.357500 | 0.0149748 | 0.0097229 |
| hsa04721 | Synaptic vesicle cycle | 70 | 2.315254 | 0.0149748 | 0.0097229 |
| hsa05010 | Alzheimer disease | 348 | 2.305927 | 0.0149748 | 0.0097229 |
| hsa03050 | Proteasome | 43 | 2.256555 | 0.0149748 | 0.0097229 |
| hsa04714 | Thermogenesis | 220 | 2.236098 | 0.0149748 | 0.0097229 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD) | 139 | 2.187360 | 0.0149748 | 0.0097229 |
| hsa01200 | Carbon metabolism | 109 | 2.162344 | 0.0149748 | 0.0097229 |
| hsa01210 | 2-Oxocarboxylic acid metabolism | 16 | 2.143368 | 0.0149748 | 0.0097229 |
| hsa00650 | Butanoate metabolism | 23 | 2.105636 | 0.0149748 | 0.0097229 |
| hsa04723 | Retrograde endocannabinoid signaling | 142 | 2.104901 | 0.0149748 | 0.0097229 |
| hsa04728 | Dopaminergic synapse | 125 | 2.030861 | 0.0149748 | 0.0097229 |
| hsa04961 | Endocrine and other factor-regulated calcium reabsorption | 48 | 2.023331 | 0.0149748 | 0.0097229 |
| hsa00620 | Pyruvate metabolism | 36 | 2.019126 | 0.0149748 | 0.0097229 |
| hsa05017 | Spinocerebellar ataxia | 124 | 1.993816 | 0.0149748 | 0.0097229 |
| hsa01230 | Biosynthesis of amino acids | 68 | 1.991617 | 0.0149748 | 0.0097229 |
| hsa04929 | GnRH secretion | 60 | 1.972337 | 0.0149748 | 0.0097229 |
| hsa00970 | Aminoacyl-tRNA biosynthesis | 44 | 1.943065 | 0.0212745 | 0.0138132 |
| hsa04910 | Insulin signaling pathway | 130 | 1.938894 | 0.0149748 | 0.0097229 |
| hsa04925 | Aldosterone synthesis and secretion | 91 | 1.935218 | 0.0149748 | 0.0097229 |
| hsa04740 | Olfactory transduction | 76 | 1.931878 | 0.0212745 | 0.0138132 |
| hsa04930 | Type II diabetes mellitus | 40 | 1.906107 | 0.0149748 | 0.0097229 |
| hsa04727 | GABAergic synapse | 82 | 1.893952 | 0.0149748 | 0.0097229 |
| hsa04261 | Adrenergic signaling in cardiomyocytes | 141 | 1.880492 | 0.0149748 | 0.0097229 |
| hsa04136 | Autophagy - other | 31 | 1.857815 | 0.0149748 | 0.0097229 |
| hsa04970 | Salivary secretion | 72 | 1.856238 | 0.0212745 | 0.0138132 |
| hsa00250 | Alanine, aspartate and glutamate metabolism | 34 | 1.849277 | 0.0149748 | 0.0097229 |
| hsa00010 | Glycolysis / Gluconeogenesis | 54 | 1.848296 | 0.0149748 | 0.0097229 |
| hsa05230 | Central carbon metabolism in cancer | 64 | 1.817534 | 0.0212745 | 0.0138132 |
| hsa04922 | Glucagon signaling pathway | 93 | 1.808411 | 0.0212745 | 0.0138132 |
| hsa04962 | Vasopressin-regulated water reabsorption | 40 | 1.792405 | 0.0287017 | 0.0186356 |
| hsa04114 | Oocyte meiosis | 108 | 1.784072 | 0.0149748 | 0.0097229 |
| hsa04966 | Collecting duct acid secretion | 23 | 1.783771 | 0.0212745 | 0.0138132 |
| hsa04720 | Long-term potentiation | 65 | 1.770606 | 0.0212745 | 0.0138132 |
| hsa04070 | Phosphatidylinositol signaling system | 95 | 1.754164 | 0.0212745 | 0.0138132 |
| hsa04750 | Inflammatory mediator regulation of TRP channels | 94 | 1.744438 | 0.0212745 | 0.0138132 |
| hsa05032 | Morphine addiction | 85 | 1.719339 | 0.0280815 | 0.0182330 |
| hsa04020 | Calcium signaling pathway | 184 | 1.696421 | 0.0212745 | 0.0138132 |
| hsa00640 | Propanoate metabolism | 32 | 1.684396 | 0.0280815 | 0.0182330 |
| hsa04973 | Carbohydrate digestion and absorption | 34 | 1.683316 | 0.0329560 | 0.0213979 |
| hsa04971 | Gastric acid secretion | 70 | 1.681012 | 0.0329560 | 0.0213979 |
| hsa04960 | Aldosterone-regulated sodium reabsorption | 32 | 1.676416 | 0.0280815 | 0.0182330 |
| hsa04211 | Longevity regulating pathway | 84 | 1.668980 | 0.0280815 | 0.0182330 |
| hsa04911 | Insulin secretion | 77 | 1.654238 | 0.0329560 | 0.0213979 |
| hsa05031 | Amphetamine addiction | 63 | 1.622657 | 0.0388357 | 0.0252155 |
| hsa04912 | GnRH signaling pathway | 86 | 1.611412 | 0.0329560 | 0.0213979 |
| hsa04725 | Cholinergic synapse | 106 | 1.610910 | 0.0212745 | 0.0138132 |
| hsa04713 | Circadian entrainment | 93 | 1.605346 | 0.0329560 | 0.0213979 |
| hsa05214 | Glioma | 72 | 1.595373 | 0.0498834 | 0.0323887 |
| hsa04152 | AMPK signaling pathway | 112 | 1.593264 | 0.0212745 | 0.0138132 |
| hsa04921 | Oxytocin signaling pathway | 149 | 1.591210 | 0.0329560 | 0.0213979 |
| hsa04140 | Autophagy - animal | 131 | 1.588714 | 0.0430699 | 0.0279647 |
| hsa04724 | Glutamatergic synapse | 108 | 1.580104 | 0.0280815 | 0.0182330 |
| hsa04137 | Mitophagy - animal | 66 | 1.576242 | 0.0440329 | 0.0285900 |
| hsa04146 | Peroxisome | 76 | 1.547012 | 0.0440329 | 0.0285900 |
| hsa04144 | Endocytosis | 240 | 1.492803 | 0.0212745 | 0.0138132 |
| hsa04150 | mTOR signaling pathway | 147 | 1.483418 | 0.0440329 | 0.0285900 |
rm(df)
for(module in top_modules){
df = enrichment_Reactome[[module]] %>% dplyr::select(ID, Description, setSize, NES, p.adjust, qvalues) %>% arrange(desc(NES)) %>% filter(NES>0)
if(nrow(df)>0){
print(kable(df, caption = paste0('Enriched terms for module ', module, ' (MTcor = ', round(dataset$MTcor[dataset$Module==module][1],2),')')))
cat('\n')
} else cat(paste0('\nNo enrichment found for module ',module,'\n'))
}
| ID | Description | setSize | NES | p.adjust | qvalues |
|---|---|---|---|---|---|
| R-HSA-163200 | Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | 122 | 2.776410 | 0.0178724 | 0.0120179 |
| R-HSA-1428517 | The citric acid (TCA) cycle and respiratory electron transport | 170 | 2.728433 | 0.0178724 | 0.0120179 |
| R-HSA-611105 | Respiratory electron transport | 100 | 2.715462 | 0.0178724 | 0.0120179 |
| R-HSA-112316 | Neuronal System | 379 | 2.651142 | 0.0178724 | 0.0120179 |
| R-HSA-112315 | Transmission across Chemical Synapses | 245 | 2.574492 | 0.0178724 | 0.0120179 |
| R-HSA-5576892 | Phase 0 - rapid depolarisation | 45 | 2.562846 | 0.0178724 | 0.0120179 |
| R-HSA-1296072 | Voltage gated Potassium channels | 40 | 2.562391 | 0.0178724 | 0.0120179 |
| R-HSA-180024 | DARPP-32 events | 25 | 2.561405 | 0.0178724 | 0.0120179 |
| R-HSA-399719 | Trafficking of AMPA receptors | 30 | 2.551657 | 0.0178724 | 0.0120179 |
| R-HSA-399721 | Glutamate binding, activation of AMPA receptors and synaptic plasticity | 30 | 2.551657 | 0.0178724 | 0.0120179 |
| R-HSA-112314 | Neurotransmitter receptors and postsynaptic signal transmission | 184 | 2.509965 | 0.0178724 | 0.0120179 |
| R-HSA-6799198 | Complex I biogenesis | 55 | 2.489791 | 0.0178724 | 0.0120179 |
| R-HSA-442755 | Activation of NMDA receptors and postsynaptic events | 84 | 2.423144 | 0.0178724 | 0.0120179 |
| R-HSA-438066 | Unblocking of NMDA receptors, glutamate binding and activation | 22 | 2.413535 | 0.0178724 | 0.0120179 |
| R-HSA-445095 | Interaction between L1 and Ankyrins | 29 | 2.408084 | 0.0178724 | 0.0120179 |
| R-HSA-442982 | Ras activation upon Ca2+ influx through NMDA receptor | 21 | 2.381275 | 0.0178724 | 0.0120179 |
| R-HSA-9620244 | Long-term potentiation | 24 | 2.352041 | 0.0178724 | 0.0120179 |
| R-HSA-5682910 | LGI-ADAM interactions | 14 | 2.335524 | 0.0178724 | 0.0120179 |
| R-HSA-9617324 | Negative regulation of NMDA receptor-mediated neuronal transmission | 22 | 2.330838 | 0.0178724 | 0.0120179 |
| R-HSA-416993 | Trafficking of GluR2-containing AMPA receptors | 16 | 2.324380 | 0.0178724 | 0.0120179 |
| R-HSA-438064 | Post NMDA receptor activation events | 73 | 2.321122 | 0.0178724 | 0.0120179 |
| R-HSA-6794362 | Protein-protein interactions at synapses | 87 | 2.291878 | 0.0178724 | 0.0120179 |
| R-HSA-111933 | Calmodulin induced events | 35 | 2.281160 | 0.0178724 | 0.0120179 |
| R-HSA-111997 | CaM pathway | 35 | 2.281160 | 0.0178724 | 0.0120179 |
| R-HSA-1489509 | DAG and IP3 signaling | 41 | 2.276476 | 0.0178724 | 0.0120179 |
| R-HSA-8849932 | Synaptic adhesion-like molecules | 21 | 2.258640 | 0.0178724 | 0.0120179 |
| R-HSA-1296071 | Potassium Channels | 92 | 2.229322 | 0.0178724 | 0.0120179 |
| R-HSA-168799 | Neurotoxicity of clostridium toxins | 10 | 2.217107 | 0.0178724 | 0.0120179 |
| R-HSA-5339562 | Uptake and actions of bacterial toxins | 30 | 2.208915 | 0.0178724 | 0.0120179 |
| R-HSA-442742 | CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 29 | 2.207101 | 0.0178724 | 0.0120179 |
| R-HSA-5576891 | Cardiac conduction | 131 | 2.202644 | 0.0178724 | 0.0120179 |
| R-HSA-111996 | Ca-dependent events | 37 | 2.201295 | 0.0178724 | 0.0120179 |
| R-HSA-888590 | GABA synthesis, release, reuptake and degradation | 19 | 2.190853 | 0.0178724 | 0.0120179 |
| R-HSA-442720 | CREB1 phosphorylation through the activation of Adenylate Cyclase | 13 | 2.190629 | 0.0178724 | 0.0120179 |
| R-HSA-111885 | Opioid Signalling | 86 | 2.187655 | 0.0178724 | 0.0120179 |
| R-HSA-1236978 | Cross-presentation of soluble exogenous antigens (endosomes) | 47 | 2.171698 | 0.0178724 | 0.0120179 |
| R-HSA-210500 | Glutamate Neurotransmitter Release Cycle | 24 | 2.165354 | 0.0178724 | 0.0120179 |
| R-HSA-1168372 | Downstream signaling events of B Cell Receptor (BCR) | 81 | 2.165205 | 0.0178724 | 0.0120179 |
| R-HSA-163615 | PKA activation | 18 | 2.157031 | 0.0178724 | 0.0120179 |
| R-HSA-69052 | Switching of origins to a post-replicative state | 87 | 2.152307 | 0.0178724 | 0.0120179 |
| R-HSA-68867 | Assembly of the pre-replicative complex | 65 | 2.151911 | 0.0178724 | 0.0120179 |
| R-HSA-68827 | CDT1 association with the CDC6:ORC:origin complex | 57 | 2.146901 | 0.0178724 | 0.0120179 |
| R-HSA-5578775 | Ion homeostasis | 53 | 2.141367 | 0.0178724 | 0.0120179 |
| R-HSA-5610783 | Degradation of GLI2 by the proteasome | 57 | 2.130907 | 0.0178724 | 0.0120179 |
| R-HSA-112310 | Neurotransmitter release cycle | 47 | 2.128431 | 0.0178724 | 0.0120179 |
| R-HSA-71403 | Citric acid cycle (TCA cycle) | 22 | 2.124935 | 0.0178724 | 0.0120179 |
| R-HSA-379716 | Cytosolic tRNA aminoacylation | 24 | 2.122526 | 0.0178724 | 0.0120179 |
| R-HSA-8986944 | Transcriptional Regulation by MECP2 | 61 | 2.114457 | 0.0178724 | 0.0120179 |
| R-HSA-5610785 | GLI3 is processed to GLI3R by the proteasome | 57 | 2.098608 | 0.0178724 | 0.0120179 |
| R-HSA-2454202 | Fc epsilon receptor (FCERI) signaling | 129 | 2.094788 | 0.0178724 | 0.0120179 |
| R-HSA-5610780 | Degradation of GLI1 by the proteasome | 57 | 2.090762 | 0.0178724 | 0.0120179 |
| R-HSA-68949 | Orc1 removal from chromatin | 69 | 2.087479 | 0.0178724 | 0.0120179 |
| R-HSA-5676590 | NIK–>noncanonical NF-kB signaling | 56 | 2.078113 | 0.0178724 | 0.0120179 |
| R-HSA-451306 | Ionotropic activity of kainate receptors | 12 | 2.076721 | 0.0178724 | 0.0120179 |
| R-HSA-451308 | Activation of Ca-permeable Kainate Receptor | 12 | 2.076721 | 0.0178724 | 0.0120179 |
| R-HSA-442729 | CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | 10 | 2.065971 | 0.0178724 | 0.0120179 |
| R-HSA-111932 | CaMK IV-mediated phosphorylation of CREB | 12 | 2.057352 | 0.0178724 | 0.0120179 |
| R-HSA-8949613 | Cristae formation | 31 | 2.044059 | 0.0178724 | 0.0120179 |
| R-HSA-174084 | Autodegradation of Cdh1 by Cdh1:APC/C | 62 | 2.036369 | 0.0178724 | 0.0120179 |
| R-HSA-174113 | SCF-beta-TrCP mediated degradation of Emi1 | 53 | 2.034984 | 0.0178724 | 0.0120179 |
| R-HSA-68689 | CDC6 association with the ORC:origin complex | 10 | 2.025660 | 0.0178724 | 0.0120179 |
| R-HSA-5607761 | Dectin-1 mediated noncanonical NF-kB signaling | 57 | 2.023513 | 0.0178724 | 0.0120179 |
| R-HSA-350562 | Regulation of ornithine decarboxylase (ODC) | 49 | 2.023146 | 0.0178724 | 0.0120179 |
| R-HSA-8939902 | Regulation of RUNX2 expression and activity | 70 | 2.021219 | 0.0178724 | 0.0120179 |
| R-HSA-6794361 | Neurexins and neuroligins | 56 | 2.020335 | 0.0178724 | 0.0120179 |
| R-HSA-112043 | PLC beta mediated events | 50 | 2.017642 | 0.0178724 | 0.0120179 |
| R-HSA-5607763 | CLEC7A (Dectin-1) induces NFAT activation | 13 | 2.015495 | 0.0215245 | 0.0144737 |
| R-HSA-176408 | Regulation of APC/C activators between G1/S and early anaphase | 76 | 2.015234 | 0.0178724 | 0.0120179 |
| R-HSA-212676 | Dopamine Neurotransmitter Release Cycle | 22 | 2.011941 | 0.0178724 | 0.0120179 |
| R-HSA-5610787 | Hedgehog ‘off’ state | 108 | 2.004448 | 0.0178724 | 0.0120179 |
| R-HSA-983705 | Signaling by the B Cell Receptor (BCR) | 107 | 2.001362 | 0.0178724 | 0.0120179 |
| R-HSA-9604323 | Negative regulation of NOTCH4 signaling | 54 | 2.000729 | 0.0178724 | 0.0120179 |
| R-HSA-69017 | CDK-mediated phosphorylation and removal of Cdc6 | 69 | 1.998678 | 0.0178724 | 0.0120179 |
| R-HSA-422356 | Regulation of insulin secretion | 73 | 1.994300 | 0.0178724 | 0.0120179 |
| R-HSA-163210 | Formation of ATP by chemiosmotic coupling | 18 | 1.990580 | 0.0178724 | 0.0120179 |
| R-HSA-8854050 | FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 52 | 1.986354 | 0.0178724 | 0.0120179 |
| R-HSA-112040 | G-protein mediated events | 51 | 1.982836 | 0.0178724 | 0.0120179 |
| R-HSA-1268020 | Mitochondrial protein import | 63 | 1.982673 | 0.0178724 | 0.0120179 |
| R-HSA-5673000 | RAF activation | 32 | 1.981718 | 0.0178724 | 0.0120179 |
| R-HSA-9609736 | Assembly and cell surface presentation of NMDA receptors | 34 | 1.979062 | 0.0178724 | 0.0120179 |
| R-HSA-2025928 | Calcineurin activates NFAT | 11 | 1.979021 | 0.0178724 | 0.0120179 |
| R-HSA-180534 | Vpu mediated degradation of CD4 | 50 | 1.976988 | 0.0178724 | 0.0120179 |
| R-HSA-174184 | Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 69 | 1.975008 | 0.0178724 | 0.0120179 |
| R-HSA-177504 | Retrograde neurotrophin signalling | 14 | 1.972319 | 0.0178724 | 0.0120179 |
| R-HSA-351202 | Metabolism of polyamines | 83 | 1.968965 | 0.0178724 | 0.0120179 |
| R-HSA-174154 | APC/C:Cdc20 mediated degradation of Securin | 64 | 1.968879 | 0.0207406 | 0.0139466 |
| R-HSA-111931 | PKA-mediated phosphorylation of CREB | 20 | 1.964091 | 0.0178724 | 0.0120179 |
| R-HSA-180585 | Vif-mediated degradation of APOBEC3G | 52 | 1.960509 | 0.0178724 | 0.0120179 |
| R-HSA-169911 | Regulation of Apoptosis | 51 | 1.956624 | 0.0178724 | 0.0120179 |
| R-HSA-179419 | APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | 70 | 1.953644 | 0.0178724 | 0.0120179 |
| R-HSA-418359 | Reduction of cytosolic Ca++ levels | 14 | 1.953115 | 0.0214105 | 0.0143970 |
| R-HSA-5362768 | Hh mutants that don’t undergo autocatalytic processing are degraded by ERAD | 54 | 1.950114 | 0.0178724 | 0.0120179 |
| R-HSA-373760 | L1CAM interactions | 111 | 1.946890 | 0.0178724 | 0.0120179 |
| R-HSA-4641258 | Degradation of DVL | 55 | 1.945154 | 0.0178724 | 0.0120179 |
| R-HSA-174178 | APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | 67 | 1.944404 | 0.0207406 | 0.0139466 |
| R-HSA-425561 | Sodium/Calcium exchangers | 12 | 1.942157 | 0.0218783 | 0.0147115 |
| R-HSA-451326 | Activation of kainate receptors upon glutamate binding | 31 | 1.938252 | 0.0178724 | 0.0120179 |
| R-HSA-75815 | Ubiquitin-dependent degradation of Cyclin D | 50 | 1.933145 | 0.0178724 | 0.0120179 |
| R-HSA-5658442 | Regulation of RAS by GAPs | 66 | 1.931985 | 0.0207406 | 0.0139466 |
| R-HSA-5607764 | CLEC7A (Dectin-1) signaling | 98 | 1.928237 | 0.0178724 | 0.0120179 |
| R-HSA-70326 | Glucose metabolism | 85 | 1.927372 | 0.0178724 | 0.0120179 |
| R-HSA-69002 | DNA Replication Pre-Initiation | 82 | 1.925271 | 0.0178724 | 0.0120179 |
| R-HSA-5387390 | Hh mutants abrogate ligand secretion | 56 | 1.922631 | 0.0178724 | 0.0120179 |
| R-HSA-211733 | Regulation of activated PAK-2p34 by proteasome mediated degradation | 48 | 1.919536 | 0.0178724 | 0.0120179 |
| R-HSA-69601 | Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 50 | 1.919144 | 0.0178724 | 0.0120179 |
| R-HSA-69610 | p53-Independent DNA Damage Response | 50 | 1.919144 | 0.0178724 | 0.0120179 |
| R-HSA-69613 | p53-Independent G1/S DNA damage checkpoint | 50 | 1.919144 | 0.0178724 | 0.0120179 |
| R-HSA-349425 | Autodegradation of the E3 ubiquitin ligase COP1 | 50 | 1.918504 | 0.0178724 | 0.0120179 |
| R-HSA-174143 | APC/C-mediated degradation of cell cycle proteins | 81 | 1.917352 | 0.0178724 | 0.0120179 |
| R-HSA-453276 | Regulation of mitotic cell cycle | 81 | 1.917352 | 0.0178724 | 0.0120179 |
| R-HSA-936837 | Ion transport by P-type ATPases | 54 | 1.915884 | 0.0178724 | 0.0120179 |
| R-HSA-164378 | PKA activation in glucagon signalling | 16 | 1.914764 | 0.0214105 | 0.0143970 |
| R-HSA-71406 | Pyruvate metabolism and Citric Acid (TCA) cycle | 52 | 1.913308 | 0.0207406 | 0.0139466 |
| R-HSA-163685 | Integration of energy metabolism | 101 | 1.908613 | 0.0178724 | 0.0120179 |
| R-HSA-176409 | APC/C:Cdc20 mediated degradation of mitotic proteins | 72 | 1.905243 | 0.0178724 | 0.0120179 |
| R-HSA-176814 | Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 72 | 1.905243 | 0.0178724 | 0.0120179 |
| R-HSA-195253 | Degradation of beta-catenin by the destruction complex | 80 | 1.900618 | 0.0178724 | 0.0120179 |
| R-HSA-181429 | Serotonin Neurotransmitter Release Cycle | 17 | 1.900033 | 0.0178724 | 0.0120179 |
| R-HSA-381676 | Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 39 | 1.899815 | 0.0178724 | 0.0120179 |
| R-HSA-983168 | Antigen processing: Ubiquitination & Proteasome degradation | 296 | 1.891104 | 0.0178724 | 0.0120179 |
| R-HSA-5628897 | TP53 Regulates Metabolic Genes | 84 | 1.882978 | 0.0178724 | 0.0120179 |
| R-HSA-1169091 | Activation of NF-kappaB in B cells | 65 | 1.869737 | 0.0207406 | 0.0139466 |
| R-HSA-70263 | Gluconeogenesis | 29 | 1.869377 | 0.0178724 | 0.0120179 |
| R-HSA-977443 | GABA receptor activation | 51 | 1.867643 | 0.0207406 | 0.0139466 |
| R-HSA-983712 | Ion channel transport | 168 | 1.866359 | 0.0178724 | 0.0120179 |
| R-HSA-5673001 | RAF/MAP kinase cascade | 224 | 1.863324 | 0.0178724 | 0.0120179 |
| R-HSA-5218921 | VEGFR2 mediated cell proliferation | 21 | 1.863316 | 0.0178724 | 0.0120179 |
| R-HSA-264642 | Acetylcholine Neurotransmitter Release Cycle | 14 | 1.861766 | 0.0214105 | 0.0143970 |
| R-HSA-917977 | Transferrin endocytosis and recycling | 29 | 1.860765 | 0.0214105 | 0.0143970 |
| R-HSA-77387 | Insulin receptor recycling | 23 | 1.856669 | 0.0214105 | 0.0143970 |
| R-HSA-6811436 | COPI-independent Golgi-to-ER retrograde traffic | 45 | 1.854048 | 0.0178724 | 0.0120179 |
| R-HSA-432040 | Vasopressin regulates renal water homeostasis via Aquaporins | 38 | 1.848467 | 0.0178724 | 0.0120179 |
| R-HSA-397014 | Muscle contraction | 187 | 1.846668 | 0.0178724 | 0.0120179 |
| R-HSA-418346 | Platelet homeostasis | 85 | 1.840075 | 0.0178724 | 0.0120179 |
| R-HSA-5621481 | C-type lectin receptors (CLRs) | 123 | 1.836159 | 0.0178724 | 0.0120179 |
| R-HSA-3858494 | Beta-catenin independent WNT signaling | 139 | 1.832935 | 0.0178724 | 0.0120179 |
| R-HSA-8948751 | Regulation of PTEN stability and activity | 67 | 1.832842 | 0.0207406 | 0.0139466 |
| R-HSA-1592230 | Mitochondrial biogenesis | 94 | 1.832590 | 0.0178724 | 0.0120179 |
| R-HSA-69541 | Stabilization of p53 | 55 | 1.823896 | 0.0207482 | 0.0139516 |
| R-HSA-187577 | SCF(Skp2)-mediated degradation of p27/p21 | 60 | 1.821204 | 0.0207406 | 0.0139466 |
| R-HSA-1855183 | Synthesis of IP2, IP, and Ins in the cytosol | 13 | 1.818648 | 0.0215245 | 0.0144737 |
| R-HSA-5099900 | WNT5A-dependent internalization of FZD4 | 15 | 1.814820 | 0.0214105 | 0.0143970 |
| R-HSA-388844 | Receptor-type tyrosine-protein phosphatases | 20 | 1.810257 | 0.0178724 | 0.0120179 |
| R-HSA-112308 | Presynaptic depolarization and calcium channel opening | 13 | 1.809298 | 0.0215245 | 0.0144737 |
| R-HSA-5684996 | MAPK1/MAPK3 signaling | 230 | 1.808475 | 0.0178724 | 0.0120179 |
| R-HSA-418360 | Platelet calcium homeostasis | 29 | 1.802779 | 0.0214105 | 0.0143970 |
| R-HSA-74752 | Signaling by Insulin receptor | 66 | 1.799373 | 0.0207406 | 0.0139466 |
| R-HSA-69306 | DNA Replication | 123 | 1.795906 | 0.0178724 | 0.0120179 |
| R-HSA-69563 | p53-Dependent G1 DNA Damage Response | 64 | 1.788087 | 0.0207406 | 0.0139466 |
| R-HSA-69580 | p53-Dependent G1/S DNA damage checkpoint | 64 | 1.788087 | 0.0207406 | 0.0139466 |
| R-HSA-450408 | AUF1 (hnRNP D0) binds and destabilizes mRNA | 54 | 1.785273 | 0.0207406 | 0.0139466 |
| R-HSA-1483255 | PI Metabolism | 82 | 1.783341 | 0.0178724 | 0.0120179 |
| R-HSA-69481 | G2/M Checkpoints | 162 | 1.779985 | 0.0178724 | 0.0120179 |
| R-HSA-70221 | Glycogen breakdown (glycogenolysis) | 17 | 1.779805 | 0.0357691 | 0.0240521 |
| R-HSA-8949664 | Processing of SMDT1 | 16 | 1.775758 | 0.0426610 | 0.0286864 |
| R-HSA-2871837 | FCERI mediated NF-kB activation | 78 | 1.772306 | 0.0178724 | 0.0120179 |
| R-HSA-5358346 | Hedgehog ligand biogenesis | 62 | 1.768960 | 0.0207406 | 0.0139466 |
| R-HSA-8951664 | Neddylation | 225 | 1.768298 | 0.0178724 | 0.0120179 |
| R-HSA-69239 | Synthesis of DNA | 116 | 1.767844 | 0.0178724 | 0.0120179 |
| R-HSA-445717 | Aquaporin-mediated transport | 44 | 1.767032 | 0.0178724 | 0.0120179 |
| R-HSA-1222556 | ROS and RNS production in phagocytes | 34 | 1.764762 | 0.0208719 | 0.0140349 |
| R-HSA-69615 | G1/S DNA Damage Checkpoints | 66 | 1.763056 | 0.0207406 | 0.0139466 |
| R-HSA-114508 | Effects of PIP2 hydrolysis | 26 | 1.763054 | 0.0214105 | 0.0143970 |
| R-HSA-5210891 | Uptake and function of anthrax toxins | 13 | 1.757143 | 0.0436155 | 0.0293283 |
| R-HSA-1632852 | Macroautophagy | 91 | 1.751486 | 0.0207406 | 0.0139466 |
| R-HSA-70171 | Glycolysis | 68 | 1.746961 | 0.0207406 | 0.0139466 |
| R-HSA-163359 | Glucagon signaling in metabolic regulation | 30 | 1.742006 | 0.0212825 | 0.0143109 |
| R-HSA-4641257 | Degradation of AXIN | 53 | 1.740082 | 0.0207406 | 0.0139466 |
| R-HSA-5683057 | MAPK family signaling cascades | 266 | 1.739771 | 0.0178724 | 0.0120179 |
| R-HSA-8856688 | Golgi-to-ER retrograde transport | 124 | 1.738128 | 0.0205499 | 0.0138183 |
| R-HSA-8949215 | Mitochondrial calcium ion transport | 23 | 1.736394 | 0.0287430 | 0.0193276 |
| R-HSA-5358351 | Signaling by Hedgehog | 143 | 1.735278 | 0.0178724 | 0.0120179 |
| R-HSA-4608870 | Asymmetric localization of PCP proteins | 62 | 1.734835 | 0.0207406 | 0.0139466 |
| R-HSA-4086400 | PCP/CE pathway | 89 | 1.733743 | 0.0178724 | 0.0120179 |
| R-HSA-8856828 | Clathrin-mediated endocytosis | 137 | 1.732979 | 0.0178724 | 0.0120179 |
| R-HSA-1852241 | Organelle biogenesis and maintenance | 286 | 1.732181 | 0.0178724 | 0.0120179 |
| R-HSA-453274 | Mitotic G2-G2/M phases | 187 | 1.727232 | 0.0178724 | 0.0120179 |
| R-HSA-1483249 | Inositol phosphate metabolism | 48 | 1.725305 | 0.0207916 | 0.0139809 |
| R-HSA-162909 | Host Interactions of HIV factors | 125 | 1.720101 | 0.0205499 | 0.0138183 |
| R-HSA-69275 | G2/M Transition | 185 | 1.715159 | 0.0178724 | 0.0120179 |
| R-HSA-8941858 | Regulation of RUNX3 expression and activity | 55 | 1.706189 | 0.0338234 | 0.0227438 |
| R-HSA-2132295 | MHC class II antigen presentation | 110 | 1.704641 | 0.0178724 | 0.0120179 |
| R-HSA-8856825 | Cargo recognition for clathrin-mediated endocytosis | 97 | 1.697754 | 0.0321613 | 0.0216261 |
| R-HSA-166520 | Signaling by NTRKs | 97 | 1.685550 | 0.0321613 | 0.0216261 |
| R-HSA-69620 | Cell Cycle Checkpoints | 279 | 1.685291 | 0.0178724 | 0.0120179 |
| R-HSA-382556 | ABC-family proteins mediated transport | 100 | 1.684830 | 0.0257145 | 0.0172911 |
| R-HSA-1855204 | Synthesis of IP3 and IP4 in the cytosol | 27 | 1.677675 | 0.0357691 | 0.0240521 |
| R-HSA-381753 | Olfactory Signaling Pathway | 49 | 1.668289 | 0.0338234 | 0.0227438 |
| R-HSA-2871809 | FCERI mediated Ca+2 mobilization | 31 | 1.663831 | 0.0344930 | 0.0231940 |
| R-HSA-379724 | tRNA Aminoacylation | 42 | 1.646165 | 0.0404812 | 0.0272207 |
| R-HSA-5205647 | Mitophagy | 29 | 1.640185 | 0.0421256 | 0.0283264 |
| R-HSA-8852276 | The role of GTSE1 in G2/M progression after G2 checkpoint | 69 | 1.639983 | 0.0329968 | 0.0221879 |
| R-HSA-2682334 | EPH-Ephrin signaling | 92 | 1.638920 | 0.0492122 | 0.0330917 |
| R-HSA-5687128 | MAPK6/MAPK4 signaling | 84 | 1.634592 | 0.0497877 | 0.0334786 |
| R-HSA-5619084 | ABC transporter disorders | 75 | 1.617943 | 0.0385323 | 0.0259102 |
| R-HSA-380270 | Recruitment of mitotic centrosome proteins and complexes | 79 | 1.584249 | 0.0385323 | 0.0259102 |
| R-HSA-380287 | Centrosome maturation | 79 | 1.584249 | 0.0385323 | 0.0259102 |
| R-HSA-9006925 | Intracellular signaling by second messengers | 285 | 1.581834 | 0.0201686 | 0.0135619 |
| R-HSA-187037 | Signaling by NTRK1 (TRKA) | 77 | 1.568724 | 0.0497877 | 0.0334786 |
| R-HSA-2467813 | Separation of Sister Chromatids | 175 | 1.560684 | 0.0239269 | 0.0160891 |
| R-HSA-162906 | HIV Infection | 224 | 1.540690 | 0.0201734 | 0.0135652 |
| R-HSA-983169 | Class I MHC mediated antigen processing & presentation | 355 | 1.536145 | 0.0196709 | 0.0132272 |
| R-HSA-9007101 | Rab regulation of trafficking | 122 | 1.535149 | 0.0369855 | 0.0248701 |
| R-HSA-69206 | G1/S Transition | 131 | 1.520515 | 0.0368454 | 0.0247758 |
| R-HSA-68882 | Mitotic Anaphase | 186 | 1.488832 | 0.0457744 | 0.0307800 |
| R-HSA-2555396 | Mitotic Metaphase and Anaphase | 187 | 1.486601 | 0.0404812 | 0.0272207 |
| R-HSA-69242 | S Phase | 158 | 1.483756 | 0.0404812 | 0.0272207 |
| R-HSA-9609507 | Protein localization | 158 | 1.479809 | 0.0404812 | 0.0272207 |
| R-HSA-5617833 | Cilium Assembly | 192 | 1.474133 | 0.0456150 | 0.0306728 |
| R-HSA-6811442 | Intra-Golgi and retrograde Golgi-to-ER traffic | 191 | 1.414316 | 0.0497877 | 0.0334786 |
| R-HSA-195721 | Signaling by WNT | 309 | 1.387903 | 0.0279923 | 0.0188228 |
| R-HSA-5663205 | Infectious disease | 368 | 1.375228 | 0.0274275 | 0.0184430 |
| R-HSA-8953897 | Cellular responses to external stimuli | 498 | 1.347697 | 0.0404812 | 0.0272207 |
| ID | Description | setSize | NES | p.adjust | qvalues |
|---|---|---|---|---|---|
| R-HSA-5625886 | Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | 59 | 3.468265 | 0.0117461 | 0.0078154 |
| R-HSA-5334118 | DNA methylation | 57 | 3.422280 | 0.0117461 | 0.0078154 |
| R-HSA-2299718 | Condensation of Prophase Chromosomes | 66 | 3.384387 | 0.0117461 | 0.0078154 |
| R-HSA-73728 | RNA Polymerase I Promoter Opening | 57 | 3.382260 | 0.0117461 | 0.0078154 |
| R-HSA-427359 | SIRT1 negatively regulates rRNA expression | 62 | 3.273416 | 0.0117461 | 0.0078154 |
| R-HSA-212300 | PRC2 methylates histones and DNA | 67 | 3.260046 | 0.0117461 | 0.0078154 |
| R-HSA-912446 | Meiotic recombination | 77 | 3.229282 | 0.0117461 | 0.0078154 |
| R-HSA-427389 | ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 70 | 3.211547 | 0.0117461 | 0.0078154 |
| R-HSA-1912408 | Pre-NOTCH Transcription and Translation | 87 | 3.192557 | 0.0117461 | 0.0078154 |
| R-HSA-1912422 | Pre-NOTCH Expression and Processing | 103 | 3.141059 | 0.0117461 | 0.0078154 |
| R-HSA-8936459 | RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | 87 | 3.121136 | 0.0117461 | 0.0078154 |
| R-HSA-171306 | Packaging Of Telomere Ends | 45 | 3.107865 | 0.0117461 | 0.0078154 |
| R-HSA-5625740 | RHO GTPases activate PKNs | 87 | 3.101239 | 0.0117461 | 0.0078154 |
| R-HSA-201722 | Formation of the beta-catenin:TCF transactivating complex | 83 | 3.089756 | 0.0117461 | 0.0078154 |
| R-HSA-110330 | Recognition and association of DNA glycosylase with site containing an affected purine | 49 | 3.083089 | 0.0117461 | 0.0078154 |
| R-HSA-110331 | Cleavage of the damaged purine | 49 | 3.083089 | 0.0117461 | 0.0078154 |
| R-HSA-73927 | Depurination | 49 | 3.083089 | 0.0117461 | 0.0078154 |
| R-HSA-1500620 | Meiosis | 106 | 3.075246 | 0.0117461 | 0.0078154 |
| R-HSA-977225 | Amyloid fiber formation | 92 | 3.070625 | 0.0117461 | 0.0078154 |
| R-HSA-1474165 | Reproduction | 121 | 3.065717 | 0.0117461 | 0.0078154 |
| R-HSA-3214815 | HDACs deacetylate histones | 89 | 3.053304 | 0.0117461 | 0.0078154 |
| R-HSA-2559582 | Senescence-Associated Secretory Phenotype (SASP) | 103 | 3.053189 | 0.0117461 | 0.0078154 |
| R-HSA-5617472 | Activation of anterior HOX genes in hindbrain development during early embryogenesis | 105 | 3.023189 | 0.0117461 | 0.0078154 |
| R-HSA-5619507 | Activation of HOX genes during differentiation | 105 | 3.023189 | 0.0117461 | 0.0078154 |
| R-HSA-3214842 | HDMs demethylate histones | 50 | 3.021979 | 0.0117461 | 0.0078154 |
| R-HSA-9018519 | Estrogen-dependent gene expression | 139 | 3.014750 | 0.0117461 | 0.0078154 |
| R-HSA-1221632 | Meiotic synapsis | 69 | 3.002054 | 0.0117461 | 0.0078154 |
| R-HSA-73772 | RNA Polymerase I Promoter Escape | 85 | 2.999443 | 0.0117461 | 0.0078154 |
| R-HSA-5250924 | B-WICH complex positively regulates rRNA expression | 85 | 2.972633 | 0.0117461 | 0.0078154 |
| R-HSA-110328 | Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 54 | 2.961401 | 0.0117461 | 0.0078154 |
| R-HSA-110329 | Cleavage of the damaged pyrimidine | 54 | 2.961401 | 0.0117461 | 0.0078154 |
| R-HSA-73928 | Depyrimidination | 54 | 2.961401 | 0.0117461 | 0.0078154 |
| R-HSA-73929 | Base-Excision Repair, AP Site Formation | 56 | 2.959082 | 0.0117461 | 0.0078154 |
| R-HSA-5578749 | Transcriptional regulation by small RNAs | 100 | 2.953369 | 0.0117461 | 0.0078154 |
| R-HSA-606279 | Deposition of new CENPA-containing nucleosomes at the centromere | 67 | 2.926504 | 0.0117461 | 0.0078154 |
| R-HSA-774815 | Nucleosome assembly | 67 | 2.926504 | 0.0117461 | 0.0078154 |
| R-HSA-3214858 | RMTs methylate histone arginines | 74 | 2.896146 | 0.0117461 | 0.0078154 |
| R-HSA-427413 | NoRC negatively regulates rRNA expression | 100 | 2.842392 | 0.0117461 | 0.0078154 |
| R-HSA-68875 | Mitotic Prophase | 134 | 2.834253 | 0.0117461 | 0.0078154 |
| R-HSA-2559586 | DNA Damage/Telomere Stress Induced Senescence | 72 | 2.823211 | 0.0117461 | 0.0078154 |
| R-HSA-5250913 | Positive epigenetic regulation of rRNA expression | 100 | 2.816024 | 0.0117461 | 0.0078154 |
| R-HSA-5250941 | Negative epigenetic regulation of rRNA expression | 103 | 2.786659 | 0.0117461 | 0.0078154 |
| R-HSA-73864 | RNA Polymerase I Transcription | 105 | 2.775882 | 0.0117461 | 0.0078154 |
| R-HSA-73854 | RNA Polymerase I Promoter Clearance | 104 | 2.753578 | 0.0117461 | 0.0078154 |
| R-HSA-3214841 | PKMTs methylate histone lysines | 68 | 2.736044 | 0.0117461 | 0.0078154 |
| R-HSA-2559580 | Oxidative Stress Induced Senescence | 116 | 2.726098 | 0.0117461 | 0.0078154 |
| R-HSA-157579 | Telomere Maintenance | 74 | 2.707148 | 0.0117461 | 0.0078154 |
| R-HSA-211000 | Gene Silencing by RNA | 128 | 2.642296 | 0.0117461 | 0.0078154 |
| R-HSA-3214847 | HATs acetylate histones | 134 | 2.626393 | 0.0117461 | 0.0078154 |
| R-HSA-8939211 | ESR-mediated signaling | 205 | 2.605186 | 0.0117461 | 0.0078154 |
| R-HSA-73884 | Base Excision Repair | 84 | 2.554506 | 0.0117461 | 0.0078154 |
| R-HSA-8939236 | RUNX1 regulates transcription of genes involved in differentiation of HSCs | 120 | 2.552006 | 0.0117461 | 0.0078154 |
| R-HSA-6785807 | Interleukin-4 and Interleukin-13 signaling | 88 | 2.512160 | 0.0117461 | 0.0078154 |
| R-HSA-73886 | Chromosome Maintenance | 101 | 2.511605 | 0.0117461 | 0.0078154 |
| R-HSA-2559583 | Cellular Senescence | 183 | 2.502976 | 0.0117461 | 0.0078154 |
| R-HSA-6783783 | Interleukin-10 signaling | 34 | 2.488127 | 0.0117461 | 0.0078154 |
| R-HSA-5693571 | Nonhomologous End-Joining (NHEJ) | 66 | 2.488032 | 0.0117461 | 0.0078154 |
| R-HSA-212165 | Epigenetic regulation of gene expression | 140 | 2.483332 | 0.0117461 | 0.0078154 |
| R-HSA-5693606 | DNA Double Strand Break Response | 74 | 2.426852 | 0.0117461 | 0.0078154 |
| R-HSA-5693565 | Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 73 | 2.423707 | 0.0117461 | 0.0078154 |
| R-HSA-8941326 | RUNX2 regulates bone development | 30 | 2.403258 | 0.0117461 | 0.0078154 |
| R-HSA-1566948 | Elastic fibre formation | 43 | 2.391125 | 0.0117461 | 0.0078154 |
| R-HSA-9006931 | Signaling by Nuclear Receptors | 244 | 2.384423 | 0.0117461 | 0.0078154 |
| R-HSA-5693607 | Processing of DNA double-strand break ends | 94 | 2.371347 | 0.0117461 | 0.0078154 |
| R-HSA-1266695 | Interleukin-7 signaling | 33 | 2.369369 | 0.0117461 | 0.0078154 |
| R-HSA-69473 | G2/M DNA damage checkpoint | 91 | 2.348016 | 0.0117461 | 0.0078154 |
| R-HSA-1474244 | Extracellular matrix organization | 263 | 2.321442 | 0.0117461 | 0.0078154 |
| R-HSA-5693567 | HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 126 | 2.273638 | 0.0117461 | 0.0078154 |
| R-HSA-3247509 | Chromatin modifying enzymes | 259 | 2.273256 | 0.0117461 | 0.0078154 |
| R-HSA-4839726 | Chromatin organization | 259 | 2.273256 | 0.0117461 | 0.0078154 |
| R-HSA-157118 | Signaling by NOTCH | 224 | 2.221206 | 0.0117461 | 0.0078154 |
| R-HSA-3000170 | Syndecan interactions | 27 | 2.212491 | 0.0117461 | 0.0078154 |
| R-HSA-2129379 | Molecules associated with elastic fibres | 36 | 2.209138 | 0.0117461 | 0.0078154 |
| R-HSA-8940973 | RUNX2 regulates osteoblast differentiation | 23 | 2.208080 | 0.0117461 | 0.0078154 |
| R-HSA-8878171 | Transcriptional regulation by RUNX1 | 218 | 2.204695 | 0.0117461 | 0.0078154 |
| R-HSA-5693538 | Homology Directed Repair | 132 | 2.198307 | 0.0117461 | 0.0078154 |
| R-HSA-8875878 | MET promotes cell motility | 40 | 2.179348 | 0.0117461 | 0.0078154 |
| R-HSA-75205 | Dissolution of Fibrin Clot | 10 | 2.112298 | 0.0117461 | 0.0078154 |
| R-HSA-3108232 | SUMO E3 ligases SUMOylate target proteins | 175 | 2.104719 | 0.0117461 | 0.0078154 |
| R-HSA-2022090 | Assembly of collagen fibrils and other multimeric structures | 56 | 2.096615 | 0.0117461 | 0.0078154 |
| R-HSA-1474290 | Collagen formation | 84 | 2.092427 | 0.0117461 | 0.0078154 |
| R-HSA-3000171 | Non-integrin membrane-ECM interactions | 59 | 2.091970 | 0.0117461 | 0.0078154 |
| R-HSA-2197563 | NOTCH2 intracellular domain regulates transcription | 10 | 2.071611 | 0.0117461 | 0.0078154 |
| R-HSA-8874081 | MET activates PTK2 signaling | 30 | 2.049986 | 0.0117461 | 0.0078154 |
| R-HSA-8941856 | RUNX3 regulates NOTCH signaling | 14 | 2.049880 | 0.0117461 | 0.0078154 |
| R-HSA-201681 | TCF dependent signaling in response to WNT | 215 | 2.041925 | 0.0117461 | 0.0078154 |
| R-HSA-209560 | NF-kB is activated and signals survival | 13 | 2.031102 | 0.0202929 | 0.0135020 |
| R-HSA-2173796 | SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 31 | 2.022195 | 0.0117461 | 0.0078154 |
| R-HSA-2990846 | SUMOylation | 181 | 2.022195 | 0.0117461 | 0.0078154 |
| R-HSA-6783589 | Interleukin-6 family signaling | 23 | 2.018325 | 0.0117461 | 0.0078154 |
| R-HSA-3000480 | Scavenging by Class A Receptors | 18 | 2.014909 | 0.0197925 | 0.0131691 |
| R-HSA-4551638 | SUMOylation of chromatin organization proteins | 70 | 2.014336 | 0.0117461 | 0.0078154 |
| R-HSA-1980145 | Signaling by NOTCH2 | 31 | 2.001981 | 0.0117461 | 0.0078154 |
| R-HSA-211976 | Endogenous sterols | 20 | 1.996679 | 0.0198251 | 0.0131908 |
| R-HSA-2173782 | Binding and Uptake of Ligands by Scavenger Receptors | 36 | 1.996595 | 0.0117461 | 0.0078154 |
| R-HSA-216083 | Integrin cell surface interactions | 75 | 1.992018 | 0.0117461 | 0.0078154 |
| R-HSA-9012852 | Signaling by NOTCH3 | 47 | 1.991023 | 0.0117461 | 0.0078154 |
| R-HSA-2173793 | Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 43 | 1.984741 | 0.0117461 | 0.0078154 |
| R-HSA-2243919 | Crosslinking of collagen fibrils | 18 | 1.979909 | 0.0197925 | 0.0131691 |
| R-HSA-2028269 | Signaling by Hippo | 20 | 1.974711 | 0.0198251 | 0.0131908 |
| R-HSA-140342 | Apoptosis induced DNA fragmentation | 13 | 1.952558 | 0.0344850 | 0.0229448 |
| R-HSA-5693532 | DNA Double-Strand Break Repair | 160 | 1.929721 | 0.0117461 | 0.0078154 |
| R-HSA-210744 | Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 13 | 1.927565 | 0.0344850 | 0.0229448 |
| R-HSA-3000178 | ECM proteoglycans | 70 | 1.926631 | 0.0117461 | 0.0078154 |
| R-HSA-9617828 | FOXO-mediated transcription of cell cycle genes | 17 | 1.923799 | 0.0202929 | 0.0135020 |
| R-HSA-3000157 | Laminin interactions | 30 | 1.914379 | 0.0117461 | 0.0078154 |
| R-HSA-193639 | p75NTR signals via NF-kB | 16 | 1.911000 | 0.0117461 | 0.0078154 |
| R-HSA-9013508 | NOTCH3 Intracellular Domain Regulates Transcription | 23 | 1.904380 | 0.0117461 | 0.0078154 |
| R-HSA-5260271 | Diseases of Immune System | 24 | 1.879596 | 0.0278870 | 0.0185548 |
| R-HSA-5602358 | Diseases associated with the TLR signaling cascade | 24 | 1.879596 | 0.0278870 | 0.0185548 |
| R-HSA-446353 | Cell-extracellular matrix interactions | 18 | 1.879476 | 0.0197925 | 0.0131691 |
| R-HSA-9013695 | NOTCH4 Intracellular Domain Regulates Transcription | 20 | 1.873682 | 0.0276905 | 0.0184241 |
| R-HSA-2032785 | YAP1- and WWTR1 (TAZ)-stimulated gene expression | 12 | 1.873360 | 0.0344850 | 0.0229448 |
| R-HSA-6803211 | TP53 Regulates Transcription of Death Receptors and Ligands | 12 | 1.868562 | 0.0344850 | 0.0229448 |
| R-HSA-111461 | Cytochrome c-mediated apoptotic response | 13 | 1.868298 | 0.0407191 | 0.0270927 |
| R-HSA-5213460 | RIPK1-mediated regulated necrosis | 19 | 1.867988 | 0.0197925 | 0.0131691 |
| R-HSA-5218859 | Regulated Necrosis | 19 | 1.867988 | 0.0197925 | 0.0131691 |
| R-HSA-2022870 | Chondroitin sulfate biosynthesis | 19 | 1.867393 | 0.0197925 | 0.0131691 |
| R-HSA-1650814 | Collagen biosynthesis and modifying enzymes | 65 | 1.837174 | 0.0117461 | 0.0078154 |
| R-HSA-1474228 | Degradation of the extracellular matrix | 117 | 1.836332 | 0.0117461 | 0.0078154 |
| R-HSA-195258 | RHO GTPase Effectors | 304 | 1.835419 | 0.0117461 | 0.0078154 |
| R-HSA-193692 | Regulated proteolysis of p75NTR | 11 | 1.831270 | 0.0283083 | 0.0188351 |
| R-HSA-449147 | Signaling by Interleukins | 393 | 1.805247 | 0.0117461 | 0.0078154 |
| R-HSA-198933 | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 95 | 1.803718 | 0.0117461 | 0.0078154 |
| R-HSA-1236977 | Endosomal/Vacuolar pathway | 11 | 1.798824 | 0.0414761 | 0.0275964 |
| R-HSA-6788467 | IL-6-type cytokine receptor ligand interactions | 16 | 1.787366 | 0.0344850 | 0.0229448 |
| R-HSA-2173795 | Downregulation of SMAD2/3:SMAD4 transcriptional activity | 23 | 1.784984 | 0.0409849 | 0.0272696 |
| R-HSA-174490 | Membrane binding and targetting of GAG proteins | 14 | 1.783827 | 0.0479042 | 0.0318734 |
| R-HSA-174495 | Synthesis And Processing Of GAG, GAGPOL Polyproteins | 14 | 1.783827 | 0.0479042 | 0.0318734 |
| R-HSA-977606 | Regulation of Complement cascade | 32 | 1.781757 | 0.0197925 | 0.0131691 |
| R-HSA-5689901 | Metalloprotease DUBs | 33 | 1.781302 | 0.0273723 | 0.0182123 |
| R-HSA-380108 | Chemokine receptors bind chemokines | 24 | 1.775479 | 0.0406867 | 0.0270712 |
| R-HSA-166658 | Complement cascade | 38 | 1.770962 | 0.0274778 | 0.0182825 |
| R-HSA-1059683 | Interleukin-6 signaling | 11 | 1.770686 | 0.0414761 | 0.0275964 |
| R-HSA-4755510 | SUMOylation of immune response proteins | 11 | 1.770228 | 0.0414761 | 0.0275964 |
| R-HSA-8957275 | Post-translational protein phosphorylation | 93 | 1.762486 | 0.0117461 | 0.0078154 |
| R-HSA-8866654 | E3 ubiquitin ligases ubiquitinate target proteins | 58 | 1.760725 | 0.0117461 | 0.0078154 |
| R-HSA-202733 | Cell surface interactions at the vascular wall | 110 | 1.752706 | 0.0117461 | 0.0078154 |
| R-HSA-909733 | Interferon alpha/beta signaling | 56 | 1.717716 | 0.0278020 | 0.0184983 |
| R-HSA-5656169 | Termination of translesion DNA synthesis | 32 | 1.710565 | 0.0388947 | 0.0258789 |
| R-HSA-381426 | Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 102 | 1.696654 | 0.0117461 | 0.0078154 |
| R-HSA-195721 | Signaling by WNT | 309 | 1.684956 | 0.0117461 | 0.0078154 |
| R-HSA-1442490 | Collagen degradation | 51 | 1.680047 | 0.0278696 | 0.0185433 |
| R-HSA-3560782 | Diseases associated with glycosaminoglycan metabolism | 40 | 1.673642 | 0.0278085 | 0.0185026 |
| R-HSA-3906995 | Diseases associated with O-glycosylation of proteins | 55 | 1.659918 | 0.0344850 | 0.0229448 |
| R-HSA-8852135 | Protein ubiquitination | 77 | 1.644277 | 0.0283083 | 0.0188351 |
| R-HSA-68886 | M Phase | 370 | 1.643709 | 0.0117461 | 0.0078154 |
| R-HSA-446728 | Cell junction organization | 78 | 1.639326 | 0.0344850 | 0.0229448 |
| R-HSA-3781865 | Diseases of glycosylation | 128 | 1.636125 | 0.0117461 | 0.0078154 |
| R-HSA-168643 | Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 55 | 1.631757 | 0.0344850 | 0.0229448 |
| R-HSA-2262752 | Cellular responses to stress | 405 | 1.625530 | 0.0117461 | 0.0078154 |
| R-HSA-1793185 | Chondroitin sulfate/dermatan sulfate metabolism | 49 | 1.625400 | 0.0278969 | 0.0185614 |
| R-HSA-381340 | Transcriptional regulation of white adipocyte differentiation | 78 | 1.618267 | 0.0344850 | 0.0229448 |
| R-HSA-9006936 | Signaling by TGF-beta family members | 97 | 1.598987 | 0.0404981 | 0.0269457 |
| R-HSA-6806834 | Signaling by MET | 78 | 1.591541 | 0.0344850 | 0.0229448 |
| R-HSA-194315 | Signaling by Rho GTPases | 427 | 1.585235 | 0.0117461 | 0.0078154 |
| R-HSA-73894 | DNA Repair | 322 | 1.439976 | 0.0117461 | 0.0078154 |
| R-HSA-6798695 | Neutrophil degranulation | 426 | 1.411085 | 0.0117461 | 0.0078154 |
| R-HSA-8953897 | Cellular responses to external stimuli | 498 | 1.368646 | 0.0117461 | 0.0078154 |
| ID | Description | setSize | NES | p.adjust | qvalues |
|---|---|---|---|---|---|
| R-HSA-5625886 | Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | 59 | 3.423865 | 0.0147558 | 0.0095281 |
| R-HSA-5334118 | DNA methylation | 57 | 3.408554 | 0.0147558 | 0.0095281 |
| R-HSA-73728 | RNA Polymerase I Promoter Opening | 57 | 3.357615 | 0.0147558 | 0.0095281 |
| R-HSA-2299718 | Condensation of Prophase Chromosomes | 66 | 3.273274 | 0.0147558 | 0.0095281 |
| R-HSA-427359 | SIRT1 negatively regulates rRNA expression | 62 | 3.258986 | 0.0147558 | 0.0095281 |
| R-HSA-212300 | PRC2 methylates histones and DNA | 67 | 3.187458 | 0.0147558 | 0.0095281 |
| R-HSA-3214815 | HDACs deacetylate histones | 89 | 3.173601 | 0.0147558 | 0.0095281 |
| R-HSA-1912408 | Pre-NOTCH Transcription and Translation | 87 | 3.151928 | 0.0147558 | 0.0095281 |
| R-HSA-912446 | Meiotic recombination | 77 | 3.147819 | 0.0147558 | 0.0095281 |
| R-HSA-427389 | ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 70 | 3.136607 | 0.0147558 | 0.0095281 |
| R-HSA-8936459 | RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | 87 | 3.126798 | 0.0147558 | 0.0095281 |
| R-HSA-5625740 | RHO GTPases activate PKNs | 87 | 3.077224 | 0.0147558 | 0.0095281 |
| R-HSA-171306 | Packaging Of Telomere Ends | 45 | 3.026010 | 0.0147558 | 0.0095281 |
| R-HSA-1500620 | Meiosis | 106 | 3.019959 | 0.0147558 | 0.0095281 |
| R-HSA-73772 | RNA Polymerase I Promoter Escape | 85 | 3.010768 | 0.0147558 | 0.0095281 |
| R-HSA-1221632 | Meiotic synapsis | 69 | 3.001838 | 0.0147558 | 0.0095281 |
| R-HSA-1912422 | Pre-NOTCH Expression and Processing | 103 | 2.983569 | 0.0147558 | 0.0095281 |
| R-HSA-1474165 | Reproduction | 121 | 2.976872 | 0.0147558 | 0.0095281 |
| R-HSA-977225 | Amyloid fiber formation | 92 | 2.976040 | 0.0147558 | 0.0095281 |
| R-HSA-110330 | Recognition and association of DNA glycosylase with site containing an affected purine | 49 | 2.945466 | 0.0147558 | 0.0095281 |
| R-HSA-110331 | Cleavage of the damaged purine | 49 | 2.945466 | 0.0147558 | 0.0095281 |
| R-HSA-73927 | Depurination | 49 | 2.945466 | 0.0147558 | 0.0095281 |
| R-HSA-5250924 | B-WICH complex positively regulates rRNA expression | 85 | 2.932192 | 0.0147558 | 0.0095281 |
| R-HSA-201722 | Formation of the beta-catenin:TCF transactivating complex | 83 | 2.915745 | 0.0147558 | 0.0095281 |
| R-HSA-2559582 | Senescence-Associated Secretory Phenotype (SASP) | 103 | 2.908049 | 0.0147558 | 0.0095281 |
| R-HSA-110328 | Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 54 | 2.866451 | 0.0147558 | 0.0095281 |
| R-HSA-110329 | Cleavage of the damaged pyrimidine | 54 | 2.866451 | 0.0147558 | 0.0095281 |
| R-HSA-73928 | Depyrimidination | 54 | 2.866451 | 0.0147558 | 0.0095281 |
| R-HSA-427413 | NoRC negatively regulates rRNA expression | 100 | 2.865425 | 0.0147558 | 0.0095281 |
| R-HSA-5578749 | Transcriptional regulation by small RNAs | 100 | 2.858178 | 0.0147558 | 0.0095281 |
| R-HSA-5617472 | Activation of anterior HOX genes in hindbrain development during early embryogenesis | 105 | 2.849947 | 0.0147558 | 0.0095281 |
| R-HSA-5619507 | Activation of HOX genes during differentiation | 105 | 2.849947 | 0.0147558 | 0.0095281 |
| R-HSA-73929 | Base-Excision Repair, AP Site Formation | 56 | 2.836182 | 0.0147558 | 0.0095281 |
| R-HSA-9018519 | Estrogen-dependent gene expression | 139 | 2.831378 | 0.0147558 | 0.0095281 |
| R-HSA-606279 | Deposition of new CENPA-containing nucleosomes at the centromere | 67 | 2.825716 | 0.0147558 | 0.0095281 |
| R-HSA-774815 | Nucleosome assembly | 67 | 2.825716 | 0.0147558 | 0.0095281 |
| R-HSA-2559586 | DNA Damage/Telomere Stress Induced Senescence | 72 | 2.813244 | 0.0147558 | 0.0095281 |
| R-HSA-5250941 | Negative epigenetic regulation of rRNA expression | 103 | 2.802212 | 0.0147558 | 0.0095281 |
| R-HSA-3214842 | HDMs demethylate histones | 50 | 2.793935 | 0.0147558 | 0.0095281 |
| R-HSA-73864 | RNA Polymerase I Transcription | 105 | 2.755552 | 0.0147558 | 0.0095281 |
| R-HSA-5250913 | Positive epigenetic regulation of rRNA expression | 100 | 2.738779 | 0.0147558 | 0.0095281 |
| R-HSA-73854 | RNA Polymerase I Promoter Clearance | 104 | 2.737481 | 0.0147558 | 0.0095281 |
| R-HSA-3214858 | RMTs methylate histone arginines | 74 | 2.725178 | 0.0147558 | 0.0095281 |
| R-HSA-3214847 | HATs acetylate histones | 134 | 2.666186 | 0.0147558 | 0.0095281 |
| R-HSA-68875 | Mitotic Prophase | 134 | 2.658509 | 0.0147558 | 0.0095281 |
| R-HSA-157579 | Telomere Maintenance | 74 | 2.658310 | 0.0147558 | 0.0095281 |
| R-HSA-5693565 | Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 73 | 2.639181 | 0.0147558 | 0.0095281 |
| R-HSA-5693606 | DNA Double Strand Break Response | 74 | 2.638258 | 0.0147558 | 0.0095281 |
| R-HSA-5693571 | Nonhomologous End-Joining (NHEJ) | 66 | 2.638140 | 0.0147558 | 0.0095281 |
| R-HSA-211000 | Gene Silencing by RNA | 128 | 2.611310 | 0.0147558 | 0.0095281 |
| R-HSA-3214841 | PKMTs methylate histone lysines | 68 | 2.549697 | 0.0147558 | 0.0095281 |
| R-HSA-2559580 | Oxidative Stress Induced Senescence | 116 | 2.536816 | 0.0147558 | 0.0095281 |
| R-HSA-212165 | Epigenetic regulation of gene expression | 140 | 2.528168 | 0.0147558 | 0.0095281 |
| R-HSA-73886 | Chromosome Maintenance | 101 | 2.477316 | 0.0147558 | 0.0095281 |
| R-HSA-73884 | Base Excision Repair | 84 | 2.462647 | 0.0147558 | 0.0095281 |
| R-HSA-8939236 | RUNX1 regulates transcription of genes involved in differentiation of HSCs | 120 | 2.451663 | 0.0147558 | 0.0095281 |
| R-HSA-8939211 | ESR-mediated signaling | 205 | 2.437913 | 0.0147558 | 0.0095281 |
| R-HSA-5693607 | Processing of DNA double-strand break ends | 94 | 2.393373 | 0.0147558 | 0.0095281 |
| R-HSA-69473 | G2/M DNA damage checkpoint | 91 | 2.384414 | 0.0147558 | 0.0095281 |
| R-HSA-3247509 | Chromatin modifying enzymes | 259 | 2.368614 | 0.0147558 | 0.0095281 |
| R-HSA-4839726 | Chromatin organization | 259 | 2.368614 | 0.0147558 | 0.0095281 |
| R-HSA-1474290 | Collagen formation | 84 | 2.319970 | 0.0147558 | 0.0095281 |
| R-HSA-2559583 | Cellular Senescence | 183 | 2.277798 | 0.0147558 | 0.0095281 |
| R-HSA-8878171 | Transcriptional regulation by RUNX1 | 218 | 2.246526 | 0.0147558 | 0.0095281 |
| R-HSA-2022090 | Assembly of collagen fibrils and other multimeric structures | 56 | 2.246405 | 0.0147558 | 0.0095281 |
| R-HSA-5693567 | HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 126 | 2.217461 | 0.0147558 | 0.0095281 |
| R-HSA-6785807 | Interleukin-4 and Interleukin-13 signaling | 88 | 2.213152 | 0.0147558 | 0.0095281 |
| R-HSA-1474244 | Extracellular matrix organization | 263 | 2.201084 | 0.0147558 | 0.0095281 |
| R-HSA-9006931 | Signaling by Nuclear Receptors | 244 | 2.195094 | 0.0147558 | 0.0095281 |
| R-HSA-1650814 | Collagen biosynthesis and modifying enzymes | 65 | 2.193222 | 0.0147558 | 0.0095281 |
| R-HSA-6783783 | Interleukin-10 signaling | 34 | 2.173643 | 0.0147558 | 0.0095281 |
| R-HSA-5260271 | Diseases of Immune System | 24 | 2.124050 | 0.0147558 | 0.0095281 |
| R-HSA-5602358 | Diseases associated with the TLR signaling cascade | 24 | 2.124050 | 0.0147558 | 0.0095281 |
| R-HSA-5693538 | Homology Directed Repair | 132 | 2.122800 | 0.0147558 | 0.0095281 |
| R-HSA-5689901 | Metalloprotease DUBs | 33 | 2.118768 | 0.0147558 | 0.0095281 |
| R-HSA-216083 | Integrin cell surface interactions | 75 | 2.070907 | 0.0147558 | 0.0095281 |
| R-HSA-3108232 | SUMO E3 ligases SUMOylate target proteins | 175 | 2.062557 | 0.0147558 | 0.0095281 |
| R-HSA-8875878 | MET promotes cell motility | 40 | 2.034390 | 0.0147558 | 0.0095281 |
| R-HSA-4551638 | SUMOylation of chromatin organization proteins | 70 | 2.026914 | 0.0147558 | 0.0095281 |
| R-HSA-977606 | Regulation of Complement cascade | 32 | 2.026791 | 0.0147558 | 0.0095281 |
| R-HSA-1266695 | Interleukin-7 signaling | 33 | 2.021810 | 0.0147558 | 0.0095281 |
| R-HSA-166658 | Complement cascade | 38 | 2.012917 | 0.0147558 | 0.0095281 |
| R-HSA-1566948 | Elastic fibre formation | 43 | 2.010537 | 0.0147558 | 0.0095281 |
| R-HSA-1442490 | Collagen degradation | 51 | 2.009278 | 0.0147558 | 0.0095281 |
| R-HSA-5693532 | DNA Double-Strand Break Repair | 160 | 1.999490 | 0.0147558 | 0.0095281 |
| R-HSA-2028269 | Signaling by Hippo | 20 | 1.977259 | 0.0147558 | 0.0095281 |
| R-HSA-2990846 | SUMOylation | 181 | 1.958994 | 0.0147558 | 0.0095281 |
| R-HSA-68884 | Mitotic Telophase/Cytokinesis | 12 | 1.944953 | 0.0147558 | 0.0095281 |
| R-HSA-157118 | Signaling by NOTCH | 224 | 1.939001 | 0.0147558 | 0.0095281 |
| R-HSA-4755510 | SUMOylation of immune response proteins | 11 | 1.938659 | 0.0147558 | 0.0095281 |
| R-HSA-198933 | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 95 | 1.934964 | 0.0147558 | 0.0095281 |
| R-HSA-8941856 | RUNX3 regulates NOTCH signaling | 14 | 1.925882 | 0.0147558 | 0.0095281 |
| R-HSA-351906 | Apoptotic cleavage of cell adhesion proteins | 11 | 1.922341 | 0.0147558 | 0.0095281 |
| R-HSA-2470946 | Cohesin Loading onto Chromatin | 10 | 1.917789 | 0.0147558 | 0.0095281 |
| R-HSA-5213460 | RIPK1-mediated regulated necrosis | 19 | 1.914879 | 0.0147558 | 0.0095281 |
| R-HSA-5218859 | Regulated Necrosis | 19 | 1.914879 | 0.0147558 | 0.0095281 |
| R-HSA-983695 | Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 29 | 1.913908 | 0.0151148 | 0.0097599 |
| R-HSA-8874081 | MET activates PTK2 signaling | 30 | 1.912836 | 0.0147558 | 0.0095281 |
| R-HSA-2173793 | Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 43 | 1.910455 | 0.0147558 | 0.0095281 |
| R-HSA-166663 | Initial triggering of complement | 18 | 1.897928 | 0.0147558 | 0.0095281 |
| R-HSA-8940973 | RUNX2 regulates osteoblast differentiation | 23 | 1.894360 | 0.0147558 | 0.0095281 |
| R-HSA-2197563 | NOTCH2 intracellular domain regulates transcription | 10 | 1.892793 | 0.0147558 | 0.0095281 |
| R-HSA-210744 | Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 13 | 1.891067 | 0.0154234 | 0.0099592 |
| R-HSA-2468052 | Establishment of Sister Chromatid Cohesion | 11 | 1.890788 | 0.0220671 | 0.0142491 |
| R-HSA-1474228 | Degradation of the extracellular matrix | 117 | 1.886363 | 0.0147558 | 0.0095281 |
| R-HSA-3000178 | ECM proteoglycans | 70 | 1.877492 | 0.0147558 | 0.0095281 |
| R-HSA-156902 | Peptide chain elongation | 85 | 1.875282 | 0.0147558 | 0.0095281 |
| R-HSA-2129379 | Molecules associated with elastic fibres | 36 | 1.869785 | 0.0147558 | 0.0095281 |
| R-HSA-877300 | Interferon gamma signaling | 83 | 1.869736 | 0.0147558 | 0.0095281 |
| R-HSA-844456 | The NLRP3 inflammasome | 15 | 1.869192 | 0.0147558 | 0.0095281 |
| R-HSA-140534 | Caspase activation via Death Receptors in the presence of ligand | 16 | 1.862439 | 0.0153052 | 0.0098828 |
| R-HSA-168928 | DDX58/IFIH1-mediated induction of interferon-alpha/beta | 63 | 1.861543 | 0.0147558 | 0.0095281 |
| R-HSA-2173796 | SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 31 | 1.851776 | 0.0148705 | 0.0096022 |
| R-HSA-380108 | Chemokine receptors bind chemokines | 24 | 1.843850 | 0.0147558 | 0.0095281 |
| R-HSA-168643 | Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 55 | 1.841317 | 0.0147558 | 0.0095281 |
| R-HSA-2871809 | FCERI mediated Ca+2 mobilization | 31 | 1.836736 | 0.0148705 | 0.0096022 |
| R-HSA-3000171 | Non-integrin membrane-ECM interactions | 59 | 1.836485 | 0.0147558 | 0.0095281 |
| R-HSA-195258 | RHO GTPase Effectors | 304 | 1.820929 | 0.0147558 | 0.0095281 |
| R-HSA-194315 | Signaling by Rho GTPases | 427 | 1.816330 | 0.0147558 | 0.0095281 |
| R-HSA-975956 | Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 91 | 1.815893 | 0.0147558 | 0.0095281 |
| R-HSA-209560 | NF-kB is activated and signals survival | 13 | 1.808667 | 0.0280512 | 0.0181132 |
| R-HSA-933542 | TRAF6 mediated NF-kB activation | 22 | 1.805904 | 0.0211187 | 0.0136367 |
| R-HSA-156842 | Eukaryotic Translation Elongation | 88 | 1.803296 | 0.0147558 | 0.0095281 |
| R-HSA-2029481 | FCGR activation | 11 | 1.798845 | 0.0336173 | 0.0217073 |
| R-HSA-8948216 | Collagen chain trimerization | 42 | 1.797346 | 0.0147558 | 0.0095281 |
| R-HSA-2173795 | Downregulation of SMAD2/3:SMAD4 transcriptional activity | 23 | 1.796343 | 0.0150909 | 0.0097445 |
| R-HSA-2173782 | Binding and Uptake of Ligands by Scavenger Receptors | 36 | 1.795118 | 0.0147558 | 0.0095281 |
| R-HSA-372708 | p130Cas linkage to MAPK signaling for integrins | 12 | 1.792613 | 0.0279866 | 0.0180715 |
| R-HSA-933543 | NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 12 | 1.791496 | 0.0279866 | 0.0180715 |
| R-HSA-5675482 | Regulation of necroptotic cell death | 17 | 1.791205 | 0.0153082 | 0.0098848 |
| R-HSA-2243919 | Crosslinking of collagen fibrils | 18 | 1.784329 | 0.0333499 | 0.0215347 |
| R-HSA-2032785 | YAP1- and WWTR1 (TAZ)-stimulated gene expression | 12 | 1.783150 | 0.0334883 | 0.0216240 |
| R-HSA-111465 | Apoptotic cleavage of cellular proteins | 38 | 1.782761 | 0.0147558 | 0.0095281 |
| R-HSA-76009 | Platelet Aggregation (Plug Formation) | 33 | 1.776749 | 0.0147558 | 0.0095281 |
| R-HSA-72689 | Formation of a pool of free 40S subunits | 97 | 1.773328 | 0.0147558 | 0.0095281 |
| R-HSA-3000480 | Scavenging by Class A Receptors | 18 | 1.770127 | 0.0333499 | 0.0215347 |
| R-HSA-192823 | Viral mRNA Translation | 85 | 1.768078 | 0.0147558 | 0.0095281 |
| R-HSA-193639 | p75NTR signals via NF-kB | 16 | 1.763027 | 0.0216744 | 0.0139956 |
| R-HSA-202433 | Generation of second messenger molecules | 26 | 1.757591 | 0.0151148 | 0.0097599 |
| R-HSA-8941326 | RUNX2 regulates bone development | 30 | 1.757124 | 0.0151148 | 0.0097599 |
| R-HSA-75205 | Dissolution of Fibrin Clot | 10 | 1.751658 | 0.0336173 | 0.0217073 |
| R-HSA-5676594 | TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | 14 | 1.739092 | 0.0439633 | 0.0283879 |
| R-HSA-75153 | Apoptotic execution phase | 52 | 1.738860 | 0.0200338 | 0.0129362 |
| R-HSA-5621480 | Dectin-2 family | 12 | 1.738387 | 0.0433056 | 0.0279633 |
| R-HSA-1810476 | RIP-mediated NFkB activation via ZBP1 | 17 | 1.737595 | 0.0433056 | 0.0279633 |
| R-HSA-202427 | Phosphorylation of CD3 and TCR zeta chains | 15 | 1.733083 | 0.0383197 | 0.0247437 |
| R-HSA-622312 | Inflammasomes | 20 | 1.732823 | 0.0277998 | 0.0179509 |
| R-HSA-5655862 | Translesion synthesis by POLK | 17 | 1.732333 | 0.0433056 | 0.0279633 |
| R-HSA-6803211 | TP53 Regulates Transcription of Death Receptors and Ligands | 12 | 1.729172 | 0.0433056 | 0.0279633 |
| R-HSA-1980145 | Signaling by NOTCH2 | 31 | 1.725154 | 0.0263370 | 0.0170063 |
| R-HSA-446353 | Cell-extracellular matrix interactions | 18 | 1.725146 | 0.0384807 | 0.0248477 |
| R-HSA-6803207 | TP53 Regulates Transcription of Caspase Activators and Caspases | 12 | 1.724677 | 0.0433056 | 0.0279633 |
| R-HSA-3000157 | Laminin interactions | 30 | 1.724279 | 0.0210780 | 0.0136105 |
| R-HSA-72764 | Eukaryotic Translation Termination | 89 | 1.720346 | 0.0147558 | 0.0095281 |
| R-HSA-354194 | GRB2:SOS provides linkage to MAPK signaling for Integrins | 12 | 1.703555 | 0.0480998 | 0.0310589 |
| R-HSA-9617828 | FOXO-mediated transcription of cell cycle genes | 17 | 1.698662 | 0.0478871 | 0.0309216 |
| R-HSA-937041 | IKK complex recruitment mediated by RIP1 | 25 | 1.682508 | 0.0325298 | 0.0210051 |
| R-HSA-350054 | Notch-HLH transcription pathway | 28 | 1.681517 | 0.0325298 | 0.0210051 |
| R-HSA-73887 | Death Receptor Signalling | 134 | 1.671640 | 0.0147558 | 0.0095281 |
| R-HSA-201681 | TCF dependent signaling in response to WNT | 215 | 1.671581 | 0.0147558 | 0.0095281 |
| R-HSA-9013508 | NOTCH3 Intracellular Domain Regulates Transcription | 23 | 1.671287 | 0.0460137 | 0.0297119 |
| R-HSA-909733 | Interferon alpha/beta signaling | 56 | 1.659692 | 0.0147558 | 0.0095281 |
| R-HSA-5083635 | Defective B3GALTL causes Peters-plus syndrome (PpS) | 35 | 1.659660 | 0.0315379 | 0.0203646 |
| R-HSA-9013695 | NOTCH4 Intracellular Domain Regulates Transcription | 20 | 1.659234 | 0.0432009 | 0.0278956 |
| R-HSA-445989 | TAK1 activates NFkB by phosphorylation and activation of IKKs complex | 31 | 1.647604 | 0.0412447 | 0.0266325 |
| R-HSA-202733 | Cell surface interactions at the vascular wall | 110 | 1.642448 | 0.0147558 | 0.0095281 |
| R-HSA-449147 | Signaling by Interleukins | 393 | 1.642303 | 0.0147558 | 0.0095281 |
| R-HSA-168898 | Toll-like Receptor Cascades | 146 | 1.640740 | 0.0147558 | 0.0095281 |
| R-HSA-114604 | GPVI-mediated activation cascade | 31 | 1.639668 | 0.0498069 | 0.0321613 |
| R-HSA-5173214 | O-glycosylation of TSR domain-containing proteins | 36 | 1.628517 | 0.0498069 | 0.0321613 |
| R-HSA-8866654 | E3 ubiquitin ligases ubiquitinate target proteins | 58 | 1.628071 | 0.0354229 | 0.0228732 |
| R-HSA-5633008 | TP53 Regulates Transcription of Cell Death Genes | 43 | 1.617457 | 0.0406272 | 0.0262337 |
| R-HSA-9012852 | Signaling by NOTCH3 | 47 | 1.605728 | 0.0366911 | 0.0236921 |
| R-HSA-68886 | M Phase | 370 | 1.602841 | 0.0147558 | 0.0095281 |
| R-HSA-2408557 | Selenocysteine synthesis | 89 | 1.600130 | 0.0147558 | 0.0095281 |
| R-HSA-170834 | Signaling by TGF-beta Receptor Complex | 72 | 1.598184 | 0.0360057 | 0.0232496 |
| R-HSA-166016 | Toll Like Receptor 4 (TLR4) Cascade | 124 | 1.596183 | 0.0147558 | 0.0095281 |
| R-HSA-156827 | L13a-mediated translational silencing of Ceruloplasmin expression | 107 | 1.587028 | 0.0147558 | 0.0095281 |
| R-HSA-2122947 | NOTCH1 Intracellular Domain Regulates Transcription | 47 | 1.580947 | 0.0457982 | 0.0295727 |
| R-HSA-381426 | Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 102 | 1.580331 | 0.0147558 | 0.0095281 |
| R-HSA-194840 | Rho GTPase cycle | 133 | 1.552178 | 0.0147558 | 0.0095281 |
| R-HSA-72706 | GTP hydrolysis and joining of the 60S ribosomal subunit | 108 | 1.550432 | 0.0147558 | 0.0095281 |
| R-HSA-913531 | Interferon Signaling | 176 | 1.548906 | 0.0147558 | 0.0095281 |
| R-HSA-9006936 | Signaling by TGF-beta family members | 97 | 1.537075 | 0.0147558 | 0.0095281 |
| R-HSA-927802 | Nonsense-Mediated Decay (NMD) | 110 | 1.535218 | 0.0147558 | 0.0095281 |
| R-HSA-975957 | Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 110 | 1.535218 | 0.0147558 | 0.0095281 |
| R-HSA-8957275 | Post-translational protein phosphorylation | 93 | 1.508154 | 0.0250671 | 0.0161863 |
| R-HSA-72613 | Eukaryotic Translation Initiation | 115 | 1.501685 | 0.0389742 | 0.0251664 |
| R-HSA-72737 | Cap-dependent Translation Initiation | 115 | 1.501685 | 0.0389742 | 0.0251664 |
| R-HSA-6806834 | Signaling by MET | 78 | 1.500242 | 0.0498069 | 0.0321613 |
| R-HSA-193704 | p75 NTR receptor-mediated signalling | 93 | 1.477552 | 0.0350586 | 0.0226380 |
| R-HSA-73894 | DNA Repair | 322 | 1.453064 | 0.0147558 | 0.0095281 |
| R-HSA-195721 | Signaling by WNT | 309 | 1.448673 | 0.0147558 | 0.0095281 |
| R-HSA-2262752 | Cellular responses to stress | 405 | 1.436950 | 0.0147558 | 0.0095281 |
| ID | Description | setSize | NES | p.adjust | qvalues |
|---|---|---|---|---|---|
| R-HSA-1428517 | The citric acid (TCA) cycle and respiratory electron transport | 170 | 3.041814 | 0.0163383 | 0.0108580 |
| R-HSA-611105 | Respiratory electron transport | 100 | 3.001511 | 0.0163383 | 0.0108580 |
| R-HSA-163200 | Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | 122 | 2.963208 | 0.0163383 | 0.0108580 |
| R-HSA-6799198 | Complex I biogenesis | 55 | 2.687405 | 0.0163383 | 0.0108580 |
| R-HSA-5576892 | Phase 0 - rapid depolarisation | 45 | 2.672837 | 0.0163383 | 0.0108580 |
| R-HSA-71406 | Pyruvate metabolism and Citric Acid (TCA) cycle | 52 | 2.566007 | 0.0163383 | 0.0108580 |
| R-HSA-888590 | GABA synthesis, release, reuptake and degradation | 19 | 2.531036 | 0.0163383 | 0.0108580 |
| R-HSA-1268020 | Mitochondrial protein import | 63 | 2.472878 | 0.0163383 | 0.0108580 |
| R-HSA-112316 | Neuronal System | 379 | 2.463509 | 0.0163383 | 0.0108580 |
| R-HSA-1296072 | Voltage gated Potassium channels | 40 | 2.462057 | 0.0163383 | 0.0108580 |
| R-HSA-71403 | Citric acid cycle (TCA cycle) | 22 | 2.459002 | 0.0163383 | 0.0108580 |
| R-HSA-399719 | Trafficking of AMPA receptors | 30 | 2.431389 | 0.0163383 | 0.0108580 |
| R-HSA-399721 | Glutamate binding, activation of AMPA receptors and synaptic plasticity | 30 | 2.431389 | 0.0163383 | 0.0108580 |
| R-HSA-112315 | Transmission across Chemical Synapses | 245 | 2.428739 | 0.0163383 | 0.0108580 |
| R-HSA-180024 | DARPP-32 events | 25 | 2.387230 | 0.0163383 | 0.0108580 |
| R-HSA-5682910 | LGI-ADAM interactions | 14 | 2.375936 | 0.0163383 | 0.0108580 |
| R-HSA-442982 | Ras activation upon Ca2+ influx through NMDA receptor | 21 | 2.369297 | 0.0163383 | 0.0108580 |
| R-HSA-112310 | Neurotransmitter release cycle | 47 | 2.337743 | 0.0163383 | 0.0108580 |
| R-HSA-5339562 | Uptake and actions of bacterial toxins | 30 | 2.313288 | 0.0163383 | 0.0108580 |
| R-HSA-442755 | Activation of NMDA receptors and postsynaptic events | 84 | 2.289119 | 0.0163383 | 0.0108580 |
| R-HSA-5389840 | Mitochondrial translation elongation | 86 | 2.273528 | 0.0163383 | 0.0108580 |
| R-HSA-445095 | Interaction between L1 and Ankyrins | 29 | 2.272928 | 0.0163383 | 0.0108580 |
| R-HSA-5368287 | Mitochondrial translation | 92 | 2.245909 | 0.0163383 | 0.0108580 |
| R-HSA-112314 | Neurotransmitter receptors and postsynaptic signal transmission | 184 | 2.245515 | 0.0163383 | 0.0108580 |
| R-HSA-111933 | Calmodulin induced events | 35 | 2.242523 | 0.0163383 | 0.0108580 |
| R-HSA-111997 | CaM pathway | 35 | 2.242523 | 0.0163383 | 0.0108580 |
| R-HSA-168799 | Neurotoxicity of clostridium toxins | 10 | 2.212582 | 0.0163383 | 0.0108580 |
| R-HSA-5368286 | Mitochondrial translation initiation | 86 | 2.207501 | 0.0163383 | 0.0108580 |
| R-HSA-111996 | Ca-dependent events | 37 | 2.207053 | 0.0163383 | 0.0108580 |
| R-HSA-5419276 | Mitochondrial translation termination | 86 | 2.203616 | 0.0163383 | 0.0108580 |
| R-HSA-351202 | Metabolism of polyamines | 83 | 2.190904 | 0.0163383 | 0.0108580 |
| R-HSA-1489509 | DAG and IP3 signaling | 41 | 2.189185 | 0.0163383 | 0.0108580 |
| R-HSA-111885 | Opioid Signalling | 86 | 2.172653 | 0.0163383 | 0.0108580 |
| R-HSA-9617324 | Negative regulation of NMDA receptor-mediated neuronal transmission | 22 | 2.157266 | 0.0163383 | 0.0108580 |
| R-HSA-350562 | Regulation of ornithine decarboxylase (ODC) | 49 | 2.153131 | 0.0163383 | 0.0108580 |
| R-HSA-438064 | Post NMDA receptor activation events | 73 | 2.150059 | 0.0163383 | 0.0108580 |
| R-HSA-1296071 | Potassium Channels | 92 | 2.126784 | 0.0163383 | 0.0108580 |
| R-HSA-379716 | Cytosolic tRNA aminoacylation | 24 | 2.120236 | 0.0163383 | 0.0108580 |
| R-HSA-1236978 | Cross-presentation of soluble exogenous antigens (endosomes) | 47 | 2.084574 | 0.0163383 | 0.0108580 |
| R-HSA-111932 | CaMK IV-mediated phosphorylation of CREB | 12 | 2.084286 | 0.0163383 | 0.0108580 |
| R-HSA-416993 | Trafficking of GluR2-containing AMPA receptors | 16 | 2.075714 | 0.0163383 | 0.0108580 |
| R-HSA-8949613 | Cristae formation | 31 | 2.075215 | 0.0163383 | 0.0108580 |
| R-HSA-438066 | Unblocking of NMDA receptors, glutamate binding and activation | 22 | 2.046009 | 0.0245170 | 0.0162933 |
| R-HSA-9604323 | Negative regulation of NOTCH4 signaling | 54 | 2.042919 | 0.0163383 | 0.0108580 |
| R-HSA-9620244 | Long-term potentiation | 24 | 2.035952 | 0.0163383 | 0.0108580 |
| R-HSA-5673000 | RAF activation | 32 | 2.019711 | 0.0163383 | 0.0108580 |
| R-HSA-9609507 | Protein localization | 158 | 2.018606 | 0.0163383 | 0.0108580 |
| R-HSA-70221 | Glycogen breakdown (glycogenolysis) | 17 | 2.016710 | 0.0163383 | 0.0108580 |
| R-HSA-5628897 | TP53 Regulates Metabolic Genes | 84 | 2.011609 | 0.0163383 | 0.0108580 |
| R-HSA-442729 | CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | 10 | 2.011388 | 0.0163383 | 0.0108580 |
| R-HSA-4641258 | Degradation of DVL | 55 | 2.006998 | 0.0163383 | 0.0108580 |
| R-HSA-163615 | PKA activation | 18 | 2.002056 | 0.0163383 | 0.0108580 |
| R-HSA-112043 | PLC beta mediated events | 50 | 2.001917 | 0.0163383 | 0.0108580 |
| R-HSA-212676 | Dopamine Neurotransmitter Release Cycle | 22 | 1.998753 | 0.0319771 | 0.0212511 |
| R-HSA-1362409 | Mitochondrial iron-sulfur cluster biogenesis | 12 | 1.997021 | 0.0163383 | 0.0108580 |
| R-HSA-210500 | Glutamate Neurotransmitter Release Cycle | 24 | 1.992552 | 0.0245170 | 0.0162933 |
| R-HSA-5610783 | Degradation of GLI2 by the proteasome | 57 | 1.979908 | 0.0163383 | 0.0108580 |
| R-HSA-442742 | CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 29 | 1.978334 | 0.0245170 | 0.0162933 |
| R-HSA-8951664 | Neddylation | 225 | 1.976975 | 0.0163383 | 0.0108580 |
| R-HSA-9609736 | Assembly and cell surface presentation of NMDA receptors | 34 | 1.976486 | 0.0245170 | 0.0162933 |
| R-HSA-442720 | CREB1 phosphorylation through the activation of Adenylate Cyclase | 13 | 1.975404 | 0.0163383 | 0.0108580 |
| R-HSA-5610780 | Degradation of GLI1 by the proteasome | 57 | 1.971102 | 0.0163383 | 0.0108580 |
| R-HSA-5578775 | Ion homeostasis | 53 | 1.970579 | 0.0163383 | 0.0108580 |
| R-HSA-112040 | G-protein mediated events | 51 | 1.967535 | 0.0163383 | 0.0108580 |
| R-HSA-5576891 | Cardiac conduction | 131 | 1.954009 | 0.0163383 | 0.0108580 |
| R-HSA-5099900 | WNT5A-dependent internalization of FZD4 | 15 | 1.945404 | 0.0245170 | 0.0162933 |
| R-HSA-169911 | Regulation of Apoptosis | 51 | 1.941266 | 0.0163383 | 0.0108580 |
| R-HSA-8939902 | Regulation of RUNX2 expression and activity | 70 | 1.938164 | 0.0163383 | 0.0108580 |
| R-HSA-5676590 | NIK–>noncanonical NF-kB signaling | 56 | 1.936767 | 0.0163383 | 0.0108580 |
| R-HSA-163685 | Integration of energy metabolism | 101 | 1.933458 | 0.0163383 | 0.0108580 |
| R-HSA-174084 | Autodegradation of Cdh1 by Cdh1:APC/C | 62 | 1.927796 | 0.0163383 | 0.0108580 |
| R-HSA-68867 | Assembly of the pre-replicative complex | 65 | 1.926250 | 0.0163383 | 0.0108580 |
| R-HSA-5210891 | Uptake and function of anthrax toxins | 13 | 1.926208 | 0.0245170 | 0.0162933 |
| R-HSA-5610785 | GLI3 is processed to GLI3R by the proteasome | 57 | 1.922772 | 0.0163383 | 0.0108580 |
| R-HSA-68827 | CDT1 association with the CDC6:ORC:origin complex | 57 | 1.921878 | 0.0163383 | 0.0108580 |
| R-HSA-6811436 | COPI-independent Golgi-to-ER retrograde traffic | 45 | 1.915043 | 0.0163383 | 0.0108580 |
| R-HSA-180585 | Vif-mediated degradation of APOBEC3G | 52 | 1.913775 | 0.0245170 | 0.0162933 |
| R-HSA-379724 | tRNA Aminoacylation | 42 | 1.913478 | 0.0248666 | 0.0165257 |
| R-HSA-451306 | Ionotropic activity of kainate receptors | 12 | 1.906336 | 0.0245170 | 0.0162933 |
| R-HSA-451308 | Activation of Ca-permeable Kainate Receptor | 12 | 1.906336 | 0.0245170 | 0.0162933 |
| R-HSA-181429 | Serotonin Neurotransmitter Release Cycle | 17 | 1.903568 | 0.0163383 | 0.0108580 |
| R-HSA-1592230 | Mitochondrial biogenesis | 94 | 1.903230 | 0.0163383 | 0.0108580 |
| R-HSA-75815 | Ubiquitin-dependent degradation of Cyclin D | 50 | 1.900190 | 0.0163383 | 0.0108580 |
| R-HSA-211733 | Regulation of activated PAK-2p34 by proteasome mediated degradation | 48 | 1.899298 | 0.0163383 | 0.0108580 |
| R-HSA-69601 | Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 50 | 1.897284 | 0.0163383 | 0.0108580 |
| R-HSA-69610 | p53-Independent DNA Damage Response | 50 | 1.897284 | 0.0163383 | 0.0108580 |
| R-HSA-69613 | p53-Independent G1/S DNA damage checkpoint | 50 | 1.897284 | 0.0163383 | 0.0108580 |
| R-HSA-163210 | Formation of ATP by chemiosmotic coupling | 18 | 1.896052 | 0.0319771 | 0.0212511 |
| R-HSA-177504 | Retrograde neurotrophin signalling | 14 | 1.894044 | 0.0245170 | 0.0162933 |
| R-HSA-5610787 | Hedgehog ‘off’ state | 108 | 1.890758 | 0.0163383 | 0.0108580 |
| R-HSA-8856688 | Golgi-to-ER retrograde transport | 124 | 1.890283 | 0.0163383 | 0.0108580 |
| R-HSA-8948751 | Regulation of PTEN stability and activity | 67 | 1.888547 | 0.0163383 | 0.0108580 |
| R-HSA-5362768 | Hh mutants that don’t undergo autocatalytic processing are degraded by ERAD | 54 | 1.883881 | 0.0245170 | 0.0162933 |
| R-HSA-8949215 | Mitochondrial calcium ion transport | 23 | 1.881357 | 0.0245170 | 0.0162933 |
| R-HSA-70263 | Gluconeogenesis | 29 | 1.878854 | 0.0245170 | 0.0162933 |
| R-HSA-422356 | Regulation of insulin secretion | 73 | 1.875978 | 0.0163383 | 0.0108580 |
| R-HSA-6794362 | Protein-protein interactions at synapses | 87 | 1.870723 | 0.0163383 | 0.0108580 |
| R-HSA-8849932 | Synaptic adhesion-like molecules | 21 | 1.869932 | 0.0383797 | 0.0255061 |
| R-HSA-8949664 | Processing of SMDT1 | 16 | 1.869291 | 0.0245170 | 0.0162933 |
| R-HSA-8854050 | FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 52 | 1.867612 | 0.0245170 | 0.0162933 |
| R-HSA-264642 | Acetylcholine Neurotransmitter Release Cycle | 14 | 1.859296 | 0.0245170 | 0.0162933 |
| R-HSA-77387 | Insulin receptor recycling | 23 | 1.858300 | 0.0319771 | 0.0212511 |
| R-HSA-5607761 | Dectin-1 mediated noncanonical NF-kB signaling | 57 | 1.857786 | 0.0163383 | 0.0108580 |
| R-HSA-180534 | Vpu mediated degradation of CD4 | 50 | 1.853985 | 0.0163383 | 0.0108580 |
| R-HSA-4086400 | PCP/CE pathway | 89 | 1.836665 | 0.0163383 | 0.0108580 |
| R-HSA-349425 | Autodegradation of the E3 ubiquitin ligase COP1 | 50 | 1.832836 | 0.0245170 | 0.0162933 |
| R-HSA-174113 | SCF-beta-TrCP mediated degradation of Emi1 | 53 | 1.831612 | 0.0245170 | 0.0162933 |
| R-HSA-5387390 | Hh mutants abrogate ligand secretion | 56 | 1.826422 | 0.0245170 | 0.0162933 |
| R-HSA-1168372 | Downstream signaling events of B Cell Receptor (BCR) | 81 | 1.816836 | 0.0245170 | 0.0162933 |
| R-HSA-1222556 | ROS and RNS production in phagocytes | 34 | 1.813762 | 0.0245170 | 0.0162933 |
| R-HSA-111931 | PKA-mediated phosphorylation of CREB | 20 | 1.812149 | 0.0440225 | 0.0292561 |
| R-HSA-4641257 | Degradation of AXIN | 53 | 1.807226 | 0.0245170 | 0.0162933 |
| R-HSA-917977 | Transferrin endocytosis and recycling | 29 | 1.805510 | 0.0319771 | 0.0212511 |
| R-HSA-5658442 | Regulation of RAS by GAPs | 66 | 1.805475 | 0.0163383 | 0.0108580 |
| R-HSA-8854214 | TBC/RABGAPs | 44 | 1.791965 | 0.0163383 | 0.0108580 |
| R-HSA-3858494 | Beta-catenin independent WNT signaling | 139 | 1.791632 | 0.0163383 | 0.0108580 |
| R-HSA-174154 | APC/C:Cdc20 mediated degradation of Securin | 64 | 1.790568 | 0.0245170 | 0.0162933 |
| R-HSA-1632852 | Macroautophagy | 91 | 1.789106 | 0.0163383 | 0.0108580 |
| R-HSA-112308 | Presynaptic depolarization and calcium channel opening | 13 | 1.777247 | 0.0383797 | 0.0255061 |
| R-HSA-164378 | PKA activation in glucagon signalling | 16 | 1.770856 | 0.0440225 | 0.0292561 |
| R-HSA-373760 | L1CAM interactions | 111 | 1.764163 | 0.0163383 | 0.0108580 |
| R-HSA-70326 | Glucose metabolism | 85 | 1.761742 | 0.0245170 | 0.0162933 |
| R-HSA-2132295 | MHC class II antigen presentation | 110 | 1.755864 | 0.0163383 | 0.0108580 |
| R-HSA-69052 | Switching of origins to a post-replicative state | 87 | 1.750889 | 0.0245170 | 0.0162933 |
| R-HSA-69017 | CDK-mediated phosphorylation and removal of Cdc6 | 69 | 1.750688 | 0.0163383 | 0.0108580 |
| R-HSA-68949 | Orc1 removal from chromatin | 69 | 1.746567 | 0.0163383 | 0.0108580 |
| R-HSA-181430 | Norepinephrine Neurotransmitter Release Cycle | 18 | 1.746453 | 0.0381679 | 0.0253653 |
| R-HSA-8941858 | Regulation of RUNX3 expression and activity | 55 | 1.741963 | 0.0319771 | 0.0212511 |
| R-HSA-195253 | Degradation of beta-catenin by the destruction complex | 80 | 1.741499 | 0.0245170 | 0.0162933 |
| R-HSA-69541 | Stabilization of p53 | 55 | 1.737300 | 0.0319771 | 0.0212511 |
| R-HSA-451326 | Activation of kainate receptors upon glutamate binding | 31 | 1.736232 | 0.0441783 | 0.0293597 |
| R-HSA-174178 | APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | 67 | 1.734365 | 0.0319771 | 0.0212511 |
| R-HSA-1852241 | Organelle biogenesis and maintenance | 286 | 1.730745 | 0.0163383 | 0.0108580 |
| R-HSA-70268 | Pyruvate metabolism | 28 | 1.728660 | 0.0440225 | 0.0292561 |
| R-HSA-380972 | Energy dependent regulation of mTOR by LKB1-AMPK | 28 | 1.727284 | 0.0440225 | 0.0292561 |
| R-HSA-74752 | Signaling by Insulin receptor | 66 | 1.726672 | 0.0383797 | 0.0255061 |
| R-HSA-179419 | APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | 70 | 1.711435 | 0.0245170 | 0.0162933 |
| R-HSA-9007101 | Rab regulation of trafficking | 122 | 1.711344 | 0.0163383 | 0.0108580 |
| R-HSA-9005891 | Loss of function of MECP2 in Rett syndrome | 14 | 1.710397 | 0.0495196 | 0.0329093 |
| R-HSA-9005895 | Pervasive developmental disorders | 14 | 1.710397 | 0.0495196 | 0.0329093 |
| R-HSA-418359 | Reduction of cytosolic Ca++ levels | 14 | 1.708907 | 0.0495196 | 0.0329093 |
| R-HSA-174184 | Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 69 | 1.707665 | 0.0245170 | 0.0162933 |
| R-HSA-6807878 | COPI-mediated anterograde transport | 92 | 1.706563 | 0.0163383 | 0.0108580 |
| R-HSA-5607763 | CLEC7A (Dectin-1) induces NFAT activation | 13 | 1.705175 | 0.0440225 | 0.0292561 |
| R-HSA-69002 | DNA Replication Pre-Initiation | 82 | 1.700688 | 0.0245170 | 0.0162933 |
| R-HSA-8856828 | Clathrin-mediated endocytosis | 137 | 1.696411 | 0.0163383 | 0.0108580 |
| R-HSA-5607764 | CLEC7A (Dectin-1) signaling | 98 | 1.694394 | 0.0319771 | 0.0212511 |
| R-HSA-176409 | APC/C:Cdc20 mediated degradation of mitotic proteins | 72 | 1.693267 | 0.0163383 | 0.0108580 |
| R-HSA-176814 | Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 72 | 1.693267 | 0.0163383 | 0.0108580 |
| R-HSA-8852276 | The role of GTSE1 in G2/M progression after G2 checkpoint | 69 | 1.690602 | 0.0319771 | 0.0212511 |
| R-HSA-382556 | ABC-family proteins mediated transport | 100 | 1.689007 | 0.0319771 | 0.0212511 |
| R-HSA-8856825 | Cargo recognition for clathrin-mediated endocytosis | 97 | 1.676854 | 0.0319771 | 0.0212511 |
| R-HSA-2454202 | Fc epsilon receptor (FCERI) signaling | 129 | 1.676732 | 0.0163383 | 0.0108580 |
| R-HSA-176408 | Regulation of APC/C activators between G1/S and early anaphase | 76 | 1.676132 | 0.0245170 | 0.0162933 |
| R-HSA-445717 | Aquaporin-mediated transport | 44 | 1.674538 | 0.0387468 | 0.0257500 |
| R-HSA-187577 | SCF(Skp2)-mediated degradation of p27/p21 | 60 | 1.666134 | 0.0319771 | 0.0212511 |
| R-HSA-5358346 | Hedgehog ligand biogenesis | 62 | 1.662053 | 0.0383797 | 0.0255061 |
| R-HSA-5673001 | RAF/MAP kinase cascade | 224 | 1.661475 | 0.0163383 | 0.0108580 |
| R-HSA-432040 | Vasopressin regulates renal water homeostasis via Aquaporins | 38 | 1.655159 | 0.0383797 | 0.0255061 |
| R-HSA-9006925 | Intracellular signaling by second messengers | 285 | 1.654087 | 0.0163383 | 0.0108580 |
| R-HSA-4608870 | Asymmetric localization of PCP proteins | 62 | 1.645004 | 0.0383797 | 0.0255061 |
| R-HSA-381676 | Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 39 | 1.640102 | 0.0387468 | 0.0257500 |
| R-HSA-69563 | p53-Dependent G1 DNA Damage Response | 64 | 1.639945 | 0.0442887 | 0.0294330 |
| R-HSA-69580 | p53-Dependent G1/S DNA damage checkpoint | 64 | 1.639945 | 0.0442887 | 0.0294330 |
| R-HSA-6811434 | COPI-dependent Golgi-to-ER retrograde traffic | 91 | 1.638914 | 0.0319771 | 0.0212511 |
| R-HSA-380270 | Recruitment of mitotic centrosome proteins and complexes | 79 | 1.636608 | 0.0319771 | 0.0212511 |
| R-HSA-380287 | Centrosome maturation | 79 | 1.636608 | 0.0319771 | 0.0212511 |
| R-HSA-453274 | Mitotic G2-G2/M phases | 187 | 1.630348 | 0.0163383 | 0.0108580 |
| R-HSA-983168 | Antigen processing: Ubiquitination & Proteasome degradation | 296 | 1.630228 | 0.0163383 | 0.0108580 |
| R-HSA-5621481 | C-type lectin receptors (CLRs) | 123 | 1.629426 | 0.0163383 | 0.0108580 |
| R-HSA-1483255 | PI Metabolism | 82 | 1.628843 | 0.0319771 | 0.0212511 |
| R-HSA-936837 | Ion transport by P-type ATPases | 54 | 1.617549 | 0.0384958 | 0.0255832 |
| R-HSA-5619084 | ABC transporter disorders | 75 | 1.615030 | 0.0319771 | 0.0212511 |
| R-HSA-69615 | G1/S DNA Damage Checkpoints | 66 | 1.613393 | 0.0383797 | 0.0255061 |
| R-HSA-69275 | G2/M Transition | 185 | 1.605572 | 0.0163383 | 0.0108580 |
| R-HSA-5684996 | MAPK1/MAPK3 signaling | 230 | 1.597186 | 0.0163383 | 0.0108580 |
| R-HSA-5358351 | Signaling by Hedgehog | 143 | 1.596534 | 0.0163383 | 0.0108580 |
| R-HSA-2871837 | FCERI mediated NF-kB activation | 78 | 1.593279 | 0.0383797 | 0.0255061 |
| R-HSA-450408 | AUF1 (hnRNP D0) binds and destabilizes mRNA | 54 | 1.591723 | 0.0496247 | 0.0329792 |
| R-HSA-5678895 | Defective CFTR causes cystic fibrosis | 59 | 1.580100 | 0.0319771 | 0.0212511 |
| R-HSA-70171 | Glycolysis | 68 | 1.577632 | 0.0440225 | 0.0292561 |
| R-HSA-162909 | Host Interactions of HIV factors | 125 | 1.575720 | 0.0245170 | 0.0162933 |
| R-HSA-6794361 | Neurexins and neuroligins | 56 | 1.574817 | 0.0440225 | 0.0292561 |
| R-HSA-8986944 | Transcriptional Regulation by MECP2 | 61 | 1.563358 | 0.0441783 | 0.0293597 |
| R-HSA-69202 | Cyclin E associated events during G1/S transition | 83 | 1.562412 | 0.0495196 | 0.0329093 |
| R-HSA-380320 | Recruitment of NuMA to mitotic centrosomes | 86 | 1.552969 | 0.0495196 | 0.0329093 |
| R-HSA-983712 | Ion channel transport | 168 | 1.520687 | 0.0163383 | 0.0108580 |
| R-HSA-397014 | Muscle contraction | 187 | 1.513686 | 0.0163383 | 0.0108580 |
| R-HSA-6811442 | Intra-Golgi and retrograde Golgi-to-ER traffic | 191 | 1.490328 | 0.0319413 | 0.0212273 |
| R-HSA-199977 | ER to Golgi Anterograde Transport | 142 | 1.478753 | 0.0319771 | 0.0212511 |
| R-HSA-162906 | HIV Infection | 224 | 1.450722 | 0.0245170 | 0.0162933 |
| R-HSA-5683057 | MAPK family signaling cascades | 266 | 1.433513 | 0.0163383 | 0.0108580 |
| R-HSA-69481 | G2/M Checkpoints | 162 | 1.433334 | 0.0434028 | 0.0288443 |
| R-HSA-195721 | Signaling by WNT | 309 | 1.385512 | 0.0319771 | 0.0212511 |
rm(df)
for(module in top_modules){
df = enrichment_GO[[module]] %>% dplyr::select(ID, Description, setSize, NES, p.adjust, qvalues) %>% arrange(desc(NES)) %>% filter(NES>0)
if(nrow(df)>0){
print(kable(df, caption = paste0('Enriched terms for module ', module, ' (MTcor = ', round(dataset$MTcor[dataset$Module==module][1],2),')')))
cat('\n')
} else cat(paste0('\nNo enrichment found for module ',module,'\n'))
}
| ID | Description | setSize | NES | p.adjust | qvalues |
|---|---|---|---|---|---|
| GO:0042775 | mitochondrial ATP synthesis coupled electron transport | 87 | 2.752686 | 0.0329885 | 0.0231737 |
| GO:0042773 | ATP synthesis coupled electron transport | 88 | 2.726014 | 0.0329885 | 0.0231737 |
| GO:0098693 | regulation of synaptic vesicle cycle | 105 | 2.684098 | 0.0329885 | 0.0231737 |
| GO:1900449 | regulation of glutamate receptor signaling pathway | 54 | 2.666107 | 0.0329885 | 0.0231737 |
| GO:0099504 | synaptic vesicle cycle | 158 | 2.665682 | 0.0329885 | 0.0231737 |
| GO:0022904 | respiratory electron transport chain | 104 | 2.661921 | 0.0329885 | 0.0231737 |
| GO:0007269 | neurotransmitter secretion | 142 | 2.655961 | 0.0329885 | 0.0231737 |
| GO:0099643 | signal release from synapse | 143 | 2.645728 | 0.0329885 | 0.0231737 |
| GO:0099003 | vesicle-mediated transport in synapse | 171 | 2.630220 | 0.0329885 | 0.0231737 |
| GO:2000310 | regulation of NMDA receptor activity | 33 | 2.616300 | 0.0329885 | 0.0231737 |
| GO:0016079 | synaptic vesicle exocytosis | 99 | 2.597362 | 0.0329885 | 0.0231737 |
| GO:1902803 | regulation of synaptic vesicle transport | 75 | 2.562522 | 0.0329885 | 0.0231737 |
| GO:0048489 | synaptic vesicle transport | 125 | 2.552998 | 0.0329885 | 0.0231737 |
| GO:0097480 | establishment of synaptic vesicle localization | 125 | 2.552998 | 0.0329885 | 0.0231737 |
| GO:0017156 | calcium ion regulated exocytosis | 124 | 2.551871 | 0.0329885 | 0.0231737 |
| GO:0097479 | synaptic vesicle localization | 135 | 2.549518 | 0.0329885 | 0.0231737 |
| GO:0099601 | regulation of neurotransmitter receptor activity | 62 | 2.546387 | 0.0329885 | 0.0231737 |
| GO:0006120 | mitochondrial electron transport, NADH to ubiquinone | 54 | 2.543747 | 0.0329885 | 0.0231737 |
| GO:0046928 | regulation of neurotransmitter secretion | 93 | 2.537430 | 0.0329885 | 0.0231737 |
| GO:2001257 | regulation of cation channel activity | 150 | 2.525697 | 0.0329885 | 0.0231737 |
| GO:0036465 | synaptic vesicle recycling | 49 | 2.514152 | 0.0329885 | 0.0231737 |
| GO:0017158 | regulation of calcium ion-dependent exocytosis | 90 | 2.499577 | 0.0329885 | 0.0231737 |
| GO:2000300 | regulation of synaptic vesicle exocytosis | 70 | 2.488736 | 0.0329885 | 0.0231737 |
| GO:0007215 | glutamate receptor signaling pathway | 81 | 2.478794 | 0.0329885 | 0.0231737 |
| GO:0045333 | cellular respiration | 171 | 2.466633 | 0.0329885 | 0.0231737 |
| GO:0006119 | oxidative phosphorylation | 128 | 2.447293 | 0.0329885 | 0.0231737 |
| GO:0032412 | regulation of ion transmembrane transporter activity | 213 | 2.443186 | 0.0329885 | 0.0231737 |
| GO:0048168 | regulation of neuronal synaptic plasticity | 46 | 2.436418 | 0.0329885 | 0.0231737 |
| GO:0051588 | regulation of neurotransmitter transport | 124 | 2.428839 | 0.0329885 | 0.0231737 |
| GO:0006836 | neurotransmitter transport | 222 | 2.425062 | 0.0329885 | 0.0231737 |
| GO:0048167 | regulation of synaptic plasticity | 163 | 2.421073 | 0.0329885 | 0.0231737 |
| GO:0010257 | NADH dehydrogenase complex assembly | 64 | 2.415002 | 0.0329885 | 0.0231737 |
| GO:0032981 | mitochondrial respiratory chain complex I assembly | 64 | 2.415002 | 0.0329885 | 0.0231737 |
| GO:0022898 | regulation of transmembrane transporter activity | 220 | 2.403669 | 0.0329885 | 0.0231737 |
| GO:0032594 | protein transport within lipid bilayer | 20 | 2.403186 | 0.0329885 | 0.0231737 |
| GO:1903421 | regulation of synaptic vesicle recycling | 24 | 2.383206 | 0.0329885 | 0.0231737 |
| GO:0032409 | regulation of transporter activity | 231 | 2.362543 | 0.0329885 | 0.0231737 |
| GO:0098877 | neurotransmitter receptor transport to plasma membrane | 12 | 2.357005 | 0.0329885 | 0.0231737 |
| GO:0098969 | neurotransmitter receptor transport to postsynaptic membrane | 12 | 2.357005 | 0.0329885 | 0.0231737 |
| GO:0106027 | neuron projection organization | 83 | 2.356722 | 0.0329885 | 0.0231737 |
| GO:0099177 | regulation of trans-synaptic signaling | 375 | 2.356608 | 0.0329885 | 0.0231737 |
| GO:0050804 | modulation of chemical synaptic transmission | 374 | 2.355858 | 0.0329885 | 0.0231737 |
| GO:1903540 | establishment of protein localization to postsynaptic membrane | 13 | 2.354112 | 0.0329885 | 0.0231737 |
| GO:0060997 | dendritic spine morphogenesis | 55 | 2.344730 | 0.0329885 | 0.0231737 |
| GO:0061001 | regulation of dendritic spine morphogenesis | 42 | 2.339339 | 0.0329885 | 0.0231737 |
| GO:0048169 | regulation of long-term neuronal synaptic plasticity | 25 | 2.312561 | 0.0329885 | 0.0231737 |
| GO:0048488 | synaptic vesicle endocytosis | 37 | 2.306396 | 0.0329885 | 0.0231737 |
| GO:0140238 | presynaptic endocytosis | 37 | 2.306396 | 0.0329885 | 0.0231737 |
| GO:0061003 | positive regulation of dendritic spine morphogenesis | 20 | 2.302480 | 0.0329885 | 0.0231737 |
| GO:0051650 | establishment of vesicle localization | 245 | 2.300951 | 0.0329885 | 0.0231737 |
| GO:0051648 | vesicle localization | 261 | 2.295127 | 0.0329885 | 0.0231737 |
| GO:0099632 | protein transport within plasma membrane | 13 | 2.281090 | 0.0329885 | 0.0231737 |
| GO:0099637 | neurotransmitter receptor transport | 13 | 2.281090 | 0.0329885 | 0.0231737 |
| GO:0014047 | glutamate secretion | 41 | 2.253292 | 0.0329885 | 0.0231737 |
| GO:0097061 | dendritic spine organization | 75 | 2.231333 | 0.0329885 | 0.0231737 |
| GO:0015672 | monovalent inorganic cation transport | 407 | 2.231038 | 0.0329885 | 0.0231737 |
| GO:0034765 | regulation of ion transmembrane transport | 408 | 2.228250 | 0.0329885 | 0.0231737 |
| GO:1902600 | proton transmembrane transport | 128 | 2.224872 | 0.0329885 | 0.0231737 |
| GO:0060078 | regulation of postsynaptic membrane potential | 119 | 2.216082 | 0.0329885 | 0.0231737 |
| GO:1904062 | regulation of cation transmembrane transport | 283 | 2.205013 | 0.0329885 | 0.0231737 |
| GO:0022900 | electron transport chain | 162 | 2.198388 | 0.0329885 | 0.0231737 |
| GO:1903008 | organelle disassembly | 78 | 2.195911 | 0.0329885 | 0.0231737 |
| GO:0006101 | citrate metabolic process | 28 | 2.194922 | 0.0329885 | 0.0231737 |
| GO:0031146 | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process | 67 | 2.184075 | 0.0329885 | 0.0231737 |
| GO:2001259 | positive regulation of cation channel activity | 63 | 2.178469 | 0.0329885 | 0.0231737 |
| GO:0006813 | potassium ion transport | 169 | 2.177620 | 0.0329885 | 0.0231737 |
| GO:0000422 | autophagy of mitochondrion | 55 | 2.159412 | 0.0329885 | 0.0231737 |
| GO:0061726 | mitochondrion disassembly | 55 | 2.159412 | 0.0329885 | 0.0231737 |
| GO:0009060 | aerobic respiration | 66 | 2.158508 | 0.0329885 | 0.0231737 |
| GO:0071804 | cellular potassium ion transport | 121 | 2.155527 | 0.0329885 | 0.0231737 |
| GO:0071805 | potassium ion transmembrane transport | 121 | 2.155527 | 0.0329885 | 0.0231737 |
| GO:0023061 | signal release | 380 | 2.154357 | 0.0329885 | 0.0231737 |
| GO:0098814 | spontaneous synaptic transmission | 11 | 2.149657 | 0.0329885 | 0.0231737 |
| GO:0007612 | learning | 137 | 2.143456 | 0.0329885 | 0.0231737 |
| GO:0008306 | associative learning | 73 | 2.138620 | 0.0329885 | 0.0231737 |
| GO:0050808 | synapse organization | 378 | 2.136757 | 0.0329885 | 0.0231737 |
| GO:0072384 | organelle transport along microtubule | 71 | 2.132737 | 0.0329885 | 0.0231737 |
| GO:0016082 | synaptic vesicle priming | 12 | 2.132542 | 0.0329885 | 0.0231737 |
| GO:0001963 | synaptic transmission, dopaminergic | 24 | 2.131702 | 0.0329885 | 0.0231737 |
| GO:0033108 | mitochondrial respiratory chain complex assembly | 87 | 2.128374 | 0.0329885 | 0.0231737 |
| GO:0015980 | energy derivation by oxidation of organic compounds | 251 | 2.124345 | 0.0329885 | 0.0231737 |
| GO:1901524 | regulation of mitophagy | 17 | 2.117759 | 0.0329885 | 0.0231737 |
| GO:0007611 | learning or memory | 229 | 2.114837 | 0.0329885 | 0.0231737 |
| GO:0034762 | regulation of transmembrane transport | 475 | 2.113879 | 0.0329885 | 0.0231737 |
| GO:0006099 | tricarboxylic acid cycle | 26 | 2.113357 | 0.0329885 | 0.0231737 |
| GO:0031111 | negative regulation of microtubule polymerization or depolymerization | 32 | 2.105158 | 0.0329885 | 0.0231737 |
| GO:0035637 | multicellular organismal signaling | 176 | 2.104921 | 0.0329885 | 0.0231737 |
| GO:0033238 | regulation of cellular amine metabolic process | 74 | 2.103478 | 0.0329885 | 0.0231737 |
| GO:0017157 | regulation of exocytosis | 181 | 2.100406 | 0.0329885 | 0.0231737 |
| GO:0060996 | dendritic spine development | 93 | 2.098832 | 0.0329885 | 0.0231737 |
| GO:0050775 | positive regulation of dendrite morphogenesis | 35 | 2.095214 | 0.0329885 | 0.0231737 |
| GO:0099132 | ATP hydrolysis coupled cation transmembrane transport | 52 | 2.090769 | 0.0329885 | 0.0231737 |
| GO:0045653 | negative regulation of megakaryocyte differentiation | 17 | 2.088769 | 0.0329885 | 0.0231737 |
| GO:0097484 | dendrite extension | 32 | 2.088652 | 0.0329885 | 0.0231737 |
| GO:0046034 | ATP metabolic process | 274 | 2.085203 | 0.0329885 | 0.0231737 |
| GO:0009126 | purine nucleoside monophosphate metabolic process | 304 | 2.080307 | 0.0329885 | 0.0231737 |
| GO:0048172 | regulation of short-term neuronal synaptic plasticity | 12 | 2.079671 | 0.0329885 | 0.0231737 |
| GO:0038095 | Fc-epsilon receptor signaling pathway | 106 | 2.079635 | 0.0329885 | 0.0231737 |
| GO:0035418 | protein localization to synapse | 55 | 2.079553 | 0.0329885 | 0.0231737 |
| GO:0042391 | regulation of membrane potential | 338 | 2.079527 | 0.0329885 | 0.0231737 |
| GO:0007007 | inner mitochondrial membrane organization | 37 | 2.078651 | 0.0329885 | 0.0231737 |
| GO:0007005 | mitochondrion organization | 452 | 2.075925 | 0.0329885 | 0.0231737 |
| GO:0042407 | cristae formation | 30 | 2.075763 | 0.0329885 | 0.0231737 |
| GO:0009205 | purine ribonucleoside triphosphate metabolic process | 300 | 2.074523 | 0.0329885 | 0.0231737 |
| GO:0035641 | locomotory exploration behavior | 12 | 2.074474 | 0.0329885 | 0.0231737 |
| GO:0009167 | purine ribonucleoside monophosphate metabolic process | 303 | 2.073122 | 0.0329885 | 0.0231737 |
| GO:0050905 | neuromuscular process | 87 | 2.072795 | 0.0329885 | 0.0231737 |
| GO:1903305 | regulation of regulated secretory pathway | 134 | 2.070448 | 0.0329885 | 0.0231737 |
| GO:0009199 | ribonucleoside triphosphate metabolic process | 305 | 2.065402 | 0.0329885 | 0.0231737 |
| GO:0048813 | dendrite morphogenesis | 130 | 2.062597 | 0.0329885 | 0.0231737 |
| GO:0009161 | ribonucleoside monophosphate metabolic process | 316 | 2.062330 | 0.0329885 | 0.0231737 |
| GO:0060998 | regulation of dendritic spine development | 70 | 2.056195 | 0.0329885 | 0.0231737 |
| GO:0051952 | regulation of amine transport | 63 | 2.055964 | 0.0329885 | 0.0231737 |
| GO:0009144 | purine nucleoside triphosphate metabolic process | 307 | 2.054471 | 0.0329885 | 0.0231737 |
| GO:0007006 | mitochondrial membrane organization | 115 | 2.053742 | 0.0329885 | 0.0231737 |
| GO:1901021 | positive regulation of calcium ion transmembrane transporter activity | 37 | 2.053205 | 0.0329885 | 0.0231737 |
| GO:0032414 | positive regulation of ion transmembrane transporter activity | 94 | 2.050044 | 0.0329885 | 0.0231737 |
| GO:0035773 | insulin secretion involved in cellular response to glucose stimulus | 57 | 2.050026 | 0.0329885 | 0.0231737 |
| GO:1903539 | protein localization to postsynaptic membrane | 27 | 2.049038 | 0.0329885 | 0.0231737 |
| GO:0035640 | exploration behavior | 23 | 2.047852 | 0.0329885 | 0.0231737 |
| GO:0045956 | positive regulation of calcium ion-dependent exocytosis | 22 | 2.044626 | 0.0329885 | 0.0231737 |
| GO:0001505 | regulation of neurotransmitter levels | 289 | 2.044403 | 0.0329885 | 0.0231737 |
| GO:0048667 | cell morphogenesis involved in neuron differentiation | 469 | 2.041336 | 0.0329885 | 0.0231737 |
| GO:0060999 | positive regulation of dendritic spine development | 41 | 2.037936 | 0.0329885 | 0.0231737 |
| GO:0048814 | regulation of dendrite morphogenesis | 81 | 2.037870 | 0.0329885 | 0.0231737 |
| GO:0009123 | nucleoside monophosphate metabolic process | 332 | 2.034644 | 0.0329885 | 0.0231737 |
| GO:0010765 | positive regulation of sodium ion transport | 29 | 2.033345 | 0.0329885 | 0.0231737 |
| GO:0051965 | positive regulation of synapse assembly | 62 | 2.032590 | 0.0329885 | 0.0231737 |
| GO:1903146 | regulation of autophagy of mitochondrion | 41 | 2.032109 | 0.0329885 | 0.0231737 |
| GO:0000266 | mitochondrial fission | 30 | 2.029498 | 0.0329885 | 0.0231737 |
| GO:1903533 | regulation of protein targeting | 79 | 2.026574 | 0.0329885 | 0.0231737 |
| GO:0015837 | amine transport | 66 | 2.025659 | 0.0329885 | 0.0231737 |
| GO:0051705 | multi-organism behavior | 60 | 2.022718 | 0.0329885 | 0.0231737 |
| GO:1903859 | regulation of dendrite extension | 23 | 2.019414 | 0.0329885 | 0.0231737 |
| GO:0009141 | nucleoside triphosphate metabolic process | 323 | 2.017744 | 0.0329885 | 0.0231737 |
| GO:0015800 | acidic amino acid transport | 60 | 2.017187 | 0.0329885 | 0.0231737 |
| GO:1990138 | neuron projection extension | 141 | 2.016415 | 0.0329885 | 0.0231737 |
| GO:1903779 | regulation of cardiac conduction | 65 | 2.015895 | 0.0329885 | 0.0231737 |
| GO:0000423 | mitophagy | 21 | 2.011547 | 0.0329885 | 0.0231737 |
| GO:0061337 | cardiac conduction | 135 | 2.011043 | 0.0329885 | 0.0231737 |
| GO:0050803 | regulation of synapse structure or activity | 211 | 2.008698 | 0.0329885 | 0.0231737 |
| GO:0051932 | synaptic transmission, GABAergic | 36 | 2.008470 | 0.0329885 | 0.0231737 |
| GO:0010976 | positive regulation of neuron projection development | 249 | 2.007464 | 0.0329885 | 0.0231737 |
| GO:0050806 | positive regulation of synaptic transmission | 138 | 2.005569 | 0.0329885 | 0.0231737 |
| GO:0097120 | receptor localization to synapse | 35 | 2.003388 | 0.0329885 | 0.0231737 |
| GO:0070050 | neuron cellular homeostasis | 30 | 2.001539 | 0.0329885 | 0.0231737 |
| GO:0050432 | catecholamine secretion | 36 | 1.999757 | 0.0329885 | 0.0231737 |
| GO:0006626 | protein targeting to mitochondrion | 84 | 1.995634 | 0.0329885 | 0.0231737 |
| GO:0051646 | mitochondrion localization | 41 | 1.995059 | 0.0329885 | 0.0231737 |
| GO:0042551 | neuron maturation | 42 | 1.995024 | 0.0329885 | 0.0231737 |
| GO:0099072 | regulation of postsynaptic membrane neurotransmitter receptor levels | 47 | 1.994632 | 0.0329885 | 0.0231737 |
| GO:0007626 | locomotory behavior | 171 | 1.990999 | 0.0329885 | 0.0231737 |
| GO:0070585 | protein localization to mitochondrion | 123 | 1.990260 | 0.0329885 | 0.0231737 |
| GO:0035249 | synaptic transmission, glutamatergic | 60 | 1.989865 | 0.0329885 | 0.0231737 |
| GO:0007409 | axonogenesis | 364 | 1.989650 | 0.0329885 | 0.0231737 |
| GO:0051937 | catecholamine transport | 48 | 1.989540 | 0.0329885 | 0.0231737 |
| GO:0072350 | tricarboxylic acid metabolic process | 31 | 1.987657 | 0.0329885 | 0.0231737 |
| GO:0072583 | clathrin-dependent endocytosis | 37 | 1.983597 | 0.0329885 | 0.0231737 |
| GO:0050770 | regulation of axonogenesis | 143 | 1.983039 | 0.0329885 | 0.0231737 |
| GO:0034643 | establishment of mitochondrion localization, microtubule-mediated | 18 | 1.982571 | 0.0329885 | 0.0231737 |
| GO:0047497 | mitochondrion transport along microtubule | 18 | 1.982571 | 0.0329885 | 0.0231737 |
| GO:0043950 | positive regulation of cAMP-mediated signaling | 19 | 1.982362 | 0.0329885 | 0.0231737 |
| GO:0051963 | regulation of synapse assembly | 99 | 1.982270 | 0.0329885 | 0.0231737 |
| GO:0051656 | establishment of organelle localization | 426 | 1.981614 | 0.0329885 | 0.0231737 |
| GO:0032411 | positive regulation of transporter activity | 102 | 1.980314 | 0.0329885 | 0.0231737 |
| GO:0007213 | G protein-coupled acetylcholine receptor signaling pathway | 17 | 1.977501 | 0.0329885 | 0.0231737 |
| GO:0010970 | transport along microtubule | 141 | 1.976551 | 0.0329885 | 0.0231737 |
| GO:0099111 | microtubule-based transport | 141 | 1.976551 | 0.0329885 | 0.0231737 |
| GO:0072655 | establishment of protein localization to mitochondrion | 120 | 1.975209 | 0.0329885 | 0.0231737 |
| GO:0007416 | synapse assembly | 163 | 1.974775 | 0.0329885 | 0.0231737 |
| GO:0030705 | cytoskeleton-dependent intracellular transport | 152 | 1.969909 | 0.0329885 | 0.0231737 |
| GO:0050890 | cognition | 261 | 1.967167 | 0.0329885 | 0.0231737 |
| GO:0016241 | regulation of macroautophagy | 161 | 1.964031 | 0.0329885 | 0.0231737 |
| GO:1900242 | regulation of synaptic vesicle endocytosis | 16 | 1.963537 | 0.0329885 | 0.0231737 |
| GO:0051654 | establishment of mitochondrion localization | 21 | 1.960714 | 0.0329885 | 0.0231737 |
| GO:0006123 | mitochondrial electron transport, cytochrome c to oxygen | 17 | 1.959332 | 0.0329885 | 0.0231737 |
| GO:0019646 | aerobic electron transport chain | 17 | 1.959332 | 0.0329885 | 0.0231737 |
| GO:0061564 | axon development | 403 | 1.956203 | 0.0329885 | 0.0231737 |
| GO:0032402 | melanosome transport | 19 | 1.955188 | 0.0372897 | 0.0261952 |
| GO:0045161 | neuronal ion channel clustering | 11 | 1.953780 | 0.0329885 | 0.0231737 |
| GO:0050433 | regulation of catecholamine secretion | 34 | 1.952564 | 0.0361638 | 0.0254042 |
| GO:0050807 | regulation of synapse organization | 207 | 1.951989 | 0.0329885 | 0.0231737 |
| GO:0010822 | positive regulation of mitochondrion organization | 113 | 1.951196 | 0.0329885 | 0.0231737 |
| GO:2000649 | regulation of sodium ion transmembrane transporter activity | 38 | 1.951137 | 0.0329885 | 0.0231737 |
| GO:0035725 | sodium ion transmembrane transport | 92 | 1.942098 | 0.0329885 | 0.0231737 |
| GO:0010975 | regulation of neuron projection development | 433 | 1.936125 | 0.0329885 | 0.0231737 |
| GO:0009150 | purine ribonucleotide metabolic process | 471 | 1.935344 | 0.0329885 | 0.0231737 |
| GO:0048308 | organelle inheritance | 13 | 1.932428 | 0.0329885 | 0.0231737 |
| GO:0048313 | Golgi inheritance | 13 | 1.932428 | 0.0329885 | 0.0231737 |
| GO:0009259 | ribonucleotide metabolic process | 485 | 1.929754 | 0.0329885 | 0.0231737 |
| GO:0006734 | NADH metabolic process | 34 | 1.926405 | 0.0361638 | 0.0254042 |
| GO:0019226 | transmission of nerve impulse | 46 | 1.925135 | 0.0361638 | 0.0254042 |
| GO:0006122 | mitochondrial electron transport, ubiquinol to cytochrome c | 12 | 1.924772 | 0.0329885 | 0.0231737 |
| GO:0018210 | peptidyl-threonine modification | 103 | 1.923904 | 0.0329885 | 0.0231737 |
| GO:0061178 | regulation of insulin secretion involved in cellular response to glucose stimulus | 50 | 1.922104 | 0.0361638 | 0.0254042 |
| GO:0000338 | protein deneddylation | 10 | 1.920473 | 0.0332231 | 0.0233385 |
| GO:0032225 | regulation of synaptic transmission, dopaminergic | 15 | 1.919432 | 0.0372328 | 0.0261552 |
| GO:0015991 | ATP hydrolysis coupled proton transport | 24 | 1.917065 | 0.0365558 | 0.0256796 |
| GO:0060079 | excitatory postsynaptic potential | 88 | 1.916596 | 0.0329885 | 0.0231737 |
| GO:0033173 | calcineurin-NFAT signaling cascade | 35 | 1.915508 | 0.0361638 | 0.0254042 |
| GO:0097720 | calcineurin-mediated signaling | 35 | 1.915508 | 0.0361638 | 0.0254042 |
| GO:0006091 | generation of precursor metabolites and energy | 464 | 1.915246 | 0.0329885 | 0.0231737 |
| GO:0015985 | energy coupled proton transport, down electrochemical gradient | 22 | 1.915053 | 0.0370308 | 0.0260133 |
| GO:0015986 | ATP synthesis coupled proton transport | 22 | 1.915053 | 0.0370308 | 0.0260133 |
| GO:0099173 | postsynapse organization | 154 | 1.915023 | 0.0329885 | 0.0231737 |
| GO:0099188 | postsynaptic cytoskeleton organization | 10 | 1.913675 | 0.0332231 | 0.0233385 |
| GO:0042537 | benzene-containing compound metabolic process | 18 | 1.913102 | 0.0329885 | 0.0231737 |
| GO:0010644 | cell communication by electrical coupling | 29 | 1.912673 | 0.0329885 | 0.0231737 |
| GO:0006883 | cellular sodium ion homeostasis | 12 | 1.912650 | 0.0329885 | 0.0231737 |
| GO:0045666 | positive regulation of neuron differentiation | 321 | 1.911493 | 0.0329885 | 0.0231737 |
| GO:0090140 | regulation of mitochondrial fission | 23 | 1.910528 | 0.0418253 | 0.0293813 |
| GO:0015988 | energy coupled proton transmembrane transport, against electrochemical gradient | 25 | 1.910508 | 0.0364581 | 0.0256110 |
| GO:0051954 | positive regulation of amine transport | 30 | 1.910092 | 0.0364581 | 0.0256110 |
| GO:0099131 | ATP hydrolysis coupled ion transmembrane transport | 26 | 1.908546 | 0.0329885 | 0.0231737 |
| GO:0007026 | negative regulation of microtubule depolymerization | 21 | 1.902486 | 0.0418288 | 0.0293838 |
| GO:0035235 | ionotropic glutamate receptor signaling pathway | 23 | 1.902453 | 0.0418253 | 0.0293813 |
| GO:0006163 | purine nucleotide metabolic process | 493 | 1.901963 | 0.0329885 | 0.0231737 |
| GO:0006839 | mitochondrial transport | 215 | 1.901035 | 0.0329885 | 0.0231737 |
| GO:0071322 | cellular response to carbohydrate stimulus | 122 | 1.900792 | 0.0329885 | 0.0231737 |
| GO:0007632 | visual behavior | 47 | 1.899945 | 0.0361638 | 0.0254042 |
| GO:0043266 | regulation of potassium ion transport | 83 | 1.898484 | 0.0329885 | 0.0231737 |
| GO:0006007 | glucose catabolic process | 33 | 1.893309 | 0.0361638 | 0.0254042 |
| GO:0032400 | melanosome localization | 23 | 1.891257 | 0.0418253 | 0.0293813 |
| GO:0018107 | peptidyl-threonine phosphorylation | 95 | 1.891067 | 0.0329885 | 0.0231737 |
| GO:0051904 | pigment granule transport | 20 | 1.889613 | 0.0371078 | 0.0260674 |
| GO:0001508 | action potential | 108 | 1.883125 | 0.0329885 | 0.0231737 |
| GO:0099565 | chemical synaptic transmission, postsynaptic | 96 | 1.882913 | 0.0329885 | 0.0231737 |
| GO:0098930 | axonal transport | 50 | 1.882348 | 0.0361638 | 0.0254042 |
| GO:0099518 | vesicle cytoskeletal trafficking | 43 | 1.882010 | 0.0329885 | 0.0231737 |
| GO:0032401 | establishment of melanosome localization | 20 | 1.880900 | 0.0371078 | 0.0260674 |
| GO:1903861 | positive regulation of dendrite extension | 21 | 1.879665 | 0.0418288 | 0.0293838 |
| GO:0047496 | vesicle transport along microtubule | 38 | 1.879176 | 0.0361638 | 0.0254042 |
| GO:0008542 | visual learning | 43 | 1.878617 | 0.0329885 | 0.0231737 |
| GO:0007018 | microtubule-based movement | 215 | 1.877469 | 0.0329885 | 0.0231737 |
| GO:0048588 | developmental cell growth | 194 | 1.877176 | 0.0329885 | 0.0231737 |
| GO:0035306 | positive regulation of dephosphorylation | 51 | 1.875293 | 0.0361638 | 0.0254042 |
| GO:0034315 | regulation of Arp2/3 complex-mediated actin nucleation | 14 | 1.874695 | 0.0422693 | 0.0296932 |
| GO:0086010 | membrane depolarization during action potential | 24 | 1.873622 | 0.0365558 | 0.0256796 |
| GO:0016358 | dendrite development | 212 | 1.872788 | 0.0329885 | 0.0231737 |
| GO:0032252 | secretory granule localization | 12 | 1.870949 | 0.0372897 | 0.0261952 |
| GO:0045773 | positive regulation of axon extension | 40 | 1.865765 | 0.0364733 | 0.0256217 |
| GO:0045760 | positive regulation of action potential | 10 | 1.862002 | 0.0332231 | 0.0233385 |
| GO:0043524 | negative regulation of neuron apoptotic process | 129 | 1.861224 | 0.0329885 | 0.0231737 |
| GO:0031338 | regulation of vesicle fusion | 24 | 1.858766 | 0.0365558 | 0.0256796 |
| GO:1901016 | regulation of potassium ion transmembrane transporter activity | 48 | 1.856563 | 0.0361638 | 0.0254042 |
| GO:0051966 | regulation of synaptic transmission, glutamatergic | 48 | 1.856446 | 0.0361638 | 0.0254042 |
| GO:1901379 | regulation of potassium ion transmembrane transport | 70 | 1.854265 | 0.0329885 | 0.0231737 |
| GO:0021955 | central nervous system neuron axonogenesis | 33 | 1.853617 | 0.0361638 | 0.0254042 |
| GO:0042776 | mitochondrial ATP synthesis coupled proton transport | 21 | 1.853299 | 0.0493475 | 0.0346655 |
| GO:0005513 | detection of calcium ion | 11 | 1.851566 | 0.0329885 | 0.0231737 |
| GO:0015872 | dopamine transport | 29 | 1.851506 | 0.0414464 | 0.0291152 |
| GO:0031115 | negative regulation of microtubule polymerization | 12 | 1.850001 | 0.0372897 | 0.0261952 |
| GO:1902305 | regulation of sodium ion transmembrane transport | 47 | 1.848530 | 0.0361638 | 0.0254042 |
| GO:0051875 | pigment granule localization | 24 | 1.848487 | 0.0365558 | 0.0256796 |
| GO:0051905 | establishment of pigment granule localization | 21 | 1.846098 | 0.0493475 | 0.0346655 |
| GO:0014046 | dopamine secretion | 19 | 1.844211 | 0.0372897 | 0.0261952 |
| GO:0014059 | regulation of dopamine secretion | 19 | 1.844211 | 0.0372897 | 0.0261952 |
| GO:0006335 | DNA replication-dependent nucleosome assembly | 32 | 1.843980 | 0.0412551 | 0.0289807 |
| GO:0034723 | DNA replication-dependent nucleosome organization | 32 | 1.843980 | 0.0412551 | 0.0289807 |
| GO:0090662 | ATP hydrolysis coupled transmembrane transport | 27 | 1.842097 | 0.0414183 | 0.0290954 |
| GO:0014075 | response to amine | 43 | 1.840971 | 0.0361638 | 0.0254042 |
| GO:0050884 | neuromuscular process controlling posture | 12 | 1.840520 | 0.0372897 | 0.0261952 |
| GO:0043039 | tRNA aminoacylation | 45 | 1.840516 | 0.0361638 | 0.0254042 |
| GO:0046785 | microtubule polymerization | 65 | 1.838624 | 0.0329885 | 0.0231737 |
| GO:2000311 | regulation of AMPA receptor activity | 18 | 1.838282 | 0.0373115 | 0.0262105 |
| GO:0099500 | vesicle fusion to plasma membrane | 10 | 1.837430 | 0.0332231 | 0.0233385 |
| GO:0043038 | amino acid activation | 46 | 1.835369 | 0.0361638 | 0.0254042 |
| GO:0008344 | adult locomotory behavior | 66 | 1.832419 | 0.0329885 | 0.0231737 |
| GO:0031110 | regulation of microtubule polymerization or depolymerization | 68 | 1.832100 | 0.0329885 | 0.0231737 |
| GO:0099560 | synaptic membrane adhesion | 25 | 1.831498 | 0.0364581 | 0.0256110 |
| GO:0071333 | cellular response to glucose stimulus | 112 | 1.830380 | 0.0329885 | 0.0231737 |
| GO:0016236 | macroautophagy | 267 | 1.830115 | 0.0329885 | 0.0231737 |
| GO:0007631 | feeding behavior | 70 | 1.829381 | 0.0329885 | 0.0231737 |
| GO:0030516 | regulation of axon extension | 73 | 1.829230 | 0.0329885 | 0.0231737 |
| GO:0006521 | regulation of cellular amino acid metabolic process | 56 | 1.828062 | 0.0329885 | 0.0231737 |
| GO:1903818 | positive regulation of voltage-gated potassium channel activity | 13 | 1.827941 | 0.0424425 | 0.0298149 |
| GO:0031346 | positive regulation of cell projection organization | 334 | 1.826776 | 0.0329885 | 0.0231737 |
| GO:0071326 | cellular response to monosaccharide stimulus | 114 | 1.826581 | 0.0329885 | 0.0231737 |
| GO:0071331 | cellular response to hexose stimulus | 114 | 1.826581 | 0.0329885 | 0.0231737 |
| GO:0086064 | cell communication by electrical coupling involved in cardiac conduction | 24 | 1.826574 | 0.0365558 | 0.0256796 |
| GO:1902259 | regulation of delayed rectifier potassium channel activity | 15 | 1.826100 | 0.0495117 | 0.0347808 |
| GO:0001967 | suckling behavior | 10 | 1.825988 | 0.0332231 | 0.0233385 |
| GO:0008038 | neuron recognition | 36 | 1.824314 | 0.0361638 | 0.0254042 |
| GO:0030534 | adult behavior | 120 | 1.823954 | 0.0329885 | 0.0231737 |
| GO:0035864 | response to potassium ion | 12 | 1.823571 | 0.0372897 | 0.0261952 |
| GO:0031114 | regulation of microtubule depolymerization | 23 | 1.823571 | 0.0418253 | 0.0293813 |
| GO:0021954 | central nervous system neuron development | 73 | 1.822958 | 0.0329885 | 0.0231737 |
| GO:0008088 | axo-dendritic transport | 60 | 1.822731 | 0.0399769 | 0.0280829 |
| GO:0035307 | positive regulation of protein dephosphorylation | 39 | 1.820643 | 0.0364581 | 0.0256110 |
| GO:0006814 | sodium ion transport | 160 | 1.820127 | 0.0329885 | 0.0231737 |
| GO:0006103 | 2-oxoglutarate metabolic process | 14 | 1.819521 | 0.0497435 | 0.0349437 |
| GO:0043267 | negative regulation of potassium ion transport | 26 | 1.818268 | 0.0413027 | 0.0290142 |
| GO:0031145 | anaphase-promoting complex-dependent catabolic process | 76 | 1.817985 | 0.0329885 | 0.0231737 |
| GO:0006865 | amino acid transport | 122 | 1.817086 | 0.0329885 | 0.0231737 |
| GO:0046717 | acid secretion | 91 | 1.817077 | 0.0329885 | 0.0231737 |
| GO:0060627 | regulation of vesicle-mediated transport | 443 | 1.816982 | 0.0329885 | 0.0231737 |
| GO:0010972 | negative regulation of G2/M transition of mitotic cell cycle | 78 | 1.816556 | 0.0329885 | 0.0231737 |
| GO:1903747 | regulation of establishment of protein localization to mitochondrion | 70 | 1.815295 | 0.0329885 | 0.0231737 |
| GO:0044106 | cellular amine metabolic process | 111 | 1.814096 | 0.0329885 | 0.0231737 |
| GO:0099175 | regulation of postsynapse organization | 95 | 1.813649 | 0.0329885 | 0.0231737 |
| GO:1903214 | regulation of protein targeting to mitochondrion | 44 | 1.812415 | 0.0361638 | 0.0254042 |
| GO:0061615 | glycolytic process through fructose-6-phosphate | 27 | 1.810486 | 0.0470662 | 0.0330630 |
| GO:0061620 | glycolytic process through glucose-6-phosphate | 27 | 1.810486 | 0.0470662 | 0.0330630 |
| GO:0016242 | negative regulation of macroautophagy | 32 | 1.809182 | 0.0412551 | 0.0289807 |
| GO:0006735 | NADH regeneration | 26 | 1.808499 | 0.0413027 | 0.0290142 |
| GO:0061621 | canonical glycolysis | 26 | 1.808499 | 0.0413027 | 0.0290142 |
| GO:0061718 | glucose catabolic process to pyruvate | 26 | 1.808499 | 0.0413027 | 0.0290142 |
| GO:0006089 | lactate metabolic process | 11 | 1.808210 | 0.0424097 | 0.0297918 |
| GO:0030073 | insulin secretion | 173 | 1.807628 | 0.0329885 | 0.0231737 |
| GO:0007020 | microtubule nucleation | 20 | 1.806025 | 0.0371078 | 0.0260674 |
| GO:1904064 | positive regulation of cation transmembrane transport | 126 | 1.803541 | 0.0329885 | 0.0231737 |
| GO:0006851 | mitochondrial calcium ion transmembrane transport | 25 | 1.799711 | 0.0414464 | 0.0291152 |
| GO:0045921 | positive regulation of exocytosis | 77 | 1.797803 | 0.0329885 | 0.0231737 |
| GO:0014850 | response to muscle activity | 22 | 1.795749 | 0.0418253 | 0.0293813 |
| GO:0015682 | ferric iron transport | 34 | 1.794657 | 0.0361638 | 0.0254042 |
| GO:0033572 | transferrin transport | 34 | 1.794657 | 0.0361638 | 0.0254042 |
| GO:0072512 | trivalent inorganic cation transport | 34 | 1.794657 | 0.0361638 | 0.0254042 |
| GO:1901019 | regulation of calcium ion transmembrane transporter activity | 80 | 1.793652 | 0.0329885 | 0.0231737 |
| GO:0010882 | regulation of cardiac muscle contraction by calcium ion signaling | 23 | 1.791149 | 0.0418253 | 0.0293813 |
| GO:0031109 | microtubule polymerization or depolymerization | 92 | 1.789393 | 0.0329885 | 0.0231737 |
| GO:0008637 | apoptotic mitochondrial changes | 110 | 1.788843 | 0.0329885 | 0.0231737 |
| GO:0030072 | peptide hormone secretion | 204 | 1.788405 | 0.0329885 | 0.0231737 |
| GO:0007019 | microtubule depolymerization | 33 | 1.785194 | 0.0361638 | 0.0254042 |
| GO:0010769 | regulation of cell morphogenesis involved in differentiation | 250 | 1.784852 | 0.0329885 | 0.0231737 |
| GO:0007613 | memory | 105 | 1.784290 | 0.0329885 | 0.0231737 |
| GO:0071871 | response to epinephrine | 15 | 1.784180 | 0.0495117 | 0.0347808 |
| GO:1903307 | positive regulation of regulated secretory pathway | 47 | 1.783901 | 0.0361638 | 0.0254042 |
| GO:0060359 | response to ammonium ion | 115 | 1.783650 | 0.0329885 | 0.0231737 |
| GO:0002028 | regulation of sodium ion transport | 67 | 1.779401 | 0.0329885 | 0.0231737 |
| GO:0015844 | monoamine transport | 59 | 1.779024 | 0.0399769 | 0.0280829 |
| GO:0008016 | regulation of heart contraction | 215 | 1.777692 | 0.0329885 | 0.0231737 |
| GO:0006835 | dicarboxylic acid transport | 85 | 1.776517 | 0.0329885 | 0.0231737 |
| GO:0048675 | axon extension | 97 | 1.773955 | 0.0329885 | 0.0231737 |
| GO:1901526 | positive regulation of mitophagy | 10 | 1.772817 | 0.0377405 | 0.0265118 |
| GO:0071242 | cellular response to ammonium ion | 59 | 1.771362 | 0.0399769 | 0.0280829 |
| GO:0009583 | detection of light stimulus | 54 | 1.770242 | 0.0452588 | 0.0317933 |
| GO:1904427 | positive regulation of calcium ion transmembrane transport | 62 | 1.770031 | 0.0399769 | 0.0280829 |
| GO:1901215 | negative regulation of neuron death | 181 | 1.768385 | 0.0329885 | 0.0231737 |
| GO:0006418 | tRNA aminoacylation for protein translation | 42 | 1.767853 | 0.0361638 | 0.0254042 |
| GO:0007413 | axonal fasciculation | 23 | 1.767492 | 0.0418253 | 0.0293813 |
| GO:0106030 | neuron projection fasciculation | 23 | 1.767492 | 0.0418253 | 0.0293813 |
| GO:0090313 | regulation of protein targeting to membrane | 34 | 1.766085 | 0.0361638 | 0.0254042 |
| GO:0007616 | long-term memory | 32 | 1.764279 | 0.0412551 | 0.0289807 |
| GO:0038093 | Fc receptor signaling pathway | 169 | 1.762124 | 0.0329885 | 0.0231737 |
| GO:0021544 | subpallium development | 25 | 1.760856 | 0.0414464 | 0.0291152 |
| GO:0098876 | vesicle-mediated transport to the plasma membrane | 67 | 1.760633 | 0.0361638 | 0.0254042 |
| GO:0140029 | exocytic process | 61 | 1.758505 | 0.0399769 | 0.0280829 |
| GO:0034767 | positive regulation of ion transmembrane transport | 137 | 1.757556 | 0.0329885 | 0.0231737 |
| GO:0061050 | regulation of cell growth involved in cardiac muscle cell development | 17 | 1.756141 | 0.0496223 | 0.0348585 |
| GO:0010821 | regulation of mitochondrion organization | 170 | 1.755546 | 0.0329885 | 0.0231737 |
| GO:0070588 | calcium ion transmembrane transport | 265 | 1.755267 | 0.0329885 | 0.0231737 |
| GO:0042053 | regulation of dopamine metabolic process | 19 | 1.752472 | 0.0496223 | 0.0348585 |
| GO:0042069 | regulation of catecholamine metabolic process | 19 | 1.752472 | 0.0496223 | 0.0348585 |
| GO:0002223 | stimulatory C-type lectin receptor signaling pathway | 93 | 1.750958 | 0.0329885 | 0.0231737 |
| GO:0019886 | antigen processing and presentation of exogenous peptide antigen via MHC class II | 90 | 1.749373 | 0.0329885 | 0.0231737 |
| GO:0001678 | cellular glucose homeostasis | 122 | 1.746522 | 0.0329885 | 0.0231737 |
| GO:0007212 | dopamine receptor signaling pathway | 32 | 1.744495 | 0.0412551 | 0.0289807 |
| GO:0009582 | detection of abiotic stimulus | 103 | 1.742630 | 0.0329885 | 0.0231737 |
| GO:0050773 | regulation of dendrite development | 137 | 1.740372 | 0.0329885 | 0.0231737 |
| GO:1900006 | positive regulation of dendrite development | 68 | 1.738244 | 0.0398385 | 0.0279856 |
| GO:0060047 | heart contraction | 239 | 1.729889 | 0.0329885 | 0.0231737 |
| GO:0050805 | negative regulation of synaptic transmission | 65 | 1.727945 | 0.0361638 | 0.0254042 |
| GO:1902750 | negative regulation of cell cycle G2/M phase transition | 89 | 1.726677 | 0.0329885 | 0.0231737 |
| GO:0050772 | positive regulation of axonogenesis | 68 | 1.726340 | 0.0398385 | 0.0279856 |
| GO:0086065 | cell communication involved in cardiac conduction | 53 | 1.721109 | 0.0451615 | 0.0317249 |
| GO:0010922 | positive regulation of phosphatase activity | 29 | 1.720764 | 0.0472546 | 0.0331953 |
| GO:0008089 | anterograde axonal transport | 42 | 1.719498 | 0.0468024 | 0.0328776 |
| GO:0009308 | amine metabolic process | 118 | 1.718747 | 0.0329885 | 0.0231737 |
| GO:1902108 | regulation of mitochondrial membrane permeability involved in apoptotic process | 57 | 1.716750 | 0.0400578 | 0.0281397 |
| GO:0051258 | protein polymerization | 212 | 1.716319 | 0.0329885 | 0.0231737 |
| GO:0002220 | innate immune response activating cell surface receptor signaling pathway | 95 | 1.714947 | 0.0329885 | 0.0231737 |
| GO:0043624 | cellular protein complex disassembly | 189 | 1.712157 | 0.0329885 | 0.0231737 |
| GO:0061387 | regulation of extent of cell growth | 87 | 1.707442 | 0.0329885 | 0.0231737 |
| GO:0032386 | regulation of intracellular transport | 384 | 1.702326 | 0.0329885 | 0.0231737 |
| GO:0021756 | striatum development | 19 | 1.700471 | 0.0496223 | 0.0348585 |
| GO:0097485 | neuron projection guidance | 190 | 1.697753 | 0.0329885 | 0.0231737 |
| GO:0050796 | regulation of insulin secretion | 147 | 1.695784 | 0.0329885 | 0.0231737 |
| GO:0050850 | positive regulation of calcium-mediated signaling | 37 | 1.694157 | 0.0468024 | 0.0328776 |
| GO:0000209 | protein polyubiquitination | 279 | 1.692666 | 0.0329885 | 0.0231737 |
| GO:0010389 | regulation of G2/M transition of mitotic cell cycle | 175 | 1.691840 | 0.0329885 | 0.0231737 |
| GO:0043270 | positive regulation of ion transport | 237 | 1.691439 | 0.0329885 | 0.0231737 |
| GO:0001504 | neurotransmitter uptake | 35 | 1.688373 | 0.0468177 | 0.0328884 |
| GO:0048639 | positive regulation of developmental growth | 148 | 1.686601 | 0.0329885 | 0.0231737 |
| GO:0098815 | modulation of excitatory postsynaptic potential | 40 | 1.686033 | 0.0414641 | 0.0291276 |
| GO:0007411 | axon guidance | 188 | 1.684894 | 0.0329885 | 0.0231737 |
| GO:0009156 | ribonucleoside monophosphate biosynthetic process | 178 | 1.684870 | 0.0329885 | 0.0231737 |
| GO:0048016 | inositol phosphate-mediated signaling | 44 | 1.683970 | 0.0411452 | 0.0289035 |
| GO:0000086 | G2/M transition of mitotic cell cycle | 227 | 1.679335 | 0.0329885 | 0.0231737 |
| GO:0009581 | detection of external stimulus | 100 | 1.676362 | 0.0329885 | 0.0231737 |
| GO:0090276 | regulation of peptide hormone secretion | 167 | 1.673736 | 0.0329885 | 0.0231737 |
| GO:1903169 | regulation of calcium ion transmembrane transport | 131 | 1.672211 | 0.0329885 | 0.0231737 |
| GO:0002495 | antigen processing and presentation of peptide antigen via MHC class II | 93 | 1.671856 | 0.0329885 | 0.0231737 |
| GO:0009152 | purine ribonucleotide biosynthetic process | 253 | 1.670815 | 0.0329885 | 0.0231737 |
| GO:0046390 | ribose phosphate biosynthetic process | 270 | 1.670552 | 0.0329885 | 0.0231737 |
| GO:0043523 | regulation of neuron apoptotic process | 185 | 1.670277 | 0.0329885 | 0.0231737 |
| GO:0032410 | negative regulation of transporter activity | 64 | 1.667364 | 0.0399769 | 0.0280829 |
| GO:0051962 | positive regulation of nervous system development | 472 | 1.664464 | 0.0329885 | 0.0231737 |
| GO:0019722 | calcium-mediated signaling | 163 | 1.663989 | 0.0329885 | 0.0231737 |
| GO:0010959 | regulation of metal ion transport | 321 | 1.662330 | 0.0329885 | 0.0231737 |
| GO:1905037 | autophagosome organization | 72 | 1.662293 | 0.0398370 | 0.0279846 |
| GO:0006164 | purine nucleotide biosynthetic process | 263 | 1.662232 | 0.0329885 | 0.0231737 |
| GO:0019884 | antigen processing and presentation of exogenous antigen | 164 | 1.659401 | 0.0329885 | 0.0231737 |
| GO:0009127 | purine nucleoside monophosphate biosynthetic process | 165 | 1.658463 | 0.0329885 | 0.0231737 |
| GO:0009168 | purine ribonucleoside monophosphate biosynthetic process | 165 | 1.658463 | 0.0329885 | 0.0231737 |
| GO:0086001 | cardiac muscle cell action potential | 65 | 1.657872 | 0.0399769 | 0.0280829 |
| GO:0009124 | nucleoside monophosphate biosynthetic process | 185 | 1.657065 | 0.0329885 | 0.0231737 |
| GO:0051402 | neuron apoptotic process | 211 | 1.651694 | 0.0329885 | 0.0231737 |
| GO:0002478 | antigen processing and presentation of exogenous peptide antigen | 162 | 1.650379 | 0.0329885 | 0.0231737 |
| GO:1903522 | regulation of blood circulation | 251 | 1.650151 | 0.0329885 | 0.0231737 |
| GO:1990778 | protein localization to cell periphery | 260 | 1.649874 | 0.0329885 | 0.0231737 |
| GO:0035304 | regulation of protein dephosphorylation | 125 | 1.649792 | 0.0329885 | 0.0231737 |
| GO:0003015 | heart process | 248 | 1.649419 | 0.0329885 | 0.0231737 |
| GO:1904063 | negative regulation of cation transmembrane transport | 70 | 1.646627 | 0.0398385 | 0.0279856 |
| GO:0097553 | calcium ion transmembrane import into cytosol | 111 | 1.646449 | 0.0329885 | 0.0231737 |
| GO:0051279 | regulation of release of sequestered calcium ion into cytosol | 68 | 1.643922 | 0.0398385 | 0.0279856 |
| GO:0009260 | ribonucleotide biosynthetic process | 266 | 1.643206 | 0.0329885 | 0.0231737 |
| GO:0035303 | regulation of dephosphorylation | 189 | 1.642118 | 0.0329885 | 0.0231737 |
| GO:0043648 | dicarboxylic acid metabolic process | 81 | 1.640228 | 0.0361638 | 0.0254042 |
| GO:0009584 | detection of visible light | 44 | 1.636438 | 0.0463643 | 0.0325699 |
| GO:0009206 | purine ribonucleoside triphosphate biosynthetic process | 150 | 1.636214 | 0.0329885 | 0.0231737 |
| GO:0006754 | ATP biosynthetic process | 142 | 1.635834 | 0.0329885 | 0.0231737 |
| GO:0000045 | autophagosome assembly | 69 | 1.635262 | 0.0398385 | 0.0279856 |
| GO:0032886 | regulation of microtubule-based process | 195 | 1.634997 | 0.0329885 | 0.0231737 |
| GO:0072347 | response to anesthetic | 67 | 1.633743 | 0.0399769 | 0.0280829 |
| GO:0002504 | antigen processing and presentation of peptide or polysaccharide antigen via MHC class II | 94 | 1.630325 | 0.0329885 | 0.0231737 |
| GO:0072522 | purine-containing compound biosynthetic process | 273 | 1.627893 | 0.0329885 | 0.0231737 |
| GO:0048013 | ephrin receptor signaling pathway | 86 | 1.626647 | 0.0359985 | 0.0252881 |
| GO:0034764 | positive regulation of transmembrane transport | 173 | 1.625043 | 0.0329885 | 0.0231737 |
| GO:0018105 | peptidyl-serine phosphorylation | 213 | 1.624816 | 0.0329885 | 0.0231737 |
| GO:0044839 | cell cycle G2/M phase transition | 246 | 1.622401 | 0.0329885 | 0.0231737 |
| GO:0030004 | cellular monovalent inorganic cation homeostasis | 73 | 1.618903 | 0.0393800 | 0.0276636 |
| GO:0009145 | purine nucleoside triphosphate biosynthetic process | 151 | 1.616011 | 0.0329885 | 0.0231737 |
| GO:0010921 | regulation of phosphatase activity | 157 | 1.613414 | 0.0329885 | 0.0231737 |
| GO:0032535 | regulation of cellular component size | 292 | 1.613411 | 0.0329885 | 0.0231737 |
| GO:0010770 | positive regulation of cell morphogenesis involved in differentiation | 130 | 1.611952 | 0.0351659 | 0.0247032 |
| GO:0010771 | negative regulation of cell morphogenesis involved in differentiation | 77 | 1.608511 | 0.0438865 | 0.0308293 |
| GO:0018209 | peptidyl-serine modification | 232 | 1.608387 | 0.0329885 | 0.0231737 |
| GO:0051592 | response to calcium ion | 115 | 1.602920 | 0.0351670 | 0.0247040 |
| GO:0006094 | gluconeogenesis | 74 | 1.601187 | 0.0393800 | 0.0276636 |
| GO:0009749 | response to glucose | 165 | 1.600291 | 0.0329885 | 0.0231737 |
| GO:0050769 | positive regulation of neurogenesis | 413 | 1.599805 | 0.0329885 | 0.0231737 |
| GO:1902749 | regulation of cell cycle G2/M phase transition | 192 | 1.598032 | 0.0329885 | 0.0231737 |
| GO:0009743 | response to carbohydrate | 196 | 1.596119 | 0.0329885 | 0.0231737 |
| GO:0031333 | negative regulation of protein complex assembly | 115 | 1.595746 | 0.0351670 | 0.0247040 |
| GO:0034763 | negative regulation of transmembrane transport | 100 | 1.591549 | 0.0422654 | 0.0296905 |
| GO:0031345 | negative regulation of cell projection organization | 151 | 1.586870 | 0.0329885 | 0.0231737 |
| GO:0009201 | ribonucleoside triphosphate biosynthetic process | 155 | 1.583576 | 0.0350660 | 0.0246330 |
| GO:0034766 | negative regulation of ion transmembrane transport | 81 | 1.579244 | 0.0498255 | 0.0350013 |
| GO:0032271 | regulation of protein polymerization | 165 | 1.578958 | 0.0329885 | 0.0231737 |
| GO:1905477 | positive regulation of protein localization to membrane | 111 | 1.574253 | 0.0358382 | 0.0251755 |
| GO:0050848 | regulation of calcium-mediated signaling | 87 | 1.571969 | 0.0496734 | 0.0348945 |
| GO:0048284 | organelle fusion | 92 | 1.571128 | 0.0393800 | 0.0276636 |
| GO:0060560 | developmental growth involved in morphogenesis | 202 | 1.570183 | 0.0329885 | 0.0231737 |
| GO:0051668 | localization within membrane | 120 | 1.568688 | 0.0487162 | 0.0342220 |
| GO:0033157 | regulation of intracellular protein transport | 210 | 1.566313 | 0.0329885 | 0.0231737 |
| GO:1901800 | positive regulation of proteasomal protein catabolic process | 90 | 1.566068 | 0.0392689 | 0.0275855 |
| GO:0043666 | regulation of phosphoprotein phosphatase activity | 104 | 1.561188 | 0.0486938 | 0.0342063 |
| GO:0009746 | response to hexose | 170 | 1.559169 | 0.0329885 | 0.0231737 |
| GO:0048193 | Golgi vesicle transport | 290 | 1.550247 | 0.0329885 | 0.0231737 |
| GO:0072659 | protein localization to plasma membrane | 223 | 1.549284 | 0.0329885 | 0.0231737 |
| GO:0061136 | regulation of proteasomal protein catabolic process | 162 | 1.545539 | 0.0350660 | 0.0246330 |
| GO:0046879 | hormone secretion | 254 | 1.543492 | 0.0329885 | 0.0231737 |
| GO:0019319 | hexose biosynthetic process | 77 | 1.542174 | 0.0497992 | 0.0349828 |
| GO:0009914 | hormone transport | 263 | 1.538192 | 0.0329885 | 0.0231737 |
| GO:0048638 | regulation of developmental growth | 275 | 1.538192 | 0.0329885 | 0.0231737 |
| GO:0070507 | regulation of microtubule cytoskeleton organization | 167 | 1.533430 | 0.0350660 | 0.0246330 |
| GO:0009142 | nucleoside triphosphate biosynthetic process | 166 | 1.532739 | 0.0378730 | 0.0266049 |
| GO:0002027 | regulation of heart rate | 84 | 1.530637 | 0.0495946 | 0.0348391 |
| GO:0010506 | regulation of autophagy | 301 | 1.528084 | 0.0329885 | 0.0231737 |
| GO:0034284 | response to monosaccharide | 174 | 1.525524 | 0.0329885 | 0.0231737 |
| GO:0019932 | second-messenger-mediated signaling | 305 | 1.519423 | 0.0329885 | 0.0231737 |
| GO:0022604 | regulation of cell morphogenesis | 411 | 1.515354 | 0.0329885 | 0.0231737 |
| GO:0050906 | detection of stimulus involved in sensory perception | 108 | 1.514434 | 0.0424097 | 0.0297918 |
| GO:0070997 | neuron death | 311 | 1.511110 | 0.0329885 | 0.0231737 |
| GO:0006914 | autophagy | 455 | 1.511034 | 0.0329885 | 0.0231737 |
| GO:0061919 | process utilizing autophagic mechanism | 455 | 1.511034 | 0.0329885 | 0.0231737 |
| GO:0006470 | protein dephosphorylation | 288 | 1.510004 | 0.0329885 | 0.0231737 |
| GO:0070838 | divalent metal ion transport | 401 | 1.509694 | 0.0329885 | 0.0231737 |
| GO:1901293 | nucleoside phosphate biosynthetic process | 343 | 1.502273 | 0.0329885 | 0.0231737 |
| GO:0072511 | divalent inorganic cation transport | 403 | 1.501848 | 0.0329885 | 0.0231737 |
| GO:0006520 | cellular amino acid metabolic process | 323 | 1.501355 | 0.0329885 | 0.0231737 |
| GO:0032984 | protein-containing complex disassembly | 286 | 1.499978 | 0.0329885 | 0.0231737 |
| GO:0010256 | endomembrane system organization | 344 | 1.498688 | 0.0329885 | 0.0231737 |
| GO:0048002 | antigen processing and presentation of peptide antigen | 174 | 1.496180 | 0.0377405 | 0.0265118 |
| GO:0009165 | nucleotide biosynthetic process | 340 | 1.496154 | 0.0329885 | 0.0231737 |
| GO:0006816 | calcium ion transport | 364 | 1.493733 | 0.0329885 | 0.0231737 |
| GO:0046883 | regulation of hormone secretion | 215 | 1.493640 | 0.0343030 | 0.0240971 |
| GO:0090150 | establishment of protein localization to membrane | 267 | 1.493224 | 0.0329885 | 0.0231737 |
| GO:0022411 | cellular component disassembly | 454 | 1.491968 | 0.0329885 | 0.0231737 |
| GO:0010720 | positive regulation of cell development | 468 | 1.491403 | 0.0329885 | 0.0231737 |
| GO:0010498 | proteasomal protein catabolic process | 369 | 1.490679 | 0.0329885 | 0.0231737 |
| GO:1903827 | regulation of cellular protein localization | 478 | 1.490491 | 0.0329885 | 0.0231737 |
| GO:1901214 | regulation of neuron death | 279 | 1.490443 | 0.0329885 | 0.0231737 |
| GO:1905475 | regulation of protein localization to membrane | 167 | 1.485561 | 0.0480538 | 0.0337567 |
| GO:0016311 | dephosphorylation | 418 | 1.483413 | 0.0329885 | 0.0231737 |
| GO:0043161 | proteasome-mediated ubiquitin-dependent protein catabolic process | 316 | 1.482798 | 0.0329885 | 0.0231737 |
| GO:0070646 | protein modification by small protein removal | 263 | 1.468921 | 0.0370498 | 0.0260266 |
| GO:0060271 | cilium assembly | 319 | 1.462095 | 0.0329885 | 0.0231737 |
| GO:0019882 | antigen processing and presentation | 202 | 1.449168 | 0.0414718 | 0.0291330 |
| GO:0046434 | organophosphate catabolic process | 211 | 1.440211 | 0.0414641 | 0.0291276 |
| GO:0000226 | microtubule cytoskeleton organization | 433 | 1.426885 | 0.0332928 | 0.0233874 |
| GO:0044782 | cilium organization | 328 | 1.423031 | 0.0403803 | 0.0283662 |
| GO:0090066 | regulation of anatomical structure size | 396 | 1.416338 | 0.0329885 | 0.0231737 |
| GO:0002768 | immune response-regulating cell surface receptor signaling pathway | 312 | 1.415533 | 0.0496734 | 0.0348945 |
| GO:0051051 | negative regulation of transport | 412 | 1.406800 | 0.0329885 | 0.0231737 |
| GO:0019941 | modification-dependent protein catabolic process | 472 | 1.402441 | 0.0329885 | 0.0231737 |
| GO:0006873 | cellular ion homeostasis | 459 | 1.398508 | 0.0329885 | 0.0231737 |
| GO:0006511 | ubiquitin-dependent protein catabolic process | 467 | 1.396923 | 0.0361638 | 0.0254042 |
| GO:0030003 | cellular cation homeostasis | 450 | 1.380773 | 0.0332231 | 0.0233385 |
| GO:0043632 | modification-dependent macromolecule catabolic process | 479 | 1.379019 | 0.0361638 | 0.0254042 |
| GO:0042176 | regulation of protein catabolic process | 335 | 1.377503 | 0.0498414 | 0.0350125 |
| GO:0010817 | regulation of hormone levels | 412 | 1.354427 | 0.0490027 | 0.0344233 |
| GO:0006875 | cellular metal ion homeostasis | 403 | 1.351955 | 0.0488689 | 0.0343293 |
| ID | Description | setSize | NES | p.adjust | qvalues |
|---|---|---|---|---|---|
| GO:0006335 | DNA replication-dependent nucleosome assembly | 32 | 3.281963 | 0.0163009 | 0.0113833 |
| GO:0034723 | DNA replication-dependent nucleosome organization | 32 | 3.281963 | 0.0163009 | 0.0113833 |
| GO:0000183 | chromatin silencing at rDNA | 39 | 3.015703 | 0.0163009 | 0.0113833 |
| GO:0051290 | protein heterotetramerization | 51 | 2.920453 | 0.0163009 | 0.0113833 |
| GO:0045653 | negative regulation of megakaryocyte differentiation | 17 | 2.823607 | 0.0163009 | 0.0113833 |
| GO:0006334 | nucleosome assembly | 119 | 2.804989 | 0.0163009 | 0.0113833 |
| GO:0045652 | regulation of megakaryocyte differentiation | 74 | 2.724017 | 0.0163009 | 0.0113833 |
| GO:0030219 | megakaryocyte differentiation | 90 | 2.682767 | 0.0163009 | 0.0113833 |
| GO:0031497 | chromatin assembly | 135 | 2.634938 | 0.0163009 | 0.0113833 |
| GO:0034728 | nucleosome organization | 144 | 2.572696 | 0.0163009 | 0.0113833 |
| GO:0034080 | CENP-A containing nucleosome assembly | 41 | 2.502281 | 0.0163009 | 0.0113833 |
| GO:0061641 | CENP-A containing chromatin organization | 41 | 2.502281 | 0.0163009 | 0.0113833 |
| GO:0006333 | chromatin assembly or disassembly | 159 | 2.494888 | 0.0163009 | 0.0113833 |
| GO:0006323 | DNA packaging | 168 | 2.476166 | 0.0163009 | 0.0113833 |
| GO:0048514 | blood vessel morphogenesis | 495 | 2.414044 | 0.0163009 | 0.0113833 |
| GO:0006342 | chromatin silencing | 76 | 2.403177 | 0.0163009 | 0.0113833 |
| GO:0031055 | chromatin remodeling at centromere | 45 | 2.353854 | 0.0163009 | 0.0113833 |
| GO:1903707 | negative regulation of hemopoiesis | 129 | 2.333940 | 0.0163009 | 0.0113833 |
| GO:0003158 | endothelium development | 106 | 2.333436 | 0.0163009 | 0.0113833 |
| GO:0038111 | interleukin-7-mediated signaling pathway | 29 | 2.326228 | 0.0163009 | 0.0113833 |
| GO:0060964 | regulation of gene silencing by miRNA | 110 | 2.318738 | 0.0163009 | 0.0113833 |
| GO:0010718 | positive regulation of epithelial to mesenchymal transition | 45 | 2.314219 | 0.0163009 | 0.0113833 |
| GO:0043486 | histone exchange | 50 | 2.313078 | 0.0163009 | 0.0113833 |
| GO:0006336 | DNA replication-independent nucleosome assembly | 52 | 2.313018 | 0.0163009 | 0.0113833 |
| GO:0034724 | DNA replication-independent nucleosome organization | 52 | 2.313018 | 0.0163009 | 0.0113833 |
| GO:0060147 | regulation of posttranscriptional gene silencing | 112 | 2.300594 | 0.0163009 | 0.0113833 |
| GO:0060966 | regulation of gene silencing by RNA | 112 | 2.300594 | 0.0163009 | 0.0113833 |
| GO:0001525 | angiogenesis | 418 | 2.298458 | 0.0163009 | 0.0113833 |
| GO:0045814 | negative regulation of gene expression, epigenetic | 94 | 2.288462 | 0.0163009 | 0.0113833 |
| GO:0065004 | protein-DNA complex assembly | 191 | 2.260830 | 0.0163009 | 0.0113833 |
| GO:1904018 | positive regulation of vasculature development | 161 | 2.253925 | 0.0163009 | 0.0113833 |
| GO:0030856 | regulation of epithelial cell differentiation | 112 | 2.248593 | 0.0163009 | 0.0113833 |
| GO:0001704 | formation of primary germ layer | 95 | 2.241676 | 0.0163009 | 0.0113833 |
| GO:0007492 | endoderm development | 60 | 2.232370 | 0.0163009 | 0.0113833 |
| GO:0046637 | regulation of alpha-beta T cell differentiation | 51 | 2.231238 | 0.0163009 | 0.0113833 |
| GO:0045637 | regulation of myeloid cell differentiation | 214 | 2.230233 | 0.0163009 | 0.0113833 |
| GO:0045446 | endothelial cell differentiation | 88 | 2.218811 | 0.0163009 | 0.0113833 |
| GO:0061614 | pri-miRNA transcription by RNA polymerase II | 43 | 2.218749 | 0.0163009 | 0.0113833 |
| GO:0030198 | extracellular matrix organization | 286 | 2.192768 | 0.0163009 | 0.0113833 |
| GO:0045766 | positive regulation of angiogenesis | 143 | 2.191895 | 0.0163009 | 0.0113833 |
| GO:0046632 | alpha-beta T cell differentiation | 78 | 2.189461 | 0.0163009 | 0.0113833 |
| GO:0046638 | positive regulation of alpha-beta T cell differentiation | 40 | 2.185307 | 0.0163009 | 0.0113833 |
| GO:1901342 | regulation of vasculature development | 274 | 2.184894 | 0.0163009 | 0.0113833 |
| GO:0034508 | centromere complex assembly | 53 | 2.182849 | 0.0163009 | 0.0113833 |
| GO:0046636 | negative regulation of alpha-beta T cell activation | 31 | 2.181756 | 0.0163009 | 0.0113833 |
| GO:0046631 | alpha-beta T cell activation | 107 | 2.163636 | 0.0163009 | 0.0113833 |
| GO:0046634 | regulation of alpha-beta T cell activation | 74 | 2.156328 | 0.0163009 | 0.0113833 |
| GO:0045765 | regulation of angiogenesis | 246 | 2.155318 | 0.0163009 | 0.0113833 |
| GO:0035195 | gene silencing by miRNA | 150 | 2.153835 | 0.0163009 | 0.0113833 |
| GO:0045638 | negative regulation of myeloid cell differentiation | 79 | 2.147018 | 0.0163009 | 0.0113833 |
| GO:0043062 | extracellular structure organization | 330 | 2.142770 | 0.0163009 | 0.0113833 |
| GO:0001706 | endoderm formation | 42 | 2.139188 | 0.0163009 | 0.0113833 |
| GO:0050866 | negative regulation of cell activation | 162 | 2.138813 | 0.0163009 | 0.0113833 |
| GO:0030260 | entry into host cell | 118 | 2.134275 | 0.0163009 | 0.0113833 |
| GO:0044409 | entry into host | 118 | 2.134275 | 0.0163009 | 0.0113833 |
| GO:0051806 | entry into cell of other organism involved in symbiotic interaction | 118 | 2.134275 | 0.0163009 | 0.0113833 |
| GO:0051828 | entry into other organism involved in symbiotic interaction | 118 | 2.134275 | 0.0163009 | 0.0113833 |
| GO:1904035 | regulation of epithelial cell apoptotic process | 61 | 2.128339 | 0.0163009 | 0.0113833 |
| GO:0014745 | negative regulation of muscle adaptation | 11 | 2.127725 | 0.0163009 | 0.0113833 |
| GO:0030855 | epithelial cell differentiation | 481 | 2.126033 | 0.0163009 | 0.0113833 |
| GO:0002286 | T cell activation involved in immune response | 70 | 2.125011 | 0.0163009 | 0.0113833 |
| GO:0030099 | myeloid cell differentiation | 357 | 2.124192 | 0.0163009 | 0.0113833 |
| GO:0045667 | regulation of osteoblast differentiation | 107 | 2.124127 | 0.0163009 | 0.0113833 |
| GO:0032200 | telomere organization | 158 | 2.124006 | 0.0163009 | 0.0113833 |
| GO:0061180 | mammary gland epithelium development | 59 | 2.120205 | 0.0163009 | 0.0113833 |
| GO:0016233 | telomere capping | 49 | 2.111809 | 0.0163009 | 0.0113833 |
| GO:0071824 | protein-DNA complex subunit organization | 216 | 2.107134 | 0.0163009 | 0.0113833 |
| GO:0071103 | DNA conformation change | 253 | 2.106475 | 0.0163009 | 0.0113833 |
| GO:0061138 | morphogenesis of a branching epithelium | 154 | 2.106262 | 0.0163009 | 0.0113833 |
| GO:0060968 | regulation of gene silencing | 132 | 2.104981 | 0.0163009 | 0.0113833 |
| GO:0034446 | substrate adhesion-dependent cell spreading | 82 | 2.102304 | 0.0163009 | 0.0113833 |
| GO:0016441 | posttranscriptional gene silencing | 155 | 2.102180 | 0.0163009 | 0.0113833 |
| GO:0031047 | gene silencing by RNA | 174 | 2.100760 | 0.0163009 | 0.0113833 |
| GO:0035194 | posttranscriptional gene silencing by RNA | 154 | 2.100144 | 0.0163009 | 0.0113833 |
| GO:0042110 | T cell activation | 376 | 2.098991 | 0.0163009 | 0.0113833 |
| GO:0002064 | epithelial cell development | 175 | 2.098650 | 0.0163009 | 0.0113833 |
| GO:0035987 | endodermal cell differentiation | 38 | 2.098008 | 0.0163009 | 0.0113833 |
| GO:0048754 | branching morphogenesis of an epithelial tube | 126 | 2.095619 | 0.0163009 | 0.0113833 |
| GO:0042307 | positive regulation of protein import into nucleus | 34 | 2.095381 | 0.0163009 | 0.0113833 |
| GO:0007369 | gastrulation | 146 | 2.095188 | 0.0163009 | 0.0113833 |
| GO:0002683 | negative regulation of immune system process | 376 | 2.094643 | 0.0163009 | 0.0113833 |
| GO:0042060 | wound healing | 458 | 2.093919 | 0.0163009 | 0.0113833 |
| GO:0110110 | positive regulation of animal organ morphogenesis | 69 | 2.093698 | 0.0163009 | 0.0113833 |
| GO:1901522 | positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus | 22 | 2.093155 | 0.0163009 | 0.0113833 |
| GO:0051291 | protein heterooligomerization | 120 | 2.088588 | 0.0163009 | 0.0113833 |
| GO:0033002 | muscle cell proliferation | 175 | 2.084705 | 0.0163009 | 0.0113833 |
| GO:0030199 | collagen fibril organization | 40 | 2.079294 | 0.0163009 | 0.0113833 |
| GO:0070431 | nucleotide-binding oligomerization domain containing 2 signaling pathway | 13 | 2.077650 | 0.0163009 | 0.0113833 |
| GO:1903708 | positive regulation of hemopoiesis | 155 | 2.075687 | 0.0163009 | 0.0113833 |
| GO:0035329 | hippo signaling | 38 | 2.071621 | 0.0163009 | 0.0113833 |
| GO:0032496 | response to lipopolysaccharide | 248 | 2.071391 | 0.0163009 | 0.0113833 |
| GO:0009617 | response to bacterium | 413 | 2.070860 | 0.0163009 | 0.0113833 |
| GO:0002237 | response to molecule of bacterial origin | 260 | 2.069487 | 0.0163009 | 0.0113833 |
| GO:0002819 | regulation of adaptive immune response | 128 | 2.068829 | 0.0163009 | 0.0113833 |
| GO:0098760 | response to interleukin-7 | 40 | 2.067516 | 0.0163009 | 0.0113833 |
| GO:0098761 | cellular response to interleukin-7 | 40 | 2.067516 | 0.0163009 | 0.0113833 |
| GO:0022612 | gland morphogenesis | 101 | 2.064871 | 0.0163009 | 0.0113833 |
| GO:0048333 | mesodermal cell differentiation | 27 | 2.062396 | 0.0163009 | 0.0113833 |
| GO:2000514 | regulation of CD4-positive, alpha-beta T cell activation | 46 | 2.055948 | 0.0163009 | 0.0113833 |
| GO:0002227 | innate immune response in mucosa | 11 | 2.052684 | 0.0163009 | 0.0113833 |
| GO:0032677 | regulation of interleukin-8 production | 53 | 2.051840 | 0.0163009 | 0.0113833 |
| GO:0060326 | cell chemotaxis | 201 | 2.050613 | 0.0163009 | 0.0113833 |
| GO:0003151 | outflow tract morphogenesis | 70 | 2.045981 | 0.0163009 | 0.0113833 |
| GO:0071216 | cellular response to biotic stimulus | 178 | 2.044258 | 0.0163009 | 0.0113833 |
| GO:1904036 | negative regulation of epithelial cell apoptotic process | 30 | 2.041644 | 0.0163009 | 0.0113833 |
| GO:0014741 | negative regulation of muscle hypertrophy | 25 | 2.039269 | 0.0163009 | 0.0113833 |
| GO:0048368 | lateral mesoderm development | 13 | 2.037636 | 0.0163009 | 0.0113833 |
| GO:1904894 | positive regulation of STAT cascade | 61 | 2.037606 | 0.0163009 | 0.0113833 |
| GO:0001570 | vasculogenesis | 68 | 2.037259 | 0.0163009 | 0.0113833 |
| GO:0072006 | nephron development | 121 | 2.037143 | 0.0163009 | 0.0113833 |
| GO:0022408 | negative regulation of cell-cell adhesion | 138 | 2.034252 | 0.0163009 | 0.0113833 |
| GO:0030217 | T cell differentiation | 193 | 2.031911 | 0.0163009 | 0.0113833 |
| GO:0046718 | viral entry into host cell | 106 | 2.031748 | 0.0163009 | 0.0113833 |
| GO:0048332 | mesoderm morphogenesis | 57 | 2.026901 | 0.0163009 | 0.0113833 |
| GO:1902107 | positive regulation of leukocyte differentiation | 122 | 2.023687 | 0.0163009 | 0.0113833 |
| GO:0002695 | negative regulation of leukocyte activation | 143 | 2.023093 | 0.0163009 | 0.0113833 |
| GO:0072028 | nephron morphogenesis | 66 | 2.021569 | 0.0163009 | 0.0113833 |
| GO:0002507 | tolerance induction | 18 | 2.019637 | 0.0163009 | 0.0113833 |
| GO:0061844 | antimicrobial humoral immune response mediated by antimicrobial peptide | 23 | 2.017153 | 0.0163009 | 0.0113833 |
| GO:0046427 | positive regulation of JAK-STAT cascade | 59 | 2.015126 | 0.0163009 | 0.0113833 |
| GO:2001236 | regulation of extrinsic apoptotic signaling pathway | 137 | 2.014815 | 0.0163009 | 0.0113833 |
| GO:0002577 | regulation of antigen processing and presentation | 15 | 2.013972 | 0.0163009 | 0.0113833 |
| GO:0030278 | regulation of ossification | 169 | 2.011543 | 0.0163009 | 0.0113833 |
| GO:1902893 | regulation of pri-miRNA transcription by RNA polymerase II | 37 | 2.011033 | 0.0163009 | 0.0113833 |
| GO:1903053 | regulation of extracellular matrix organization | 36 | 2.009104 | 0.0163009 | 0.0113833 |
| GO:0071222 | cellular response to lipopolysaccharide | 148 | 2.007952 | 0.0163009 | 0.0113833 |
| GO:0043124 | negative regulation of I-kappaB kinase/NF-kappaB signaling | 39 | 2.005453 | 0.0256950 | 0.0179433 |
| GO:0045616 | regulation of keratinocyte differentiation | 30 | 2.004612 | 0.0163009 | 0.0113833 |
| GO:0090183 | regulation of kidney development | 46 | 2.004535 | 0.0256950 | 0.0179433 |
| GO:0072073 | kidney epithelium development | 120 | 2.002833 | 0.0163009 | 0.0113833 |
| GO:0007566 | embryo implantation | 43 | 2.002232 | 0.0258183 | 0.0180295 |
| GO:0001890 | placenta development | 131 | 2.000883 | 0.0163009 | 0.0113833 |
| GO:0045621 | positive regulation of lymphocyte differentiation | 81 | 2.000118 | 0.0163009 | 0.0113833 |
| GO:0050868 | negative regulation of T cell activation | 89 | 1.998171 | 0.0163009 | 0.0113833 |
| GO:0003181 | atrioventricular valve morphogenesis | 22 | 1.997860 | 0.0163009 | 0.0113833 |
| GO:0001763 | morphogenesis of a branching structure | 167 | 1.997080 | 0.0163009 | 0.0113833 |
| GO:0051250 | negative regulation of lymphocyte activation | 117 | 1.996758 | 0.0163009 | 0.0113833 |
| GO:2000482 | regulation of interleukin-8 secretion | 20 | 1.994918 | 0.0163009 | 0.0113833 |
| GO:0060479 | lung cell differentiation | 15 | 1.990732 | 0.0256950 | 0.0179433 |
| GO:0071219 | cellular response to molecule of bacterial origin | 155 | 1.990147 | 0.0163009 | 0.0113833 |
| GO:2000179 | positive regulation of neural precursor cell proliferation | 44 | 1.989036 | 0.0256950 | 0.0179433 |
| GO:1904019 | epithelial cell apoptotic process | 81 | 1.987989 | 0.0163009 | 0.0113833 |
| GO:0002285 | lymphocyte activation involved in immune response | 128 | 1.986501 | 0.0163009 | 0.0113833 |
| GO:0032060 | bleb assembly | 11 | 1.985604 | 0.0163009 | 0.0113833 |
| GO:0045669 | positive regulation of osteoblast differentiation | 61 | 1.985265 | 0.0163009 | 0.0113833 |
| GO:0061005 | cell differentiation involved in kidney development | 48 | 1.984123 | 0.0257133 | 0.0179562 |
| GO:1901626 | regulation of postsynaptic membrane organization | 14 | 1.982813 | 0.0163009 | 0.0113833 |
| GO:2000826 | regulation of heart morphogenesis | 32 | 1.982671 | 0.0163009 | 0.0113833 |
| GO:0042129 | regulation of T cell proliferation | 123 | 1.980702 | 0.0163009 | 0.0113833 |
| GO:2000351 | regulation of endothelial cell apoptotic process | 36 | 1.978509 | 0.0163009 | 0.0113833 |
| GO:0048708 | astrocyte differentiation | 71 | 1.978094 | 0.0163009 | 0.0113833 |
| GO:0030206 | chondroitin sulfate biosynthetic process | 25 | 1.976975 | 0.0163009 | 0.0113833 |
| GO:0002821 | positive regulation of adaptive immune response | 78 | 1.976761 | 0.0163009 | 0.0113833 |
| GO:0009595 | detection of biotic stimulus | 17 | 1.975224 | 0.0163009 | 0.0113833 |
| GO:0001655 | urogenital system development | 286 | 1.975188 | 0.0163009 | 0.0113833 |
| GO:0045604 | regulation of epidermal cell differentiation | 45 | 1.974814 | 0.0256950 | 0.0179433 |
| GO:0002287 | alpha-beta T cell activation involved in immune response | 47 | 1.974340 | 0.0256950 | 0.0179433 |
| GO:0002293 | alpha-beta T cell differentiation involved in immune response | 47 | 1.974340 | 0.0256950 | 0.0179433 |
| GO:0002294 | CD4-positive, alpha-beta T cell differentiation involved in immune response | 47 | 1.974340 | 0.0256950 | 0.0179433 |
| GO:0045582 | positive regulation of T cell differentiation | 71 | 1.974294 | 0.0163009 | 0.0113833 |
| GO:0035710 | CD4-positive, alpha-beta T cell activation | 71 | 1.973952 | 0.0163009 | 0.0113833 |
| GO:0046635 | positive regulation of alpha-beta T cell activation | 51 | 1.971458 | 0.0163009 | 0.0113833 |
| GO:0046639 | negative regulation of alpha-beta T cell differentiation | 21 | 1.971344 | 0.0163009 | 0.0113833 |
| GO:0002824 | positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 73 | 1.971195 | 0.0163009 | 0.0113833 |
| GO:0072207 | metanephric epithelium development | 23 | 1.970801 | 0.0163009 | 0.0113833 |
| GO:0003183 | mitral valve morphogenesis | 10 | 1.970504 | 0.0163009 | 0.0113833 |
| GO:2000147 | positive regulation of cell motility | 442 | 1.969086 | 0.0163009 | 0.0113833 |
| GO:0002460 | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 197 | 1.966630 | 0.0163009 | 0.0113833 |
| GO:0030335 | positive regulation of cell migration | 427 | 1.966054 | 0.0163009 | 0.0113833 |
| GO:0072132 | mesenchyme morphogenesis | 47 | 1.964821 | 0.0256950 | 0.0179433 |
| GO:0072001 | renal system development | 260 | 1.963360 | 0.0163009 | 0.0113833 |
| GO:0072009 | nephron epithelium development | 90 | 1.963098 | 0.0163009 | 0.0113833 |
| GO:0001822 | kidney development | 245 | 1.962898 | 0.0163009 | 0.0113833 |
| GO:0060411 | cardiac septum morphogenesis | 67 | 1.961579 | 0.0163009 | 0.0113833 |
| GO:0030858 | positive regulation of epithelial cell differentiation | 49 | 1.960627 | 0.0256950 | 0.0179433 |
| GO:0001707 | mesoderm formation | 55 | 1.960582 | 0.0163009 | 0.0113833 |
| GO:0032637 | interleukin-8 production | 58 | 1.959157 | 0.0163009 | 0.0113833 |
| GO:0097150 | neuronal stem cell population maintenance | 22 | 1.958891 | 0.0163009 | 0.0113833 |
| GO:0060561 | apoptotic process involved in morphogenesis | 21 | 1.958723 | 0.0163009 | 0.0113833 |
| GO:0061326 | renal tubule development | 79 | 1.955483 | 0.0163009 | 0.0113833 |
| GO:0003007 | heart morphogenesis | 213 | 1.954472 | 0.0163009 | 0.0113833 |
| GO:0002250 | adaptive immune response | 290 | 1.951776 | 0.0163009 | 0.0113833 |
| GO:2000811 | negative regulation of anoikis | 15 | 1.951105 | 0.0256950 | 0.0179433 |
| GO:0002822 | regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 114 | 1.948942 | 0.0163009 | 0.0113833 |
| GO:0072080 | nephron tubule development | 77 | 1.948245 | 0.0163009 | 0.0113833 |
| GO:0072088 | nephron epithelium morphogenesis | 64 | 1.947935 | 0.0163009 | 0.0113833 |
| GO:0042742 | defense response to bacterium | 120 | 1.946931 | 0.0163009 | 0.0113833 |
| GO:0042093 | T-helper cell differentiation | 46 | 1.945784 | 0.0256950 | 0.0179433 |
| GO:0003382 | epithelial cell morphogenesis | 25 | 1.944556 | 0.0163009 | 0.0113833 |
| GO:0002088 | lens development in camera-type eye | 58 | 1.943813 | 0.0163009 | 0.0113833 |
| GO:2000036 | regulation of stem cell population maintenance | 25 | 1.940979 | 0.0163009 | 0.0113833 |
| GO:0006968 | cellular defense response | 40 | 1.940089 | 0.0256950 | 0.0179433 |
| GO:1905332 | positive regulation of morphogenesis of an epithelium | 31 | 1.939865 | 0.0163009 | 0.0113833 |
| GO:0003171 | atrioventricular valve development | 23 | 1.939460 | 0.0163009 | 0.0113833 |
| GO:0010463 | mesenchymal cell proliferation | 41 | 1.938546 | 0.0256950 | 0.0179433 |
| GO:0048844 | artery morphogenesis | 58 | 1.938415 | 0.0163009 | 0.0113833 |
| GO:0043297 | apical junction assembly | 55 | 1.938197 | 0.0163009 | 0.0113833 |
| GO:2000515 | negative regulation of CD4-positive, alpha-beta T cell activation | 23 | 1.936605 | 0.0163009 | 0.0113833 |
| GO:0001656 | metanephros development | 74 | 1.936547 | 0.0163009 | 0.0113833 |
| GO:0072243 | metanephric nephron epithelium development | 20 | 1.934631 | 0.0163009 | 0.0113833 |
| GO:1904591 | positive regulation of protein import | 36 | 1.934484 | 0.0163009 | 0.0113833 |
| GO:0006509 | membrane protein ectodomain proteolysis | 37 | 1.933582 | 0.0163009 | 0.0113833 |
| GO:0002292 | T cell differentiation involved in immune response | 49 | 1.933045 | 0.0256950 | 0.0179433 |
| GO:0035635 | entry of bacterium into host cell | 14 | 1.931106 | 0.0256950 | 0.0179433 |
| GO:0050900 | leukocyte migration | 335 | 1.929425 | 0.0163009 | 0.0113833 |
| GO:0001885 | endothelial cell development | 53 | 1.928683 | 0.0163009 | 0.0113833 |
| GO:0072170 | metanephric tubule development | 22 | 1.927899 | 0.0163009 | 0.0113833 |
| GO:0043367 | CD4-positive, alpha-beta T cell differentiation | 58 | 1.927700 | 0.0163009 | 0.0113833 |
| GO:0050777 | negative regulation of immune response | 116 | 1.926393 | 0.0163009 | 0.0113833 |
| GO:0050673 | epithelial cell proliferation | 326 | 1.925842 | 0.0163009 | 0.0113833 |
| GO:0072577 | endothelial cell apoptotic process | 42 | 1.925825 | 0.0256950 | 0.0179433 |
| GO:0001503 | ossification | 339 | 1.925490 | 0.0163009 | 0.0113833 |
| GO:0060993 | kidney morphogenesis | 81 | 1.922369 | 0.0163009 | 0.0113833 |
| GO:0051568 | histone H3-K4 methylation | 46 | 1.921827 | 0.0256950 | 0.0179433 |
| GO:0002385 | mucosal immune response | 14 | 1.920873 | 0.0325638 | 0.0227400 |
| GO:0001892 | embryonic placenta development | 78 | 1.920229 | 0.0163009 | 0.0113833 |
| GO:0050830 | defense response to Gram-positive bacterium | 45 | 1.919976 | 0.0256950 | 0.0179433 |
| GO:0000768 | syncytium formation by plasma membrane fusion | 41 | 1.919721 | 0.0256950 | 0.0179433 |
| GO:0140253 | cell-cell fusion | 41 | 1.919721 | 0.0256950 | 0.0179433 |
| GO:1902807 | negative regulation of cell cycle G1/S phase transition | 102 | 1.918019 | 0.0163009 | 0.0113833 |
| GO:0072078 | nephron tubule morphogenesis | 62 | 1.918014 | 0.0163009 | 0.0113833 |
| GO:0042102 | positive regulation of T cell proliferation | 69 | 1.917452 | 0.0163009 | 0.0113833 |
| GO:0042267 | natural killer cell mediated cytotoxicity | 43 | 1.916163 | 0.0327718 | 0.0228853 |
| GO:0010759 | positive regulation of macrophage chemotaxis | 14 | 1.915875 | 0.0325638 | 0.0227400 |
| GO:2000134 | negative regulation of G1/S transition of mitotic cell cycle | 100 | 1.915439 | 0.0163009 | 0.0113833 |
| GO:0002825 | regulation of T-helper 1 type immune response | 18 | 1.915277 | 0.0163009 | 0.0113833 |
| GO:0051272 | positive regulation of cellular component movement | 455 | 1.914921 | 0.0163009 | 0.0113833 |
| GO:1903038 | negative regulation of leukocyte cell-cell adhesion | 98 | 1.914414 | 0.0163009 | 0.0113833 |
| GO:0036119 | response to platelet-derived growth factor | 21 | 1.910974 | 0.0163009 | 0.0113833 |
| GO:1903706 | regulation of hemopoiesis | 409 | 1.910713 | 0.0163009 | 0.0113833 |
| GO:0046697 | decidualization | 22 | 1.909212 | 0.0163009 | 0.0113833 |
| GO:0045655 | regulation of monocyte differentiation | 16 | 1.908668 | 0.0256950 | 0.0179433 |
| GO:0043370 | regulation of CD4-positive, alpha-beta T cell differentiation | 37 | 1.907452 | 0.0163009 | 0.0113833 |
| GO:0061053 | somite development | 65 | 1.907433 | 0.0163009 | 0.0113833 |
| GO:0042269 | regulation of natural killer cell mediated cytotoxicity | 29 | 1.907006 | 0.0163009 | 0.0113833 |
| GO:0003170 | heart valve development | 54 | 1.906001 | 0.0163009 | 0.0113833 |
| GO:0010614 | negative regulation of cardiac muscle hypertrophy | 23 | 1.905537 | 0.0163009 | 0.0113833 |
| GO:1905523 | positive regulation of macrophage migration | 19 | 1.904808 | 0.0256950 | 0.0179433 |
| GO:0042098 | T cell proliferation | 151 | 1.903371 | 0.0163009 | 0.0113833 |
| GO:0048661 | positive regulation of smooth muscle cell proliferation | 81 | 1.902375 | 0.0163009 | 0.0113833 |
| GO:0030323 | respiratory tube development | 156 | 1.902275 | 0.0163009 | 0.0113833 |
| GO:1900101 | regulation of endoplasmic reticulum unfolded protein response | 24 | 1.900477 | 0.0163009 | 0.0113833 |
| GO:0072171 | mesonephric tubule morphogenesis | 57 | 1.900140 | 0.0163009 | 0.0113833 |
| GO:0007498 | mesoderm development | 100 | 1.899509 | 0.0163009 | 0.0113833 |
| GO:0030324 | lung development | 152 | 1.898808 | 0.0163009 | 0.0113833 |
| GO:0031589 | cell-substrate adhesion | 295 | 1.896323 | 0.0163009 | 0.0113833 |
| GO:0060487 | lung epithelial cell differentiation | 14 | 1.895789 | 0.0325638 | 0.0227400 |
| GO:0001773 | myeloid dendritic cell activation | 21 | 1.894269 | 0.0163009 | 0.0113833 |
| GO:0010631 | epithelial cell migration | 256 | 1.893528 | 0.0163009 | 0.0113833 |
| GO:0002827 | positive regulation of T-helper 1 type immune response | 12 | 1.893490 | 0.0163009 | 0.0113833 |
| GO:0014015 | positive regulation of gliogenesis | 69 | 1.892174 | 0.0163009 | 0.0113833 |
| GO:2001237 | negative regulation of extrinsic apoptotic signaling pathway | 87 | 1.891388 | 0.0163009 | 0.0113833 |
| GO:0043044 | ATP-dependent chromatin remodeling | 72 | 1.891105 | 0.0163009 | 0.0113833 |
| GO:1901213 | regulation of transcription from RNA polymerase II promoter involved in heart development | 12 | 1.890390 | 0.0163009 | 0.0113833 |
| GO:0002715 | regulation of natural killer cell mediated immunity | 31 | 1.887702 | 0.0163009 | 0.0113833 |
| GO:0060135 | maternal process involved in female pregnancy | 56 | 1.887460 | 0.0163009 | 0.0113833 |
| GO:0045601 | regulation of endothelial cell differentiation | 26 | 1.887459 | 0.0163009 | 0.0113833 |
| GO:1902895 | positive regulation of pri-miRNA transcription by RNA polymerase II | 27 | 1.886344 | 0.0163009 | 0.0113833 |
| GO:0090594 | inflammatory response to wounding | 12 | 1.885613 | 0.0163009 | 0.0113833 |
| GO:0001667 | ameboidal-type cell migration | 333 | 1.885574 | 0.0163009 | 0.0113833 |
| GO:2000516 | positive regulation of CD4-positive, alpha-beta T cell activation | 28 | 1.885434 | 0.0163009 | 0.0113833 |
| GO:0043122 | regulation of I-kappaB kinase/NF-kappaB signaling | 204 | 1.884494 | 0.0163009 | 0.0113833 |
| GO:0016458 | gene silencing | 227 | 1.882284 | 0.0163009 | 0.0113833 |
| GO:0007249 | I-kappaB kinase/NF-kappaB signaling | 231 | 1.882138 | 0.0163009 | 0.0113833 |
| GO:0014855 | striated muscle cell proliferation | 58 | 1.878940 | 0.0163009 | 0.0113833 |
| GO:0045581 | negative regulation of T cell differentiation | 38 | 1.877032 | 0.0256950 | 0.0179433 |
| GO:0032757 | positive regulation of interleukin-8 production | 36 | 1.876516 | 0.0256950 | 0.0179433 |
| GO:0090132 | epithelium migration | 257 | 1.875151 | 0.0163009 | 0.0113833 |
| GO:0007157 | heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules | 27 | 1.874601 | 0.0163009 | 0.0113833 |
| GO:0061333 | renal tubule morphogenesis | 66 | 1.874248 | 0.0163009 | 0.0113833 |
| GO:0002040 | sprouting angiogenesis | 100 | 1.872913 | 0.0163009 | 0.0113833 |
| GO:0060675 | ureteric bud morphogenesis | 56 | 1.871069 | 0.0163009 | 0.0113833 |
| GO:0043542 | endothelial cell migration | 187 | 1.869551 | 0.0163009 | 0.0113833 |
| GO:0001658 | branching involved in ureteric bud morphogenesis | 51 | 1.869461 | 0.0259198 | 0.0181004 |
| GO:2000737 | negative regulation of stem cell differentiation | 19 | 1.869447 | 0.0256950 | 0.0179433 |
| GO:0040017 | positive regulation of locomotion | 470 | 1.868969 | 0.0163009 | 0.0113833 |
| GO:0030098 | lymphocyte differentiation | 272 | 1.868650 | 0.0163009 | 0.0113833 |
| GO:0001837 | epithelial to mesenchymal transition | 121 | 1.867779 | 0.0163009 | 0.0113833 |
| GO:0071674 | mononuclear cell migration | 54 | 1.867547 | 0.0163009 | 0.0113833 |
| GO:0036120 | cellular response to platelet-derived growth factor stimulus | 20 | 1.866624 | 0.0256950 | 0.0179433 |
| GO:0070663 | regulation of leukocyte proliferation | 177 | 1.866292 | 0.0163009 | 0.0113833 |
| GO:0002697 | regulation of immune effector process | 310 | 1.864815 | 0.0163009 | 0.0113833 |
| GO:0007159 | leukocyte cell-cell adhesion | 272 | 1.864264 | 0.0163009 | 0.0113833 |
| GO:0001756 | somitogenesis | 49 | 1.864114 | 0.0256950 | 0.0179433 |
| GO:0006949 | syncytium formation | 42 | 1.863773 | 0.0256950 | 0.0179433 |
| GO:0007596 | blood coagulation | 276 | 1.863759 | 0.0163009 | 0.0113833 |
| GO:0050817 | coagulation | 278 | 1.862314 | 0.0163009 | 0.0113833 |
| GO:0060541 | respiratory system development | 174 | 1.862072 | 0.0163009 | 0.0113833 |
| GO:0072234 | metanephric nephron tubule development | 19 | 1.861117 | 0.0256950 | 0.0179433 |
| GO:0090130 | tissue migration | 262 | 1.859746 | 0.0163009 | 0.0113833 |
| GO:0007221 | positive regulation of transcription of Notch receptor target | 17 | 1.859224 | 0.0325638 | 0.0227400 |
| GO:1990868 | response to chemokine | 47 | 1.859103 | 0.0256950 | 0.0179433 |
| GO:1990869 | cellular response to chemokine | 47 | 1.859103 | 0.0256950 | 0.0179433 |
| GO:0048762 | mesenchymal cell differentiation | 171 | 1.858978 | 0.0163009 | 0.0113833 |
| GO:0001657 | ureteric bud development | 87 | 1.858747 | 0.0163009 | 0.0113833 |
| GO:0002714 | positive regulation of B cell mediated immunity | 28 | 1.857075 | 0.0163009 | 0.0113833 |
| GO:0002891 | positive regulation of immunoglobulin mediated immune response | 28 | 1.857075 | 0.0163009 | 0.0113833 |
| GO:0003174 | mitral valve development | 11 | 1.855191 | 0.0256950 | 0.0179433 |
| GO:0002228 | natural killer cell mediated immunity | 47 | 1.854758 | 0.0256950 | 0.0179433 |
| GO:0002291 | T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell | 10 | 1.853873 | 0.0163009 | 0.0113833 |
| GO:0032611 | interleukin-1 beta production | 71 | 1.853723 | 0.0163009 | 0.0113833 |
| GO:0046640 | regulation of alpha-beta T cell proliferation | 23 | 1.852490 | 0.0163009 | 0.0113833 |
| GO:0072163 | mesonephric epithelium development | 88 | 1.851483 | 0.0163009 | 0.0113833 |
| GO:0072164 | mesonephric tubule development | 88 | 1.851483 | 0.0163009 | 0.0113833 |
| GO:0032963 | collagen metabolic process | 79 | 1.851348 | 0.0163009 | 0.0113833 |
| GO:0002521 | leukocyte differentiation | 407 | 1.849519 | 0.0163009 | 0.0113833 |
| GO:0050678 | regulation of epithelial cell proliferation | 276 | 1.847584 | 0.0163009 | 0.0113833 |
| GO:0002920 | regulation of humoral immune response | 46 | 1.846352 | 0.0256950 | 0.0179433 |
| GO:0010594 | regulation of endothelial cell migration | 145 | 1.846086 | 0.0163009 | 0.0113833 |
| GO:0045778 | positive regulation of ossification | 85 | 1.845822 | 0.0163009 | 0.0113833 |
| GO:0002753 | cytoplasmic pattern recognition receptor signaling pathway | 59 | 1.845744 | 0.0163009 | 0.0113833 |
| GO:0061045 | negative regulation of wound healing | 58 | 1.845279 | 0.0163009 | 0.0113833 |
| GO:1903670 | regulation of sprouting angiogenesis | 63 | 1.844496 | 0.0163009 | 0.0113833 |
| GO:0060713 | labyrinthine layer morphogenesis | 18 | 1.844154 | 0.0468647 | 0.0327267 |
| GO:0032944 | regulation of mononuclear cell proliferation | 169 | 1.843834 | 0.0163009 | 0.0113833 |
| GO:0061041 | regulation of wound healing | 113 | 1.843206 | 0.0163009 | 0.0113833 |
| GO:0036003 | positive regulation of transcription from RNA polymerase II promoter in response to stress | 24 | 1.842983 | 0.0256950 | 0.0179433 |
| GO:0019915 | lipid storage | 57 | 1.841538 | 0.0163009 | 0.0113833 |
| GO:0002703 | regulation of leukocyte mediated immunity | 155 | 1.840757 | 0.0163009 | 0.0113833 |
| GO:0060317 | cardiac epithelial to mesenchymal transition | 32 | 1.840155 | 0.0163009 | 0.0113833 |
| GO:0033687 | osteoblast proliferation | 22 | 1.840090 | 0.0163009 | 0.0113833 |
| GO:0055092 | sterol homeostasis | 59 | 1.839947 | 0.0163009 | 0.0113833 |
| GO:0061383 | trabecula morphogenesis | 44 | 1.839812 | 0.0325638 | 0.0227400 |
| GO:1901890 | positive regulation of cell junction assembly | 31 | 1.839795 | 0.0163009 | 0.0113833 |
| GO:0060485 | mesenchyme development | 210 | 1.839608 | 0.0163009 | 0.0113833 |
| GO:0048660 | regulation of smooth muscle cell proliferation | 125 | 1.837426 | 0.0163009 | 0.0113833 |
| GO:0033631 | cell-cell adhesion mediated by integrin | 14 | 1.837265 | 0.0325638 | 0.0227400 |
| GO:0046633 | alpha-beta T cell proliferation | 26 | 1.836904 | 0.0163009 | 0.0113833 |
| GO:0007565 | female pregnancy | 159 | 1.835430 | 0.0163009 | 0.0113833 |
| GO:0040029 | regulation of gene expression, epigenetic | 283 | 1.833592 | 0.0163009 | 0.0113833 |
| GO:0098581 | detection of external biotic stimulus | 13 | 1.833551 | 0.0399030 | 0.0278651 |
| GO:0060562 | epithelial tube morphogenesis | 274 | 1.833518 | 0.0163009 | 0.0113833 |
| GO:0050670 | regulation of lymphocyte proliferation | 168 | 1.832897 | 0.0163009 | 0.0113833 |
| GO:0060009 | Sertoli cell development | 14 | 1.832823 | 0.0325638 | 0.0227400 |
| GO:0001710 | mesodermal cell fate commitment | 15 | 1.832544 | 0.0397381 | 0.0277500 |
| GO:0001823 | mesonephros development | 90 | 1.832539 | 0.0163009 | 0.0113833 |
| GO:0060425 | lung morphogenesis | 45 | 1.832494 | 0.0325638 | 0.0227400 |
| GO:0030224 | monocyte differentiation | 31 | 1.832143 | 0.0163009 | 0.0113833 |
| GO:1903131 | mononuclear cell differentiation | 31 | 1.832143 | 0.0163009 | 0.0113833 |
| GO:1903037 | regulation of leukocyte cell-cell adhesion | 244 | 1.830181 | 0.0163009 | 0.0113833 |
| GO:0002532 | production of molecular mediator involved in inflammatory response | 56 | 1.829235 | 0.0163009 | 0.0113833 |
| GO:0048260 | positive regulation of receptor-mediated endocytosis | 43 | 1.825883 | 0.0327718 | 0.0228853 |
| GO:0072111 | cell proliferation involved in kidney development | 16 | 1.825036 | 0.0467758 | 0.0326645 |
| GO:0050679 | positive regulation of epithelial cell proliferation | 159 | 1.824577 | 0.0163009 | 0.0113833 |
| GO:0001649 | osteoblast differentiation | 193 | 1.823856 | 0.0163009 | 0.0113833 |
| GO:0050702 | interleukin-1 beta secretion | 42 | 1.823766 | 0.0325638 | 0.0227400 |
| GO:0010811 | positive regulation of cell-substrate adhesion | 98 | 1.823616 | 0.0163009 | 0.0113833 |
| GO:0002706 | regulation of lymphocyte mediated immunity | 109 | 1.823408 | 0.0163009 | 0.0113833 |
| GO:0046641 | positive regulation of alpha-beta T cell proliferation | 14 | 1.823202 | 0.0325638 | 0.0227400 |
| GO:0045620 | negative regulation of lymphocyte differentiation | 44 | 1.822794 | 0.0325638 | 0.0227400 |
| GO:0034121 | regulation of toll-like receptor signaling pathway | 59 | 1.821114 | 0.0163009 | 0.0113833 |
| GO:0007599 | hemostasis | 280 | 1.819826 | 0.0163009 | 0.0113833 |
| GO:0050863 | regulation of T cell activation | 259 | 1.818125 | 0.0163009 | 0.0113833 |
| GO:0003179 | heart valve morphogenesis | 46 | 1.818028 | 0.0256950 | 0.0179433 |
| GO:0007507 | heart development | 479 | 1.817890 | 0.0163009 | 0.0113833 |
| GO:0022407 | regulation of cell-cell adhesion | 321 | 1.816402 | 0.0163009 | 0.0113833 |
| GO:0007179 | transforming growth factor beta receptor signaling pathway | 162 | 1.816087 | 0.0163009 | 0.0113833 |
| GO:0048659 | smooth muscle cell proliferation | 127 | 1.815300 | 0.0163009 | 0.0113833 |
| GO:0060669 | embryonic placenta morphogenesis | 23 | 1.814344 | 0.0256950 | 0.0179433 |
| GO:0060008 | Sertoli cell differentiation | 18 | 1.813795 | 0.0468647 | 0.0327267 |
| GO:0045785 | positive regulation of cell adhesion | 334 | 1.813704 | 0.0163009 | 0.0113833 |
| GO:0002449 | lymphocyte mediated immunity | 187 | 1.813407 | 0.0163009 | 0.0113833 |
| GO:0097201 | negative regulation of transcription from RNA polymerase II promoter in response to stress | 12 | 1.813050 | 0.0327126 | 0.0228439 |
| GO:0050650 | chondroitin sulfate proteoglycan biosynthetic process | 28 | 1.812344 | 0.0256950 | 0.0179433 |
| GO:0003206 | cardiac chamber morphogenesis | 108 | 1.811903 | 0.0163009 | 0.0113833 |
| GO:1903039 | positive regulation of leukocyte cell-cell adhesion | 178 | 1.811751 | 0.0163009 | 0.0113833 |
| GO:0034329 | cell junction assembly | 201 | 1.811580 | 0.0163009 | 0.0113833 |
| GO:0003215 | cardiac right ventricle morphogenesis | 11 | 1.811505 | 0.0325638 | 0.0227400 |
| GO:0043484 | regulation of RNA splicing | 106 | 1.809896 | 0.0163009 | 0.0113833 |
| GO:0042531 | positive regulation of tyrosine phosphorylation of STAT protein | 44 | 1.808973 | 0.0325638 | 0.0227400 |
| GO:1900026 | positive regulation of substrate adhesion-dependent cell spreading | 32 | 1.808237 | 0.0163009 | 0.0113833 |
| GO:0002712 | regulation of B cell mediated immunity | 40 | 1.808092 | 0.0325638 | 0.0227400 |
| GO:0002889 | regulation of immunoglobulin mediated immune response | 40 | 1.808092 | 0.0325638 | 0.0227400 |
| GO:0002221 | pattern recognition receptor signaling pathway | 168 | 1.807998 | 0.0163009 | 0.0113833 |
| GO:1903671 | negative regulation of sprouting angiogenesis | 23 | 1.807662 | 0.0256950 | 0.0179433 |
| GO:1905953 | negative regulation of lipid localization | 33 | 1.804654 | 0.0163009 | 0.0113833 |
| GO:2000050 | regulation of non-canonical Wnt signaling pathway | 22 | 1.804380 | 0.0325638 | 0.0227400 |
| GO:0001893 | maternal placenta development | 33 | 1.803910 | 0.0163009 | 0.0113833 |
| GO:0032612 | interleukin-1 production | 80 | 1.803802 | 0.0163009 | 0.0113833 |
| GO:0043372 | positive regulation of CD4-positive, alpha-beta T cell differentiation | 24 | 1.802113 | 0.0256950 | 0.0179433 |
| GO:0002548 | monocyte chemotaxis | 33 | 1.801957 | 0.0163009 | 0.0113833 |
| GO:0033619 | membrane protein proteolysis | 52 | 1.800198 | 0.0259198 | 0.0181004 |
| GO:0060142 | regulation of syncytium formation by plasma membrane fusion | 21 | 1.799761 | 0.0256950 | 0.0179433 |
| GO:0085029 | extracellular matrix assembly | 25 | 1.799709 | 0.0325638 | 0.0227400 |
| GO:0048644 | muscle organ morphogenesis | 62 | 1.799307 | 0.0163009 | 0.0113833 |
| GO:0043535 | regulation of blood vessel endothelial cell migration | 83 | 1.798916 | 0.0163009 | 0.0113833 |
| GO:0032675 | regulation of interleukin-6 production | 106 | 1.798374 | 0.0163009 | 0.0113833 |
| GO:0010632 | regulation of epithelial cell migration | 201 | 1.797881 | 0.0163009 | 0.0113833 |
| GO:0019731 | antibacterial humoral response | 20 | 1.796163 | 0.0397381 | 0.0277500 |
| GO:1900016 | negative regulation of cytokine production involved in inflammatory response | 15 | 1.795767 | 0.0397381 | 0.0277500 |
| GO:0002251 | organ or tissue specific immune response | 17 | 1.794706 | 0.0467808 | 0.0326681 |
| GO:2000177 | regulation of neural precursor cell proliferation | 78 | 1.794394 | 0.0163009 | 0.0113833 |
| GO:1901343 | negative regulation of vasculature development | 100 | 1.794285 | 0.0163009 | 0.0113833 |
| GO:0006023 | aminoglycan biosynthetic process | 103 | 1.792814 | 0.0163009 | 0.0113833 |
| GO:0060412 | ventricular septum morphogenesis | 41 | 1.792802 | 0.0397381 | 0.0277500 |
| GO:0006352 | DNA-templated transcription, initiation | 215 | 1.792801 | 0.0163009 | 0.0113833 |
| GO:1903909 | regulation of receptor clustering | 12 | 1.791603 | 0.0327126 | 0.0228439 |
| GO:0071560 | cellular response to transforming growth factor beta stimulus | 207 | 1.790781 | 0.0163009 | 0.0113833 |
| GO:0051262 | protein tetramerization | 157 | 1.790668 | 0.0163009 | 0.0113833 |
| GO:1902337 | regulation of apoptotic process involved in morphogenesis | 11 | 1.790413 | 0.0464540 | 0.0324398 |
| GO:1904748 | regulation of apoptotic process involved in development | 11 | 1.790413 | 0.0464540 | 0.0324398 |
| GO:0050870 | positive regulation of T cell activation | 165 | 1.790322 | 0.0163009 | 0.0113833 |
| GO:0042632 | cholesterol homeostasis | 58 | 1.789960 | 0.0259198 | 0.0181004 |
| GO:0019724 | B cell mediated immunity | 88 | 1.789203 | 0.0163009 | 0.0113833 |
| GO:0006024 | glycosaminoglycan biosynthetic process | 102 | 1.788838 | 0.0163009 | 0.0113833 |
| GO:0048339 | paraxial mesoderm development | 15 | 1.788537 | 0.0397381 | 0.0277500 |
| GO:1902105 | regulation of leukocyte differentiation | 223 | 1.788017 | 0.0163009 | 0.0113833 |
| GO:0030879 | mammary gland development | 118 | 1.787845 | 0.0163009 | 0.0113833 |
| GO:0003272 | endocardial cushion formation | 23 | 1.785965 | 0.0325638 | 0.0227400 |
| GO:2000696 | regulation of epithelial cell differentiation involved in kidney development | 16 | 1.785645 | 0.0467758 | 0.0326645 |
| GO:0045639 | positive regulation of myeloid cell differentiation | 71 | 1.784747 | 0.0163009 | 0.0113833 |
| GO:0071559 | response to transforming growth factor beta | 213 | 1.781451 | 0.0163009 | 0.0113833 |
| GO:0035909 | aorta morphogenesis | 28 | 1.781122 | 0.0325638 | 0.0227400 |
| GO:0036499 | PERK-mediated unfolded protein response | 20 | 1.780651 | 0.0397381 | 0.0277500 |
| GO:0048732 | gland development | 355 | 1.779743 | 0.0163009 | 0.0113833 |
| GO:0016064 | immunoglobulin mediated immune response | 86 | 1.779681 | 0.0163009 | 0.0113833 |
| GO:0034505 | tooth mineralization | 16 | 1.778963 | 0.0467758 | 0.0326645 |
| GO:0046209 | nitric oxide metabolic process | 66 | 1.778213 | 0.0163009 | 0.0113833 |
| GO:0045685 | regulation of glial cell differentiation | 71 | 1.777066 | 0.0163009 | 0.0113833 |
| GO:0010742 | macrophage derived foam cell differentiation | 28 | 1.776461 | 0.0325638 | 0.0227400 |
| GO:0090077 | foam cell differentiation | 28 | 1.776461 | 0.0325638 | 0.0227400 |
| GO:2000352 | negative regulation of endothelial cell apoptotic process | 20 | 1.775820 | 0.0397381 | 0.0277500 |
| GO:0060977 | coronary vasculature morphogenesis | 14 | 1.774879 | 0.0399030 | 0.0278651 |
| GO:0010470 | regulation of gastrulation | 32 | 1.773164 | 0.0163009 | 0.0113833 |
| GO:0030166 | proteoglycan biosynthetic process | 52 | 1.772613 | 0.0336977 | 0.0235318 |
| GO:0001954 | positive regulation of cell-matrix adhesion | 44 | 1.772239 | 0.0325638 | 0.0227400 |
| GO:0045622 | regulation of T-helper cell differentiation | 27 | 1.771855 | 0.0256950 | 0.0179433 |
| GO:0001654 | eye development | 303 | 1.771519 | 0.0163009 | 0.0113833 |
| GO:0050878 | regulation of body fluid levels | 413 | 1.770007 | 0.0163009 | 0.0113833 |
| GO:2000136 | regulation of cell proliferation involved in heart morphogenesis | 12 | 1.768370 | 0.0399030 | 0.0278651 |
| GO:0043371 | negative regulation of CD4-positive, alpha-beta T cell differentiation | 18 | 1.768002 | 0.0468647 | 0.0327267 |
| GO:0032835 | glomerulus development | 52 | 1.767365 | 0.0336977 | 0.0235318 |
| GO:0051249 | regulation of lymphocyte activation | 345 | 1.764462 | 0.0163009 | 0.0113833 |
| GO:0072202 | cell differentiation involved in metanephros development | 23 | 1.764297 | 0.0325638 | 0.0227400 |
| GO:0043534 | blood vessel endothelial cell migration | 107 | 1.763994 | 0.0163009 | 0.0113833 |
| GO:0010888 | negative regulation of lipid storage | 15 | 1.762937 | 0.0467808 | 0.0326681 |
| GO:2001238 | positive regulation of extrinsic apoptotic signaling pathway | 48 | 1.762073 | 0.0399030 | 0.0278651 |
| GO:0003229 | ventricular cardiac muscle tissue development | 45 | 1.761894 | 0.0399030 | 0.0278651 |
| GO:0042306 | regulation of protein import into nucleus | 51 | 1.761182 | 0.0404520 | 0.0282485 |
| GO:0050865 | regulation of cell activation | 453 | 1.761097 | 0.0163009 | 0.0113833 |
| GO:0150063 | visual system development | 307 | 1.761070 | 0.0163009 | 0.0113833 |
| GO:0002708 | positive regulation of lymphocyte mediated immunity | 72 | 1.760566 | 0.0163009 | 0.0113833 |
| GO:0007160 | cell-matrix adhesion | 192 | 1.760495 | 0.0163009 | 0.0113833 |
| GO:0050921 | positive regulation of chemotaxis | 114 | 1.760388 | 0.0163009 | 0.0113833 |
| GO:0042304 | regulation of fatty acid biosynthetic process | 36 | 1.759831 | 0.0256950 | 0.0179433 |
| GO:0045682 | regulation of epidermis development | 63 | 1.759361 | 0.0163009 | 0.0113833 |
| GO:0045619 | regulation of lymphocyte differentiation | 139 | 1.758581 | 0.0163009 | 0.0113833 |
| GO:0010575 | positive regulation of vascular endothelial growth factor production | 24 | 1.758009 | 0.0397381 | 0.0277500 |
| GO:0060428 | lung epithelium development | 28 | 1.757250 | 0.0325638 | 0.0227400 |
| GO:0007162 | negative regulation of cell adhesion | 223 | 1.756730 | 0.0163009 | 0.0113833 |
| GO:0051251 | positive regulation of lymphocyte activation | 218 | 1.756096 | 0.0163009 | 0.0113833 |
| GO:0032964 | collagen biosynthetic process | 40 | 1.755332 | 0.0325638 | 0.0227400 |
| GO:0043010 | camera-type eye development | 263 | 1.755043 | 0.0163009 | 0.0113833 |
| GO:0010831 | positive regulation of myotube differentiation | 23 | 1.754484 | 0.0325638 | 0.0227400 |
| GO:0035850 | epithelial cell differentiation involved in kidney development | 39 | 1.754133 | 0.0325638 | 0.0227400 |
| GO:0043277 | apoptotic cell clearance | 35 | 1.751872 | 0.0325638 | 0.0227400 |
| GO:0061448 | connective tissue development | 202 | 1.751458 | 0.0163009 | 0.0113833 |
| GO:0003281 | ventricular septum development | 68 | 1.751388 | 0.0259198 | 0.0181004 |
| GO:0003279 | cardiac septum development | 101 | 1.750747 | 0.0163009 | 0.0113833 |
| GO:2001057 | reactive nitrogen species metabolic process | 69 | 1.749285 | 0.0163009 | 0.0113833 |
| GO:0042089 | cytokine biosynthetic process | 89 | 1.748636 | 0.0163009 | 0.0113833 |
| GO:0048880 | sensory system development | 308 | 1.748489 | 0.0163009 | 0.0113833 |
| GO:0051147 | regulation of muscle cell differentiation | 138 | 1.748004 | 0.0163009 | 0.0113833 |
| GO:0044706 | multi-multicellular organism process | 186 | 1.747020 | 0.0163009 | 0.0113833 |
| GO:0042692 | muscle cell differentiation | 289 | 1.746236 | 0.0163009 | 0.0113833 |
| GO:0043536 | positive regulation of blood vessel endothelial cell migration | 53 | 1.745795 | 0.0404520 | 0.0282485 |
| GO:0050728 | negative regulation of inflammatory response | 110 | 1.745551 | 0.0163009 | 0.0113833 |
| GO:0045687 | positive regulation of glial cell differentiation | 45 | 1.745505 | 0.0399030 | 0.0278651 |
| GO:0044319 | wound healing, spreading of cells | 28 | 1.745239 | 0.0325638 | 0.0227400 |
| GO:0090505 | epiboly involved in wound healing | 28 | 1.745239 | 0.0325638 | 0.0227400 |
| GO:0001825 | blastocyst formation | 32 | 1.745151 | 0.0163009 | 0.0113833 |
| GO:1902106 | negative regulation of leukocyte differentiation | 84 | 1.745144 | 0.0163009 | 0.0113833 |
| GO:0051894 | positive regulation of focal adhesion assembly | 23 | 1.744498 | 0.0395251 | 0.0276012 |
| GO:0035791 | platelet-derived growth factor receptor-beta signaling pathway | 14 | 1.744128 | 0.0468647 | 0.0327267 |
| GO:0042789 | mRNA transcription by RNA polymerase II | 16 | 1.743970 | 0.0467758 | 0.0326645 |
| GO:0018022 | peptidyl-lysine methylation | 112 | 1.743645 | 0.0163009 | 0.0113833 |
| GO:0060333 | interferon-gamma-mediated signaling pathway | 83 | 1.743626 | 0.0163009 | 0.0113833 |
| GO:0048608 | reproductive structure development | 354 | 1.742536 | 0.0163009 | 0.0113833 |
| GO:0018126 | protein hydroxylation | 22 | 1.741543 | 0.0397381 | 0.0277500 |
| GO:0061311 | cell surface receptor signaling pathway involved in heart development | 27 | 1.741464 | 0.0325926 | 0.0227601 |
| GO:0072574 | hepatocyte proliferation | 16 | 1.741105 | 0.0467758 | 0.0326645 |
| GO:0072575 | epithelial cell proliferation involved in liver morphogenesis | 16 | 1.741105 | 0.0467758 | 0.0326645 |
| GO:0050864 | regulation of B cell activation | 97 | 1.740461 | 0.0259198 | 0.0181004 |
| GO:0010595 | positive regulation of endothelial cell migration | 95 | 1.740267 | 0.0259198 | 0.0181004 |
| GO:2000379 | positive regulation of reactive oxygen species metabolic process | 83 | 1.740147 | 0.0163009 | 0.0113833 |
| GO:0034330 | cell junction organization | 259 | 1.739877 | 0.0163009 | 0.0113833 |
| GO:0033688 | regulation of osteoblast proliferation | 21 | 1.738387 | 0.0399030 | 0.0278651 |
| GO:0034968 | histone lysine methylation | 100 | 1.738066 | 0.0163009 | 0.0113833 |
| GO:1902042 | negative regulation of extrinsic apoptotic signaling pathway via death domain receptors | 32 | 1.737712 | 0.0163009 | 0.0113833 |
| GO:1903035 | negative regulation of response to wounding | 71 | 1.737445 | 0.0163009 | 0.0113833 |
| GO:0019058 | viral life cycle | 292 | 1.737349 | 0.0163009 | 0.0113833 |
| GO:0071604 | transforming growth factor beta production | 32 | 1.737176 | 0.0163009 | 0.0113833 |
| GO:0070935 | 3’-UTR-mediated mRNA stabilization | 14 | 1.736828 | 0.0468647 | 0.0327267 |
| GO:0003203 | endocardial cushion morphogenesis | 32 | 1.736728 | 0.0163009 | 0.0113833 |
| GO:2000778 | positive regulation of interleukin-6 secretion | 23 | 1.736182 | 0.0465001 | 0.0324720 |
| GO:0010717 | regulation of epithelial to mesenchymal transition | 77 | 1.735835 | 0.0163009 | 0.0113833 |
| GO:0070661 | leukocyte proliferation | 227 | 1.735540 | 0.0163009 | 0.0113833 |
| GO:0045580 | regulation of T cell differentiation | 117 | 1.733667 | 0.0163009 | 0.0113833 |
| GO:0070423 | nucleotide-binding oligomerization domain containing signaling pathway | 35 | 1.733401 | 0.0325638 | 0.0227400 |
| GO:0032103 | positive regulation of response to external stimulus | 251 | 1.733346 | 0.0163009 | 0.0113833 |
| GO:0048598 | embryonic morphogenesis | 462 | 1.732915 | 0.0163009 | 0.0113833 |
| GO:1903034 | regulation of response to wounding | 140 | 1.731253 | 0.0163009 | 0.0113833 |
| GO:0001569 | branching involved in blood vessel morphogenesis | 26 | 1.730460 | 0.0399030 | 0.0278651 |
| GO:0035313 | wound healing, spreading of epidermal cells | 14 | 1.730444 | 0.0468647 | 0.0327267 |
| GO:0003231 | cardiac ventricle development | 112 | 1.730000 | 0.0163009 | 0.0113833 |
| GO:0002262 | myeloid cell homeostasis | 130 | 1.728983 | 0.0163009 | 0.0113833 |
| GO:0002694 | regulation of leukocyte activation | 420 | 1.728955 | 0.0163009 | 0.0113833 |
| GO:0045598 | regulation of fat cell differentiation | 108 | 1.728722 | 0.0163009 | 0.0113833 |
| GO:0043123 | positive regulation of I-kappaB kinase/NF-kappaB signaling | 159 | 1.728286 | 0.0163009 | 0.0113833 |
| GO:0035886 | vascular smooth muscle cell differentiation | 24 | 1.727656 | 0.0397381 | 0.0277500 |
| GO:1901222 | regulation of NIK/NF-kappaB signaling | 93 | 1.727335 | 0.0259198 | 0.0181004 |
| GO:0016577 | histone demethylation | 24 | 1.726554 | 0.0397381 | 0.0277500 |
| GO:0034341 | response to interferon-gamma | 159 | 1.726475 | 0.0163009 | 0.0113833 |
| GO:0060563 | neuroepithelial cell differentiation | 45 | 1.725731 | 0.0468647 | 0.0327267 |
| GO:0014031 | mesenchymal cell development | 56 | 1.725517 | 0.0399424 | 0.0278926 |
| GO:0014013 | regulation of gliogenesis | 111 | 1.725452 | 0.0163009 | 0.0113833 |
| GO:0070664 | negative regulation of leukocyte proliferation | 63 | 1.723531 | 0.0163009 | 0.0113833 |
| GO:0035767 | endothelial cell chemotaxis | 24 | 1.723053 | 0.0397381 | 0.0277500 |
| GO:0060840 | artery development | 81 | 1.722713 | 0.0163009 | 0.0113833 |
| GO:0008360 | regulation of cell shape | 118 | 1.722624 | 0.0163009 | 0.0113833 |
| GO:0042107 | cytokine metabolic process | 90 | 1.722333 | 0.0163009 | 0.0113833 |
| GO:0007044 | cell-substrate junction assembly | 93 | 1.722018 | 0.0259198 | 0.0181004 |
| GO:0032922 | circadian regulation of gene expression | 57 | 1.722014 | 0.0399030 | 0.0278651 |
| GO:0010634 | positive regulation of epithelial cell migration | 134 | 1.721574 | 0.0163009 | 0.0113833 |
| GO:0070665 | positive regulation of leukocyte proliferation | 103 | 1.721500 | 0.0163009 | 0.0113833 |
| GO:0032943 | mononuclear cell proliferation | 210 | 1.721224 | 0.0163009 | 0.0113833 |
| GO:0030595 | leukocyte chemotaxis | 149 | 1.719725 | 0.0163009 | 0.0113833 |
| GO:0010837 | regulation of keratinocyte proliferation | 28 | 1.717783 | 0.0325638 | 0.0227400 |
| GO:0046651 | lymphocyte proliferation | 208 | 1.715920 | 0.0163009 | 0.0113833 |
| GO:0009952 | anterior/posterior pattern specification | 136 | 1.714609 | 0.0163009 | 0.0113833 |
| GO:1902041 | regulation of extrinsic apoptotic signaling pathway via death domain receptors | 51 | 1.714336 | 0.0479310 | 0.0334712 |
| GO:0034101 | erythrocyte homeostasis | 105 | 1.714278 | 0.0163009 | 0.0113833 |
| GO:0071634 | regulation of transforming growth factor beta production | 30 | 1.713948 | 0.0325638 | 0.0227400 |
| GO:0002673 | regulation of acute inflammatory response | 69 | 1.713691 | 0.0163009 | 0.0113833 |
| GO:0098542 | defense response to other organism | 314 | 1.713686 | 0.0163009 | 0.0113833 |
| GO:0045066 | regulatory T cell differentiation | 29 | 1.713231 | 0.0325638 | 0.0227400 |
| GO:0035282 | segmentation | 70 | 1.712278 | 0.0163009 | 0.0113833 |
| GO:0030449 | regulation of complement activation | 36 | 1.712009 | 0.0399030 | 0.0278651 |
| GO:2000353 | positive regulation of endothelial cell apoptotic process | 16 | 1.711954 | 0.0467758 | 0.0326645 |
| GO:0097191 | extrinsic apoptotic signaling pathway | 192 | 1.711116 | 0.0163009 | 0.0113833 |
| GO:0002699 | positive regulation of immune effector process | 164 | 1.709659 | 0.0163009 | 0.0113833 |
| GO:0032635 | interleukin-6 production | 114 | 1.708735 | 0.0163009 | 0.0113833 |
| GO:0060976 | coronary vasculature development | 43 | 1.708733 | 0.0399459 | 0.0278951 |
| GO:0048593 | camera-type eye morphogenesis | 99 | 1.708604 | 0.0259198 | 0.0181004 |
| GO:1905314 | semi-lunar valve development | 33 | 1.707667 | 0.0394902 | 0.0275769 |
| GO:0002224 | toll-like receptor signaling pathway | 126 | 1.706628 | 0.0163009 | 0.0113833 |
| GO:0002526 | acute inflammatory response | 111 | 1.705466 | 0.0163009 | 0.0113833 |
| GO:1903426 | regulation of reactive oxygen species biosynthetic process | 76 | 1.705132 | 0.0163009 | 0.0113833 |
| GO:0035872 | nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway | 36 | 1.704823 | 0.0399030 | 0.0278651 |
| GO:1903427 | negative regulation of reactive oxygen species biosynthetic process | 27 | 1.704792 | 0.0399030 | 0.0278651 |
| GO:0032755 | positive regulation of interleukin-6 production | 67 | 1.704175 | 0.0259198 | 0.0181004 |
| GO:2000181 | negative regulation of blood vessel morphogenesis | 90 | 1.703702 | 0.0163009 | 0.0113833 |
| GO:0060795 | cell fate commitment involved in formation of primary germ layer | 25 | 1.701599 | 0.0467587 | 0.0326526 |
| GO:0030857 | negative regulation of epithelial cell differentiation | 28 | 1.701021 | 0.0325638 | 0.0227400 |
| GO:0071675 | regulation of mononuclear cell migration | 41 | 1.700848 | 0.0468268 | 0.0327001 |
| GO:0010464 | regulation of mesenchymal cell proliferation | 32 | 1.700782 | 0.0256950 | 0.0179433 |
| GO:0006606 | protein import into nucleus | 96 | 1.700140 | 0.0259198 | 0.0181004 |
| GO:0097581 | lamellipodium organization | 71 | 1.699903 | 0.0163009 | 0.0113833 |
| GO:0007259 | JAK-STAT cascade | 102 | 1.699291 | 0.0163009 | 0.0113833 |
| GO:0061458 | reproductive system development | 357 | 1.698398 | 0.0163009 | 0.0113833 |
| GO:0051053 | negative regulation of DNA metabolic process | 119 | 1.697216 | 0.0163009 | 0.0113833 |
| GO:0048592 | eye morphogenesis | 126 | 1.697189 | 0.0163009 | 0.0113833 |
| GO:0022409 | positive regulation of cell-cell adhesion | 206 | 1.696118 | 0.0163009 | 0.0113833 |
| GO:0006956 | complement activation | 43 | 1.696047 | 0.0399459 | 0.0278951 |
| GO:0003205 | cardiac chamber development | 148 | 1.695877 | 0.0163009 | 0.0113833 |
| GO:0042088 | T-helper 1 type immune response | 34 | 1.695840 | 0.0468647 | 0.0327267 |
| GO:0007043 | cell-cell junction assembly | 88 | 1.694962 | 0.0163009 | 0.0113833 |
| GO:1900015 | regulation of cytokine production involved in inflammatory response | 34 | 1.693597 | 0.0468647 | 0.0327267 |
| GO:0060537 | muscle tissue development | 323 | 1.692796 | 0.0163009 | 0.0113833 |
| GO:0071260 | cellular response to mechanical stimulus | 69 | 1.692460 | 0.0259198 | 0.0181004 |
| GO:0048565 | digestive tract development | 106 | 1.692063 | 0.0163009 | 0.0113833 |
| GO:0002696 | positive regulation of leukocyte activation | 255 | 1.692010 | 0.0163009 | 0.0113833 |
| GO:0032946 | positive regulation of mononuclear cell proliferation | 100 | 1.691647 | 0.0163009 | 0.0113833 |
| GO:0050727 | regulation of inflammatory response | 299 | 1.691469 | 0.0163009 | 0.0113833 |
| GO:0007435 | salivary gland morphogenesis | 32 | 1.691318 | 0.0394902 | 0.0275769 |
| GO:0060759 | regulation of response to cytokine stimulus | 154 | 1.687517 | 0.0163009 | 0.0113833 |
| GO:0060415 | muscle tissue morphogenesis | 58 | 1.686603 | 0.0481798 | 0.0336450 |
| GO:0007431 | salivary gland development | 36 | 1.686508 | 0.0399030 | 0.0278651 |
| GO:0048536 | spleen development | 26 | 1.686255 | 0.0399030 | 0.0278651 |
| GO:0001701 | in utero embryonic development | 307 | 1.685789 | 0.0163009 | 0.0113833 |
| GO:0050867 | positive regulation of cell activation | 265 | 1.684700 | 0.0163009 | 0.0113833 |
| GO:0048144 | fibroblast proliferation | 76 | 1.684354 | 0.0163009 | 0.0113833 |
| GO:0072273 | metanephric nephron morphogenesis | 25 | 1.683234 | 0.0467587 | 0.0326526 |
| GO:0045668 | negative regulation of osteoblast differentiation | 36 | 1.683213 | 0.0469681 | 0.0327988 |
| GO:0030279 | negative regulation of ossification | 57 | 1.682032 | 0.0399030 | 0.0278651 |
| GO:0007423 | sensory organ development | 449 | 1.681285 | 0.0163009 | 0.0113833 |
| GO:0045216 | cell-cell junction organization | 116 | 1.681215 | 0.0163009 | 0.0113833 |
| GO:0032945 | negative regulation of mononuclear cell proliferation | 58 | 1.681199 | 0.0481798 | 0.0336450 |
| GO:0050672 | negative regulation of lymphocyte proliferation | 58 | 1.681199 | 0.0481798 | 0.0336450 |
| GO:0035270 | endocrine system development | 93 | 1.681029 | 0.0259198 | 0.0181004 |
| GO:0001959 | regulation of cytokine-mediated signaling pathway | 143 | 1.681008 | 0.0163009 | 0.0113833 |
| GO:0001501 | skeletal system development | 394 | 1.680399 | 0.0163009 | 0.0113833 |
| GO:0071354 | cellular response to interleukin-6 | 33 | 1.677193 | 0.0464565 | 0.0324416 |
| GO:0097696 | STAT cascade | 106 | 1.676635 | 0.0163009 | 0.0113833 |
| GO:0048568 | embryonic organ development | 338 | 1.675988 | 0.0163009 | 0.0113833 |
| GO:0060348 | bone development | 163 | 1.675805 | 0.0163009 | 0.0113833 |
| GO:0007517 | muscle organ development | 327 | 1.673995 | 0.0163009 | 0.0113833 |
| GO:0042035 | regulation of cytokine biosynthetic process | 83 | 1.673547 | 0.0163009 | 0.0113833 |
| GO:0032570 | response to progesterone | 40 | 1.672925 | 0.0469124 | 0.0327599 |
| GO:0050871 | positive regulation of B cell activation | 59 | 1.672629 | 0.0408088 | 0.0284976 |
| GO:0090184 | positive regulation of kidney development | 32 | 1.672472 | 0.0464565 | 0.0324416 |
| GO:0030218 | erythrocyte differentiation | 99 | 1.672314 | 0.0259198 | 0.0181004 |
| GO:0070741 | response to interleukin-6 | 36 | 1.671636 | 0.0469681 | 0.0327988 |
| GO:0006303 | double-strand break repair via nonhomologous end joining | 77 | 1.671189 | 0.0163009 | 0.0113833 |
| GO:0002573 | myeloid leukocyte differentiation | 166 | 1.670663 | 0.0163009 | 0.0113833 |
| GO:0050671 | positive regulation of lymphocyte proliferation | 99 | 1.669844 | 0.0259198 | 0.0181004 |
| GO:0090504 | epiboly | 29 | 1.668664 | 0.0397381 | 0.0277500 |
| GO:0016525 | negative regulation of angiogenesis | 89 | 1.666168 | 0.0259198 | 0.0181004 |
| GO:0045165 | cell fate commitment | 173 | 1.665609 | 0.0163009 | 0.0113833 |
| GO:0048710 | regulation of astrocyte differentiation | 31 | 1.665507 | 0.0467758 | 0.0326645 |
| GO:0070613 | regulation of protein processing | 83 | 1.664982 | 0.0163009 | 0.0113833 |
| GO:0097421 | liver regeneration | 29 | 1.664737 | 0.0397381 | 0.0277500 |
| GO:1902532 | negative regulation of intracellular signal transduction | 461 | 1.664042 | 0.0163009 | 0.0113833 |
| GO:0031348 | negative regulation of defense response | 170 | 1.663617 | 0.0163009 | 0.0113833 |
| GO:0000726 | non-recombinational repair | 83 | 1.663509 | 0.0163009 | 0.0113833 |
| GO:0009913 | epidermal cell differentiation | 153 | 1.660987 | 0.0163009 | 0.0113833 |
| GO:0043433 | negative regulation of DNA-binding transcription factor activity | 144 | 1.658615 | 0.0163009 | 0.0113833 |
| GO:0050818 | regulation of coagulation | 64 | 1.658435 | 0.0163009 | 0.0113833 |
| GO:0043409 | negative regulation of MAPK cascade | 146 | 1.658242 | 0.0163009 | 0.0113833 |
| GO:0031532 | actin cytoskeleton reorganization | 82 | 1.657939 | 0.0259198 | 0.0181004 |
| GO:0048771 | tissue remodeling | 133 | 1.656716 | 0.0163009 | 0.0113833 |
| GO:0031099 | regeneration | 163 | 1.656489 | 0.0163009 | 0.0113833 |
| GO:0031100 | animal organ regeneration | 67 | 1.656231 | 0.0259198 | 0.0181004 |
| GO:0007178 | transmembrane receptor protein serine/threonine kinase signaling pathway | 276 | 1.655423 | 0.0163009 | 0.0113833 |
| GO:0098742 | cell-cell adhesion via plasma-membrane adhesion molecules | 204 | 1.655252 | 0.0163009 | 0.0113833 |
| GO:0051384 | response to glucocorticoid | 119 | 1.654085 | 0.0259198 | 0.0181004 |
| GO:0032651 | regulation of interleukin-1 beta production | 61 | 1.654041 | 0.0334693 | 0.0233723 |
| GO:0120162 | positive regulation of cold-induced thermogenesis | 84 | 1.653133 | 0.0163009 | 0.0113833 |
| GO:0030216 | keratinocyte differentiation | 112 | 1.653075 | 0.0259198 | 0.0181004 |
| GO:2000146 | negative regulation of cell motility | 238 | 1.651712 | 0.0163009 | 0.0113833 |
| GO:0007173 | epidermal growth factor receptor signaling pathway | 104 | 1.646665 | 0.0163009 | 0.0113833 |
| GO:0034332 | adherens junction organization | 129 | 1.644699 | 0.0163009 | 0.0113833 |
| GO:0050663 | cytokine secretion | 178 | 1.644155 | 0.0163009 | 0.0113833 |
| GO:0071901 | negative regulation of protein serine/threonine kinase activity | 114 | 1.643109 | 0.0259198 | 0.0181004 |
| GO:0014706 | striated muscle tissue development | 310 | 1.641667 | 0.0163009 | 0.0113833 |
| GO:0070373 | negative regulation of ERK1 and ERK2 cascade | 64 | 1.640789 | 0.0338318 | 0.0236255 |
| GO:0031960 | response to corticosteroid | 135 | 1.640053 | 0.0163009 | 0.0113833 |
| GO:0010810 | regulation of cell-substrate adhesion | 178 | 1.639850 | 0.0163009 | 0.0113833 |
| GO:0030336 | negative regulation of cell migration | 227 | 1.638925 | 0.0163009 | 0.0113833 |
| GO:0050920 | regulation of chemotaxis | 157 | 1.638685 | 0.0163009 | 0.0113833 |
| GO:0001935 | endothelial cell proliferation | 119 | 1.638411 | 0.0259198 | 0.0181004 |
| GO:0001818 | negative regulation of cytokine production | 225 | 1.637597 | 0.0163009 | 0.0113833 |
| GO:0030183 | B cell differentiation | 98 | 1.636794 | 0.0259198 | 0.0181004 |
| GO:0048145 | regulation of fibroblast proliferation | 75 | 1.635742 | 0.0163009 | 0.0113833 |
| GO:0055123 | digestive system development | 115 | 1.635506 | 0.0259198 | 0.0181004 |
| GO:0032102 | negative regulation of response to external stimulus | 258 | 1.633242 | 0.0163009 | 0.0113833 |
| GO:0030522 | intracellular receptor signaling pathway | 253 | 1.631735 | 0.0163009 | 0.0113833 |
| GO:0002698 | negative regulation of immune effector process | 99 | 1.630417 | 0.0259198 | 0.0181004 |
| GO:0048705 | skeletal system morphogenesis | 160 | 1.630014 | 0.0163009 | 0.0113833 |
| GO:0002685 | regulation of leukocyte migration | 157 | 1.629967 | 0.0163009 | 0.0113833 |
| GO:0019827 | stem cell population maintenance | 140 | 1.629590 | 0.0163009 | 0.0113833 |
| GO:0000723 | telomere maintenance | 145 | 1.628975 | 0.0163009 | 0.0113833 |
| GO:0050729 | positive regulation of inflammatory response | 114 | 1.628065 | 0.0259198 | 0.0181004 |
| GO:0098727 | maintenance of cell number | 142 | 1.627375 | 0.0163009 | 0.0113833 |
| GO:0030203 | glycosaminoglycan metabolic process | 143 | 1.625647 | 0.0163009 | 0.0113833 |
| GO:0042326 | negative regulation of phosphorylation | 396 | 1.623966 | 0.0163009 | 0.0113833 |
| GO:0042113 | B cell activation | 186 | 1.623769 | 0.0163009 | 0.0113833 |
| GO:1903317 | regulation of protein maturation | 85 | 1.623546 | 0.0163009 | 0.0113833 |
| GO:0035051 | cardiocyte differentiation | 112 | 1.623116 | 0.0341122 | 0.0238213 |
| GO:0006909 | phagocytosis | 219 | 1.622168 | 0.0163009 | 0.0113833 |
| GO:0048738 | cardiac muscle tissue development | 173 | 1.621893 | 0.0163009 | 0.0113833 |
| GO:0071346 | cellular response to interferon-gamma | 142 | 1.618006 | 0.0163009 | 0.0113833 |
| GO:0051216 | cartilage development | 151 | 1.617303 | 0.0259198 | 0.0181004 |
| GO:0051271 | negative regulation of cellular component movement | 254 | 1.616671 | 0.0163009 | 0.0113833 |
| GO:0016485 | protein processing | 184 | 1.615846 | 0.0163009 | 0.0113833 |
| GO:0006022 | aminoglycan metabolic process | 146 | 1.614960 | 0.0163009 | 0.0113833 |
| GO:1901888 | regulation of cell junction assembly | 86 | 1.612291 | 0.0163009 | 0.0113833 |
| GO:0006986 | response to unfolded protein | 156 | 1.611920 | 0.0259198 | 0.0181004 |
| GO:0007229 | integrin-mediated signaling pathway | 90 | 1.611530 | 0.0259198 | 0.0181004 |
| GO:1903555 | regulation of tumor necrosis factor superfamily cytokine production | 120 | 1.610275 | 0.0338658 | 0.0236492 |
| GO:0042542 | response to hydrogen peroxide | 129 | 1.609989 | 0.0336977 | 0.0235318 |
| GO:0071887 | leukocyte apoptotic process | 83 | 1.609179 | 0.0487739 | 0.0340598 |
| GO:0001936 | regulation of endothelial cell proliferation | 104 | 1.608784 | 0.0259198 | 0.0181004 |
| GO:0001819 | positive regulation of cytokine production | 364 | 1.606572 | 0.0163009 | 0.0113833 |
| GO:0032680 | regulation of tumor necrosis factor production | 117 | 1.604140 | 0.0163009 | 0.0113833 |
| GO:0002761 | regulation of myeloid leukocyte differentiation | 93 | 1.603591 | 0.0341052 | 0.0238164 |
| GO:2000045 | regulation of G1/S transition of mitotic cell cycle | 139 | 1.603339 | 0.0332441 | 0.0232151 |
| GO:0008544 | epidermis development | 242 | 1.602838 | 0.0163009 | 0.0113833 |
| GO:0046425 | regulation of JAK-STAT cascade | 87 | 1.601873 | 0.0259198 | 0.0181004 |
| GO:0048545 | response to steroid hormone | 337 | 1.601295 | 0.0163009 | 0.0113833 |
| GO:0032609 | interferon-gamma production | 78 | 1.598320 | 0.0163009 | 0.0113833 |
| GO:0097529 | myeloid leukocyte migration | 136 | 1.598172 | 0.0259198 | 0.0181004 |
| GO:0051701 | interaction with host | 187 | 1.597637 | 0.0163009 | 0.0113833 |
| GO:0009101 | glycoprotein biosynthetic process | 265 | 1.597310 | 0.0163009 | 0.0113833 |
| GO:0071706 | tumor necrosis factor superfamily cytokine production | 125 | 1.596908 | 0.0337309 | 0.0235550 |
| GO:0002688 | regulation of leukocyte chemotaxis | 89 | 1.596103 | 0.0259198 | 0.0181004 |
| GO:0050707 | regulation of cytokine secretion | 153 | 1.595940 | 0.0259198 | 0.0181004 |
| GO:0048872 | homeostasis of number of cells | 212 | 1.595358 | 0.0163009 | 0.0113833 |
| GO:0040013 | negative regulation of locomotion | 265 | 1.595025 | 0.0163009 | 0.0113833 |
| GO:0007156 | homophilic cell adhesion via plasma membrane adhesion molecules | 119 | 1.592729 | 0.0259198 | 0.0181004 |
| GO:0001659 | temperature homeostasis | 152 | 1.592354 | 0.0259198 | 0.0181004 |
| GO:0048010 | vascular endothelial growth factor receptor signaling pathway | 87 | 1.591525 | 0.0259198 | 0.0181004 |
| GO:0007569 | cell aging | 99 | 1.590731 | 0.0341052 | 0.0238164 |
| GO:0001776 | leukocyte homeostasis | 74 | 1.589042 | 0.0336977 | 0.0235318 |
| GO:0045444 | fat cell differentiation | 192 | 1.587415 | 0.0163009 | 0.0113833 |
| GO:0001933 | negative regulation of protein phosphorylation | 363 | 1.585326 | 0.0163009 | 0.0113833 |
| GO:0043588 | skin development | 214 | 1.585202 | 0.0163009 | 0.0113833 |
| GO:1905952 | regulation of lipid localization | 115 | 1.583176 | 0.0259198 | 0.0181004 |
| GO:1904892 | regulation of STAT cascade | 90 | 1.579647 | 0.0341122 | 0.0238213 |
| GO:0070371 | ERK1 and ERK2 cascade | 241 | 1.579013 | 0.0163009 | 0.0113833 |
| GO:0034333 | adherens junction assembly | 88 | 1.578991 | 0.0420626 | 0.0293732 |
| GO:0032526 | response to retinoic acid | 93 | 1.577909 | 0.0341052 | 0.0238164 |
| GO:0106106 | cold-induced thermogenesis | 129 | 1.573761 | 0.0486648 | 0.0339837 |
| GO:0120161 | regulation of cold-induced thermogenesis | 129 | 1.573761 | 0.0486648 | 0.0339837 |
| GO:0010001 | glial cell differentiation | 200 | 1.571772 | 0.0163009 | 0.0113833 |
| GO:0006959 | humoral immune response | 119 | 1.569872 | 0.0337643 | 0.0235784 |
| GO:0007265 | Ras protein signal transduction | 314 | 1.568428 | 0.0163009 | 0.0113833 |
| GO:0035265 | organ growth | 138 | 1.566270 | 0.0479310 | 0.0334712 |
| GO:1901184 | regulation of ERBB signaling pathway | 83 | 1.565565 | 0.0487739 | 0.0340598 |
| GO:0032640 | tumor necrosis factor production | 121 | 1.565178 | 0.0414987 | 0.0289794 |
| GO:0002009 | morphogenesis of an epithelium | 461 | 1.564542 | 0.0163009 | 0.0113833 |
| GO:0007266 | Rho protein signal transduction | 151 | 1.563486 | 0.0259198 | 0.0181004 |
| GO:0043009 | chordate embryonic development | 496 | 1.560149 | 0.0163009 | 0.0113833 |
| GO:0051090 | regulation of DNA-binding transcription factor activity | 377 | 1.559297 | 0.0163009 | 0.0113833 |
| GO:0006493 | protein O-linked glycosylation | 87 | 1.558964 | 0.0493729 | 0.0344781 |
| GO:0001906 | cell killing | 94 | 1.552809 | 0.0341096 | 0.0238195 |
| GO:0033673 | negative regulation of kinase activity | 214 | 1.549712 | 0.0163009 | 0.0113833 |
| GO:0051170 | import into nucleus | 117 | 1.549609 | 0.0259198 | 0.0181004 |
| GO:0006469 | negative regulation of protein kinase activity | 197 | 1.548833 | 0.0163009 | 0.0113833 |
| GO:0019216 | regulation of lipid metabolic process | 339 | 1.543705 | 0.0163009 | 0.0113833 |
| GO:0001101 | response to acid chemical | 298 | 1.543320 | 0.0163009 | 0.0113833 |
| GO:0042063 | gliogenesis | 262 | 1.541951 | 0.0163009 | 0.0113833 |
| GO:1902806 | regulation of cell cycle G1/S phase transition | 152 | 1.539691 | 0.0259198 | 0.0181004 |
| GO:1903409 | reactive oxygen species biosynthetic process | 96 | 1.538200 | 0.0419599 | 0.0293015 |
| GO:0062014 | negative regulation of small molecule metabolic process | 84 | 1.533317 | 0.0494299 | 0.0345180 |
| GO:2000377 | regulation of reactive oxygen species metabolic process | 161 | 1.527025 | 0.0259198 | 0.0181004 |
| GO:0045936 | negative regulation of phosphate metabolic process | 498 | 1.522672 | 0.0163009 | 0.0113833 |
| GO:0051146 | striated muscle cell differentiation | 212 | 1.518334 | 0.0163009 | 0.0113833 |
| GO:2001020 | regulation of response to DNA damage stimulus | 194 | 1.517527 | 0.0256950 | 0.0179433 |
| GO:0070372 | regulation of ERK1 and ERK2 cascade | 226 | 1.513326 | 0.0163009 | 0.0113833 |
| GO:0090596 | sensory organ morphogenesis | 207 | 1.509917 | 0.0163009 | 0.0113833 |
| GO:0010563 | negative regulation of phosphorus metabolic process | 499 | 1.509790 | 0.0163009 | 0.0113833 |
| GO:0007219 | Notch signaling pathway | 157 | 1.504911 | 0.0259198 | 0.0181004 |
| GO:0035966 | response to topologically incorrect protein | 170 | 1.500023 | 0.0163009 | 0.0113833 |
| GO:1901652 | response to peptide | 433 | 1.497208 | 0.0163009 | 0.0113833 |
| GO:0071407 | cellular response to organic cyclic compound | 489 | 1.495282 | 0.0163009 | 0.0113833 |
| GO:0042330 | taxis | 461 | 1.489261 | 0.0163009 | 0.0113833 |
| GO:0006302 | double-strand break repair | 200 | 1.477868 | 0.0256950 | 0.0179433 |
| GO:0006935 | chemotaxis | 459 | 1.475953 | 0.0163009 | 0.0113833 |
| GO:0009612 | response to mechanical stimulus | 180 | 1.475874 | 0.0259198 | 0.0181004 |
| GO:0007568 | aging | 276 | 1.472302 | 0.0259198 | 0.0181004 |
| GO:0043583 | ear development | 180 | 1.465610 | 0.0259198 | 0.0181004 |
| GO:0043405 | regulation of MAP kinase activity | 293 | 1.462833 | 0.0256950 | 0.0179433 |
| GO:2001234 | negative regulation of apoptotic signaling pathway | 199 | 1.460054 | 0.0325638 | 0.0227400 |
| GO:0009100 | glycoprotein metabolic process | 321 | 1.459553 | 0.0163009 | 0.0113833 |
| GO:0043434 | response to peptide hormone | 359 | 1.454162 | 0.0163009 | 0.0113833 |
| GO:0043281 | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 176 | 1.453980 | 0.0163009 | 0.0113833 |
| GO:2000116 | regulation of cysteine-type endopeptidase activity | 200 | 1.451070 | 0.0325638 | 0.0227400 |
| GO:0000302 | response to reactive oxygen species | 204 | 1.448319 | 0.0256950 | 0.0179433 |
| GO:0071214 | cellular response to abiotic stimulus | 277 | 1.438212 | 0.0258183 | 0.0180295 |
| GO:0104004 | cellular response to environmental stimulus | 277 | 1.438212 | 0.0258183 | 0.0180295 |
| GO:0045088 | regulation of innate immune response | 367 | 1.436410 | 0.0163009 | 0.0113833 |
| GO:0051604 | protein maturation | 238 | 1.432332 | 0.0163009 | 0.0113833 |
| GO:2001233 | regulation of apoptotic signaling pathway | 360 | 1.425854 | 0.0163009 | 0.0113833 |
| GO:0042119 | neutrophil activation | 442 | 1.425386 | 0.0163009 | 0.0113833 |
| GO:0052547 | regulation of peptidase activity | 311 | 1.424759 | 0.0256950 | 0.0179433 |
| GO:0007548 | sex differentiation | 219 | 1.423387 | 0.0325638 | 0.0227400 |
| GO:0002446 | neutrophil mediated immunity | 442 | 1.420592 | 0.0163009 | 0.0113833 |
| GO:0043410 | positive regulation of MAPK cascade | 430 | 1.420062 | 0.0163009 | 0.0113833 |
| GO:0002253 | activation of immune response | 482 | 1.418634 | 0.0163009 | 0.0113833 |
| GO:0097193 | intrinsic apoptotic signaling pathway | 252 | 1.413788 | 0.0325638 | 0.0227400 |
| GO:0071383 | cellular response to steroid hormone stimulus | 224 | 1.413623 | 0.0325638 | 0.0227400 |
| GO:0046578 | regulation of Ras protein signal transduction | 208 | 1.407638 | 0.0399857 | 0.0279229 |
| GO:0048562 | embryonic organ morphogenesis | 217 | 1.404412 | 0.0399030 | 0.0278651 |
| GO:1901653 | cellular response to peptide | 322 | 1.402946 | 0.0391379 | 0.0273308 |
| GO:0036230 | granulocyte activation | 449 | 1.392785 | 0.0163009 | 0.0113833 |
| GO:0043312 | neutrophil degranulation | 431 | 1.389726 | 0.0163009 | 0.0113833 |
| GO:0002283 | neutrophil activation involved in immune response | 433 | 1.388856 | 0.0163009 | 0.0113833 |
| GO:0000082 | G1/S transition of mitotic cell cycle | 229 | 1.388597 | 0.0468647 | 0.0327267 |
| GO:0072593 | reactive oxygen species metabolic process | 229 | 1.387864 | 0.0468647 | 0.0327267 |
| GO:0045926 | negative regulation of growth | 211 | 1.386956 | 0.0399030 | 0.0278651 |
| GO:0052548 | regulation of endopeptidase activity | 287 | 1.384939 | 0.0468647 | 0.0327267 |
| GO:0007264 | small GTPase mediated signal transduction | 449 | 1.383349 | 0.0163009 | 0.0113833 |
| GO:0071900 | regulation of protein serine/threonine kinase activity | 433 | 1.378355 | 0.0163009 | 0.0113833 |
| GO:0044843 | cell cycle G1/S phase transition | 243 | 1.376693 | 0.0399030 | 0.0278651 |
| GO:0090287 | regulation of cellular response to growth factor stimulus | 225 | 1.372181 | 0.0473740 | 0.0330823 |
| GO:0051348 | negative regulation of transferase activity | 241 | 1.367540 | 0.0469681 | 0.0327988 |
| GO:0048871 | multicellular organismal homeostasis | 393 | 1.362653 | 0.0384836 | 0.0268740 |
| GO:0043299 | leukocyte degranulation | 475 | 1.355314 | 0.0256950 | 0.0179433 |
| GO:0031349 | positive regulation of defense response | 415 | 1.352573 | 0.0325638 | 0.0227400 |
| GO:0002444 | myeloid leukocyte mediated immunity | 490 | 1.342794 | 0.0256950 | 0.0179433 |
| GO:0002275 | myeloid cell activation involved in immune response | 483 | 1.338694 | 0.0256950 | 0.0179433 |
| ID | Description | setSize | NES | p.adjust | qvalues |
|---|---|---|---|---|---|
| GO:0006335 | DNA replication-dependent nucleosome assembly | 32 | 2.996751 | 0.0159016 | 0.0102626 |
| GO:0034723 | DNA replication-dependent nucleosome organization | 32 | 2.996751 | 0.0159016 | 0.0102626 |
| GO:0000183 | chromatin silencing at rDNA | 39 | 2.777755 | 0.0159016 | 0.0102626 |
| GO:0030219 | megakaryocyte differentiation | 90 | 2.673639 | 0.0159016 | 0.0102626 |
| GO:0045652 | regulation of megakaryocyte differentiation | 74 | 2.668044 | 0.0159016 | 0.0102626 |
| GO:0045653 | negative regulation of megakaryocyte differentiation | 17 | 2.640593 | 0.0159016 | 0.0102626 |
| GO:0046637 | regulation of alpha-beta T cell differentiation | 51 | 2.599135 | 0.0159016 | 0.0102626 |
| GO:0002250 | adaptive immune response | 290 | 2.578289 | 0.0159016 | 0.0102626 |
| GO:0051290 | protein heterotetramerization | 51 | 2.569952 | 0.0159016 | 0.0102626 |
| GO:1902107 | positive regulation of leukocyte differentiation | 122 | 2.565363 | 0.0159016 | 0.0102626 |
| GO:0002819 | regulation of adaptive immune response | 128 | 2.547999 | 0.0159016 | 0.0102626 |
| GO:0043370 | regulation of CD4-positive, alpha-beta T cell differentiation | 37 | 2.545056 | 0.0159016 | 0.0102626 |
| GO:2000514 | regulation of CD4-positive, alpha-beta T cell activation | 46 | 2.521920 | 0.0159016 | 0.0102626 |
| GO:0045621 | positive regulation of lymphocyte differentiation | 81 | 2.519959 | 0.0159016 | 0.0102626 |
| GO:0046634 | regulation of alpha-beta T cell activation | 74 | 2.495200 | 0.0159016 | 0.0102626 |
| GO:0006334 | nucleosome assembly | 119 | 2.491964 | 0.0159016 | 0.0102626 |
| GO:1903708 | positive regulation of hemopoiesis | 155 | 2.475645 | 0.0159016 | 0.0102626 |
| GO:0002460 | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 197 | 2.468648 | 0.0159016 | 0.0102626 |
| GO:0046638 | positive regulation of alpha-beta T cell differentiation | 40 | 2.468390 | 0.0159016 | 0.0102626 |
| GO:1903707 | negative regulation of hemopoiesis | 129 | 2.465092 | 0.0159016 | 0.0102626 |
| GO:0045582 | positive regulation of T cell differentiation | 71 | 2.462210 | 0.0159016 | 0.0102626 |
| GO:0042129 | regulation of T cell proliferation | 123 | 2.446160 | 0.0159016 | 0.0102626 |
| GO:0070663 | regulation of leukocyte proliferation | 177 | 2.437859 | 0.0159016 | 0.0102626 |
| GO:0002822 | regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 114 | 2.437506 | 0.0159016 | 0.0102626 |
| GO:0046631 | alpha-beta T cell activation | 107 | 2.428381 | 0.0159016 | 0.0102626 |
| GO:0042098 | T cell proliferation | 151 | 2.424494 | 0.0159016 | 0.0102626 |
| GO:0032944 | regulation of mononuclear cell proliferation | 169 | 2.420905 | 0.0159016 | 0.0102626 |
| GO:0051250 | negative regulation of lymphocyte activation | 117 | 2.413892 | 0.0159016 | 0.0102626 |
| GO:0046635 | positive regulation of alpha-beta T cell activation | 51 | 2.413465 | 0.0159016 | 0.0102626 |
| GO:2000515 | negative regulation of CD4-positive, alpha-beta T cell activation | 23 | 2.410038 | 0.0159016 | 0.0102626 |
| GO:0045622 | regulation of T-helper cell differentiation | 27 | 2.404610 | 0.0159016 | 0.0102626 |
| GO:0050670 | regulation of lymphocyte proliferation | 168 | 2.400951 | 0.0159016 | 0.0102626 |
| GO:1902105 | regulation of leukocyte differentiation | 223 | 2.391644 | 0.0159016 | 0.0102626 |
| GO:0043371 | negative regulation of CD4-positive, alpha-beta T cell differentiation | 18 | 2.387865 | 0.0159016 | 0.0102626 |
| GO:0002821 | positive regulation of adaptive immune response | 78 | 2.387704 | 0.0159016 | 0.0102626 |
| GO:0042110 | T cell activation | 376 | 2.385384 | 0.0159016 | 0.0102626 |
| GO:0034728 | nucleosome organization | 144 | 2.382611 | 0.0159016 | 0.0102626 |
| GO:0031497 | chromatin assembly | 135 | 2.382550 | 0.0159016 | 0.0102626 |
| GO:0045580 | regulation of T cell differentiation | 117 | 2.363514 | 0.0159016 | 0.0102626 |
| GO:0046632 | alpha-beta T cell differentiation | 78 | 2.363269 | 0.0159016 | 0.0102626 |
| GO:0002385 | mucosal immune response | 14 | 2.360574 | 0.0159016 | 0.0102626 |
| GO:0045619 | regulation of lymphocyte differentiation | 139 | 2.357851 | 0.0159016 | 0.0102626 |
| GO:0046639 | negative regulation of alpha-beta T cell differentiation | 21 | 2.355658 | 0.0159016 | 0.0102626 |
| GO:0043367 | CD4-positive, alpha-beta T cell differentiation | 58 | 2.353200 | 0.0159016 | 0.0102626 |
| GO:0002824 | positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 73 | 2.352232 | 0.0159016 | 0.0102626 |
| GO:0070661 | leukocyte proliferation | 227 | 2.347786 | 0.0159016 | 0.0102626 |
| GO:0045637 | regulation of myeloid cell differentiation | 214 | 2.342380 | 0.0159016 | 0.0102626 |
| GO:0030217 | T cell differentiation | 193 | 2.336414 | 0.0159016 | 0.0102626 |
| GO:0002695 | negative regulation of leukocyte activation | 143 | 2.335048 | 0.0159016 | 0.0102626 |
| GO:0050863 | regulation of T cell activation | 259 | 2.334270 | 0.0159016 | 0.0102626 |
| GO:0002285 | lymphocyte activation involved in immune response | 128 | 2.329127 | 0.0159016 | 0.0102626 |
| GO:0032943 | mononuclear cell proliferation | 210 | 2.328515 | 0.0159016 | 0.0102626 |
| GO:0050866 | negative regulation of cell activation | 162 | 2.325771 | 0.0159016 | 0.0102626 |
| GO:0050853 | B cell receptor signaling pathway | 43 | 2.324354 | 0.0159016 | 0.0102626 |
| GO:0030199 | collagen fibril organization | 40 | 2.319824 | 0.0159016 | 0.0102626 |
| GO:0046651 | lymphocyte proliferation | 208 | 2.315219 | 0.0159016 | 0.0102626 |
| GO:0006342 | chromatin silencing | 76 | 2.311585 | 0.0159016 | 0.0102626 |
| GO:0007159 | leukocyte cell-cell adhesion | 272 | 2.310113 | 0.0159016 | 0.0102626 |
| GO:0046636 | negative regulation of alpha-beta T cell activation | 31 | 2.307623 | 0.0159016 | 0.0102626 |
| GO:0002286 | T cell activation involved in immune response | 70 | 2.303469 | 0.0159016 | 0.0102626 |
| GO:0035710 | CD4-positive, alpha-beta T cell activation | 71 | 2.301925 | 0.0159016 | 0.0102626 |
| GO:0006333 | chromatin assembly or disassembly | 159 | 2.301213 | 0.0159016 | 0.0102626 |
| GO:0051249 | regulation of lymphocyte activation | 345 | 2.296515 | 0.0159016 | 0.0102626 |
| GO:0050868 | negative regulation of T cell activation | 89 | 2.294916 | 0.0159016 | 0.0102626 |
| GO:0022408 | negative regulation of cell-cell adhesion | 138 | 2.292432 | 0.0159016 | 0.0102626 |
| GO:1903037 | regulation of leukocyte cell-cell adhesion | 244 | 2.285001 | 0.0159016 | 0.0102626 |
| GO:0030098 | lymphocyte differentiation | 272 | 2.282246 | 0.0159016 | 0.0102626 |
| GO:1903038 | negative regulation of leukocyte cell-cell adhesion | 98 | 2.280447 | 0.0159016 | 0.0102626 |
| GO:0002227 | innate immune response in mucosa | 11 | 2.268398 | 0.0162534 | 0.0104897 |
| GO:1903039 | positive regulation of leukocyte cell-cell adhesion | 178 | 2.268072 | 0.0159016 | 0.0102626 |
| GO:0060964 | regulation of gene silencing by miRNA | 110 | 2.265707 | 0.0159016 | 0.0102626 |
| GO:0002449 | lymphocyte mediated immunity | 187 | 2.264338 | 0.0159016 | 0.0102626 |
| GO:0002467 | germinal center formation | 14 | 2.264219 | 0.0159016 | 0.0102626 |
| GO:0002694 | regulation of leukocyte activation | 420 | 2.263749 | 0.0159016 | 0.0102626 |
| GO:0070664 | negative regulation of leukocyte proliferation | 63 | 2.263131 | 0.0159016 | 0.0102626 |
| GO:0007492 | endoderm development | 60 | 2.260271 | 0.0159016 | 0.0102626 |
| GO:0060333 | interferon-gamma-mediated signaling pathway | 83 | 2.258355 | 0.0159016 | 0.0102626 |
| GO:0002683 | negative regulation of immune system process | 376 | 2.255517 | 0.0159016 | 0.0102626 |
| GO:1902106 | negative regulation of leukocyte differentiation | 84 | 2.252447 | 0.0159016 | 0.0102626 |
| GO:0002251 | organ or tissue specific immune response | 17 | 2.251300 | 0.0159016 | 0.0102626 |
| GO:0034508 | centromere complex assembly | 53 | 2.243692 | 0.0159016 | 0.0102626 |
| GO:0050870 | positive regulation of T cell activation | 165 | 2.241986 | 0.0159016 | 0.0102626 |
| GO:0060326 | cell chemotaxis | 201 | 2.238333 | 0.0159016 | 0.0102626 |
| GO:0042102 | positive regulation of T cell proliferation | 69 | 2.237726 | 0.0159016 | 0.0102626 |
| GO:0045581 | negative regulation of T cell differentiation | 38 | 2.233343 | 0.0159016 | 0.0102626 |
| GO:0050865 | regulation of cell activation | 453 | 2.231562 | 0.0159016 | 0.0102626 |
| GO:0002521 | leukocyte differentiation | 407 | 2.231494 | 0.0159016 | 0.0102626 |
| GO:0060147 | regulation of posttranscriptional gene silencing | 112 | 2.229272 | 0.0159016 | 0.0102626 |
| GO:0060966 | regulation of gene silencing by RNA | 112 | 2.229272 | 0.0159016 | 0.0102626 |
| GO:0002577 | regulation of antigen processing and presentation | 15 | 2.227794 | 0.0159016 | 0.0102626 |
| GO:0048514 | blood vessel morphogenesis | 495 | 2.224973 | 0.0159016 | 0.0102626 |
| GO:0045624 | positive regulation of T-helper cell differentiation | 17 | 2.224029 | 0.0159016 | 0.0102626 |
| GO:0032677 | regulation of interleukin-8 production | 53 | 2.217004 | 0.0159016 | 0.0102626 |
| GO:0016064 | immunoglobulin mediated immune response | 86 | 2.214410 | 0.0159016 | 0.0102626 |
| GO:0032945 | negative regulation of mononuclear cell proliferation | 58 | 2.211020 | 0.0159016 | 0.0102626 |
| GO:0050672 | negative regulation of lymphocyte proliferation | 58 | 2.211020 | 0.0159016 | 0.0102626 |
| GO:0043372 | positive regulation of CD4-positive, alpha-beta T cell differentiation | 24 | 2.209178 | 0.0159016 | 0.0102626 |
| GO:0006323 | DNA packaging | 168 | 2.206612 | 0.0159016 | 0.0102626 |
| GO:2000516 | positive regulation of CD4-positive, alpha-beta T cell activation | 28 | 2.206398 | 0.0159016 | 0.0102626 |
| GO:0019731 | antibacterial humoral response | 20 | 2.205999 | 0.0159016 | 0.0102626 |
| GO:0045066 | regulatory T cell differentiation | 29 | 2.203715 | 0.0159016 | 0.0102626 |
| GO:0002703 | regulation of leukocyte mediated immunity | 155 | 2.201637 | 0.0159016 | 0.0102626 |
| GO:0019724 | B cell mediated immunity | 88 | 2.201544 | 0.0159016 | 0.0102626 |
| GO:0045616 | regulation of keratinocyte differentiation | 30 | 2.198550 | 0.0159016 | 0.0102626 |
| GO:0002696 | positive regulation of leukocyte activation | 255 | 2.197440 | 0.0159016 | 0.0102626 |
| GO:0050867 | positive regulation of cell activation | 265 | 2.196000 | 0.0159016 | 0.0102626 |
| GO:0045814 | negative regulation of gene expression, epigenetic | 94 | 2.195384 | 0.0159016 | 0.0102626 |
| GO:0010718 | positive regulation of epithelial to mesenchymal transition | 45 | 2.192845 | 0.0159016 | 0.0102626 |
| GO:0022407 | regulation of cell-cell adhesion | 321 | 2.192025 | 0.0159016 | 0.0102626 |
| GO:0001710 | mesodermal cell fate commitment | 15 | 2.191462 | 0.0159016 | 0.0102626 |
| GO:0002706 | regulation of lymphocyte mediated immunity | 109 | 2.186002 | 0.0159016 | 0.0102626 |
| GO:0006968 | cellular defense response | 40 | 2.185394 | 0.0159016 | 0.0102626 |
| GO:0045638 | negative regulation of myeloid cell differentiation | 79 | 2.183768 | 0.0159016 | 0.0102626 |
| GO:0051251 | positive regulation of lymphocyte activation | 218 | 2.180389 | 0.0159016 | 0.0102626 |
| GO:0030099 | myeloid cell differentiation | 357 | 2.180262 | 0.0159016 | 0.0102626 |
| GO:0002287 | alpha-beta T cell activation involved in immune response | 47 | 2.177864 | 0.0159016 | 0.0102626 |
| GO:0002293 | alpha-beta T cell differentiation involved in immune response | 47 | 2.177864 | 0.0159016 | 0.0102626 |
| GO:0002294 | CD4-positive, alpha-beta T cell differentiation involved in immune response | 47 | 2.177864 | 0.0159016 | 0.0102626 |
| GO:0002697 | regulation of immune effector process | 310 | 2.176051 | 0.0159016 | 0.0102626 |
| GO:0002292 | T cell differentiation involved in immune response | 49 | 2.174498 | 0.0159016 | 0.0102626 |
| GO:0042113 | B cell activation | 186 | 2.172635 | 0.0159016 | 0.0102626 |
| GO:0001704 | formation of primary germ layer | 95 | 2.165954 | 0.0159016 | 0.0102626 |
| GO:0009617 | response to bacterium | 413 | 2.162041 | 0.0159016 | 0.0102626 |
| GO:0022409 | positive regulation of cell-cell adhesion | 206 | 2.159242 | 0.0159016 | 0.0102626 |
| GO:1903706 | regulation of hemopoiesis | 409 | 2.155280 | 0.0159016 | 0.0102626 |
| GO:0070431 | nucleotide-binding oligomerization domain containing 2 signaling pathway | 13 | 2.154887 | 0.0159016 | 0.0102626 |
| GO:0003272 | endocardial cushion formation | 23 | 2.152902 | 0.0159016 | 0.0102626 |
| GO:0031055 | chromatin remodeling at centromere | 45 | 2.151889 | 0.0159016 | 0.0102626 |
| GO:0042093 | T-helper cell differentiation | 46 | 2.151698 | 0.0159016 | 0.0102626 |
| GO:0001773 | myeloid dendritic cell activation | 21 | 2.151516 | 0.0159016 | 0.0102626 |
| GO:0048333 | mesodermal cell differentiation | 27 | 2.148310 | 0.0159016 | 0.0102626 |
| GO:0045589 | regulation of regulatory T cell differentiation | 28 | 2.147716 | 0.0159016 | 0.0102626 |
| GO:0032060 | bleb assembly | 11 | 2.146013 | 0.0162534 | 0.0104897 |
| GO:0070665 | positive regulation of leukocyte proliferation | 103 | 2.145809 | 0.0159016 | 0.0102626 |
| GO:2000482 | regulation of interleukin-8 secretion | 20 | 2.144121 | 0.0159016 | 0.0102626 |
| GO:0050864 | regulation of B cell activation | 97 | 2.140673 | 0.0159016 | 0.0102626 |
| GO:0046633 | alpha-beta T cell proliferation | 26 | 2.136271 | 0.0159016 | 0.0102626 |
| GO:0045620 | negative regulation of lymphocyte differentiation | 44 | 2.134582 | 0.0159016 | 0.0102626 |
| GO:2000036 | regulation of stem cell population maintenance | 25 | 2.132358 | 0.0159016 | 0.0102626 |
| GO:0038111 | interleukin-7-mediated signaling pathway | 29 | 2.129577 | 0.0159016 | 0.0102626 |
| GO:0001525 | angiogenesis | 418 | 2.124523 | 0.0159016 | 0.0102626 |
| GO:0035329 | hippo signaling | 38 | 2.122046 | 0.0159016 | 0.0102626 |
| GO:0045623 | negative regulation of T-helper cell differentiation | 14 | 2.121473 | 0.0159016 | 0.0102626 |
| GO:2000319 | regulation of T-helper 17 cell differentiation | 13 | 2.120336 | 0.0159016 | 0.0102626 |
| GO:0034341 | response to interferon-gamma | 159 | 2.112033 | 0.0159016 | 0.0102626 |
| GO:0032729 | positive regulation of interferon-gamma production | 46 | 2.111243 | 0.0159016 | 0.0102626 |
| GO:0032946 | positive regulation of mononuclear cell proliferation | 100 | 2.110927 | 0.0159016 | 0.0102626 |
| GO:0043486 | histone exchange | 50 | 2.110727 | 0.0159016 | 0.0102626 |
| GO:0009595 | detection of biotic stimulus | 17 | 2.107029 | 0.0159016 | 0.0102626 |
| GO:0007162 | negative regulation of cell adhesion | 223 | 2.105805 | 0.0159016 | 0.0102626 |
| GO:0051291 | protein heterooligomerization | 120 | 2.103920 | 0.0159016 | 0.0102626 |
| GO:0002064 | epithelial cell development | 175 | 2.102489 | 0.0159016 | 0.0102626 |
| GO:0045785 | positive regulation of cell adhesion | 334 | 2.098971 | 0.0159016 | 0.0102626 |
| GO:1904018 | positive regulation of vasculature development | 161 | 2.096105 | 0.0159016 | 0.0102626 |
| GO:0003158 | endothelium development | 106 | 2.096033 | 0.0159016 | 0.0102626 |
| GO:0061844 | antimicrobial humoral immune response mediated by antimicrobial peptide | 23 | 2.092080 | 0.0159016 | 0.0102626 |
| GO:0006911 | phagocytosis, engulfment | 40 | 2.091847 | 0.0159016 | 0.0102626 |
| GO:0050671 | positive regulation of lymphocyte proliferation | 99 | 2.088629 | 0.0159016 | 0.0102626 |
| GO:0060968 | regulation of gene silencing | 132 | 2.088293 | 0.0159016 | 0.0102626 |
| GO:0002237 | response to molecule of bacterial origin | 260 | 2.086782 | 0.0159016 | 0.0102626 |
| GO:0002507 | tolerance induction | 18 | 2.083241 | 0.0159016 | 0.0102626 |
| GO:0032637 | interleukin-8 production | 58 | 2.082901 | 0.0159016 | 0.0102626 |
| GO:0034080 | CENP-A containing nucleosome assembly | 41 | 2.080170 | 0.0159016 | 0.0102626 |
| GO:0061641 | CENP-A containing chromatin organization | 41 | 2.080170 | 0.0159016 | 0.0102626 |
| GO:0032757 | positive regulation of interleukin-8 production | 36 | 2.079433 | 0.0159016 | 0.0102626 |
| GO:2001026 | regulation of endothelial cell chemotaxis | 17 | 2.077567 | 0.0159016 | 0.0102626 |
| GO:2000050 | regulation of non-canonical Wnt signaling pathway | 22 | 2.076022 | 0.0159016 | 0.0102626 |
| GO:0065004 | protein-DNA complex assembly | 191 | 2.073912 | 0.0159016 | 0.0102626 |
| GO:0030183 | B cell differentiation | 98 | 2.073187 | 0.0159016 | 0.0102626 |
| GO:0008360 | regulation of cell shape | 118 | 2.073166 | 0.0159016 | 0.0102626 |
| GO:0030856 | regulation of epithelial cell differentiation | 112 | 2.071347 | 0.0159016 | 0.0102626 |
| GO:0002708 | positive regulation of lymphocyte mediated immunity | 72 | 2.071081 | 0.0159016 | 0.0102626 |
| GO:0072160 | nephron tubule epithelial cell differentiation | 13 | 2.070807 | 0.0159016 | 0.0102626 |
| GO:0072574 | hepatocyte proliferation | 16 | 2.069090 | 0.0159016 | 0.0102626 |
| GO:0072575 | epithelial cell proliferation involved in liver morphogenesis | 16 | 2.069090 | 0.0159016 | 0.0102626 |
| GO:0090049 | regulation of cell migration involved in sprouting angiogenesis | 37 | 2.068410 | 0.0159016 | 0.0102626 |
| GO:0060795 | cell fate commitment involved in formation of primary germ layer | 25 | 2.067592 | 0.0159016 | 0.0102626 |
| GO:0016233 | telomere capping | 49 | 2.067202 | 0.0159016 | 0.0102626 |
| GO:0035767 | endothelial cell chemotaxis | 24 | 2.067169 | 0.0159016 | 0.0102626 |
| GO:2000316 | regulation of T-helper 17 type immune response | 15 | 2.066747 | 0.0159016 | 0.0102626 |
| GO:0002755 | MyD88-dependent toll-like receptor signaling pathway | 34 | 2.066536 | 0.0159016 | 0.0102626 |
| GO:0043484 | regulation of RNA splicing | 106 | 2.061311 | 0.0159016 | 0.0102626 |
| GO:0050854 | regulation of antigen receptor-mediated signaling pathway | 50 | 2.058590 | 0.0159016 | 0.0102626 |
| GO:0071216 | cellular response to biotic stimulus | 178 | 2.056995 | 0.0159016 | 0.0102626 |
| GO:0006336 | DNA replication-independent nucleosome assembly | 52 | 2.052734 | 0.0159016 | 0.0102626 |
| GO:0034724 | DNA replication-independent nucleosome organization | 52 | 2.052734 | 0.0159016 | 0.0102626 |
| GO:0033622 | integrin activation | 19 | 2.051575 | 0.0159016 | 0.0102626 |
| GO:0014855 | striated muscle cell proliferation | 58 | 2.049696 | 0.0159016 | 0.0102626 |
| GO:0071346 | cellular response to interferon-gamma | 142 | 2.047801 | 0.0159016 | 0.0102626 |
| GO:2000826 | regulation of heart morphogenesis | 32 | 2.045632 | 0.0159016 | 0.0102626 |
| GO:0010452 | histone H3-K36 methylation | 12 | 2.043796 | 0.0159016 | 0.0102626 |
| GO:0002699 | positive regulation of immune effector process | 164 | 2.040104 | 0.0159016 | 0.0102626 |
| GO:0003151 | outflow tract morphogenesis | 70 | 2.038889 | 0.0159016 | 0.0102626 |
| GO:0061053 | somite development | 65 | 2.036500 | 0.0159016 | 0.0102626 |
| GO:0001756 | somitogenesis | 49 | 2.035314 | 0.0159016 | 0.0102626 |
| GO:2000737 | negative regulation of stem cell differentiation | 19 | 2.034768 | 0.0159016 | 0.0102626 |
| GO:0097150 | neuronal stem cell population maintenance | 22 | 2.033552 | 0.0159016 | 0.0102626 |
| GO:0032496 | response to lipopolysaccharide | 248 | 2.033551 | 0.0159016 | 0.0102626 |
| GO:0007498 | mesoderm development | 100 | 2.033095 | 0.0159016 | 0.0102626 |
| GO:0030449 | regulation of complement activation | 36 | 2.033087 | 0.0159016 | 0.0102626 |
| GO:0050777 | negative regulation of immune response | 116 | 2.031395 | 0.0159016 | 0.0102626 |
| GO:0030198 | extracellular matrix organization | 286 | 2.031014 | 0.0159016 | 0.0102626 |
| GO:2000257 | regulation of protein activation cascade | 37 | 2.030388 | 0.0159016 | 0.0102626 |
| GO:0034968 | histone lysine methylation | 100 | 2.028889 | 0.0159016 | 0.0102626 |
| GO:0050830 | defense response to Gram-positive bacterium | 45 | 2.023377 | 0.0159016 | 0.0102626 |
| GO:0071675 | regulation of mononuclear cell migration | 41 | 2.020780 | 0.0159016 | 0.0102626 |
| GO:0016441 | posttranscriptional gene silencing | 155 | 2.020633 | 0.0159016 | 0.0102626 |
| GO:0046640 | regulation of alpha-beta T cell proliferation | 23 | 2.020561 | 0.0159016 | 0.0102626 |
| GO:0035195 | gene silencing by miRNA | 150 | 2.020028 | 0.0159016 | 0.0102626 |
| GO:0043044 | ATP-dependent chromatin remodeling | 72 | 2.018077 | 0.0159016 | 0.0102626 |
| GO:1904036 | negative regulation of epithelial cell apoptotic process | 30 | 2.017284 | 0.0159016 | 0.0102626 |
| GO:0045446 | endothelial cell differentiation | 88 | 2.015375 | 0.0159016 | 0.0102626 |
| GO:0045649 | regulation of macrophage differentiation | 19 | 2.013752 | 0.0159016 | 0.0102626 |
| GO:0002761 | regulation of myeloid leukocyte differentiation | 93 | 2.010662 | 0.0159016 | 0.0102626 |
| GO:0007369 | gastrulation | 146 | 2.009882 | 0.0159016 | 0.0102626 |
| GO:0045579 | positive regulation of B cell differentiation | 11 | 2.007057 | 0.0162534 | 0.0104897 |
| GO:0072132 | mesenchyme morphogenesis | 47 | 2.006785 | 0.0159016 | 0.0102626 |
| GO:0071824 | protein-DNA complex subunit organization | 216 | 2.006527 | 0.0159016 | 0.0102626 |
| GO:0006956 | complement activation | 43 | 2.005610 | 0.0159016 | 0.0102626 |
| GO:0008340 | determination of adult lifespan | 14 | 2.003847 | 0.0159016 | 0.0102626 |
| GO:1904035 | regulation of epithelial cell apoptotic process | 61 | 2.002353 | 0.0159016 | 0.0102626 |
| GO:0016577 | histone demethylation | 24 | 2.001585 | 0.0159016 | 0.0102626 |
| GO:0098581 | detection of external biotic stimulus | 13 | 2.000402 | 0.0159016 | 0.0102626 |
| GO:0045778 | positive regulation of ossification | 85 | 2.000043 | 0.0159016 | 0.0102626 |
| GO:0045639 | positive regulation of myeloid cell differentiation | 71 | 2.000001 | 0.0159016 | 0.0102626 |
| GO:0050900 | leukocyte migration | 335 | 1.998014 | 0.0159016 | 0.0102626 |
| GO:0045766 | positive regulation of angiogenesis | 143 | 1.997812 | 0.0159016 | 0.0102626 |
| GO:0007229 | integrin-mediated signaling pathway | 90 | 1.996853 | 0.0159016 | 0.0102626 |
| GO:0002920 | regulation of humoral immune response | 46 | 1.996339 | 0.0159016 | 0.0102626 |
| GO:0035194 | posttranscriptional gene silencing by RNA | 154 | 1.996125 | 0.0159016 | 0.0102626 |
| GO:0045604 | regulation of epidermal cell differentiation | 45 | 1.994987 | 0.0159016 | 0.0102626 |
| GO:1905523 | positive regulation of macrophage migration | 19 | 1.993109 | 0.0159016 | 0.0102626 |
| GO:0043011 | myeloid dendritic cell differentiation | 14 | 1.992992 | 0.0159016 | 0.0102626 |
| GO:0003382 | epithelial cell morphogenesis | 25 | 1.991944 | 0.0159016 | 0.0102626 |
| GO:0042089 | cytokine biosynthetic process | 89 | 1.991620 | 0.0159016 | 0.0102626 |
| GO:1903557 | positive regulation of tumor necrosis factor superfamily cytokine production | 65 | 1.990390 | 0.0159016 | 0.0102626 |
| GO:0071219 | cellular response to molecule of bacterial origin | 155 | 1.990373 | 0.0159016 | 0.0102626 |
| GO:0042060 | wound healing | 458 | 1.990057 | 0.0159016 | 0.0102626 |
| GO:0043124 | negative regulation of I-kappaB kinase/NF-kappaB signaling | 39 | 1.990055 | 0.0159016 | 0.0102626 |
| GO:0072576 | liver morphogenesis | 17 | 1.989076 | 0.0159016 | 0.0102626 |
| GO:0030225 | macrophage differentiation | 38 | 1.988708 | 0.0159016 | 0.0102626 |
| GO:0003229 | ventricular cardiac muscle tissue development | 45 | 1.988014 | 0.0159016 | 0.0102626 |
| GO:0060411 | cardiac septum morphogenesis | 67 | 1.988007 | 0.0159016 | 0.0102626 |
| GO:0042107 | cytokine metabolic process | 90 | 1.987084 | 0.0159016 | 0.0102626 |
| GO:0042130 | negative regulation of T cell proliferation | 47 | 1.986294 | 0.0159016 | 0.0102626 |
| GO:0002714 | positive regulation of B cell mediated immunity | 28 | 1.985472 | 0.0159016 | 0.0102626 |
| GO:0002891 | positive regulation of immunoglobulin mediated immune response | 28 | 1.985472 | 0.0159016 | 0.0102626 |
| GO:0002673 | regulation of acute inflammatory response | 69 | 1.985236 | 0.0159016 | 0.0102626 |
| GO:2000677 | regulation of transcription regulatory region DNA binding | 42 | 1.983749 | 0.0159016 | 0.0102626 |
| GO:0002712 | regulation of B cell mediated immunity | 40 | 1.983496 | 0.0159016 | 0.0102626 |
| GO:0002889 | regulation of immunoglobulin mediated immune response | 40 | 1.983496 | 0.0159016 | 0.0102626 |
| GO:0110110 | positive regulation of animal organ morphogenesis | 69 | 1.983304 | 0.0159016 | 0.0102626 |
| GO:0010575 | positive regulation of vascular endothelial growth factor production | 24 | 1.982622 | 0.0159016 | 0.0102626 |
| GO:0048332 | mesoderm morphogenesis | 57 | 1.981666 | 0.0159016 | 0.0102626 |
| GO:0045628 | regulation of T-helper 2 cell differentiation | 11 | 1.981046 | 0.0162534 | 0.0104897 |
| GO:1901342 | regulation of vasculature development | 274 | 1.980583 | 0.0159016 | 0.0102626 |
| GO:0042116 | macrophage activation | 78 | 1.980234 | 0.0159016 | 0.0102626 |
| GO:0006959 | humoral immune response | 119 | 1.979436 | 0.0159016 | 0.0102626 |
| GO:2000679 | positive regulation of transcription regulatory region DNA binding | 19 | 1.979197 | 0.0159016 | 0.0102626 |
| GO:0003198 | epithelial to mesenchymal transition involved in endocardial cushion formation | 17 | 1.979054 | 0.0159016 | 0.0102626 |
| GO:0014842 | regulation of skeletal muscle satellite cell proliferation | 12 | 1.978968 | 0.0159016 | 0.0102626 |
| GO:0071222 | cellular response to lipopolysaccharide | 148 | 1.976056 | 0.0159016 | 0.0102626 |
| GO:0042742 | defense response to bacterium | 120 | 1.975638 | 0.0159016 | 0.0102626 |
| GO:0002763 | positive regulation of myeloid leukocyte differentiation | 41 | 1.975124 | 0.0159016 | 0.0102626 |
| GO:0032623 | interleukin-2 production | 54 | 1.974236 | 0.0159016 | 0.0102626 |
| GO:0099024 | plasma membrane invagination | 48 | 1.972812 | 0.0159016 | 0.0102626 |
| GO:0050798 | activated T cell proliferation | 31 | 1.972576 | 0.0159016 | 0.0102626 |
| GO:0035872 | nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway | 36 | 1.971354 | 0.0159016 | 0.0102626 |
| GO:0072606 | interleukin-8 secretion | 23 | 1.970205 | 0.0159016 | 0.0102626 |
| GO:0061614 | pri-miRNA transcription by RNA polymerase II | 43 | 1.969405 | 0.0159016 | 0.0102626 |
| GO:0035666 | TRIF-dependent toll-like receptor signaling pathway | 29 | 1.967972 | 0.0159016 | 0.0102626 |
| GO:0048644 | muscle organ morphogenesis | 62 | 1.967900 | 0.0159016 | 0.0102626 |
| GO:2001236 | regulation of extrinsic apoptotic signaling pathway | 137 | 1.967410 | 0.0159016 | 0.0102626 |
| GO:0070423 | nucleotide-binding oligomerization domain containing signaling pathway | 35 | 1.967118 | 0.0159016 | 0.0102626 |
| GO:0050702 | interleukin-1 beta secretion | 42 | 1.963622 | 0.0159016 | 0.0102626 |
| GO:1901522 | positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus | 22 | 1.961361 | 0.0159016 | 0.0102626 |
| GO:0030855 | epithelial cell differentiation | 481 | 1.957537 | 0.0159016 | 0.0102626 |
| GO:0022612 | gland morphogenesis | 101 | 1.957471 | 0.0159016 | 0.0102626 |
| GO:0050920 | regulation of chemotaxis | 157 | 1.956884 | 0.0159016 | 0.0102626 |
| GO:0003279 | cardiac septum development | 101 | 1.956674 | 0.0159016 | 0.0102626 |
| GO:0035987 | endodermal cell differentiation | 38 | 1.956129 | 0.0159016 | 0.0102626 |
| GO:0032663 | regulation of interleukin-2 production | 46 | 1.954072 | 0.0159016 | 0.0102626 |
| GO:0001706 | endoderm formation | 42 | 1.953888 | 0.0159016 | 0.0102626 |
| GO:0060142 | regulation of syncytium formation by plasma membrane fusion | 21 | 1.953618 | 0.0159016 | 0.0102626 |
| GO:0050869 | negative regulation of B cell activation | 28 | 1.951449 | 0.0159016 | 0.0102626 |
| GO:0030595 | leukocyte chemotaxis | 149 | 1.950895 | 0.0159016 | 0.0102626 |
| GO:0002291 | T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell | 10 | 1.950753 | 0.0204307 | 0.0131856 |
| GO:0045682 | regulation of epidermis development | 63 | 1.950337 | 0.0159016 | 0.0102626 |
| GO:1990776 | response to angiotensin | 25 | 1.949864 | 0.0159016 | 0.0102626 |
| GO:0035282 | segmentation | 70 | 1.949668 | 0.0159016 | 0.0102626 |
| GO:0003170 | heart valve development | 54 | 1.949245 | 0.0159016 | 0.0102626 |
| GO:0002705 | positive regulation of leukocyte mediated immunity | 97 | 1.948220 | 0.0159016 | 0.0102626 |
| GO:0002573 | myeloid leukocyte differentiation | 166 | 1.947939 | 0.0159016 | 0.0102626 |
| GO:0050713 | negative regulation of interleukin-1 beta secretion | 10 | 1.945093 | 0.0204307 | 0.0131856 |
| GO:0045064 | T-helper 2 cell differentiation | 12 | 1.944399 | 0.0159016 | 0.0102626 |
| GO:0001707 | mesoderm formation | 55 | 1.943634 | 0.0159016 | 0.0102626 |
| GO:0098760 | response to interleukin-7 | 40 | 1.943011 | 0.0159016 | 0.0102626 |
| GO:0098761 | cellular response to interleukin-7 | 40 | 1.943011 | 0.0159016 | 0.0102626 |
| GO:0072182 | regulation of nephron tubule epithelial cell differentiation | 11 | 1.941712 | 0.0162534 | 0.0104897 |
| GO:0046641 | positive regulation of alpha-beta T cell proliferation | 14 | 1.941564 | 0.0159016 | 0.0102626 |
| GO:0018022 | peptidyl-lysine methylation | 112 | 1.941119 | 0.0159016 | 0.0102626 |
| GO:0032609 | interferon-gamma production | 78 | 1.940796 | 0.0159016 | 0.0102626 |
| GO:0002548 | monocyte chemotaxis | 33 | 1.940102 | 0.0159016 | 0.0102626 |
| GO:0043062 | extracellular structure organization | 330 | 1.939101 | 0.0159016 | 0.0102626 |
| GO:0070076 | histone lysine demethylation | 23 | 1.938599 | 0.0159016 | 0.0102626 |
| GO:0046831 | regulation of RNA export from nucleus | 11 | 1.937940 | 0.0162534 | 0.0104897 |
| GO:0042035 | regulation of cytokine biosynthetic process | 83 | 1.936657 | 0.0159016 | 0.0102626 |
| GO:0014857 | regulation of skeletal muscle cell proliferation | 13 | 1.935150 | 0.0159016 | 0.0102626 |
| GO:0031047 | gene silencing by RNA | 174 | 1.934478 | 0.0159016 | 0.0102626 |
| GO:0060977 | coronary vasculature morphogenesis | 14 | 1.932245 | 0.0159016 | 0.0102626 |
| GO:0090195 | chemokine secretion | 16 | 1.932141 | 0.0159016 | 0.0102626 |
| GO:0051101 | regulation of DNA binding | 106 | 1.931130 | 0.0159016 | 0.0102626 |
| GO:0051567 | histone H3-K9 methylation | 35 | 1.930734 | 0.0159016 | 0.0102626 |
| GO:0045655 | regulation of monocyte differentiation | 16 | 1.930230 | 0.0159016 | 0.0102626 |
| GO:0032743 | positive regulation of interleukin-2 production | 27 | 1.929536 | 0.0159016 | 0.0102626 |
| GO:1901213 | regulation of transcription from RNA polymerase II promoter involved in heart development | 12 | 1.929135 | 0.0159016 | 0.0102626 |
| GO:0030216 | keratinocyte differentiation | 112 | 1.927246 | 0.0159016 | 0.0102626 |
| GO:0150076 | neuroinflammatory response | 54 | 1.926403 | 0.0159016 | 0.0102626 |
| GO:0010528 | regulation of transposition | 18 | 1.926016 | 0.0159016 | 0.0102626 |
| GO:0010529 | negative regulation of transposition | 18 | 1.926016 | 0.0159016 | 0.0102626 |
| GO:0032760 | positive regulation of tumor necrosis factor production | 63 | 1.925842 | 0.0159016 | 0.0102626 |
| GO:0045577 | regulation of B cell differentiation | 24 | 1.925295 | 0.0159016 | 0.0102626 |
| GO:0045651 | positive regulation of macrophage differentiation | 13 | 1.922123 | 0.0159016 | 0.0102626 |
| GO:0050855 | regulation of B cell receptor signaling pathway | 20 | 1.921984 | 0.0159016 | 0.0102626 |
| GO:0042088 | T-helper 1 type immune response | 34 | 1.920935 | 0.0159016 | 0.0102626 |
| GO:0003231 | cardiac ventricle development | 112 | 1.919741 | 0.0159016 | 0.0102626 |
| GO:2000052 | positive regulation of non-canonical Wnt signaling pathway | 12 | 1.919267 | 0.0159016 | 0.0102626 |
| GO:0032722 | positive regulation of chemokine production | 46 | 1.919169 | 0.0159016 | 0.0102626 |
| GO:0060759 | regulation of response to cytokine stimulus | 154 | 1.918880 | 0.0159016 | 0.0102626 |
| GO:0061900 | glial cell activation | 44 | 1.918561 | 0.0159016 | 0.0102626 |
| GO:0000768 | syncytium formation by plasma membrane fusion | 41 | 1.918345 | 0.0159016 | 0.0102626 |
| GO:0140253 | cell-cell fusion | 41 | 1.918345 | 0.0159016 | 0.0102626 |
| GO:2001237 | negative regulation of extrinsic apoptotic signaling pathway | 87 | 1.914418 | 0.0159016 | 0.0102626 |
| GO:1901222 | regulation of NIK/NF-kappaB signaling | 93 | 1.912684 | 0.0159016 | 0.0102626 |
| GO:0030278 | regulation of ossification | 169 | 1.911704 | 0.0159016 | 0.0102626 |
| GO:0001959 | regulation of cytokine-mediated signaling pathway | 143 | 1.909492 | 0.0159016 | 0.0102626 |
| GO:0002688 | regulation of leukocyte chemotaxis | 89 | 1.908966 | 0.0159016 | 0.0102626 |
| GO:0001771 | immunological synapse formation | 11 | 1.908597 | 0.0162534 | 0.0104897 |
| GO:0006338 | chromatin remodeling | 145 | 1.907939 | 0.0159016 | 0.0102626 |
| GO:1990868 | response to chemokine | 47 | 1.907536 | 0.0159016 | 0.0102626 |
| GO:1990869 | cellular response to chemokine | 47 | 1.907536 | 0.0159016 | 0.0102626 |
| GO:0003281 | ventricular septum development | 68 | 1.906723 | 0.0159016 | 0.0102626 |
| GO:0030335 | positive regulation of cell migration | 427 | 1.906160 | 0.0159016 | 0.0102626 |
| GO:0098727 | maintenance of cell number | 142 | 1.904374 | 0.0159016 | 0.0102626 |
| GO:0060395 | SMAD protein signal transduction | 47 | 1.904358 | 0.0159016 | 0.0102626 |
| GO:0001503 | ossification | 339 | 1.904357 | 0.0159016 | 0.0102626 |
| GO:0042108 | positive regulation of cytokine biosynthetic process | 51 | 1.904243 | 0.0159016 | 0.0102626 |
| GO:2000147 | positive regulation of cell motility | 442 | 1.902984 | 0.0159016 | 0.0102626 |
| GO:0040029 | regulation of gene expression, epigenetic | 283 | 1.902963 | 0.0159016 | 0.0102626 |
| GO:0006949 | syncytium formation | 42 | 1.902869 | 0.0159016 | 0.0102626 |
| GO:0045591 | positive regulation of regulatory T cell differentiation | 12 | 1.902219 | 0.0159016 | 0.0102626 |
| GO:0045576 | mast cell activation | 52 | 1.900166 | 0.0159016 | 0.0102626 |
| GO:0033627 | cell adhesion mediated by integrin | 57 | 1.898605 | 0.0159016 | 0.0102626 |
| GO:0002825 | regulation of T-helper 1 type immune response | 18 | 1.897308 | 0.0159016 | 0.0102626 |
| GO:0002685 | regulation of leukocyte migration | 157 | 1.895378 | 0.0159016 | 0.0102626 |
| GO:0002709 | regulation of T cell mediated immunity | 53 | 1.895353 | 0.0159016 | 0.0102626 |
| GO:0032494 | response to peptidoglycan | 11 | 1.894001 | 0.0203686 | 0.0131455 |
| GO:0072539 | T-helper 17 cell differentiation | 18 | 1.893888 | 0.0159016 | 0.0102626 |
| GO:0010463 | mesenchymal cell proliferation | 41 | 1.893831 | 0.0159016 | 0.0102626 |
| GO:0090197 | positive regulation of chemokine secretion | 13 | 1.891444 | 0.0159016 | 0.0102626 |
| GO:0014841 | skeletal muscle satellite cell proliferation | 13 | 1.891213 | 0.0159016 | 0.0102626 |
| GO:0032611 | interleukin-1 beta production | 71 | 1.889475 | 0.0159016 | 0.0102626 |
| GO:0071103 | DNA conformation change | 253 | 1.889396 | 0.0159016 | 0.0102626 |
| GO:2000696 | regulation of epithelial cell differentiation involved in kidney development | 16 | 1.888025 | 0.0159016 | 0.0102626 |
| GO:0043297 | apical junction assembly | 55 | 1.885889 | 0.0159016 | 0.0102626 |
| GO:2001028 | positive regulation of endothelial cell chemotaxis | 14 | 1.885876 | 0.0159016 | 0.0102626 |
| GO:0036499 | PERK-mediated unfolded protein response | 20 | 1.885593 | 0.0159016 | 0.0102626 |
| GO:0061647 | histone H3-K9 modification | 45 | 1.884986 | 0.0159016 | 0.0102626 |
| GO:0032732 | positive regulation of interleukin-1 production | 40 | 1.884932 | 0.0159016 | 0.0102626 |
| GO:2000351 | regulation of endothelial cell apoptotic process | 36 | 1.884912 | 0.0159016 | 0.0102626 |
| GO:0001782 | B cell homeostasis | 26 | 1.884167 | 0.0159016 | 0.0102626 |
| GO:0019827 | stem cell population maintenance | 140 | 1.883757 | 0.0159016 | 0.0102626 |
| GO:0034446 | substrate adhesion-dependent cell spreading | 82 | 1.882150 | 0.0159016 | 0.0102626 |
| GO:0071677 | positive regulation of mononuclear cell migration | 19 | 1.882003 | 0.0159016 | 0.0102626 |
| GO:0032200 | telomere organization | 158 | 1.879343 | 0.0159016 | 0.0102626 |
| GO:0033003 | regulation of mast cell activation | 36 | 1.877610 | 0.0159016 | 0.0102626 |
| GO:0045667 | regulation of osteoblast differentiation | 107 | 1.876388 | 0.0159016 | 0.0102626 |
| GO:0050871 | positive regulation of B cell activation | 59 | 1.876015 | 0.0159016 | 0.0102626 |
| GO:0033002 | muscle cell proliferation | 175 | 1.875741 | 0.0159016 | 0.0102626 |
| GO:0032612 | interleukin-1 production | 80 | 1.874850 | 0.0159016 | 0.0102626 |
| GO:0002711 | positive regulation of T cell mediated immunity | 33 | 1.874776 | 0.0159016 | 0.0102626 |
| GO:0045765 | regulation of angiogenesis | 246 | 1.874682 | 0.0159016 | 0.0102626 |
| GO:0002526 | acute inflammatory response | 111 | 1.873877 | 0.0159016 | 0.0102626 |
| GO:0002820 | negative regulation of adaptive immune response | 38 | 1.872689 | 0.0159016 | 0.0102626 |
| GO:2000095 | regulation of Wnt signaling pathway, planar cell polarity pathway | 14 | 1.871924 | 0.0159016 | 0.0102626 |
| GO:0032196 | transposition | 21 | 1.868497 | 0.0159016 | 0.0102626 |
| GO:0043535 | regulation of blood vessel endothelial cell migration | 83 | 1.868467 | 0.0159016 | 0.0102626 |
| GO:0045669 | positive regulation of osteoblast differentiation | 61 | 1.868142 | 0.0159016 | 0.0102626 |
| GO:0050706 | regulation of interleukin-1 beta secretion | 35 | 1.867738 | 0.0159016 | 0.0102626 |
| GO:0003401 | axis elongation | 25 | 1.866647 | 0.0159016 | 0.0102626 |
| GO:0007249 | I-kappaB kinase/NF-kappaB signaling | 231 | 1.865616 | 0.0159016 | 0.0102626 |
| GO:0002224 | toll-like receptor signaling pathway | 126 | 1.864033 | 0.0159016 | 0.0102626 |
| GO:0048844 | artery morphogenesis | 58 | 1.863530 | 0.0159016 | 0.0102626 |
| GO:0001819 | positive regulation of cytokine production | 364 | 1.863384 | 0.0159016 | 0.0102626 |
| GO:0090050 | positive regulation of cell migration involved in sprouting angiogenesis | 20 | 1.862362 | 0.0159016 | 0.0102626 |
| GO:0032490 | detection of molecule of bacterial origin | 10 | 1.862120 | 0.0204307 | 0.0131856 |
| GO:0032633 | interleukin-4 production | 25 | 1.862024 | 0.0159016 | 0.0102626 |
| GO:0060561 | apoptotic process involved in morphogenesis | 21 | 1.861257 | 0.0159016 | 0.0102626 |
| GO:0072376 | protein activation cascade | 58 | 1.860262 | 0.0159016 | 0.0102626 |
| GO:0001776 | leukocyte homeostasis | 74 | 1.859524 | 0.0159016 | 0.0102626 |
| GO:0072073 | kidney epithelium development | 120 | 1.858270 | 0.0159016 | 0.0102626 |
| GO:0002643 | regulation of tolerance induction | 12 | 1.858143 | 0.0197595 | 0.0127525 |
| GO:0032835 | glomerulus development | 52 | 1.858010 | 0.0159016 | 0.0102626 |
| GO:0032103 | positive regulation of response to external stimulus | 251 | 1.856278 | 0.0159016 | 0.0102626 |
| GO:0045342 | MHC class II biosynthetic process | 11 | 1.855797 | 0.0273893 | 0.0176766 |
| GO:2000778 | positive regulation of interleukin-6 secretion | 23 | 1.855353 | 0.0159016 | 0.0102626 |
| GO:0030888 | regulation of B cell proliferation | 49 | 1.854950 | 0.0159016 | 0.0102626 |
| GO:0003179 | heart valve morphogenesis | 46 | 1.854925 | 0.0159016 | 0.0102626 |
| GO:0060415 | muscle tissue morphogenesis | 58 | 1.854238 | 0.0159016 | 0.0102626 |
| GO:0050921 | positive regulation of chemotaxis | 114 | 1.853568 | 0.0159016 | 0.0102626 |
| GO:0002221 | pattern recognition receptor signaling pathway | 168 | 1.852932 | 0.0159016 | 0.0102626 |
| GO:0032239 | regulation of nucleobase-containing compound transport | 13 | 1.852647 | 0.0265576 | 0.0171398 |
| GO:0071674 | mononuclear cell migration | 54 | 1.848777 | 0.0159016 | 0.0102626 |
| GO:0042100 | B cell proliferation | 57 | 1.848374 | 0.0159016 | 0.0102626 |
| GO:0001892 | embryonic placenta development | 78 | 1.846747 | 0.0159016 | 0.0102626 |
| GO:0045600 | positive regulation of fat cell differentiation | 55 | 1.846010 | 0.0159016 | 0.0102626 |
| GO:0032731 | positive regulation of interleukin-1 beta production | 36 | 1.845689 | 0.0159016 | 0.0102626 |
| GO:0002381 | immunoglobulin production involved in immunoglobulin mediated immune response | 44 | 1.845314 | 0.0159016 | 0.0102626 |
| GO:0060602 | branch elongation of an epithelium | 17 | 1.844510 | 0.0159016 | 0.0102626 |
| GO:0072538 | T-helper 17 type immune response | 20 | 1.844498 | 0.0159016 | 0.0102626 |
| GO:1903209 | positive regulation of oxidative stress-induced cell death | 13 | 1.844202 | 0.0320996 | 0.0207165 |
| GO:0043534 | blood vessel endothelial cell migration | 107 | 1.843567 | 0.0159016 | 0.0102626 |
| GO:0055008 | cardiac muscle tissue morphogenesis | 50 | 1.842807 | 0.0159016 | 0.0102626 |
| GO:0051272 | positive regulation of cellular component movement | 455 | 1.842325 | 0.0159016 | 0.0102626 |
| GO:0032635 | interleukin-6 production | 114 | 1.842206 | 0.0159016 | 0.0102626 |
| GO:0002827 | positive regulation of T-helper 1 type immune response | 12 | 1.841313 | 0.0265900 | 0.0171607 |
| GO:0097028 | dendritic cell differentiation | 34 | 1.840625 | 0.0159016 | 0.0102626 |
| GO:2000345 | regulation of hepatocyte proliferation | 12 | 1.840346 | 0.0265900 | 0.0171607 |
| GO:1900409 | positive regulation of cellular response to oxidative stress | 14 | 1.839527 | 0.0197048 | 0.0127172 |
| GO:0090025 | regulation of monocyte chemotaxis | 22 | 1.838861 | 0.0159016 | 0.0102626 |
| GO:0062033 | positive regulation of mitotic sister chromatid segregation | 12 | 1.838753 | 0.0265900 | 0.0171607 |
| GO:0003203 | endocardial cushion morphogenesis | 32 | 1.838738 | 0.0159016 | 0.0102626 |
| GO:0048745 | smooth muscle tissue development | 17 | 1.838502 | 0.0159016 | 0.0102626 |
| GO:0035850 | epithelial cell differentiation involved in kidney development | 39 | 1.838298 | 0.0159016 | 0.0102626 |
| GO:0050856 | regulation of T cell receptor signaling pathway | 33 | 1.837707 | 0.0159016 | 0.0102626 |
| GO:0050701 | interleukin-1 secretion | 46 | 1.837602 | 0.0159016 | 0.0102626 |
| GO:0043536 | positive regulation of blood vessel endothelial cell migration | 53 | 1.837136 | 0.0159016 | 0.0102626 |
| GO:0043122 | regulation of I-kappaB kinase/NF-kappaB signaling | 204 | 1.837084 | 0.0159016 | 0.0102626 |
| GO:0014856 | skeletal muscle cell proliferation | 14 | 1.836477 | 0.0197048 | 0.0127172 |
| GO:0032642 | regulation of chemokine production | 65 | 1.836350 | 0.0159016 | 0.0102626 |
| GO:1901798 | positive regulation of signal transduction by p53 class mediator | 19 | 1.834798 | 0.0159016 | 0.0102626 |
| GO:0007501 | mesodermal cell fate specification | 11 | 1.834673 | 0.0273893 | 0.0176766 |
| GO:0010324 | membrane invagination | 56 | 1.834297 | 0.0159016 | 0.0102626 |
| GO:0072006 | nephron development | 121 | 1.834188 | 0.0159016 | 0.0102626 |
| GO:0007517 | muscle organ development | 327 | 1.832733 | 0.0159016 | 0.0102626 |
| GO:1902042 | negative regulation of extrinsic apoptotic signaling pathway via death domain receptors | 32 | 1.832515 | 0.0159016 | 0.0102626 |
| GO:0001885 | endothelial cell development | 53 | 1.831371 | 0.0159016 | 0.0102626 |
| GO:0055010 | ventricular cardiac muscle tissue morphogenesis | 39 | 1.829912 | 0.0159016 | 0.0102626 |
| GO:0030224 | monocyte differentiation | 31 | 1.829335 | 0.0159016 | 0.0102626 |
| GO:1903131 | mononuclear cell differentiation | 31 | 1.829335 | 0.0159016 | 0.0102626 |
| GO:0035791 | platelet-derived growth factor receptor-beta signaling pathway | 14 | 1.829280 | 0.0197048 | 0.0127172 |
| GO:0046006 | regulation of activated T cell proliferation | 27 | 1.829036 | 0.0159016 | 0.0102626 |
| GO:0043392 | negative regulation of DNA binding | 43 | 1.828329 | 0.0159016 | 0.0102626 |
| GO:0033628 | regulation of cell adhesion mediated by integrin | 41 | 1.828047 | 0.0159016 | 0.0102626 |
| GO:0003205 | cardiac chamber development | 148 | 1.826673 | 0.0159016 | 0.0102626 |
| GO:0051570 | regulation of histone H3-K9 methylation | 22 | 1.826448 | 0.0197048 | 0.0127172 |
| GO:0090594 | inflammatory response to wounding | 12 | 1.826228 | 0.0321942 | 0.0207776 |
| GO:0050727 | regulation of inflammatory response | 299 | 1.825642 | 0.0159016 | 0.0102626 |
| GO:0045165 | cell fate commitment | 173 | 1.825579 | 0.0159016 | 0.0102626 |
| GO:0070613 | regulation of protein processing | 83 | 1.824910 | 0.0159016 | 0.0102626 |
| GO:0001774 | microglial cell activation | 37 | 1.824135 | 0.0159016 | 0.0102626 |
| GO:0002269 | leukocyte activation involved in inflammatory response | 37 | 1.824135 | 0.0159016 | 0.0102626 |
| GO:0031060 | regulation of histone methylation | 58 | 1.824079 | 0.0159016 | 0.0102626 |
| GO:0045063 | T-helper 1 cell differentiation | 16 | 1.823253 | 0.0159016 | 0.0102626 |
| GO:0002456 | T cell mediated immunity | 79 | 1.821986 | 0.0159016 | 0.0102626 |
| GO:0010837 | regulation of keratinocyte proliferation | 28 | 1.821786 | 0.0159016 | 0.0102626 |
| GO:0045618 | positive regulation of keratinocyte differentiation | 13 | 1.821416 | 0.0375938 | 0.0242624 |
| GO:1902893 | regulation of pri-miRNA transcription by RNA polymerase II | 37 | 1.819091 | 0.0159016 | 0.0102626 |
| GO:0032755 | positive regulation of interleukin-6 production | 67 | 1.816677 | 0.0159016 | 0.0102626 |
| GO:0043032 | positive regulation of macrophage activation | 24 | 1.815363 | 0.0264554 | 0.0170738 |
| GO:0032373 | positive regulation of sterol transport | 20 | 1.815061 | 0.0159016 | 0.0102626 |
| GO:0032376 | positive regulation of cholesterol transport | 20 | 1.815061 | 0.0159016 | 0.0102626 |
| GO:0016571 | histone methylation | 119 | 1.814959 | 0.0159016 | 0.0102626 |
| GO:0008544 | epidermis development | 242 | 1.814736 | 0.0159016 | 0.0102626 |
| GO:0035313 | wound healing, spreading of epidermal cells | 14 | 1.814266 | 0.0265576 | 0.0171398 |
| GO:0036037 | CD8-positive, alpha-beta T cell activation | 17 | 1.813591 | 0.0159016 | 0.0102626 |
| GO:0034086 | maintenance of sister chromatid cohesion | 12 | 1.812161 | 0.0434232 | 0.0280246 |
| GO:0034088 | maintenance of mitotic sister chromatid cohesion | 12 | 1.812161 | 0.0434232 | 0.0280246 |
| GO:0072009 | nephron epithelium development | 90 | 1.810670 | 0.0159016 | 0.0102626 |
| GO:0016458 | gene silencing | 227 | 1.809978 | 0.0159016 | 0.0102626 |
| GO:1905521 | regulation of macrophage migration | 31 | 1.809713 | 0.0159016 | 0.0102626 |
| GO:0097581 | lamellipodium organization | 71 | 1.808668 | 0.0159016 | 0.0102626 |
| GO:0003206 | cardiac chamber morphogenesis | 108 | 1.808651 | 0.0159016 | 0.0102626 |
| GO:0042226 | interleukin-6 biosynthetic process | 18 | 1.808337 | 0.0198333 | 0.0128001 |
| GO:0034329 | cell junction assembly | 201 | 1.808048 | 0.0159016 | 0.0102626 |
| GO:1901888 | regulation of cell junction assembly | 86 | 1.807964 | 0.0159016 | 0.0102626 |
| GO:1904019 | epithelial cell apoptotic process | 81 | 1.807663 | 0.0159016 | 0.0102626 |
| GO:1902041 | regulation of extrinsic apoptotic signaling pathway via death domain receptors | 51 | 1.807237 | 0.0159016 | 0.0102626 |
| GO:0032675 | regulation of interleukin-6 production | 106 | 1.806698 | 0.0159016 | 0.0102626 |
| GO:0040017 | positive regulation of locomotion | 470 | 1.806416 | 0.0159016 | 0.0102626 |
| GO:1903317 | regulation of protein maturation | 85 | 1.806376 | 0.0159016 | 0.0102626 |
| GO:0070266 | necroptotic process | 33 | 1.805738 | 0.0159016 | 0.0102626 |
| GO:0036119 | response to platelet-derived growth factor | 21 | 1.802855 | 0.0159016 | 0.0102626 |
| GO:0061448 | connective tissue development | 202 | 1.801726 | 0.0159016 | 0.0102626 |
| GO:0002756 | MyD88-independent toll-like receptor signaling pathway | 33 | 1.801717 | 0.0159016 | 0.0102626 |
| GO:0042554 | superoxide anion generation | 29 | 1.801536 | 0.0159016 | 0.0102626 |
| GO:0006909 | phagocytosis | 219 | 1.800905 | 0.0159016 | 0.0102626 |
| GO:0033631 | cell-cell adhesion mediated by integrin | 14 | 1.800522 | 0.0320996 | 0.0207165 |
| GO:0002260 | lymphocyte homeostasis | 52 | 1.799426 | 0.0159016 | 0.0102626 |
| GO:0090169 | regulation of spindle assembly | 26 | 1.798345 | 0.0159016 | 0.0102626 |
| GO:0030858 | positive regulation of epithelial cell differentiation | 49 | 1.798153 | 0.0159016 | 0.0102626 |
| GO:0060537 | muscle tissue development | 323 | 1.795333 | 0.0159016 | 0.0102626 |
| GO:0036342 | post-anal tail morphogenesis | 15 | 1.794048 | 0.0159016 | 0.0102626 |
| GO:0060038 | cardiac muscle cell proliferation | 45 | 1.793642 | 0.0159016 | 0.0102626 |
| GO:0072678 | T cell migration | 47 | 1.792363 | 0.0197048 | 0.0127172 |
| GO:0043922 | negative regulation by host of viral transcription | 10 | 1.792066 | 0.0274543 | 0.0177185 |
| GO:0090196 | regulation of chemokine secretion | 14 | 1.791961 | 0.0320996 | 0.0207165 |
| GO:2000117 | negative regulation of cysteine-type endopeptidase activity | 76 | 1.791895 | 0.0159016 | 0.0102626 |
| GO:0032649 | regulation of interferon-gamma production | 69 | 1.791683 | 0.0159016 | 0.0102626 |
| GO:0051092 | positive regulation of NF-kappaB transcription factor activity | 138 | 1.791230 | 0.0159016 | 0.0102626 |
| GO:0050718 | positive regulation of interleukin-1 beta secretion | 25 | 1.791179 | 0.0159016 | 0.0102626 |
| GO:0061005 | cell differentiation involved in kidney development | 48 | 1.790834 | 0.0197048 | 0.0127172 |
| GO:0097300 | programmed necrotic cell death | 37 | 1.790489 | 0.0159016 | 0.0102626 |
| GO:0007175 | negative regulation of epidermal growth factor-activated receptor activity | 11 | 1.790206 | 0.0273893 | 0.0176766 |
| GO:0001570 | vasculogenesis | 68 | 1.790056 | 0.0159016 | 0.0102626 |
| GO:0003197 | endocardial cushion development | 39 | 1.789537 | 0.0197048 | 0.0127172 |
| GO:0006957 | complement activation, alternative pathway | 10 | 1.788942 | 0.0274543 | 0.0177185 |
| GO:0002228 | natural killer cell mediated immunity | 47 | 1.787778 | 0.0197048 | 0.0127172 |
| GO:0009913 | epidermal cell differentiation | 153 | 1.786766 | 0.0159016 | 0.0102626 |
| GO:0050663 | cytokine secretion | 178 | 1.786763 | 0.0159016 | 0.0102626 |
| GO:0060143 | positive regulation of syncytium formation by plasma membrane fusion | 19 | 1.786232 | 0.0197048 | 0.0127172 |
| GO:0009048 | dosage compensation by inactivation of X chromosome | 14 | 1.784684 | 0.0375938 | 0.0242624 |
| GO:0030889 | negative regulation of B cell proliferation | 14 | 1.783965 | 0.0375938 | 0.0242624 |
| GO:0001906 | cell killing | 94 | 1.783955 | 0.0159016 | 0.0102626 |
| GO:0043516 | regulation of DNA damage response, signal transduction by p53 class mediator | 31 | 1.782842 | 0.0197048 | 0.0127172 |
| GO:1904738 | vascular associated smooth muscle cell migration | 21 | 1.782671 | 0.0159016 | 0.0102626 |
| GO:1904752 | regulation of vascular associated smooth muscle cell migration | 21 | 1.782671 | 0.0159016 | 0.0102626 |
| GO:0010759 | positive regulation of macrophage chemotaxis | 14 | 1.782527 | 0.0375938 | 0.0242624 |
| GO:0002562 | somatic diversification of immune receptors via germline recombination within a single locus | 51 | 1.782434 | 0.0159016 | 0.0102626 |
| GO:0016444 | somatic cell DNA recombination | 51 | 1.782434 | 0.0159016 | 0.0102626 |
| GO:0031663 | lipopolysaccharide-mediated signaling pathway | 50 | 1.782364 | 0.0159016 | 0.0102626 |
| GO:0001910 | regulation of leukocyte mediated cytotoxicity | 48 | 1.782318 | 0.0197048 | 0.0127172 |
| GO:0042267 | natural killer cell mediated cytotoxicity | 43 | 1.782111 | 0.0159016 | 0.0102626 |
| GO:0001818 | negative regulation of cytokine production | 225 | 1.781499 | 0.0159016 | 0.0102626 |
| GO:1904385 | cellular response to angiotensin | 22 | 1.781400 | 0.0197048 | 0.0127172 |
| GO:0050673 | epithelial cell proliferation | 326 | 1.781044 | 0.0159016 | 0.0102626 |
| GO:0002312 | B cell activation involved in immune response | 58 | 1.779864 | 0.0159016 | 0.0102626 |
| GO:0014015 | positive regulation of gliogenesis | 69 | 1.779598 | 0.0159016 | 0.0102626 |
| GO:0002687 | positive regulation of leukocyte migration | 104 | 1.779018 | 0.0159016 | 0.0102626 |
| GO:0060043 | regulation of cardiac muscle cell proliferation | 35 | 1.778492 | 0.0159016 | 0.0102626 |
| GO:0060993 | kidney morphogenesis | 81 | 1.778479 | 0.0159016 | 0.0102626 |
| GO:0048339 | paraxial mesoderm development | 15 | 1.778448 | 0.0159016 | 0.0102626 |
| GO:0048872 | homeostasis of number of cells | 212 | 1.777820 | 0.0159016 | 0.0102626 |
| GO:0043517 | positive regulation of DNA damage response, signal transduction by p53 class mediator | 12 | 1.776545 | 0.0483532 | 0.0312063 |
| GO:0048565 | digestive tract development | 106 | 1.776344 | 0.0159016 | 0.0102626 |
| GO:0060669 | embryonic placenta morphogenesis | 23 | 1.775885 | 0.0197048 | 0.0127172 |
| GO:0001780 | neutrophil homeostasis | 16 | 1.775843 | 0.0159016 | 0.0102626 |
| GO:0002040 | sprouting angiogenesis | 100 | 1.774975 | 0.0159016 | 0.0102626 |
| GO:0032652 | regulation of interleukin-1 production | 69 | 1.774452 | 0.0159016 | 0.0102626 |
| GO:0060099 | regulation of phagocytosis, engulfment | 13 | 1.771086 | 0.0375938 | 0.0242624 |
| GO:0050817 | coagulation | 278 | 1.770573 | 0.0159016 | 0.0102626 |
| GO:0010464 | regulation of mesenchymal cell proliferation | 32 | 1.770290 | 0.0197048 | 0.0127172 |
| GO:0051053 | negative regulation of DNA metabolic process | 119 | 1.770101 | 0.0159016 | 0.0102626 |
| GO:0050729 | positive regulation of inflammatory response | 114 | 1.769475 | 0.0159016 | 0.0102626 |
| GO:0090026 | positive regulation of monocyte chemotaxis | 15 | 1.769075 | 0.0264462 | 0.0170679 |
| GO:0072001 | renal system development | 260 | 1.768404 | 0.0159016 | 0.0102626 |
| GO:0061323 | cell proliferation involved in heart morphogenesis | 11 | 1.767924 | 0.0273893 | 0.0176766 |
| GO:0061180 | mammary gland epithelium development | 59 | 1.767544 | 0.0159016 | 0.0102626 |
| GO:0072028 | nephron morphogenesis | 66 | 1.767270 | 0.0159016 | 0.0102626 |
| GO:0050716 | positive regulation of interleukin-1 secretion | 27 | 1.767115 | 0.0197048 | 0.0127172 |
| GO:0071599 | otic vesicle development | 14 | 1.766572 | 0.0433215 | 0.0279589 |
| GO:0045824 | negative regulation of innate immune response | 46 | 1.765943 | 0.0159016 | 0.0102626 |
| GO:0050711 | negative regulation of interleukin-1 secretion | 12 | 1.765659 | 0.0483532 | 0.0312063 |
| GO:0055123 | digestive system development | 115 | 1.765231 | 0.0159016 | 0.0102626 |
| GO:2001198 | regulation of dendritic cell differentiation | 11 | 1.764433 | 0.0273893 | 0.0176766 |
| GO:0001822 | kidney development | 245 | 1.764288 | 0.0159016 | 0.0102626 |
| GO:0097529 | myeloid leukocyte migration | 136 | 1.764026 | 0.0159016 | 0.0102626 |
| GO:2000106 | regulation of leukocyte apoptotic process | 65 | 1.763899 | 0.0159016 | 0.0102626 |
| GO:0002823 | negative regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 34 | 1.763889 | 0.0159016 | 0.0102626 |
| GO:0002088 | lens development in camera-type eye | 58 | 1.763267 | 0.0159016 | 0.0102626 |
| GO:0007596 | blood coagulation | 276 | 1.763032 | 0.0159016 | 0.0102626 |
| GO:0002690 | positive regulation of leukocyte chemotaxis | 69 | 1.762997 | 0.0159016 | 0.0102626 |
| GO:0002042 | cell migration involved in sprouting angiogenesis | 53 | 1.762668 | 0.0159016 | 0.0102626 |
| GO:0045685 | regulation of glial cell differentiation | 71 | 1.762664 | 0.0159016 | 0.0102626 |
| GO:0070231 | T cell apoptotic process | 36 | 1.762107 | 0.0197048 | 0.0127172 |
| GO:0072080 | nephron tubule development | 77 | 1.761785 | 0.0159016 | 0.0102626 |
| GO:0032963 | collagen metabolic process | 79 | 1.761651 | 0.0159016 | 0.0102626 |
| GO:0036005 | response to macrophage colony-stimulating factor | 11 | 1.761452 | 0.0273893 | 0.0176766 |
| GO:0036006 | cellular response to macrophage colony-stimulating factor stimulus | 11 | 1.761452 | 0.0273893 | 0.0176766 |
| GO:0001501 | skeletal system development | 394 | 1.760832 | 0.0159016 | 0.0102626 |
| GO:0018023 | peptidyl-lysine trimethylation | 40 | 1.760697 | 0.0197048 | 0.0127172 |
| GO:0090084 | negative regulation of inclusion body assembly | 10 | 1.759677 | 0.0274543 | 0.0177185 |
| GO:0072643 | interferon-gamma secretion | 13 | 1.759566 | 0.0375938 | 0.0242624 |
| GO:0002753 | cytoplasmic pattern recognition receptor signaling pathway | 59 | 1.759054 | 0.0159016 | 0.0102626 |
| GO:0043542 | endothelial cell migration | 187 | 1.758009 | 0.0159016 | 0.0102626 |
| GO:0035855 | megakaryocyte development | 16 | 1.757791 | 0.0159016 | 0.0102626 |
| GO:0001655 | urogenital system development | 286 | 1.757291 | 0.0159016 | 0.0102626 |
| GO:0071385 | cellular response to glucocorticoid stimulus | 50 | 1.757098 | 0.0159016 | 0.0102626 |
| GO:1900101 | regulation of endoplasmic reticulum unfolded protein response | 24 | 1.756906 | 0.0264554 | 0.0170738 |
| GO:0002377 | immunoglobulin production | 81 | 1.755560 | 0.0159016 | 0.0102626 |
| GO:0002700 | regulation of production of molecular mediator of immune response | 113 | 1.755499 | 0.0159016 | 0.0102626 |
| GO:0001657 | ureteric bud development | 87 | 1.755266 | 0.0159016 | 0.0102626 |
| GO:0051984 | positive regulation of chromosome segregation | 23 | 1.755042 | 0.0264462 | 0.0170679 |
| GO:0045346 | regulation of MHC class II biosynthetic process | 10 | 1.754483 | 0.0333001 | 0.0214913 |
| GO:0060348 | bone development | 163 | 1.753287 | 0.0159016 | 0.0102626 |
| GO:0034340 | response to type I interferon | 79 | 1.751717 | 0.0159016 | 0.0102626 |
| GO:0045687 | positive regulation of glial cell differentiation | 45 | 1.751650 | 0.0159016 | 0.0102626 |
| GO:2000134 | negative regulation of G1/S transition of mitotic cell cycle | 100 | 1.750987 | 0.0159016 | 0.0102626 |
| GO:0071887 | leukocyte apoptotic process | 83 | 1.750973 | 0.0159016 | 0.0102626 |
| GO:0007520 | myoblast fusion | 30 | 1.749631 | 0.0197048 | 0.0127172 |
| GO:0071157 | negative regulation of cell cycle arrest | 20 | 1.749398 | 0.0197048 | 0.0127172 |
| GO:0061326 | renal tubule development | 79 | 1.748423 | 0.0159016 | 0.0102626 |
| GO:0061842 | microtubule organizing center localization | 24 | 1.748174 | 0.0264554 | 0.0170738 |
| GO:0031589 | cell-substrate adhesion | 295 | 1.748047 | 0.0159016 | 0.0102626 |
| GO:1901224 | positive regulation of NIK/NF-kappaB signaling | 65 | 1.746970 | 0.0159016 | 0.0102626 |
| GO:0050704 | regulation of interleukin-1 secretion | 38 | 1.746791 | 0.0263057 | 0.0169772 |
| GO:0007173 | epidermal growth factor receptor signaling pathway | 104 | 1.746629 | 0.0159016 | 0.0102626 |
| GO:0098542 | defense response to other organism | 314 | 1.746327 | 0.0159016 | 0.0102626 |
| GO:2000136 | regulation of cell proliferation involved in heart morphogenesis | 12 | 1.746302 | 0.0483532 | 0.0312063 |
| GO:0072088 | nephron epithelium morphogenesis | 64 | 1.746195 | 0.0159016 | 0.0102626 |
| GO:0045598 | regulation of fat cell differentiation | 108 | 1.745709 | 0.0159016 | 0.0102626 |
| GO:2000484 | positive regulation of interleukin-8 secretion | 12 | 1.744731 | 0.0483532 | 0.0312063 |
| GO:0043409 | negative regulation of MAPK cascade | 146 | 1.744633 | 0.0159016 | 0.0102626 |
| GO:0033077 | T cell differentiation in thymus | 60 | 1.744315 | 0.0159016 | 0.0102626 |
| GO:0071559 | response to transforming growth factor beta | 213 | 1.743084 | 0.0159016 | 0.0102626 |
| GO:0050678 | regulation of epithelial cell proliferation | 276 | 1.743006 | 0.0159016 | 0.0102626 |
| GO:0032735 | positive regulation of interleukin-12 production | 23 | 1.742468 | 0.0264462 | 0.0170679 |
| GO:0051216 | cartilage development | 151 | 1.742406 | 0.0159016 | 0.0102626 |
| GO:0048010 | vascular endothelial growth factor receptor signaling pathway | 87 | 1.742333 | 0.0159016 | 0.0102626 |
| GO:0045932 | negative regulation of muscle contraction | 21 | 1.741989 | 0.0264462 | 0.0170679 |
| GO:0034770 | histone H4-K20 methylation | 10 | 1.741871 | 0.0391612 | 0.0252740 |
| GO:0032651 | regulation of interleukin-1 beta production | 61 | 1.741727 | 0.0159016 | 0.0102626 |
| GO:0019730 | antimicrobial humoral response | 44 | 1.741602 | 0.0197048 | 0.0127172 |
| GO:0010573 | vascular endothelial growth factor production | 30 | 1.741538 | 0.0197048 | 0.0127172 |
| GO:0014812 | muscle cell migration | 78 | 1.741504 | 0.0159016 | 0.0102626 |
| GO:0002279 | mast cell activation involved in immune response | 43 | 1.741022 | 0.0197048 | 0.0127172 |
| GO:1901739 | regulation of myoblast fusion | 15 | 1.740615 | 0.0319261 | 0.0206045 |
| GO:0060412 | ventricular septum morphogenesis | 41 | 1.740595 | 0.0264462 | 0.0170679 |
| GO:0043405 | regulation of MAP kinase activity | 293 | 1.738556 | 0.0159016 | 0.0102626 |
| GO:0001823 | mesonephros development | 90 | 1.738153 | 0.0159016 | 0.0102626 |
| GO:1902894 | negative regulation of pri-miRNA transcription by RNA polymerase II | 13 | 1.737840 | 0.0375938 | 0.0242624 |
| GO:0050679 | positive regulation of epithelial cell proliferation | 159 | 1.736970 | 0.0159016 | 0.0102626 |
| GO:1902884 | positive regulation of response to oxidative stress | 16 | 1.736459 | 0.0159016 | 0.0102626 |
| GO:0032615 | interleukin-12 production | 41 | 1.736317 | 0.0264462 | 0.0170679 |
| GO:0001649 | osteoblast differentiation | 193 | 1.735343 | 0.0159016 | 0.0102626 |
| GO:0006482 | protein demethylation | 26 | 1.734219 | 0.0197048 | 0.0127172 |
| GO:0008214 | protein dealkylation | 26 | 1.734219 | 0.0197048 | 0.0127172 |
| GO:0051894 | positive regulation of focal adhesion assembly | 23 | 1.734171 | 0.0319261 | 0.0206045 |
| GO:0010631 | epithelial cell migration | 256 | 1.733934 | 0.0159016 | 0.0102626 |
| GO:0001909 | leukocyte mediated cytotoxicity | 74 | 1.733642 | 0.0194000 | 0.0125204 |
| GO:0048738 | cardiac muscle tissue development | 173 | 1.733347 | 0.0159016 | 0.0102626 |
| GO:0002828 | regulation of type 2 immune response | 24 | 1.732897 | 0.0264554 | 0.0170738 |
| GO:0060485 | mesenchyme development | 210 | 1.732241 | 0.0159016 | 0.0102626 |
| GO:0072163 | mesonephric epithelium development | 88 | 1.731744 | 0.0159016 | 0.0102626 |
| GO:0072164 | mesonephric tubule development | 88 | 1.731744 | 0.0159016 | 0.0102626 |
| GO:0007549 | dosage compensation | 16 | 1.731523 | 0.0159016 | 0.0102626 |
| GO:0061333 | renal tubule morphogenesis | 66 | 1.731275 | 0.0159016 | 0.0102626 |
| GO:0010574 | regulation of vascular endothelial growth factor production | 28 | 1.730542 | 0.0159016 | 0.0102626 |
| GO:0009299 | mRNA transcription | 22 | 1.730517 | 0.0374799 | 0.0241889 |
| GO:0032753 | positive regulation of interleukin-4 production | 19 | 1.729985 | 0.0197048 | 0.0127172 |
| GO:0010818 | T cell chemotaxis | 17 | 1.729262 | 0.0197048 | 0.0127172 |
| GO:0032964 | collagen biosynthetic process | 40 | 1.729016 | 0.0319128 | 0.0205960 |
| GO:0097530 | granulocyte migration | 76 | 1.728509 | 0.0159016 | 0.0102626 |
| GO:0090132 | epithelium migration | 257 | 1.728302 | 0.0159016 | 0.0102626 |
| GO:0060479 | lung cell differentiation | 15 | 1.727852 | 0.0319261 | 0.0206045 |
| GO:0072078 | nephron tubule morphogenesis | 62 | 1.727813 | 0.0159016 | 0.0102626 |
| GO:0048705 | skeletal system morphogenesis | 160 | 1.727186 | 0.0159016 | 0.0102626 |
| GO:0032655 | regulation of interleukin-12 production | 40 | 1.726788 | 0.0319128 | 0.0205960 |
| GO:0043616 | keratinocyte proliferation | 36 | 1.726787 | 0.0263057 | 0.0169772 |
| GO:0010819 | regulation of T cell chemotaxis | 11 | 1.725942 | 0.0331329 | 0.0213834 |
| GO:0007599 | hemostasis | 280 | 1.725723 | 0.0159016 | 0.0102626 |
| GO:2000810 | regulation of bicellular tight junction assembly | 20 | 1.725523 | 0.0263057 | 0.0169772 |
| GO:0036120 | cellular response to platelet-derived growth factor stimulus | 20 | 1.724955 | 0.0263057 | 0.0169772 |
| GO:0007252 | I-kappaB phosphorylation | 17 | 1.724637 | 0.0197048 | 0.0127172 |
| GO:0030866 | cortical actin cytoskeleton organization | 29 | 1.724197 | 0.0319128 | 0.0205960 |
| GO:0071900 | regulation of protein serine/threonine kinase activity | 433 | 1.723793 | 0.0159016 | 0.0102626 |
| GO:0048024 | regulation of mRNA splicing, via spliceosome | 68 | 1.722403 | 0.0159016 | 0.0102626 |
| GO:0032602 | chemokine production | 72 | 1.721751 | 0.0159016 | 0.0102626 |
| GO:0002262 | myeloid cell homeostasis | 130 | 1.721577 | 0.0159016 | 0.0102626 |
| GO:0007043 | cell-cell junction assembly | 88 | 1.721402 | 0.0159016 | 0.0102626 |
| GO:0031341 | regulation of cell killing | 56 | 1.720943 | 0.0159016 | 0.0102626 |
| GO:0032673 | regulation of interleukin-4 production | 22 | 1.720471 | 0.0374799 | 0.0241889 |
| GO:0014706 | striated muscle tissue development | 310 | 1.720435 | 0.0159016 | 0.0102626 |
| GO:0045058 | T cell selection | 33 | 1.720380 | 0.0197048 | 0.0127172 |
| GO:0010803 | regulation of tumor necrosis factor-mediated signaling pathway | 53 | 1.720286 | 0.0159016 | 0.0102626 |
| GO:0050857 | positive regulation of antigen receptor-mediated signaling pathway | 17 | 1.720223 | 0.0197048 | 0.0127172 |
| GO:0051409 | response to nitrosative stress | 10 | 1.720201 | 0.0448092 | 0.0289191 |
| GO:0002369 | T cell cytokine production | 33 | 1.719814 | 0.0197048 | 0.0127172 |
| GO:0090322 | regulation of superoxide metabolic process | 31 | 1.719692 | 0.0319128 | 0.0205960 |
| GO:1903670 | regulation of sprouting angiogenesis | 63 | 1.719486 | 0.0159016 | 0.0102626 |
| GO:0032495 | response to muramyl dipeptide | 19 | 1.719439 | 0.0197048 | 0.0127172 |
| GO:0045408 | regulation of interleukin-6 biosynthetic process | 17 | 1.719167 | 0.0197048 | 0.0127172 |
| GO:0007507 | heart development | 479 | 1.719142 | 0.0159016 | 0.0102626 |
| GO:0007099 | centriole replication | 31 | 1.717945 | 0.0319128 | 0.0205960 |
| GO:0035456 | response to interferon-beta | 23 | 1.717023 | 0.0319261 | 0.0206045 |
| GO:0048598 | embryonic morphogenesis | 462 | 1.716917 | 0.0159016 | 0.0102626 |
| GO:1903036 | positive regulation of response to wounding | 55 | 1.716504 | 0.0159016 | 0.0102626 |
| GO:0090083 | regulation of inclusion body assembly | 15 | 1.716475 | 0.0319261 | 0.0206045 |
| GO:0002724 | regulation of T cell cytokine production | 26 | 1.716460 | 0.0263057 | 0.0169772 |
| GO:0071901 | negative regulation of protein serine/threonine kinase activity | 114 | 1.715957 | 0.0159016 | 0.0102626 |
| GO:0002062 | chondrocyte differentiation | 86 | 1.715530 | 0.0159016 | 0.0102626 |
| GO:0070988 | demethylation | 51 | 1.714830 | 0.0159016 | 0.0102626 |
| GO:2001185 | regulation of CD8-positive, alpha-beta T cell activation | 14 | 1.714713 | 0.0433215 | 0.0279589 |
| GO:0043583 | ear development | 180 | 1.713264 | 0.0159016 | 0.0102626 |
| GO:0030852 | regulation of granulocyte differentiation | 13 | 1.712574 | 0.0375938 | 0.0242624 |
| GO:0061041 | regulation of wound healing | 113 | 1.712218 | 0.0159016 | 0.0102626 |
| GO:1900402 | regulation of carbohydrate metabolic process by regulation of transcription from RNA polymerase II promoter | 11 | 1.710765 | 0.0331329 | 0.0213834 |
| GO:0071706 | tumor necrosis factor superfamily cytokine production | 125 | 1.710714 | 0.0159016 | 0.0102626 |
| GO:0050707 | regulation of cytokine secretion | 153 | 1.710422 | 0.0159016 | 0.0102626 |
| GO:0010742 | macrophage derived foam cell differentiation | 28 | 1.710096 | 0.0197048 | 0.0127172 |
| GO:0090077 | foam cell differentiation | 28 | 1.710096 | 0.0197048 | 0.0127172 |
| GO:0030903 | notochord development | 15 | 1.710025 | 0.0319261 | 0.0206045 |
| GO:0060713 | labyrinthine layer morphogenesis | 18 | 1.709459 | 0.0322532 | 0.0208156 |
| GO:0150077 | regulation of neuroinflammatory response | 31 | 1.709284 | 0.0319128 | 0.0205960 |
| GO:0002204 | somatic recombination of immunoglobulin genes involved in immune response | 39 | 1.708885 | 0.0319261 | 0.0206045 |
| GO:0002208 | somatic diversification of immunoglobulins involved in immune response | 39 | 1.708885 | 0.0319261 | 0.0206045 |
| GO:0045190 | isotype switching | 39 | 1.708885 | 0.0319261 | 0.0206045 |
| GO:0003007 | heart morphogenesis | 213 | 1.708862 | 0.0159016 | 0.0102626 |
| GO:0008156 | negative regulation of DNA replication | 31 | 1.708773 | 0.0319128 | 0.0205960 |
| GO:0033006 | regulation of mast cell activation involved in immune response | 28 | 1.708755 | 0.0197048 | 0.0127172 |
| GO:1902807 | negative regulation of cell cycle G1/S phase transition | 102 | 1.708707 | 0.0159016 | 0.0102626 |
| GO:0035886 | vascular smooth muscle cell differentiation | 24 | 1.708602 | 0.0375938 | 0.0242624 |
| GO:0002347 | response to tumor cell | 19 | 1.708432 | 0.0197048 | 0.0127172 |
| GO:0003176 | aortic valve development | 28 | 1.707419 | 0.0197048 | 0.0127172 |
| GO:0043407 | negative regulation of MAP kinase activity | 59 | 1.706592 | 0.0159016 | 0.0102626 |
| GO:0072171 | mesonephric tubule morphogenesis | 57 | 1.706170 | 0.0159016 | 0.0102626 |
| GO:0061138 | morphogenesis of a branching epithelium | 154 | 1.705484 | 0.0159016 | 0.0102626 |
| GO:0002253 | activation of immune response | 482 | 1.705183 | 0.0159016 | 0.0102626 |
| GO:0070373 | negative regulation of ERK1 and ERK2 cascade | 64 | 1.703926 | 0.0159016 | 0.0102626 |
| GO:0034101 | erythrocyte homeostasis | 105 | 1.703652 | 0.0194000 | 0.0125204 |
| GO:0071560 | cellular response to transforming growth factor beta stimulus | 207 | 1.703601 | 0.0159016 | 0.0102626 |
| GO:0090130 | tissue migration | 262 | 1.703279 | 0.0159016 | 0.0102626 |
| GO:0060065 | uterus development | 17 | 1.702878 | 0.0197048 | 0.0127172 |
| GO:0042246 | tissue regeneration | 59 | 1.702226 | 0.0159016 | 0.0102626 |
| GO:0002440 | production of molecular mediator of immune response | 159 | 1.702047 | 0.0159016 | 0.0102626 |
| GO:0090051 | negative regulation of cell migration involved in sprouting angiogenesis | 15 | 1.701218 | 0.0319261 | 0.0206045 |
| GO:0003208 | cardiac ventricle morphogenesis | 57 | 1.700933 | 0.0159016 | 0.0102626 |
| GO:0097067 | cellular response to thyroid hormone stimulus | 14 | 1.700658 | 0.0433215 | 0.0279589 |
| GO:0042692 | muscle cell differentiation | 289 | 1.700639 | 0.0159016 | 0.0102626 |
| GO:0070102 | interleukin-6-mediated signaling pathway | 19 | 1.699888 | 0.0197048 | 0.0127172 |
| GO:0048762 | mesenchymal cell differentiation | 171 | 1.699817 | 0.0159016 | 0.0102626 |
| GO:0001763 | morphogenesis of a branching structure | 167 | 1.699520 | 0.0159016 | 0.0102626 |
| GO:0002455 | humoral immune response mediated by circulating immunoglobulin | 32 | 1.699296 | 0.0260810 | 0.0168322 |
| GO:1901673 | regulation of mitotic spindle assembly | 19 | 1.699292 | 0.0197048 | 0.0127172 |
| GO:0003180 | aortic valve morphogenesis | 24 | 1.699038 | 0.0375938 | 0.0242624 |
| GO:0051225 | spindle assembly | 85 | 1.698416 | 0.0159016 | 0.0102626 |
| GO:0060544 | regulation of necroptotic process | 17 | 1.697964 | 0.0197048 | 0.0127172 |
| GO:2001251 | negative regulation of chromosome organization | 115 | 1.697737 | 0.0159016 | 0.0102626 |
| GO:0033004 | negative regulation of mast cell activation | 11 | 1.697672 | 0.0389629 | 0.0251460 |
| GO:0001656 | metanephros development | 74 | 1.697086 | 0.0194000 | 0.0125204 |
| GO:1901186 | positive regulation of ERBB signaling pathway | 30 | 1.697002 | 0.0263057 | 0.0169772 |
| GO:0007063 | regulation of sister chromatid cohesion | 21 | 1.696877 | 0.0319261 | 0.0206045 |
| GO:0003230 | cardiac atrium development | 27 | 1.695940 | 0.0374799 | 0.0241889 |
| GO:0010165 | response to X-ray | 26 | 1.695241 | 0.0319261 | 0.0206045 |
| GO:0060562 | epithelial tube morphogenesis | 274 | 1.694943 | 0.0159016 | 0.0102626 |
| GO:0007044 | cell-substrate junction assembly | 93 | 1.694481 | 0.0159016 | 0.0102626 |
| GO:0016447 | somatic recombination of immunoglobulin gene segments | 41 | 1.693616 | 0.0319261 | 0.0206045 |
| GO:0051148 | negative regulation of muscle cell differentiation | 52 | 1.693158 | 0.0159016 | 0.0102626 |
| GO:0071354 | cellular response to interleukin-6 | 33 | 1.692290 | 0.0197048 | 0.0127172 |
| GO:0010594 | regulation of endothelial cell migration | 145 | 1.691870 | 0.0159016 | 0.0102626 |
| GO:0030218 | erythrocyte differentiation | 99 | 1.691794 | 0.0159016 | 0.0102626 |
| GO:0048771 | tissue remodeling | 133 | 1.691614 | 0.0193893 | 0.0125135 |
| GO:0010656 | negative regulation of muscle cell apoptotic process | 33 | 1.691224 | 0.0197048 | 0.0127172 |
| GO:0002834 | regulation of response to tumor cell | 11 | 1.690939 | 0.0496855 | 0.0320662 |
| GO:0002837 | regulation of immune response to tumor cell | 11 | 1.690939 | 0.0496855 | 0.0320662 |
| GO:0048708 | astrocyte differentiation | 71 | 1.690388 | 0.0193760 | 0.0125049 |
| GO:0035924 | cellular response to vascular endothelial growth factor stimulus | 48 | 1.690231 | 0.0197048 | 0.0127172 |
| GO:0043303 | mast cell degranulation | 41 | 1.690198 | 0.0319261 | 0.0206045 |
| GO:0070265 | necrotic cell death | 45 | 1.689783 | 0.0197048 | 0.0127172 |
| GO:0043433 | negative regulation of DNA-binding transcription factor activity | 144 | 1.689639 | 0.0193760 | 0.0125049 |
| GO:0060390 | regulation of SMAD protein signal transduction | 22 | 1.689180 | 0.0374799 | 0.0241889 |
| GO:0010259 | multicellular organism aging | 28 | 1.689171 | 0.0197048 | 0.0127172 |
| GO:0033119 | negative regulation of RNA splicing | 24 | 1.688955 | 0.0375938 | 0.0242624 |
| GO:2001224 | positive regulation of neuron migration | 14 | 1.688781 | 0.0433215 | 0.0279589 |
| GO:1904994 | regulation of leukocyte adhesion to vascular endothelial cell | 17 | 1.688635 | 0.0197048 | 0.0127172 |
| GO:0043030 | regulation of macrophage activation | 51 | 1.687092 | 0.0159016 | 0.0102626 |
| GO:1903555 | regulation of tumor necrosis factor superfamily cytokine production | 120 | 1.686601 | 0.0193760 | 0.0125049 |
| GO:0043588 | skin development | 214 | 1.686000 | 0.0159016 | 0.0102626 |
| GO:0045601 | regulation of endothelial cell differentiation | 26 | 1.685928 | 0.0319261 | 0.0206045 |
| GO:0002532 | production of molecular mediator involved in inflammatory response | 56 | 1.685889 | 0.0159016 | 0.0102626 |
| GO:0035729 | cellular response to hepatocyte growth factor stimulus | 15 | 1.685665 | 0.0375213 | 0.0242156 |
| GO:2000178 | negative regulation of neural precursor cell proliferation | 23 | 1.684850 | 0.0375402 | 0.0242278 |
| GO:1901223 | negative regulation of NIK/NF-kappaB signaling | 22 | 1.684626 | 0.0374799 | 0.0241889 |
| GO:0060487 | lung epithelial cell differentiation | 14 | 1.684471 | 0.0433215 | 0.0279589 |
| GO:0001569 | branching involved in blood vessel morphogenesis | 26 | 1.684022 | 0.0319261 | 0.0206045 |
| GO:0045742 | positive regulation of epidermal growth factor receptor signaling pathway | 28 | 1.683940 | 0.0197048 | 0.0127172 |
| GO:0061383 | trabecula morphogenesis | 44 | 1.683233 | 0.0197048 | 0.0127172 |
| GO:2000352 | negative regulation of endothelial cell apoptotic process | 20 | 1.683192 | 0.0319261 | 0.0206045 |
| GO:0002698 | negative regulation of immune effector process | 99 | 1.682919 | 0.0159016 | 0.0102626 |
| GO:0007266 | Rho protein signal transduction | 151 | 1.680327 | 0.0159016 | 0.0102626 |
| GO:0043281 | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 176 | 1.679771 | 0.0159016 | 0.0102626 |
| GO:0051090 | regulation of DNA-binding transcription factor activity | 377 | 1.679371 | 0.0159016 | 0.0102626 |
| GO:0051642 | centrosome localization | 23 | 1.678593 | 0.0375402 | 0.0242278 |
| GO:0042330 | taxis | 461 | 1.678522 | 0.0159016 | 0.0102626 |
| GO:0003159 | morphogenesis of an endothelium | 18 | 1.676972 | 0.0322532 | 0.0208156 |
| GO:0061154 | endothelial tube morphogenesis | 18 | 1.676972 | 0.0322532 | 0.0208156 |
| GO:0007221 | positive regulation of transcription of Notch receptor target | 17 | 1.676867 | 0.0320537 | 0.0206869 |
| GO:0007423 | sensory organ development | 449 | 1.676590 | 0.0159016 | 0.0102626 |
| GO:0048839 | inner ear development | 158 | 1.676317 | 0.0159016 | 0.0102626 |
| GO:2000116 | regulation of cysteine-type endopeptidase activity | 200 | 1.676160 | 0.0159016 | 0.0102626 |
| GO:0060675 | ureteric bud morphogenesis | 56 | 1.674972 | 0.0197048 | 0.0127172 |
| GO:0072089 | stem cell proliferation | 102 | 1.674636 | 0.0193760 | 0.0125049 |
| GO:0006935 | chemotaxis | 459 | 1.674622 | 0.0159016 | 0.0102626 |
| GO:0010667 | negative regulation of cardiac muscle cell apoptotic process | 20 | 1.674356 | 0.0319261 | 0.0206045 |
| GO:0030330 | DNA damage response, signal transduction by p53 class mediator | 101 | 1.674300 | 0.0193760 | 0.0125049 |
| GO:0060443 | mammary gland morphogenesis | 39 | 1.673613 | 0.0374799 | 0.0241889 |
| GO:1905314 | semi-lunar valve development | 33 | 1.673501 | 0.0319128 | 0.0205960 |
| GO:2001238 | positive regulation of extrinsic apoptotic signaling pathway | 48 | 1.673466 | 0.0197048 | 0.0127172 |
| GO:0021983 | pituitary gland development | 31 | 1.672560 | 0.0319128 | 0.0205960 |
| GO:0010758 | regulation of macrophage chemotaxis | 20 | 1.672143 | 0.0319261 | 0.0206045 |
| GO:0072577 | endothelial cell apoptotic process | 42 | 1.671673 | 0.0375402 | 0.0242278 |
| GO:0007566 | embryo implantation | 43 | 1.670773 | 0.0263057 | 0.0169772 |
| GO:0072673 | lamellipodium morphogenesis | 16 | 1.669202 | 0.0264462 | 0.0170679 |
| GO:0045686 | negative regulation of glial cell differentiation | 22 | 1.668482 | 0.0431083 | 0.0278214 |
| GO:0072111 | cell proliferation involved in kidney development | 16 | 1.667810 | 0.0264462 | 0.0170679 |
| GO:0007160 | cell-matrix adhesion | 192 | 1.666823 | 0.0188136 | 0.0121420 |
| GO:0010664 | negative regulation of striated muscle cell apoptotic process | 23 | 1.666762 | 0.0432170 | 0.0278915 |
| GO:0002726 | positive regulation of T cell cytokine production | 17 | 1.665782 | 0.0320537 | 0.0206869 |
| GO:0032928 | regulation of superoxide anion generation | 20 | 1.665736 | 0.0319261 | 0.0206045 |
| GO:0034109 | homotypic cell-cell adhesion | 68 | 1.665514 | 0.0193760 | 0.0125049 |
| GO:2000648 | positive regulation of stem cell proliferation | 33 | 1.664710 | 0.0319128 | 0.0205960 |
| GO:0060541 | respiratory system development | 174 | 1.664124 | 0.0188683 | 0.0121773 |
| GO:0043304 | regulation of mast cell degranulation | 26 | 1.663605 | 0.0374229 | 0.0241521 |
| GO:0043300 | regulation of leukocyte degranulation | 42 | 1.662125 | 0.0375402 | 0.0242278 |
| GO:0043123 | positive regulation of I-kappaB kinase/NF-kappaB signaling | 159 | 1.661090 | 0.0159016 | 0.0102626 |
| GO:0014911 | positive regulation of smooth muscle cell migration | 37 | 1.660726 | 0.0372315 | 0.0240286 |
| GO:0060008 | Sertoli cell differentiation | 18 | 1.660621 | 0.0378372 | 0.0244195 |
| GO:0009952 | anterior/posterior pattern specification | 136 | 1.660144 | 0.0193760 | 0.0125049 |
| GO:0042533 | tumor necrosis factor biosynthetic process | 21 | 1.659768 | 0.0319261 | 0.0206045 |
| GO:0042534 | regulation of tumor necrosis factor biosynthetic process | 21 | 1.659768 | 0.0319261 | 0.0206045 |
| GO:0098534 | centriole assembly | 33 | 1.659250 | 0.0319128 | 0.0205960 |
| GO:0030323 | respiratory tube development | 156 | 1.658955 | 0.0159016 | 0.0102626 |
| GO:0034405 | response to fluid shear stress | 33 | 1.658654 | 0.0319128 | 0.0205960 |
| GO:0030316 | osteoclast differentiation | 78 | 1.657688 | 0.0193760 | 0.0125049 |
| GO:0006303 | double-strand break repair via nonhomologous end joining | 77 | 1.657018 | 0.0193760 | 0.0125049 |
| GO:0014910 | regulation of smooth muscle cell migration | 60 | 1.656277 | 0.0159016 | 0.0102626 |
| GO:0060009 | Sertoli cell development | 14 | 1.656253 | 0.0433215 | 0.0279589 |
| GO:0002448 | mast cell mediated immunity | 43 | 1.656121 | 0.0374229 | 0.0241521 |
| GO:0061045 | negative regulation of wound healing | 58 | 1.655519 | 0.0159016 | 0.0102626 |
| GO:0060216 | definitive hemopoiesis | 16 | 1.655259 | 0.0264462 | 0.0170679 |
| GO:0061028 | establishment of endothelial barrier | 39 | 1.655028 | 0.0430890 | 0.0278089 |
| GO:0043388 | positive regulation of DNA binding | 50 | 1.654902 | 0.0197048 | 0.0127172 |
| GO:0048568 | embryonic organ development | 338 | 1.654659 | 0.0159016 | 0.0102626 |
| GO:0051147 | regulation of muscle cell differentiation | 138 | 1.654647 | 0.0193760 | 0.0125049 |
| GO:0032680 | regulation of tumor necrosis factor production | 117 | 1.654443 | 0.0193760 | 0.0125049 |
| GO:0010717 | regulation of epithelial to mesenchymal transition | 77 | 1.653435 | 0.0193760 | 0.0125049 |
| GO:0090303 | positive regulation of wound healing | 45 | 1.653093 | 0.0319261 | 0.0206045 |
| GO:0032691 | negative regulation of interleukin-1 beta production | 21 | 1.652860 | 0.0319261 | 0.0206045 |
| GO:0034330 | cell junction organization | 259 | 1.652797 | 0.0159016 | 0.0102626 |
| GO:1902275 | regulation of chromatin organization | 154 | 1.652574 | 0.0193760 | 0.0125049 |
| GO:0071800 | podosome assembly | 15 | 1.652446 | 0.0478749 | 0.0308976 |
| GO:0043154 | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 70 | 1.652334 | 0.0306432 | 0.0197766 |
| GO:0048525 | negative regulation of viral process | 80 | 1.652208 | 0.0193760 | 0.0125049 |
| GO:0060914 | heart formation | 19 | 1.650946 | 0.0482102 | 0.0311141 |
| GO:0032640 | tumor necrosis factor production | 121 | 1.650859 | 0.0193760 | 0.0125049 |
| GO:0001837 | epithelial to mesenchymal transition | 121 | 1.649856 | 0.0193760 | 0.0125049 |
| GO:0042276 | error-prone translesion synthesis | 18 | 1.649016 | 0.0378372 | 0.0244195 |
| GO:0071621 | granulocyte chemotaxis | 64 | 1.648357 | 0.0159016 | 0.0102626 |
| GO:0070098 | chemokine-mediated signaling pathway | 39 | 1.648338 | 0.0430890 | 0.0278089 |
| GO:0046330 | positive regulation of JNK cascade | 107 | 1.648305 | 0.0193760 | 0.0125049 |
| GO:0003209 | cardiac atrium morphogenesis | 22 | 1.647890 | 0.0478191 | 0.0308616 |
| GO:2000142 | regulation of DNA-templated transcription, initiation | 26 | 1.647430 | 0.0429443 | 0.0277155 |
| GO:0031532 | actin cytoskeleton reorganization | 82 | 1.647379 | 0.0193760 | 0.0125049 |
| GO:0032570 | response to progesterone | 40 | 1.647047 | 0.0473358 | 0.0305497 |
| GO:0010470 | regulation of gastrulation | 32 | 1.645978 | 0.0370796 | 0.0239305 |
| GO:0010595 | positive regulation of endothelial cell migration | 95 | 1.645432 | 0.0193760 | 0.0125049 |
| GO:0072012 | glomerulus vasculature development | 19 | 1.644769 | 0.0482102 | 0.0311141 |
| GO:0071384 | cellular response to corticosteroid stimulus | 54 | 1.643561 | 0.0260810 | 0.0168322 |
| GO:0034121 | regulation of toll-like receptor signaling pathway | 59 | 1.643399 | 0.0159016 | 0.0102626 |
| GO:0045071 | negative regulation of viral genome replication | 50 | 1.641648 | 0.0264462 | 0.0170679 |
| GO:0007179 | transforming growth factor beta receptor signaling pathway | 162 | 1.641158 | 0.0159016 | 0.0102626 |
| GO:0002637 | regulation of immunoglobulin production | 50 | 1.639619 | 0.0264462 | 0.0170679 |
| GO:0048754 | branching morphogenesis of an epithelial tube | 126 | 1.639309 | 0.0193760 | 0.0125049 |
| GO:0031062 | positive regulation of histone methylation | 36 | 1.638810 | 0.0429443 | 0.0277155 |
| GO:0060428 | lung epithelium development | 28 | 1.638555 | 0.0476773 | 0.0307701 |
| GO:0120193 | tight junction organization | 51 | 1.637827 | 0.0263057 | 0.0169772 |
| GO:0006614 | SRP-dependent cotranslational protein targeting to membrane | 92 | 1.636756 | 0.0159016 | 0.0102626 |
| GO:0045445 | myoblast differentiation | 70 | 1.636026 | 0.0306432 | 0.0197766 |
| GO:1903034 | regulation of response to wounding | 140 | 1.634943 | 0.0193760 | 0.0125049 |
| GO:0045830 | positive regulation of isotype switching | 21 | 1.634767 | 0.0375402 | 0.0242278 |
| GO:0035728 | response to hepatocyte growth factor | 17 | 1.634492 | 0.0482102 | 0.0311141 |
| GO:1904706 | negative regulation of vascular smooth muscle cell proliferation | 17 | 1.633855 | 0.0482102 | 0.0311141 |
| GO:0150063 | visual system development | 307 | 1.633458 | 0.0159016 | 0.0102626 |
| GO:0048880 | sensory system development | 308 | 1.633448 | 0.0159016 | 0.0102626 |
| GO:1904888 | cranial skeletal system development | 56 | 1.633236 | 0.0261757 | 0.0168934 |
| GO:0050878 | regulation of body fluid levels | 413 | 1.633143 | 0.0159016 | 0.0102626 |
| GO:0036003 | positive regulation of transcription from RNA polymerase II promoter in response to stress | 24 | 1.633131 | 0.0482102 | 0.0311141 |
| GO:0001667 | ameboidal-type cell migration | 333 | 1.633123 | 0.0159016 | 0.0102626 |
| GO:0070371 | ERK1 and ERK2 cascade | 241 | 1.632785 | 0.0159016 | 0.0102626 |
| GO:0045606 | positive regulation of epidermal cell differentiation | 19 | 1.632305 | 0.0482102 | 0.0311141 |
| GO:0001658 | branching involved in ureteric bud morphogenesis | 51 | 1.631431 | 0.0263057 | 0.0169772 |
| GO:0070830 | bicellular tight junction assembly | 47 | 1.630710 | 0.0197048 | 0.0127172 |
| GO:0060337 | type I interferon signaling pathway | 75 | 1.630452 | 0.0193760 | 0.0125049 |
| GO:0071357 | cellular response to type I interferon | 75 | 1.630452 | 0.0193760 | 0.0125049 |
| GO:0060840 | artery development | 81 | 1.630166 | 0.0193760 | 0.0125049 |
| GO:0002715 | regulation of natural killer cell mediated immunity | 31 | 1.628855 | 0.0372354 | 0.0240311 |
| GO:0050715 | positive regulation of cytokine secretion | 103 | 1.628801 | 0.0193760 | 0.0125049 |
| GO:0051146 | striated muscle cell differentiation | 212 | 1.628567 | 0.0159016 | 0.0102626 |
| GO:0042789 | mRNA transcription by RNA polymerase II | 16 | 1.628472 | 0.0319261 | 0.0206045 |
| GO:0001890 | placenta development | 131 | 1.627659 | 0.0193760 | 0.0125049 |
| GO:0002886 | regulation of myeloid leukocyte mediated immunity | 49 | 1.626735 | 0.0319128 | 0.0205960 |
| GO:2000177 | regulation of neural precursor cell proliferation | 78 | 1.624597 | 0.0193760 | 0.0125049 |
| GO:0033673 | negative regulation of kinase activity | 214 | 1.624591 | 0.0159016 | 0.0102626 |
| GO:0097191 | extrinsic apoptotic signaling pathway | 192 | 1.623581 | 0.0188136 | 0.0121420 |
| GO:0038127 | ERBB signaling pathway | 125 | 1.622297 | 0.0193760 | 0.0125049 |
| GO:1904894 | positive regulation of STAT cascade | 61 | 1.622054 | 0.0256715 | 0.0165680 |
| GO:0030324 | lung development | 152 | 1.621762 | 0.0193760 | 0.0125049 |
| GO:0002718 | regulation of cytokine production involved in immune response | 69 | 1.621591 | 0.0307259 | 0.0198300 |
| GO:2000404 | regulation of T cell migration | 34 | 1.619174 | 0.0372354 | 0.0240311 |
| GO:0042094 | interleukin-2 biosynthetic process | 19 | 1.618605 | 0.0482102 | 0.0311141 |
| GO:0042307 | positive regulation of protein import into nucleus | 34 | 1.617661 | 0.0372354 | 0.0240311 |
| GO:0014909 | smooth muscle cell migration | 66 | 1.616343 | 0.0194000 | 0.0125204 |
| GO:0071902 | positive regulation of protein serine/threonine kinase activity | 297 | 1.615329 | 0.0159016 | 0.0102626 |
| GO:2000353 | positive regulation of endothelial cell apoptotic process | 16 | 1.615307 | 0.0432170 | 0.0278915 |
| GO:0042026 | protein refolding | 18 | 1.614373 | 0.0378372 | 0.0244195 |
| GO:0030206 | chondroitin sulfate biosynthetic process | 25 | 1.614203 | 0.0480182 | 0.0309901 |
| GO:0061437 | renal system vasculature development | 21 | 1.614113 | 0.0431968 | 0.0278785 |
| GO:0061440 | kidney vasculature development | 21 | 1.614113 | 0.0431968 | 0.0278785 |
| GO:0010001 | glial cell differentiation | 200 | 1.612794 | 0.0188136 | 0.0121420 |
| GO:0051893 | regulation of focal adhesion assembly | 59 | 1.612649 | 0.0197048 | 0.0127172 |
| GO:0090109 | regulation of cell-substrate junction assembly | 59 | 1.612649 | 0.0197048 | 0.0127172 |
| GO:1903053 | regulation of extracellular matrix organization | 36 | 1.612020 | 0.0475746 | 0.0307038 |
| GO:0060317 | cardiac epithelial to mesenchymal transition | 32 | 1.610616 | 0.0424757 | 0.0274131 |
| GO:0002757 | immune response-activating signal transduction | 427 | 1.608768 | 0.0159016 | 0.0102626 |
| GO:0060760 | positive regulation of response to cytokine stimulus | 53 | 1.608257 | 0.0197048 | 0.0127172 |
| GO:0002702 | positive regulation of production of molecular mediator of immune response | 77 | 1.607586 | 0.0193760 | 0.0125049 |
| GO:1901184 | regulation of ERBB signaling pathway | 83 | 1.606535 | 0.0193760 | 0.0125049 |
| GO:0007140 | male meiotic nuclear division | 32 | 1.606502 | 0.0424757 | 0.0274131 |
| GO:0014013 | regulation of gliogenesis | 111 | 1.605840 | 0.0193760 | 0.0125049 |
| GO:0051568 | histone H3-K4 methylation | 46 | 1.604962 | 0.0476773 | 0.0307701 |
| GO:0072091 | regulation of stem cell proliferation | 57 | 1.604658 | 0.0159016 | 0.0102626 |
| GO:0006469 | negative regulation of protein kinase activity | 197 | 1.604334 | 0.0188136 | 0.0121420 |
| GO:0010830 | regulation of myotube differentiation | 44 | 1.604328 | 0.0319261 | 0.0206045 |
| GO:0032088 | negative regulation of NF-kappaB transcription factor activity | 76 | 1.604119 | 0.0193760 | 0.0125049 |
| GO:0014068 | positive regulation of phosphatidylinositol 3-kinase signaling | 71 | 1.602707 | 0.0306432 | 0.0197766 |
| GO:0045005 | DNA-dependent DNA replication maintenance of fidelity | 33 | 1.602378 | 0.0472826 | 0.0305154 |
| GO:0031214 | biomineral tissue development | 127 | 1.601758 | 0.0193760 | 0.0125049 |
| GO:0043406 | positive regulation of MAP kinase activity | 231 | 1.600961 | 0.0159016 | 0.0102626 |
| GO:2000379 | positive regulation of reactive oxygen species metabolic process | 83 | 1.599147 | 0.0193760 | 0.0125049 |
| GO:0010811 | positive regulation of cell-substrate adhesion | 98 | 1.598895 | 0.0247948 | 0.0160021 |
| GO:0002764 | immune response-regulating signaling pathway | 456 | 1.598504 | 0.0159016 | 0.0102626 |
| GO:0070372 | regulation of ERK1 and ERK2 cascade | 226 | 1.597478 | 0.0159016 | 0.0102626 |
| GO:0048713 | regulation of oligodendrocyte differentiation | 38 | 1.596679 | 0.0474352 | 0.0306138 |
| GO:0007062 | sister chromatid cohesion | 45 | 1.596322 | 0.0430890 | 0.0278089 |
| GO:0002200 | somatic diversification of immune receptors | 58 | 1.594089 | 0.0197048 | 0.0127172 |
| GO:0051154 | negative regulation of striated muscle cell differentiation | 34 | 1.593661 | 0.0473813 | 0.0305791 |
| GO:0050684 | regulation of mRNA processing | 101 | 1.593209 | 0.0247948 | 0.0160021 |
| GO:0014902 | myotube differentiation | 87 | 1.591942 | 0.0159016 | 0.0102626 |
| GO:0043410 | positive regulation of MAPK cascade | 430 | 1.591917 | 0.0159016 | 0.0102626 |
| GO:0090183 | regulation of kidney development | 46 | 1.589529 | 0.0476773 | 0.0307701 |
| GO:0046427 | positive regulation of JAK-STAT cascade | 59 | 1.589181 | 0.0261514 | 0.0168776 |
| GO:0060761 | negative regulation of response to cytokine stimulus | 53 | 1.588439 | 0.0370676 | 0.0239228 |
| GO:0001654 | eye development | 303 | 1.588298 | 0.0159016 | 0.0102626 |
| GO:0050922 | negative regulation of chemotaxis | 33 | 1.587057 | 0.0472826 | 0.0305154 |
| GO:0070206 | protein trimerization | 47 | 1.586973 | 0.0429443 | 0.0277155 |
| GO:0061035 | regulation of cartilage development | 57 | 1.586969 | 0.0197048 | 0.0127172 |
| GO:0000018 | regulation of DNA recombination | 77 | 1.586472 | 0.0193760 | 0.0125049 |
| GO:0120192 | tight junction assembly | 48 | 1.585657 | 0.0319128 | 0.0205960 |
| GO:0051153 | regulation of striated muscle cell differentiation | 87 | 1.585066 | 0.0159016 | 0.0102626 |
| GO:0032922 | circadian regulation of gene expression | 57 | 1.584912 | 0.0197048 | 0.0127172 |
| GO:2000146 | negative regulation of cell motility | 238 | 1.584632 | 0.0159016 | 0.0102626 |
| GO:0030336 | negative regulation of cell migration | 227 | 1.583821 | 0.0159016 | 0.0102626 |
| GO:1900026 | positive regulation of substrate adhesion-dependent cell spreading | 32 | 1.582697 | 0.0472169 | 0.0304730 |
| GO:0050710 | negative regulation of cytokine secretion | 53 | 1.582509 | 0.0424757 | 0.0274131 |
| GO:0002639 | positive regulation of immunoglobulin production | 32 | 1.582412 | 0.0472169 | 0.0304730 |
| GO:0045444 | fat cell differentiation | 192 | 1.581299 | 0.0188136 | 0.0121420 |
| GO:0042058 | regulation of epidermal growth factor receptor signaling pathway | 77 | 1.580286 | 0.0193760 | 0.0125049 |
| GO:0045995 | regulation of embryonic development | 110 | 1.579517 | 0.0193760 | 0.0125049 |
| GO:0018205 | peptidyl-lysine modification | 350 | 1.578856 | 0.0159016 | 0.0102626 |
| GO:0006613 | cotranslational protein targeting to membrane | 95 | 1.578639 | 0.0247948 | 0.0160021 |
| GO:0035148 | tube formation | 130 | 1.578060 | 0.0248321 | 0.0160262 |
| GO:0045047 | protein targeting to ER | 97 | 1.578037 | 0.0306432 | 0.0197766 |
| GO:0048661 | positive regulation of smooth muscle cell proliferation | 81 | 1.577414 | 0.0193760 | 0.0125049 |
| GO:0034333 | adherens junction assembly | 88 | 1.577320 | 0.0159016 | 0.0102626 |
| GO:0030859 | polarized epithelial cell differentiation | 18 | 1.577243 | 0.0378372 | 0.0244195 |
| GO:0050918 | positive chemotaxis | 55 | 1.576506 | 0.0371184 | 0.0239556 |
| GO:0033044 | regulation of chromosome organization | 290 | 1.576322 | 0.0159016 | 0.0102626 |
| GO:1900024 | regulation of substrate adhesion-dependent cell spreading | 47 | 1.576038 | 0.0429443 | 0.0277155 |
| GO:0090307 | mitotic spindle assembly | 49 | 1.574693 | 0.0426607 | 0.0275325 |
| GO:0001961 | positive regulation of cytokine-mediated signaling pathway | 46 | 1.574445 | 0.0476773 | 0.0307701 |
| GO:1905954 | positive regulation of lipid localization | 71 | 1.574266 | 0.0355565 | 0.0229475 |
| GO:0007405 | neuroblast proliferation | 53 | 1.572657 | 0.0472169 | 0.0304730 |
| GO:0007178 | transmembrane receptor protein serine/threonine kinase signaling pathway | 276 | 1.571713 | 0.0159016 | 0.0102626 |
| GO:0051271 | negative regulation of cellular component movement | 254 | 1.571128 | 0.0159016 | 0.0102626 |
| GO:0030032 | lamellipodium assembly | 54 | 1.570900 | 0.0424757 | 0.0274131 |
| GO:0001960 | negative regulation of cytokine-mediated signaling pathway | 49 | 1.570795 | 0.0426607 | 0.0275325 |
| GO:1905952 | regulation of lipid localization | 115 | 1.570432 | 0.0193760 | 0.0125049 |
| GO:0042770 | signal transduction in response to DNA damage | 124 | 1.569165 | 0.0247948 | 0.0160021 |
| GO:0032970 | regulation of actin filament-based process | 307 | 1.566530 | 0.0159016 | 0.0102626 |
| GO:0046718 | viral entry into host cell | 106 | 1.566444 | 0.0249569 | 0.0161068 |
| GO:0048706 | embryonic skeletal system development | 86 | 1.563905 | 0.0247948 | 0.0160021 |
| GO:0001708 | cell fate specification | 53 | 1.563160 | 0.0472169 | 0.0304730 |
| GO:0030522 | intracellular receptor signaling pathway | 253 | 1.562617 | 0.0159016 | 0.0102626 |
| GO:0042303 | molting cycle | 86 | 1.561371 | 0.0247948 | 0.0160021 |
| GO:0042633 | hair cycle | 86 | 1.561371 | 0.0247948 | 0.0160021 |
| GO:0051145 | smooth muscle cell differentiation | 54 | 1.560849 | 0.0472169 | 0.0304730 |
| GO:0006801 | superoxide metabolic process | 57 | 1.560493 | 0.0370796 | 0.0239305 |
| GO:0007264 | small GTPase mediated signal transduction | 449 | 1.560206 | 0.0159016 | 0.0102626 |
| GO:0060021 | roof of mouth development | 80 | 1.560045 | 0.0247948 | 0.0160021 |
| GO:0071622 | regulation of granulocyte chemotaxis | 34 | 1.559391 | 0.0473813 | 0.0305791 |
| GO:0002367 | cytokine production involved in immune response | 85 | 1.558968 | 0.0247948 | 0.0160021 |
| GO:0000726 | non-recombinational repair | 83 | 1.558966 | 0.0247249 | 0.0159570 |
| GO:0007045 | cell-substrate adherens junction assembly | 79 | 1.557622 | 0.0247601 | 0.0159798 |
| GO:0048041 | focal adhesion assembly | 79 | 1.557622 | 0.0247601 | 0.0159798 |
| GO:0016569 | covalent chromatin modification | 403 | 1.555151 | 0.0159016 | 0.0102626 |
| GO:0042063 | gliogenesis | 262 | 1.554680 | 0.0159016 | 0.0102626 |
| GO:0045216 | cell-cell junction organization | 116 | 1.553463 | 0.0248321 | 0.0160262 |
| GO:0060349 | bone morphogenesis | 75 | 1.552902 | 0.0248321 | 0.0160262 |
| GO:0048704 | embryonic skeletal system morphogenesis | 62 | 1.552842 | 0.0368442 | 0.0237786 |
| GO:0051983 | regulation of chromosome segregation | 85 | 1.552341 | 0.0247948 | 0.0160021 |
| GO:0035023 | regulation of Rho protein signal transduction | 118 | 1.550478 | 0.0306432 | 0.0197766 |
| GO:0061008 | hepaticobiliary system development | 120 | 1.549316 | 0.0247948 | 0.0160021 |
| GO:0010632 | regulation of epithelial cell migration | 201 | 1.546296 | 0.0188226 | 0.0121478 |
| GO:0051781 | positive regulation of cell division | 68 | 1.545734 | 0.0451956 | 0.0291685 |
| GO:0042326 | negative regulation of phosphorylation | 396 | 1.545011 | 0.0159016 | 0.0102626 |
| GO:0090288 | negative regulation of cellular response to growth factor stimulus | 123 | 1.543845 | 0.0193760 | 0.0125049 |
| GO:1903035 | negative regulation of response to wounding | 71 | 1.542021 | 0.0355565 | 0.0229475 |
| GO:0051056 | regulation of small GTPase mediated signal transduction | 305 | 1.540444 | 0.0159016 | 0.0102626 |
| GO:0043507 | positive regulation of JUN kinase activity | 62 | 1.539523 | 0.0467119 | 0.0301470 |
| GO:0016570 | histone modification | 392 | 1.538633 | 0.0159016 | 0.0102626 |
| GO:0050818 | regulation of coagulation | 64 | 1.537981 | 0.0464996 | 0.0300100 |
| GO:1902532 | negative regulation of intracellular signal transduction | 461 | 1.537920 | 0.0159016 | 0.0102626 |
| GO:0048660 | regulation of smooth muscle cell proliferation | 125 | 1.537857 | 0.0352673 | 0.0227609 |
| GO:0002431 | Fc receptor mediated stimulatory signaling pathway | 78 | 1.537543 | 0.0350445 | 0.0226171 |
| GO:0050764 | regulation of phagocytosis | 75 | 1.534482 | 0.0248321 | 0.0160262 |
| GO:0048545 | response to steroid hormone | 337 | 1.533894 | 0.0159016 | 0.0102626 |
| GO:0040013 | negative regulation of locomotion | 265 | 1.533721 | 0.0188136 | 0.0121420 |
| GO:0031056 | regulation of histone modification | 129 | 1.532957 | 0.0306432 | 0.0197766 |
| GO:2001234 | negative regulation of apoptotic signaling pathway | 199 | 1.531848 | 0.0188136 | 0.0121420 |
| GO:0045088 | regulation of innate immune response | 367 | 1.530379 | 0.0159016 | 0.0102626 |
| GO:0090101 | negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 103 | 1.528565 | 0.0248321 | 0.0160262 |
| GO:0051091 | positive regulation of DNA-binding transcription factor activity | 233 | 1.528187 | 0.0159016 | 0.0102626 |
| GO:0052548 | regulation of endopeptidase activity | 287 | 1.528158 | 0.0159016 | 0.0102626 |
| GO:0007015 | actin filament organization | 299 | 1.528005 | 0.0159016 | 0.0102626 |
| GO:0033045 | regulation of sister chromatid segregation | 65 | 1.527800 | 0.0456122 | 0.0294374 |
| GO:0042476 | odontogenesis | 105 | 1.525454 | 0.0307538 | 0.0198480 |
| GO:0043506 | regulation of JUN kinase activity | 75 | 1.525270 | 0.0355565 | 0.0229475 |
| GO:0031099 | regeneration | 163 | 1.525078 | 0.0240307 | 0.0155090 |
| GO:0030838 | positive regulation of actin filament polymerization | 73 | 1.524823 | 0.0450884 | 0.0290993 |
| GO:0048659 | smooth muscle cell proliferation | 127 | 1.524026 | 0.0353581 | 0.0228195 |
| GO:0052547 | regulation of peptidase activity | 311 | 1.523719 | 0.0185164 | 0.0119502 |
| GO:0051384 | response to glucocorticoid | 119 | 1.523049 | 0.0306432 | 0.0197766 |
| GO:0001889 | liver development | 117 | 1.520731 | 0.0306432 | 0.0197766 |
| GO:0051262 | protein tetramerization | 157 | 1.519759 | 0.0300692 | 0.0194062 |
| GO:0010951 | negative regulation of endopeptidase activity | 145 | 1.519574 | 0.0248321 | 0.0160262 |
| GO:0042475 | odontogenesis of dentin-containing tooth | 69 | 1.517813 | 0.0453344 | 0.0292581 |
| GO:0048608 | reproductive structure development | 354 | 1.516569 | 0.0159016 | 0.0102626 |
| GO:0071260 | cellular response to mechanical stimulus | 69 | 1.514274 | 0.0453344 | 0.0292581 |
| GO:0043901 | negative regulation of multi-organism process | 143 | 1.511554 | 0.0306432 | 0.0197766 |
| GO:0001933 | negative regulation of protein phosphorylation | 363 | 1.510792 | 0.0159016 | 0.0102626 |
| GO:0006606 | protein import into nucleus | 96 | 1.510361 | 0.0352673 | 0.0227609 |
| GO:0048732 | gland development | 355 | 1.510302 | 0.0159016 | 0.0102626 |
| GO:0000184 | nuclear-transcribed mRNA catabolic process, nonsense-mediated decay | 116 | 1.509756 | 0.0355157 | 0.0229212 |
| GO:0051302 | regulation of cell division | 140 | 1.508449 | 0.0306432 | 0.0197766 |
| GO:0010810 | regulation of cell-substrate adhesion | 178 | 1.506937 | 0.0291339 | 0.0188025 |
| GO:0048144 | fibroblast proliferation | 76 | 1.505964 | 0.0306432 | 0.0197766 |
| GO:0007265 | Ras protein signal transduction | 314 | 1.503164 | 0.0185994 | 0.0120037 |
| GO:0051052 | regulation of DNA metabolic process | 361 | 1.502831 | 0.0159016 | 0.0102626 |
| GO:0072599 | establishment of protein localization to endoplasmic reticulum | 101 | 1.502448 | 0.0306432 | 0.0197766 |
| GO:0006352 | DNA-templated transcription, initiation | 215 | 1.502219 | 0.0188136 | 0.0121420 |
| GO:0001942 | hair follicle development | 72 | 1.501251 | 0.0495485 | 0.0319778 |
| GO:0032102 | negative regulation of response to external stimulus | 258 | 1.499971 | 0.0188136 | 0.0121420 |
| GO:0030260 | entry into host cell | 118 | 1.499378 | 0.0352673 | 0.0227609 |
| GO:0044409 | entry into host | 118 | 1.499378 | 0.0352673 | 0.0227609 |
| GO:0051806 | entry into cell of other organism involved in symbiotic interaction | 118 | 1.499378 | 0.0352673 | 0.0227609 |
| GO:0051828 | entry into other organism involved in symbiotic interaction | 118 | 1.499378 | 0.0352673 | 0.0227609 |
| GO:0032956 | regulation of actin cytoskeleton organization | 267 | 1.499080 | 0.0231200 | 0.0149212 |
| GO:0070304 | positive regulation of stress-activated protein kinase signaling cascade | 130 | 1.498967 | 0.0404474 | 0.0261040 |
| GO:0009612 | response to mechanical stimulus | 180 | 1.496244 | 0.0336129 | 0.0216932 |
| GO:0046849 | bone remodeling | 71 | 1.494655 | 0.0495485 | 0.0319778 |
| GO:0006479 | protein methylation | 156 | 1.494622 | 0.0301179 | 0.0194376 |
| GO:0008213 | protein alkylation | 156 | 1.494622 | 0.0301179 | 0.0194376 |
| GO:0000723 | telomere maintenance | 145 | 1.494499 | 0.0306432 | 0.0197766 |
| GO:0007569 | cell aging | 99 | 1.493633 | 0.0401798 | 0.0259313 |
| GO:0043010 | camera-type eye development | 263 | 1.493101 | 0.0187720 | 0.0121151 |
| GO:0051348 | negative regulation of transferase activity | 241 | 1.492540 | 0.0233030 | 0.0150394 |
| GO:0031334 | positive regulation of protein complex assembly | 212 | 1.492490 | 0.0188136 | 0.0121420 |
| GO:2000045 | regulation of G1/S transition of mitotic cell cycle | 139 | 1.491819 | 0.0306432 | 0.0197766 |
| GO:0070302 | regulation of stress-activated protein kinase signaling cascade | 188 | 1.491710 | 0.0289365 | 0.0186751 |
| GO:0045860 | positive regulation of protein kinase activity | 456 | 1.490393 | 0.0159016 | 0.0102626 |
| GO:0022404 | molting cycle process | 74 | 1.489680 | 0.0499031 | 0.0322066 |
| GO:0022405 | hair cycle process | 74 | 1.489680 | 0.0499031 | 0.0322066 |
| GO:0018108 | peptidyl-tyrosine phosphorylation | 297 | 1.484074 | 0.0186645 | 0.0120457 |
| GO:0032526 | response to retinoic acid | 93 | 1.483506 | 0.0450431 | 0.0290700 |
| GO:0035265 | organ growth | 138 | 1.482493 | 0.0306432 | 0.0197766 |
| GO:0061458 | reproductive system development | 357 | 1.481139 | 0.0159016 | 0.0102626 |
| GO:0072175 | epithelial tube formation | 117 | 1.480118 | 0.0447895 | 0.0289064 |
| GO:0018212 | peptidyl-tyrosine modification | 300 | 1.480041 | 0.0185994 | 0.0120037 |
| GO:0050731 | positive regulation of peptidyl-tyrosine phosphorylation | 147 | 1.479343 | 0.0306432 | 0.0197766 |
| GO:0010466 | negative regulation of peptidase activity | 152 | 1.479306 | 0.0350391 | 0.0226137 |
| GO:0046328 | regulation of JNK cascade | 149 | 1.473598 | 0.0306432 | 0.0197766 |
| GO:0032874 | positive regulation of stress-activated MAPK cascade | 129 | 1.472039 | 0.0493954 | 0.0318789 |
| GO:0007389 | pattern specification process | 322 | 1.470523 | 0.0183551 | 0.0118461 |
| GO:0046546 | development of primary male sexual characteristics | 113 | 1.469931 | 0.0493954 | 0.0318789 |
| GO:0032872 | regulation of stress-activated MAPK cascade | 186 | 1.468648 | 0.0380555 | 0.0245604 |
| GO:0031348 | negative regulation of defense response | 170 | 1.465406 | 0.0379636 | 0.0245011 |
| GO:0051607 | defense response to virus | 189 | 1.465127 | 0.0286513 | 0.0184911 |
| GO:0071407 | cellular response to organic cyclic compound | 489 | 1.464697 | 0.0159016 | 0.0102626 |
| GO:0043087 | regulation of GTPase activity | 392 | 1.464144 | 0.0159016 | 0.0102626 |
| GO:2001020 | regulation of response to DNA damage stimulus | 194 | 1.462309 | 0.0233030 | 0.0150394 |
| GO:0061351 | neural precursor cell proliferation | 131 | 1.461875 | 0.0448487 | 0.0289446 |
| GO:0033674 | positive regulation of kinase activity | 494 | 1.461655 | 0.0159016 | 0.0102626 |
| GO:0007565 | female pregnancy | 159 | 1.459833 | 0.0297585 | 0.0192056 |
| GO:0051897 | positive regulation of protein kinase B signaling | 133 | 1.459693 | 0.0406290 | 0.0262213 |
| GO:0030168 | platelet activation | 131 | 1.459078 | 0.0448487 | 0.0289446 |
| GO:0034332 | adherens junction organization | 129 | 1.458939 | 0.0493954 | 0.0318789 |
| GO:0030879 | mammary gland development | 118 | 1.458833 | 0.0447454 | 0.0288779 |
| GO:0043009 | chordate embryonic development | 496 | 1.458308 | 0.0159016 | 0.0102626 |
| GO:0021915 | neural tube development | 141 | 1.454769 | 0.0306432 | 0.0197766 |
| GO:0051028 | mRNA transport | 138 | 1.453037 | 0.0352673 | 0.0227609 |
| GO:1902905 | positive regulation of supramolecular fiber organization | 169 | 1.451102 | 0.0431545 | 0.0278511 |
| GO:0048562 | embryonic organ morphogenesis | 217 | 1.448161 | 0.0285672 | 0.0184368 |
| GO:0110053 | regulation of actin filament organization | 208 | 1.447671 | 0.0286513 | 0.0184911 |
| GO:1902806 | regulation of cell cycle G1/S phase transition | 152 | 1.443387 | 0.0350391 | 0.0226137 |
| GO:0002009 | morphogenesis of an epithelium | 461 | 1.439933 | 0.0159016 | 0.0102626 |
| GO:0031960 | response to corticosteroid | 135 | 1.438319 | 0.0451041 | 0.0291094 |
| GO:0031349 | positive regulation of defense response | 415 | 1.436665 | 0.0180628 | 0.0116574 |
| GO:0045936 | negative regulation of phosphate metabolic process | 498 | 1.435827 | 0.0159016 | 0.0102626 |
| GO:0090596 | sensory organ morphogenesis | 207 | 1.434792 | 0.0329418 | 0.0212600 |
| GO:0008154 | actin polymerization or depolymerization | 155 | 1.430854 | 0.0485015 | 0.0313020 |
| GO:0071214 | cellular response to abiotic stimulus | 277 | 1.428203 | 0.0279137 | 0.0180150 |
| GO:0104004 | cellular response to environmental stimulus | 277 | 1.428203 | 0.0279137 | 0.0180150 |
| GO:0001701 | in utero embryonic development | 307 | 1.422623 | 0.0185164 | 0.0119502 |
| GO:0000819 | sister chromatid segregation | 148 | 1.422302 | 0.0404532 | 0.0261078 |
| GO:0016485 | protein processing | 184 | 1.422255 | 0.0472437 | 0.0304903 |
| GO:0010563 | negative regulation of phosphorus metabolic process | 499 | 1.422064 | 0.0159016 | 0.0102626 |
| GO:0043547 | positive regulation of GTPase activity | 322 | 1.418397 | 0.0223178 | 0.0144035 |
| GO:0006302 | double-strand break repair | 200 | 1.417340 | 0.0427401 | 0.0275837 |
| GO:2001233 | regulation of apoptotic signaling pathway | 360 | 1.414907 | 0.0268566 | 0.0173328 |
| GO:0050851 | antigen receptor-mediated signaling pathway | 191 | 1.414319 | 0.0425678 | 0.0274725 |
| GO:0002768 | immune response-regulating cell surface receptor signaling pathway | 312 | 1.413609 | 0.0185164 | 0.0119502 |
| GO:2001242 | regulation of intrinsic apoptotic signaling pathway | 147 | 1.413431 | 0.0494462 | 0.0319117 |
| GO:0051495 | positive regulation of cytoskeleton organization | 188 | 1.409979 | 0.0429443 | 0.0277155 |
| GO:0002429 | immune response-activating cell surface receptor signaling pathway | 284 | 1.409151 | 0.0372315 | 0.0240286 |
| GO:0003002 | regionalization | 248 | 1.387532 | 0.0374229 | 0.0241521 |
| GO:0045089 | positive regulation of innate immune response | 311 | 1.376130 | 0.0226241 | 0.0146012 |
| GO:0009615 | response to virus | 264 | 1.373906 | 0.0374799 | 0.0241889 |
| GO:0051493 | regulation of cytoskeleton organization | 439 | 1.372295 | 0.0180490 | 0.0116485 |
| GO:0008380 | RNA splicing | 386 | 1.368319 | 0.0220555 | 0.0142342 |
| GO:1902903 | regulation of supramolecular fiber organization | 286 | 1.356384 | 0.0453344 | 0.0292581 |
| ID | Description | setSize | NES | p.adjust | qvalues |
|---|---|---|---|---|---|
| GO:0042773 | ATP synthesis coupled electron transport | 88 | 2.828241 | 0.0223578 | 0.0162795 |
| GO:0042775 | mitochondrial ATP synthesis coupled electron transport | 87 | 2.817455 | 0.0223578 | 0.0162795 |
| GO:0022904 | respiratory electron transport chain | 104 | 2.814443 | 0.0223578 | 0.0162795 |
| GO:0045333 | cellular respiration | 171 | 2.775592 | 0.0223578 | 0.0162795 |
| GO:0007269 | neurotransmitter secretion | 142 | 2.677088 | 0.0223578 | 0.0162795 |
| GO:0099643 | signal release from synapse | 143 | 2.668203 | 0.0223578 | 0.0162795 |
| GO:0006120 | mitochondrial electron transport, NADH to ubiquinone | 54 | 2.650402 | 0.0223578 | 0.0162795 |
| GO:0006119 | oxidative phosphorylation | 128 | 2.646906 | 0.0223578 | 0.0162795 |
| GO:0098693 | regulation of synaptic vesicle cycle | 105 | 2.623405 | 0.0223578 | 0.0162795 |
| GO:0016079 | synaptic vesicle exocytosis | 99 | 2.593716 | 0.0223578 | 0.0162795 |
| GO:0048489 | synaptic vesicle transport | 125 | 2.586872 | 0.0223578 | 0.0162795 |
| GO:0097480 | establishment of synaptic vesicle localization | 125 | 2.586872 | 0.0223578 | 0.0162795 |
| GO:0010257 | NADH dehydrogenase complex assembly | 64 | 2.584921 | 0.0223578 | 0.0162795 |
| GO:0032981 | mitochondrial respiratory chain complex I assembly | 64 | 2.584921 | 0.0223578 | 0.0162795 |
| GO:0097479 | synaptic vesicle localization | 135 | 2.570717 | 0.0223578 | 0.0162795 |
| GO:0017156 | calcium ion regulated exocytosis | 124 | 2.566309 | 0.0223578 | 0.0162795 |
| GO:0099003 | vesicle-mediated transport in synapse | 171 | 2.564606 | 0.0223578 | 0.0162795 |
| GO:0099504 | synaptic vesicle cycle | 158 | 2.549670 | 0.0223578 | 0.0162795 |
| GO:1902803 | regulation of synaptic vesicle transport | 75 | 2.547550 | 0.0223578 | 0.0162795 |
| GO:0046928 | regulation of neurotransmitter secretion | 93 | 2.539251 | 0.0223578 | 0.0162795 |
| GO:0006101 | citrate metabolic process | 28 | 2.524150 | 0.0223578 | 0.0162795 |
| GO:0009060 | aerobic respiration | 66 | 2.510141 | 0.0223578 | 0.0162795 |
| GO:0033108 | mitochondrial respiratory chain complex assembly | 87 | 2.503824 | 0.0223578 | 0.0162795 |
| GO:1900449 | regulation of glutamate receptor signaling pathway | 54 | 2.497750 | 0.0223578 | 0.0162795 |
| GO:0006099 | tricarboxylic acid cycle | 26 | 2.480137 | 0.0223578 | 0.0162795 |
| GO:2000300 | regulation of synaptic vesicle exocytosis | 70 | 2.461367 | 0.0223578 | 0.0162795 |
| GO:0015980 | energy derivation by oxidation of organic compounds | 251 | 2.446646 | 0.0223578 | 0.0162795 |
| GO:0017158 | regulation of calcium ion-dependent exocytosis | 90 | 2.438766 | 0.0223578 | 0.0162795 |
| GO:0072350 | tricarboxylic acid metabolic process | 31 | 2.428176 | 0.0223578 | 0.0162795 |
| GO:0051588 | regulation of neurotransmitter transport | 124 | 2.406984 | 0.0223578 | 0.0162795 |
| GO:0022900 | electron transport chain | 162 | 2.402303 | 0.0223578 | 0.0162795 |
| GO:0006836 | neurotransmitter transport | 222 | 2.395609 | 0.0223578 | 0.0162795 |
| GO:0007005 | mitochondrion organization | 452 | 2.363754 | 0.0223578 | 0.0162795 |
| GO:2001257 | regulation of cation channel activity | 150 | 2.355495 | 0.0223578 | 0.0162795 |
| GO:0048168 | regulation of neuronal synaptic plasticity | 46 | 2.347220 | 0.0223578 | 0.0162795 |
| GO:0051648 | vesicle localization | 261 | 2.322752 | 0.0223578 | 0.0162795 |
| GO:0051650 | establishment of vesicle localization | 245 | 2.317448 | 0.0223578 | 0.0162795 |
| GO:0006335 | DNA replication-dependent nucleosome assembly | 32 | 2.315180 | 0.0223578 | 0.0162795 |
| GO:0034723 | DNA replication-dependent nucleosome organization | 32 | 2.315180 | 0.0223578 | 0.0162795 |
| GO:0099177 | regulation of trans-synaptic signaling | 375 | 2.288237 | 0.0223578 | 0.0162795 |
| GO:0050804 | modulation of chemical synaptic transmission | 374 | 2.287089 | 0.0223578 | 0.0162795 |
| GO:2000310 | regulation of NMDA receptor activity | 33 | 2.286404 | 0.0223578 | 0.0162795 |
| GO:0032543 | mitochondrial translation | 124 | 2.280576 | 0.0223578 | 0.0162795 |
| GO:1901524 | regulation of mitophagy | 17 | 2.273647 | 0.0223578 | 0.0162795 |
| GO:0099601 | regulation of neurotransmitter receptor activity | 62 | 2.272499 | 0.0223578 | 0.0162795 |
| GO:1902600 | proton transmembrane transport | 128 | 2.272480 | 0.0223578 | 0.0162795 |
| GO:0006103 | 2-oxoglutarate metabolic process | 14 | 2.256982 | 0.0223578 | 0.0162795 |
| GO:0032412 | regulation of ion transmembrane transporter activity | 213 | 2.247505 | 0.0223578 | 0.0162795 |
| GO:0036465 | synaptic vesicle recycling | 49 | 2.244697 | 0.0223578 | 0.0162795 |
| GO:0006091 | generation of precursor metabolites and energy | 464 | 2.236065 | 0.0223578 | 0.0162795 |
| GO:0070125 | mitochondrial translational elongation | 85 | 2.227963 | 0.0223578 | 0.0162795 |
| GO:0022898 | regulation of transmembrane transporter activity | 220 | 2.223322 | 0.0223578 | 0.0162795 |
| GO:0007007 | inner mitochondrial membrane organization | 37 | 2.221033 | 0.0223578 | 0.0162795 |
| GO:0023061 | signal release | 380 | 2.215097 | 0.0223578 | 0.0162795 |
| GO:0009126 | purine nucleoside monophosphate metabolic process | 304 | 2.211605 | 0.0223578 | 0.0162795 |
| GO:0009167 | purine ribonucleoside monophosphate metabolic process | 303 | 2.205684 | 0.0223578 | 0.0162795 |
| GO:0000422 | autophagy of mitochondrion | 55 | 2.204424 | 0.0223578 | 0.0162795 |
| GO:0061726 | mitochondrion disassembly | 55 | 2.204424 | 0.0223578 | 0.0162795 |
| GO:0015672 | monovalent inorganic cation transport | 407 | 2.197697 | 0.0223578 | 0.0162795 |
| GO:0046034 | ATP metabolic process | 274 | 2.197151 | 0.0223578 | 0.0162795 |
| GO:0070126 | mitochondrial translational termination | 87 | 2.197053 | 0.0223578 | 0.0162795 |
| GO:0009161 | ribonucleoside monophosphate metabolic process | 316 | 2.182006 | 0.0223578 | 0.0162795 |
| GO:0098877 | neurotransmitter receptor transport to plasma membrane | 12 | 2.177158 | 0.0223578 | 0.0162795 |
| GO:0098969 | neurotransmitter receptor transport to postsynaptic membrane | 12 | 2.177158 | 0.0223578 | 0.0162795 |
| GO:0009205 | purine ribonucleoside triphosphate metabolic process | 300 | 2.176266 | 0.0223578 | 0.0162795 |
| GO:0035640 | exploration behavior | 23 | 2.172891 | 0.0223578 | 0.0162795 |
| GO:0009199 | ribonucleoside triphosphate metabolic process | 305 | 2.171970 | 0.0223578 | 0.0162795 |
| GO:1903540 | establishment of protein localization to postsynaptic membrane | 13 | 2.168906 | 0.0223578 | 0.0162795 |
| GO:0032409 | regulation of transporter activity | 231 | 2.164542 | 0.0223578 | 0.0162795 |
| GO:0000423 | mitophagy | 21 | 2.160674 | 0.0223578 | 0.0162795 |
| GO:0009144 | purine nucleoside triphosphate metabolic process | 307 | 2.160562 | 0.0223578 | 0.0162795 |
| GO:0009123 | nucleoside monophosphate metabolic process | 332 | 2.153721 | 0.0223578 | 0.0162795 |
| GO:0031146 | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process | 67 | 2.150552 | 0.0223578 | 0.0162795 |
| GO:0042407 | cristae formation | 30 | 2.146410 | 0.0223578 | 0.0162795 |
| GO:1903533 | regulation of protein targeting | 79 | 2.143354 | 0.0223578 | 0.0162795 |
| GO:0000266 | mitochondrial fission | 30 | 2.139862 | 0.0223578 | 0.0162795 |
| GO:0045653 | negative regulation of megakaryocyte differentiation | 17 | 2.137809 | 0.0223578 | 0.0162795 |
| GO:0006734 | NADH metabolic process | 34 | 2.132332 | 0.0223578 | 0.0162795 |
| GO:0009141 | nucleoside triphosphate metabolic process | 323 | 2.128344 | 0.0223578 | 0.0162795 |
| GO:0032594 | protein transport within lipid bilayer | 20 | 2.121697 | 0.0223578 | 0.0162795 |
| GO:0006415 | translational termination | 99 | 2.117017 | 0.0223578 | 0.0162795 |
| GO:1903008 | organelle disassembly | 78 | 2.116569 | 0.0223578 | 0.0162795 |
| GO:1903146 | regulation of autophagy of mitochondrion | 41 | 2.111945 | 0.0223578 | 0.0162795 |
| GO:0072384 | organelle transport along microtubule | 71 | 2.104751 | 0.0223578 | 0.0162795 |
| GO:0070585 | protein localization to mitochondrion | 123 | 2.104079 | 0.0223578 | 0.0162795 |
| GO:0035418 | protein localization to synapse | 55 | 2.099575 | 0.0223578 | 0.0162795 |
| GO:0007006 | mitochondrial membrane organization | 115 | 2.098256 | 0.0223578 | 0.0162795 |
| GO:0007215 | glutamate receptor signaling pathway | 81 | 2.098103 | 0.0223578 | 0.0162795 |
| GO:0098930 | axonal transport | 50 | 2.093806 | 0.0223578 | 0.0162795 |
| GO:0006839 | mitochondrial transport | 215 | 2.088816 | 0.0223578 | 0.0162795 |
| GO:1903421 | regulation of synaptic vesicle recycling | 24 | 2.087482 | 0.0223578 | 0.0162795 |
| GO:0006626 | protein targeting to mitochondrion | 84 | 2.087343 | 0.0223578 | 0.0162795 |
| GO:0006007 | glucose catabolic process | 33 | 2.084569 | 0.0223578 | 0.0162795 |
| GO:0006735 | NADH regeneration | 26 | 2.079659 | 0.0223578 | 0.0162795 |
| GO:0061621 | canonical glycolysis | 26 | 2.079659 | 0.0223578 | 0.0162795 |
| GO:0061718 | glucose catabolic process to pyruvate | 26 | 2.079659 | 0.0223578 | 0.0162795 |
| GO:0032400 | melanosome localization | 23 | 2.073243 | 0.0223578 | 0.0162795 |
| GO:0072655 | establishment of protein localization to mitochondrion | 120 | 2.071044 | 0.0223578 | 0.0162795 |
| GO:0050905 | neuromuscular process | 87 | 2.070235 | 0.0223578 | 0.0162795 |
| GO:0001505 | regulation of neurotransmitter levels | 289 | 2.069485 | 0.0223578 | 0.0162795 |
| GO:0016241 | regulation of macroautophagy | 161 | 2.068810 | 0.0223578 | 0.0162795 |
| GO:0000338 | protein deneddylation | 10 | 2.067647 | 0.0223578 | 0.0162795 |
| GO:0033238 | regulation of cellular amine metabolic process | 74 | 2.066447 | 0.0223578 | 0.0162795 |
| GO:0099632 | protein transport within plasma membrane | 13 | 2.065506 | 0.0223578 | 0.0162795 |
| GO:0099637 | neurotransmitter receptor transport | 13 | 2.065506 | 0.0223578 | 0.0162795 |
| GO:0048167 | regulation of synaptic plasticity | 163 | 2.064887 | 0.0223578 | 0.0162795 |
| GO:0048488 | synaptic vesicle endocytosis | 37 | 2.060549 | 0.0223578 | 0.0162795 |
| GO:0140238 | presynaptic endocytosis | 37 | 2.060549 | 0.0223578 | 0.0162795 |
| GO:0140053 | mitochondrial gene expression | 147 | 2.059212 | 0.0223578 | 0.0162795 |
| GO:1901021 | positive regulation of calcium ion transmembrane transporter activity | 37 | 2.055423 | 0.0223578 | 0.0162795 |
| GO:0061615 | glycolytic process through fructose-6-phosphate | 27 | 2.039727 | 0.0223578 | 0.0162795 |
| GO:0061620 | glycolytic process through glucose-6-phosphate | 27 | 2.039727 | 0.0223578 | 0.0162795 |
| GO:1904062 | regulation of cation transmembrane transport | 283 | 2.033419 | 0.0223578 | 0.0162795 |
| GO:0016082 | synaptic vesicle priming | 12 | 2.032477 | 0.0223578 | 0.0162795 |
| GO:0051875 | pigment granule localization | 24 | 2.032323 | 0.0223578 | 0.0162795 |
| GO:0006851 | mitochondrial calcium ion transmembrane transport | 25 | 2.032321 | 0.0223578 | 0.0162795 |
| GO:2000311 | regulation of AMPA receptor activity | 18 | 2.031251 | 0.0223578 | 0.0162795 |
| GO:0051705 | multi-organism behavior | 60 | 2.031153 | 0.0223578 | 0.0162795 |
| GO:0010822 | positive regulation of mitochondrion organization | 113 | 2.021605 | 0.0223578 | 0.0162795 |
| GO:0090140 | regulation of mitochondrial fission | 23 | 2.019707 | 0.0223578 | 0.0162795 |
| GO:0009150 | purine ribonucleotide metabolic process | 471 | 2.013367 | 0.0223578 | 0.0162795 |
| GO:0032402 | melanosome transport | 19 | 2.010979 | 0.0223578 | 0.0162795 |
| GO:0035641 | locomotory exploration behavior | 12 | 2.010047 | 0.0223578 | 0.0162795 |
| GO:0050884 | neuromuscular process controlling posture | 12 | 2.009172 | 0.0223578 | 0.0162795 |
| GO:0034765 | regulation of ion transmembrane transport | 408 | 2.008212 | 0.0223578 | 0.0162795 |
| GO:0009259 | ribonucleotide metabolic process | 485 | 2.008072 | 0.0223578 | 0.0162795 |
| GO:2001259 | positive regulation of cation channel activity | 63 | 2.001511 | 0.0223578 | 0.0162795 |
| GO:0048169 | regulation of long-term neuronal synaptic plasticity | 25 | 1.997028 | 0.0223578 | 0.0162795 |
| GO:0006123 | mitochondrial electron transport, cytochrome c to oxygen | 17 | 1.996994 | 0.0322778 | 0.0235026 |
| GO:0019646 | aerobic electron transport chain | 17 | 1.996994 | 0.0322778 | 0.0235026 |
| GO:0006813 | potassium ion transport | 169 | 1.995549 | 0.0223578 | 0.0162795 |
| GO:0016999 | antibiotic metabolic process | 106 | 1.987685 | 0.0223578 | 0.0162795 |
| GO:0032401 | establishment of melanosome localization | 20 | 1.983706 | 0.0223578 | 0.0162795 |
| GO:0047496 | vesicle transport along microtubule | 38 | 1.981060 | 0.0223578 | 0.0162795 |
| GO:0048857 | neural nucleus development | 55 | 1.976708 | 0.0223578 | 0.0162795 |
| GO:0051904 | pigment granule transport | 20 | 1.974316 | 0.0223578 | 0.0162795 |
| GO:0051646 | mitochondrion localization | 41 | 1.968018 | 0.0223578 | 0.0162795 |
| GO:0071333 | cellular response to glucose stimulus | 112 | 1.967897 | 0.0223578 | 0.0162795 |
| GO:0006163 | purine nucleotide metabolic process | 493 | 1.966354 | 0.0223578 | 0.0162795 |
| GO:0043039 | tRNA aminoacylation | 45 | 1.957513 | 0.0223578 | 0.0162795 |
| GO:0070584 | mitochondrion morphogenesis | 20 | 1.955266 | 0.0223578 | 0.0162795 |
| GO:0051932 | synaptic transmission, GABAergic | 36 | 1.953458 | 0.0223578 | 0.0162795 |
| GO:0017157 | regulation of exocytosis | 181 | 1.951179 | 0.0223578 | 0.0162795 |
| GO:0106027 | neuron projection organization | 83 | 1.947896 | 0.0223578 | 0.0162795 |
| GO:1903861 | positive regulation of dendrite extension | 21 | 1.944171 | 0.0322778 | 0.0235026 |
| GO:0008089 | anterograde axonal transport | 42 | 1.943317 | 0.0223578 | 0.0162795 |
| GO:0071322 | cellular response to carbohydrate stimulus | 122 | 1.942160 | 0.0223578 | 0.0162795 |
| GO:0010765 | positive regulation of sodium ion transport | 29 | 1.941056 | 0.0223578 | 0.0162795 |
| GO:0010970 | transport along microtubule | 141 | 1.940548 | 0.0223578 | 0.0162795 |
| GO:0099111 | microtubule-based transport | 141 | 1.940548 | 0.0223578 | 0.0162795 |
| GO:0071326 | cellular response to monosaccharide stimulus | 114 | 1.939894 | 0.0223578 | 0.0162795 |
| GO:0071331 | cellular response to hexose stimulus | 114 | 1.939894 | 0.0223578 | 0.0162795 |
| GO:0051905 | establishment of pigment granule localization | 21 | 1.939555 | 0.0322778 | 0.0235026 |
| GO:0043648 | dicarboxylic acid metabolic process | 81 | 1.939448 | 0.0223578 | 0.0162795 |
| GO:1903859 | regulation of dendrite extension | 23 | 1.937957 | 0.0322778 | 0.0235026 |
| GO:0099500 | vesicle fusion to plasma membrane | 10 | 1.936617 | 0.0223578 | 0.0162795 |
| GO:0031111 | negative regulation of microtubule polymerization or depolymerization | 32 | 1.931813 | 0.0223578 | 0.0162795 |
| GO:0016242 | negative regulation of macroautophagy | 32 | 1.929146 | 0.0223578 | 0.0162795 |
| GO:0071804 | cellular potassium ion transport | 121 | 1.928829 | 0.0223578 | 0.0162795 |
| GO:0071805 | potassium ion transmembrane transport | 121 | 1.928829 | 0.0223578 | 0.0162795 |
| GO:0070129 | regulation of mitochondrial translation | 25 | 1.926568 | 0.0406563 | 0.0296032 |
| GO:0060078 | regulation of postsynaptic membrane potential | 119 | 1.921361 | 0.0223578 | 0.0162795 |
| GO:0099072 | regulation of postsynaptic membrane neurotransmitter receptor levels | 47 | 1.920872 | 0.0223578 | 0.0162795 |
| GO:0072583 | clathrin-dependent endocytosis | 37 | 1.919903 | 0.0223578 | 0.0162795 |
| GO:0099132 | ATP hydrolysis coupled cation transmembrane transport | 52 | 1.918763 | 0.0223578 | 0.0162795 |
| GO:0006122 | mitochondrial electron transport, ubiquinol to cytochrome c | 12 | 1.918033 | 0.0223578 | 0.0162795 |
| GO:1903305 | regulation of regulated secretory pathway | 134 | 1.916798 | 0.0223578 | 0.0162795 |
| GO:0006521 | regulation of cellular amino acid metabolic process | 56 | 1.916787 | 0.0223578 | 0.0162795 |
| GO:0097120 | receptor localization to synapse | 35 | 1.916778 | 0.0223578 | 0.0162795 |
| GO:0010821 | regulation of mitochondrion organization | 170 | 1.914481 | 0.0223578 | 0.0162795 |
| GO:0042551 | neuron maturation | 42 | 1.907931 | 0.0223578 | 0.0162795 |
| GO:0008088 | axo-dendritic transport | 60 | 1.905457 | 0.0223578 | 0.0162795 |
| GO:0030705 | cytoskeleton-dependent intracellular transport | 152 | 1.905058 | 0.0223578 | 0.0162795 |
| GO:0099518 | vesicle cytoskeletal trafficking | 43 | 1.903245 | 0.0223578 | 0.0162795 |
| GO:0016236 | macroautophagy | 267 | 1.902817 | 0.0223578 | 0.0162795 |
| GO:1903539 | protein localization to postsynaptic membrane | 27 | 1.899904 | 0.0223578 | 0.0162795 |
| GO:0007213 | G protein-coupled acetylcholine receptor signaling pathway | 17 | 1.898958 | 0.0322778 | 0.0235026 |
| GO:0070131 | positive regulation of mitochondrial translation | 17 | 1.898371 | 0.0322778 | 0.0235026 |
| GO:0043950 | positive regulation of cAMP-mediated signaling | 19 | 1.896103 | 0.0412231 | 0.0300159 |
| GO:0043038 | amino acid activation | 46 | 1.892211 | 0.0223578 | 0.0162795 |
| GO:0099188 | postsynaptic cytoskeleton organization | 10 | 1.890066 | 0.0322778 | 0.0235026 |
| GO:0090313 | regulation of protein targeting to membrane | 34 | 1.889918 | 0.0223578 | 0.0162795 |
| GO:0006418 | tRNA aminoacylation for protein translation | 42 | 1.889703 | 0.0223578 | 0.0162795 |
| GO:0061003 | positive regulation of dendritic spine morphogenesis | 20 | 1.889239 | 0.0409811 | 0.0298397 |
| GO:0051656 | establishment of organelle localization | 426 | 1.885636 | 0.0223578 | 0.0162795 |
| GO:0034762 | regulation of transmembrane transport | 475 | 1.884657 | 0.0223578 | 0.0162795 |
| GO:0043624 | cellular protein complex disassembly | 189 | 1.880512 | 0.0223578 | 0.0162795 |
| GO:0032414 | positive regulation of ion transmembrane transporter activity | 94 | 1.877641 | 0.0223578 | 0.0162795 |
| GO:0050432 | catecholamine secretion | 36 | 1.876824 | 0.0223578 | 0.0162795 |
| GO:0001963 | synaptic transmission, dopaminergic | 24 | 1.873459 | 0.0488308 | 0.0355553 |
| GO:2000785 | regulation of autophagosome assembly | 32 | 1.872715 | 0.0322778 | 0.0235026 |
| GO:0071871 | response to epinephrine | 15 | 1.872703 | 0.0409811 | 0.0298397 |
| GO:0006414 | translational elongation | 122 | 1.872548 | 0.0223578 | 0.0162795 |
| GO:0140029 | exocytic process | 61 | 1.871625 | 0.0223578 | 0.0162795 |
| GO:0035637 | multicellular organismal signaling | 176 | 1.865403 | 0.0223578 | 0.0162795 |
| GO:0048311 | mitochondrion distribution | 13 | 1.865114 | 0.0322778 | 0.0235026 |
| GO:0048813 | dendrite morphogenesis | 130 | 1.861945 | 0.0223578 | 0.0162795 |
| GO:0008637 | apoptotic mitochondrial changes | 110 | 1.861401 | 0.0223578 | 0.0162795 |
| GO:0035773 | insulin secretion involved in cellular response to glucose stimulus | 57 | 1.859820 | 0.0223578 | 0.0162795 |
| GO:0014047 | glutamate secretion | 41 | 1.859517 | 0.0223578 | 0.0162795 |
| GO:0097484 | dendrite extension | 32 | 1.858119 | 0.0322778 | 0.0235026 |
| GO:0050808 | synapse organization | 378 | 1.857439 | 0.0223578 | 0.0162795 |
| GO:0044106 | cellular amine metabolic process | 111 | 1.854721 | 0.0223578 | 0.0162795 |
| GO:0060079 | excitatory postsynaptic potential | 88 | 1.853358 | 0.0223578 | 0.0162795 |
| GO:0090314 | positive regulation of protein targeting to membrane | 29 | 1.852956 | 0.0322778 | 0.0235026 |
| GO:0015991 | ATP hydrolysis coupled proton transport | 24 | 1.849629 | 0.0488308 | 0.0355553 |
| GO:0060997 | dendritic spine morphogenesis | 55 | 1.848544 | 0.0223578 | 0.0162795 |
| GO:0007612 | learning | 137 | 1.847873 | 0.0223578 | 0.0162795 |
| GO:0042391 | regulation of membrane potential | 338 | 1.846104 | 0.0223578 | 0.0162795 |
| GO:0008053 | mitochondrial fusion | 21 | 1.841318 | 0.0491806 | 0.0358101 |
| GO:0099565 | chemical synaptic transmission, postsynaptic | 96 | 1.839139 | 0.0223578 | 0.0162795 |
| GO:0021762 | substantia nigra development | 40 | 1.837172 | 0.0322778 | 0.0235026 |
| GO:0001678 | cellular glucose homeostasis | 122 | 1.829115 | 0.0223578 | 0.0162795 |
| GO:0051290 | protein heterotetramerization | 51 | 1.824872 | 0.0223578 | 0.0162795 |
| GO:0038003 | opioid receptor signaling pathway | 11 | 1.823995 | 0.0223578 | 0.0162795 |
| GO:0007416 | synapse assembly | 163 | 1.821593 | 0.0223578 | 0.0162795 |
| GO:0090141 | positive regulation of mitochondrial fission | 14 | 1.820792 | 0.0486375 | 0.0354146 |
| GO:0035864 | response to potassium ion | 12 | 1.820304 | 0.0493488 | 0.0359325 |
| GO:0050433 | regulation of catecholamine secretion | 34 | 1.818383 | 0.0406563 | 0.0296032 |
| GO:0006883 | cellular sodium ion homeostasis | 12 | 1.817844 | 0.0493488 | 0.0359325 |
| GO:1901526 | positive regulation of mitophagy | 10 | 1.817454 | 0.0415419 | 0.0302480 |
| GO:0030534 | adult behavior | 120 | 1.817174 | 0.0223578 | 0.0162795 |
| GO:0018210 | peptidyl-threonine modification | 103 | 1.813500 | 0.0223578 | 0.0162795 |
| GO:0061001 | regulation of dendritic spine morphogenesis | 42 | 1.811413 | 0.0223578 | 0.0162795 |
| GO:0030072 | peptide hormone secretion | 204 | 1.808586 | 0.0223578 | 0.0162795 |
| GO:0010644 | cell communication by electrical coupling | 29 | 1.806425 | 0.0483524 | 0.0352070 |
| GO:0030073 | insulin secretion | 173 | 1.805960 | 0.0223578 | 0.0162795 |
| GO:0035307 | positive regulation of protein dephosphorylation | 39 | 1.803262 | 0.0406563 | 0.0296032 |
| GO:1990542 | mitochondrial transmembrane transport | 64 | 1.802349 | 0.0223578 | 0.0162795 |
| GO:0051952 | regulation of amine transport | 63 | 1.801349 | 0.0223578 | 0.0162795 |
| GO:0043524 | negative regulation of neuron apoptotic process | 129 | 1.799533 | 0.0322778 | 0.0235026 |
| GO:0018107 | peptidyl-threonine phosphorylation | 95 | 1.793408 | 0.0223578 | 0.0162795 |
| GO:1903214 | regulation of protein targeting to mitochondrion | 44 | 1.792350 | 0.0322778 | 0.0235026 |
| GO:2000786 | positive regulation of autophagosome assembly | 11 | 1.792139 | 0.0322778 | 0.0235026 |
| GO:0051937 | catecholamine transport | 48 | 1.790691 | 0.0223578 | 0.0162795 |
| GO:0019320 | hexose catabolic process | 50 | 1.789735 | 0.0223578 | 0.0162795 |
| GO:0050775 | positive regulation of dendrite morphogenesis | 35 | 1.786120 | 0.0322778 | 0.0235026 |
| GO:0007611 | learning or memory | 229 | 1.781654 | 0.0223578 | 0.0162795 |
| GO:0032411 | positive regulation of transporter activity | 102 | 1.778558 | 0.0223578 | 0.0162795 |
| GO:0015800 | acidic amino acid transport | 60 | 1.773786 | 0.0223578 | 0.0162795 |
| GO:1901019 | regulation of calcium ion transmembrane transporter activity | 80 | 1.772436 | 0.0223578 | 0.0162795 |
| GO:0090199 | regulation of release of cytochrome c from mitochondria | 44 | 1.770651 | 0.0322778 | 0.0235026 |
| GO:0008344 | adult locomotory behavior | 66 | 1.770444 | 0.0223578 | 0.0162795 |
| GO:0061337 | cardiac conduction | 135 | 1.767448 | 0.0223578 | 0.0162795 |
| GO:0097061 | dendritic spine organization | 75 | 1.766925 | 0.0223578 | 0.0162795 |
| GO:0048667 | cell morphogenesis involved in neuron differentiation | 469 | 1.763595 | 0.0223578 | 0.0162795 |
| GO:0019226 | transmission of nerve impulse | 46 | 1.756020 | 0.0223578 | 0.0162795 |
| GO:0048814 | regulation of dendrite morphogenesis | 81 | 1.755244 | 0.0223578 | 0.0162795 |
| GO:0000183 | chromatin silencing at rDNA | 39 | 1.752559 | 0.0406563 | 0.0296032 |
| GO:0006006 | glucose metabolic process | 180 | 1.752368 | 0.0223578 | 0.0162795 |
| GO:0019886 | antigen processing and presentation of exogenous peptide antigen via MHC class II | 90 | 1.752298 | 0.0223578 | 0.0162795 |
| GO:0008306 | associative learning | 73 | 1.748468 | 0.0322778 | 0.0235026 |
| GO:0046365 | monosaccharide catabolic process | 57 | 1.744426 | 0.0322778 | 0.0235026 |
| GO:0009749 | response to glucose | 165 | 1.740851 | 0.0223578 | 0.0162795 |
| GO:0016358 | dendrite development | 212 | 1.737918 | 0.0223578 | 0.0162795 |
| GO:0007018 | microtubule-based movement | 215 | 1.733848 | 0.0223578 | 0.0162795 |
| GO:0006520 | cellular amino acid metabolic process | 323 | 1.731993 | 0.0223578 | 0.0162795 |
| GO:0009308 | amine metabolic process | 118 | 1.731877 | 0.0223578 | 0.0162795 |
| GO:0060627 | regulation of vesicle-mediated transport | 443 | 1.728295 | 0.0223578 | 0.0162795 |
| GO:0035306 | positive regulation of dephosphorylation | 51 | 1.726995 | 0.0322778 | 0.0235026 |
| GO:0035304 | regulation of protein dephosphorylation | 125 | 1.722718 | 0.0322778 | 0.0235026 |
| GO:0051963 | regulation of synapse assembly | 99 | 1.721303 | 0.0223578 | 0.0162795 |
| GO:0050890 | cognition | 261 | 1.719962 | 0.0223578 | 0.0162795 |
| GO:0035176 | social behavior | 46 | 1.719651 | 0.0223578 | 0.0162795 |
| GO:0051703 | intraspecies interaction between organisms | 46 | 1.719651 | 0.0223578 | 0.0162795 |
| GO:0001508 | action potential | 108 | 1.718387 | 0.0223578 | 0.0162795 |
| GO:0015837 | amine transport | 66 | 1.709635 | 0.0406563 | 0.0296032 |
| GO:1903747 | regulation of establishment of protein localization to mitochondrion | 70 | 1.706602 | 0.0322778 | 0.0235026 |
| GO:0050885 | neuromuscular process controlling balance | 41 | 1.706275 | 0.0406563 | 0.0296032 |
| GO:0032386 | regulation of intracellular transport | 384 | 1.698225 | 0.0223578 | 0.0162795 |
| GO:0007626 | locomotory behavior | 171 | 1.697666 | 0.0223578 | 0.0162795 |
| GO:0046717 | acid secretion | 91 | 1.694416 | 0.0223578 | 0.0162795 |
| GO:1904427 | positive regulation of calcium ion transmembrane transport | 62 | 1.693830 | 0.0406563 | 0.0296032 |
| GO:1901215 | negative regulation of neuron death | 181 | 1.688678 | 0.0223578 | 0.0162795 |
| GO:0060999 | positive regulation of dendritic spine development | 41 | 1.687612 | 0.0406563 | 0.0296032 |
| GO:0061178 | regulation of insulin secretion involved in cellular response to glucose stimulus | 50 | 1.687056 | 0.0406563 | 0.0296032 |
| GO:0099173 | postsynapse organization | 154 | 1.684717 | 0.0223578 | 0.0162795 |
| GO:0051965 | positive regulation of synapse assembly | 62 | 1.683552 | 0.0481498 | 0.0350594 |
| GO:0060996 | dendritic spine development | 93 | 1.682415 | 0.0406563 | 0.0296032 |
| GO:1990138 | neuron projection extension | 141 | 1.681285 | 0.0322778 | 0.0235026 |
| GO:0010975 | regulation of neuron projection development | 433 | 1.679506 | 0.0223578 | 0.0162795 |
| GO:0032984 | protein-containing complex disassembly | 286 | 1.676087 | 0.0223578 | 0.0162795 |
| GO:0007409 | axonogenesis | 364 | 1.674457 | 0.0223578 | 0.0162795 |
| GO:0090276 | regulation of peptide hormone secretion | 167 | 1.674122 | 0.0223578 | 0.0162795 |
| GO:0060359 | response to ammonium ion | 115 | 1.670481 | 0.0223578 | 0.0162795 |
| GO:0043242 | negative regulation of protein complex disassembly | 58 | 1.669751 | 0.0406563 | 0.0296032 |
| GO:0061564 | axon development | 403 | 1.669393 | 0.0223578 | 0.0162795 |
| GO:0009746 | response to hexose | 170 | 1.667157 | 0.0223578 | 0.0162795 |
| GO:0046390 | ribose phosphate biosynthetic process | 270 | 1.665120 | 0.0223578 | 0.0162795 |
| GO:1905037 | autophagosome organization | 72 | 1.664485 | 0.0322778 | 0.0235026 |
| GO:0050796 | regulation of insulin secretion | 147 | 1.663763 | 0.0223578 | 0.0162795 |
| GO:0051261 | protein depolymerization | 88 | 1.663742 | 0.0322778 | 0.0235026 |
| GO:1903779 | regulation of cardiac conduction | 65 | 1.662983 | 0.0406563 | 0.0296032 |
| GO:0035249 | synaptic transmission, glutamatergic | 60 | 1.659985 | 0.0406563 | 0.0296032 |
| GO:0009152 | purine ribonucleotide biosynthetic process | 253 | 1.658978 | 0.0223578 | 0.0162795 |
| GO:0050806 | positive regulation of synaptic transmission | 138 | 1.654886 | 0.0322778 | 0.0235026 |
| GO:0009260 | ribonucleotide biosynthetic process | 266 | 1.648019 | 0.0223578 | 0.0162795 |
| GO:0009127 | purine nucleoside monophosphate biosynthetic process | 165 | 1.647936 | 0.0223578 | 0.0162795 |
| GO:0009168 | purine ribonucleoside monophosphate biosynthetic process | 165 | 1.647936 | 0.0223578 | 0.0162795 |
| GO:0010972 | negative regulation of G2/M transition of mitotic cell cycle | 78 | 1.647492 | 0.0322778 | 0.0235026 |
| GO:0010823 | negative regulation of mitochondrion organization | 51 | 1.647404 | 0.0406563 | 0.0296032 |
| GO:0009743 | response to carbohydrate | 196 | 1.646944 | 0.0223578 | 0.0162795 |
| GO:0006914 | autophagy | 455 | 1.646826 | 0.0223578 | 0.0162795 |
| GO:0061919 | process utilizing autophagic mechanism | 455 | 1.646826 | 0.0223578 | 0.0162795 |
| GO:0006826 | iron ion transport | 50 | 1.645785 | 0.0481498 | 0.0350594 |
| GO:0002478 | antigen processing and presentation of exogenous peptide antigen | 162 | 1.642622 | 0.0223578 | 0.0162795 |
| GO:0019884 | antigen processing and presentation of exogenous antigen | 164 | 1.642118 | 0.0223578 | 0.0162795 |
| GO:0009156 | ribonucleoside monophosphate biosynthetic process | 178 | 1.640985 | 0.0223578 | 0.0162795 |
| GO:0002495 | antigen processing and presentation of peptide antigen via MHC class II | 93 | 1.639894 | 0.0406563 | 0.0296032 |
| GO:0031145 | anaphase-promoting complex-dependent catabolic process | 76 | 1.639840 | 0.0223578 | 0.0162795 |
| GO:0070588 | calcium ion transmembrane transport | 265 | 1.638377 | 0.0223578 | 0.0162795 |
| GO:0006164 | purine nucleotide biosynthetic process | 263 | 1.636370 | 0.0223578 | 0.0162795 |
| GO:0007032 | endosome organization | 70 | 1.635396 | 0.0406563 | 0.0296032 |
| GO:0032456 | endocytic recycling | 42 | 1.635125 | 0.0482200 | 0.0351106 |
| GO:0009145 | purine nucleoside triphosphate biosynthetic process | 151 | 1.628637 | 0.0223578 | 0.0162795 |
| GO:0010976 | positive regulation of neuron projection development | 249 | 1.628464 | 0.0223578 | 0.0162795 |
| GO:0010506 | regulation of autophagy | 301 | 1.624676 | 0.0223578 | 0.0162795 |
| GO:0022411 | cellular component disassembly | 454 | 1.624089 | 0.0223578 | 0.0162795 |
| GO:0001836 | release of cytochrome c from mitochondria | 55 | 1.623500 | 0.0406563 | 0.0296032 |
| GO:0034284 | response to monosaccharide | 174 | 1.621427 | 0.0223578 | 0.0162795 |
| GO:0008016 | regulation of heart contraction | 215 | 1.621068 | 0.0223578 | 0.0162795 |
| GO:0006865 | amino acid transport | 122 | 1.618646 | 0.0322778 | 0.0235026 |
| GO:0060998 | regulation of dendritic spine development | 70 | 1.617898 | 0.0406563 | 0.0296032 |
| GO:0050803 | regulation of synapse structure or activity | 211 | 1.617753 | 0.0223578 | 0.0162795 |
| GO:0032272 | negative regulation of protein polymerization | 54 | 1.617000 | 0.0483524 | 0.0352070 |
| GO:0035725 | sodium ion transmembrane transport | 92 | 1.610313 | 0.0406563 | 0.0296032 |
| GO:0009206 | purine ribonucleoside triphosphate biosynthetic process | 150 | 1.609436 | 0.0322778 | 0.0235026 |
| GO:0043270 | positive regulation of ion transport | 237 | 1.608919 | 0.0223578 | 0.0162795 |
| GO:0002504 | antigen processing and presentation of peptide or polysaccharide antigen via MHC class II | 94 | 1.607915 | 0.0477472 | 0.0347664 |
| GO:0048193 | Golgi vesicle transport | 290 | 1.607064 | 0.0223578 | 0.0162795 |
| GO:0006814 | sodium ion transport | 160 | 1.605574 | 0.0223578 | 0.0162795 |
| GO:0033157 | regulation of intracellular protein transport | 210 | 1.605225 | 0.0223578 | 0.0162795 |
| GO:0042180 | cellular ketone metabolic process | 197 | 1.600646 | 0.0223578 | 0.0162795 |
| GO:0043523 | regulation of neuron apoptotic process | 185 | 1.600244 | 0.0223578 | 0.0162795 |
| GO:0006890 | retrograde vesicle-mediated transport, Golgi to ER | 74 | 1.599848 | 0.0406563 | 0.0296032 |
| GO:0048588 | developmental cell growth | 194 | 1.596777 | 0.0223578 | 0.0162795 |
| GO:1901880 | negative regulation of protein depolymerization | 52 | 1.596148 | 0.0479719 | 0.0349300 |
| GO:0045921 | positive regulation of exocytosis | 77 | 1.595622 | 0.0406563 | 0.0296032 |
| GO:0043687 | post-translational protein modification | 335 | 1.593346 | 0.0223578 | 0.0162795 |
| GO:0009201 | ribonucleoside triphosphate biosynthetic process | 155 | 1.592022 | 0.0223578 | 0.0162795 |
| GO:0009124 | nucleoside monophosphate biosynthetic process | 185 | 1.591763 | 0.0223578 | 0.0162795 |
| GO:0086065 | cell communication involved in cardiac conduction | 53 | 1.589545 | 0.0481936 | 0.0350913 |
| GO:0006754 | ATP biosynthetic process | 142 | 1.588961 | 0.0322778 | 0.0235026 |
| GO:0072522 | purine-containing compound biosynthetic process | 273 | 1.588010 | 0.0223578 | 0.0162795 |
| GO:0050770 | regulation of axonogenesis | 143 | 1.585651 | 0.0322778 | 0.0235026 |
| GO:1905477 | positive regulation of protein localization to membrane | 111 | 1.584776 | 0.0322778 | 0.0235026 |
| GO:0038095 | Fc-epsilon receptor signaling pathway | 106 | 1.584156 | 0.0474974 | 0.0345845 |
| GO:1904064 | positive regulation of cation transmembrane transport | 126 | 1.582798 | 0.0322778 | 0.0235026 |
| GO:0031333 | negative regulation of protein complex assembly | 115 | 1.577292 | 0.0322778 | 0.0235026 |
| GO:0051402 | neuron apoptotic process | 211 | 1.572632 | 0.0223578 | 0.0162795 |
| GO:0060047 | heart contraction | 239 | 1.569107 | 0.0223578 | 0.0162795 |
| GO:0000209 | protein polyubiquitination | 279 | 1.566710 | 0.0223578 | 0.0162795 |
| GO:0000086 | G2/M transition of mitotic cell cycle | 227 | 1.561001 | 0.0223578 | 0.0162795 |
| GO:0019318 | hexose metabolic process | 213 | 1.560866 | 0.0223578 | 0.0162795 |
| GO:0009142 | nucleoside triphosphate biosynthetic process | 166 | 1.560120 | 0.0322778 | 0.0235026 |
| GO:1903827 | regulation of cellular protein localization | 478 | 1.551928 | 0.0223578 | 0.0162795 |
| GO:0031109 | microtubule polymerization or depolymerization | 92 | 1.551384 | 0.0476670 | 0.0347079 |
| GO:0006399 | tRNA metabolic process | 157 | 1.550574 | 0.0467707 | 0.0340553 |
| GO:0016482 | cytosolic transport | 136 | 1.548533 | 0.0322778 | 0.0235026 |
| GO:0010389 | regulation of G2/M transition of mitotic cell cycle | 175 | 1.545398 | 0.0322778 | 0.0235026 |
| GO:0046879 | hormone secretion | 254 | 1.540837 | 0.0223578 | 0.0162795 |
| GO:0050807 | regulation of synapse organization | 207 | 1.538865 | 0.0223578 | 0.0162795 |
| GO:0051668 | localization within membrane | 120 | 1.535453 | 0.0468065 | 0.0340813 |
| GO:0008277 | regulation of G protein-coupled receptor signaling pathway | 135 | 1.526512 | 0.0322778 | 0.0235026 |
| GO:0009165 | nucleotide biosynthetic process | 340 | 1.523839 | 0.0223578 | 0.0162795 |
| GO:0010769 | regulation of cell morphogenesis involved in differentiation | 250 | 1.523596 | 0.0223578 | 0.0162795 |
| GO:1901293 | nucleoside phosphate biosynthetic process | 343 | 1.522242 | 0.0223578 | 0.0162795 |
| GO:0045666 | positive regulation of neuron differentiation | 321 | 1.515355 | 0.0223578 | 0.0162795 |
| GO:0010498 | proteasomal protein catabolic process | 369 | 1.511369 | 0.0223578 | 0.0162795 |
| GO:0034767 | positive regulation of ion transmembrane transport | 137 | 1.508585 | 0.0322778 | 0.0235026 |
| GO:0009914 | hormone transport | 263 | 1.503732 | 0.0223578 | 0.0162795 |
| GO:1903169 | regulation of calcium ion transmembrane transport | 131 | 1.502357 | 0.0474585 | 0.0345561 |
| GO:0035303 | regulation of dephosphorylation | 189 | 1.501302 | 0.0223578 | 0.0162795 |
| GO:0050773 | regulation of dendrite development | 137 | 1.500003 | 0.0322778 | 0.0235026 |
| GO:0005996 | monosaccharide metabolic process | 234 | 1.498350 | 0.0223578 | 0.0162795 |
| GO:0048639 | positive regulation of developmental growth | 148 | 1.496156 | 0.0466491 | 0.0339667 |
| GO:0046883 | regulation of hormone secretion | 215 | 1.492888 | 0.0322778 | 0.0235026 |
| GO:0003015 | heart process | 248 | 1.484907 | 0.0223578 | 0.0162795 |
| GO:0048002 | antigen processing and presentation of peptide antigen | 174 | 1.482991 | 0.0322778 | 0.0235026 |
| GO:0043161 | proteasome-mediated ubiquitin-dependent protein catabolic process | 316 | 1.478598 | 0.0223578 | 0.0162795 |
| GO:0051494 | negative regulation of cytoskeleton organization | 116 | 1.476216 | 0.0474585 | 0.0345561 |
| GO:0051186 | cofactor metabolic process | 489 | 1.469441 | 0.0223578 | 0.0162795 |
| GO:0044839 | cell cycle G2/M phase transition | 246 | 1.467143 | 0.0223578 | 0.0162795 |
| GO:0010959 | regulation of metal ion transport | 321 | 1.459582 | 0.0223578 | 0.0162795 |
| GO:0006090 | pyruvate metabolic process | 137 | 1.456922 | 0.0475367 | 0.0346130 |
| GO:1903522 | regulation of blood circulation | 251 | 1.452451 | 0.0322778 | 0.0235026 |
| GO:0051258 | protein polymerization | 212 | 1.448075 | 0.0322778 | 0.0235026 |
| GO:1990778 | protein localization to cell periphery | 260 | 1.445071 | 0.0322778 | 0.0235026 |
| GO:0140056 | organelle localization by membrane tethering | 138 | 1.441590 | 0.0474585 | 0.0345561 |
| GO:1902749 | regulation of cell cycle G2/M phase transition | 192 | 1.440348 | 0.0456751 | 0.0332576 |
| GO:1903829 | positive regulation of cellular protein localization | 297 | 1.430599 | 0.0223578 | 0.0162795 |
| GO:0034764 | positive regulation of transmembrane transport | 173 | 1.428905 | 0.0461894 | 0.0336321 |
| GO:0031346 | positive regulation of cell projection organization | 334 | 1.426292 | 0.0223578 | 0.0162795 |
| GO:0033500 | carbohydrate homeostasis | 188 | 1.417367 | 0.0453990 | 0.0330565 |
| GO:0070997 | neuron death | 311 | 1.414492 | 0.0223578 | 0.0162795 |
| GO:0019882 | antigen processing and presentation | 202 | 1.412522 | 0.0457074 | 0.0332811 |
| GO:0018209 | peptidyl-serine modification | 232 | 1.410053 | 0.0459884 | 0.0334857 |
| GO:0010256 | endomembrane system organization | 344 | 1.400693 | 0.0223578 | 0.0162795 |
| GO:0016311 | dephosphorylation | 418 | 1.391967 | 0.0322778 | 0.0235026 |
| GO:0010817 | regulation of hormone levels | 412 | 1.388222 | 0.0223578 | 0.0162795 |
| GO:0070838 | divalent metal ion transport | 401 | 1.383133 | 0.0322778 | 0.0235026 |
| GO:0072511 | divalent inorganic cation transport | 403 | 1.380272 | 0.0322778 | 0.0235026 |
| GO:0006816 | calcium ion transport | 364 | 1.379089 | 0.0322778 | 0.0235026 |
| GO:0032535 | regulation of cellular component size | 292 | 1.377722 | 0.0453990 | 0.0330565 |
| GO:1901214 | regulation of neuron death | 279 | 1.372852 | 0.0453368 | 0.0330113 |
| GO:0019941 | modification-dependent protein catabolic process | 472 | 1.368516 | 0.0443827 | 0.0323165 |
| GO:0006511 | ubiquitin-dependent protein catabolic process | 467 | 1.360809 | 0.0450364 | 0.0327925 |
| GO:0044282 | small molecule catabolic process | 363 | 1.350433 | 0.0322778 | 0.0235026 |
| GO:0022604 | regulation of cell morphogenesis | 411 | 1.345709 | 0.0453061 | 0.0329889 |
rm(df)
for(module in top_modules){
df = enrichment_DGN[[module]] %>% dplyr::select(ID, Description, setSize, NES, p.adjust, qvalues) %>% arrange(desc(NES)) %>% filter(NES>0)
if(nrow(df)>0){
print(kable(df, caption = paste0('Enriched terms for module ', module, ' (MTcor = ', round(dataset$MTcor[dataset$Module==module][1],2),')')))
cat('\n')
} else cat(paste0('\nNo enrichment found for module ',module,'\n'))
}
| ID | Description | setSize | NES | p.adjust | qvalues |
|---|---|---|---|---|---|
| umls:C0543888 | Epileptic encephalopathy | 51 | 2.517619 | 0.0466231 | 0.0349444 |
| umls:C1838979 | MITOCHONDRIAL COMPLEX I DEFICIENCY | 29 | 2.409845 | 0.0466231 | 0.0349444 |
| umls:C0751122 | Infantile Severe Myoclonic Epilepsy | 25 | 2.303187 | 0.0466231 | 0.0349444 |
| umls:C0014547 | Epilepsies, Partial | 42 | 2.291802 | 0.0466231 | 0.0349444 |
| umls:C0406810 | Carney Complex | 27 | 2.207425 | 0.0466231 | 0.0349444 |
| umls:C0085292 | Stiff-Person Syndrome | 19 | 2.160874 | 0.0466231 | 0.0349444 |
| umls:C0037769 | West Syndrome | 58 | 2.137014 | 0.0466231 | 0.0349444 |
| umls:C0270850 | Idiopathic generalized epilepsy | 45 | 2.125396 | 0.0466231 | 0.0349444 |
| umls:C0393706 | Early infantile epileptic encephalopathy with suppression bursts | 19 | 2.120049 | 0.0466231 | 0.0349444 |
| umls:C2936907 | NADH:Q(1) Oxidoreductase deficiency | 20 | 2.097329 | 0.0466231 | 0.0349444 |
| umls:C0014548 | Epilepsy, Generalized | 44 | 2.086088 | 0.0466231 | 0.0349444 |
| umls:C0014550 | Epilepsies, Myoclonic | 36 | 2.079689 | 0.0466231 | 0.0349444 |
| umls:C1955869 | Malformations of Cortical Development | 45 | 2.063900 | 0.0466231 | 0.0349444 |
| umls:C2931919 | X-linked infantile spasm syndrome | 15 | 2.055925 | 0.0466231 | 0.0349444 |
| umls:C0427086 | Involuntary Movements | 13 | 2.054965 | 0.0466231 | 0.0349444 |
| umls:C0342776 | Nicotinamide adenine dinucleotide coenzyme Q reductase deficiency | 38 | 2.036608 | 0.0466231 | 0.0349444 |
| umls:C0270736 | Essential Tremor | 49 | 2.033486 | 0.0466231 | 0.0349444 |
| umls:C0238111 | Lennox-Gastaut syndrome | 11 | 2.028922 | 0.0466231 | 0.0349444 |
| umls:C0026650 | Movement Disorders | 95 | 1.998762 | 0.0466231 | 0.0349444 |
| umls:C0023264 | Leigh Disease | 77 | 1.985598 | 0.0466231 | 0.0349444 |
| umls:C1838951 | LEIGH SYNDROME DUE TO MITOCHONDRIAL COMPLEX I DEFICIENCY | 14 | 1.968265 | 0.0466231 | 0.0349444 |
| umls:C1096063 | Drug Resistant Epilepsy | 53 | 1.958415 | 0.0466231 | 0.0349444 |
| umls:C0162635 | Angelman Syndrome | 53 | 1.956889 | 0.0466231 | 0.0349444 |
| umls:C0376532 | Epilepsy, Rolandic | 15 | 1.950209 | 0.0466231 | 0.0349444 |
| umls:C1849156 | Spastic Ataxia | 14 | 1.947152 | 0.0466231 | 0.0349444 |
| umls:C0004134 | Ataxia | 221 | 1.944100 | 0.0466231 | 0.0349444 |
| umls:C0751214 | Hyperalgesia, Thermal | 24 | 1.942523 | 0.0466231 | 0.0349444 |
| umls:C0234166 | Hyperexplexia | 10 | 1.916174 | 0.0466231 | 0.0349444 |
| umls:C0014553 | Absence Epilepsy | 49 | 1.888701 | 0.0466231 | 0.0349444 |
| umls:C0391957 | idiopathic epilepsy | 17 | 1.883950 | 0.0466231 | 0.0349444 |
| umls:C0014556 | Epilepsy, Temporal Lobe | 175 | 1.873512 | 0.0466231 | 0.0349444 |
| umls:C1306341 | Mental handicap | 20 | 1.857124 | 0.0482247 | 0.0361448 |
| umls:C0525045 | Mood Disorders | 238 | 1.850502 | 0.0466231 | 0.0349444 |
| umls:C0751495 | Seizures, Focal | 18 | 1.836239 | 0.0482247 | 0.0361448 |
| umls:C0035372 | Rett Syndrome | 111 | 1.834904 | 0.0466231 | 0.0349444 |
| umls:C1142166 | Brugada Syndrome (disorder) | 46 | 1.828296 | 0.0466231 | 0.0349444 |
| umls:C1510586 | Autism Spectrum Disorders | 216 | 1.824252 | 0.0466231 | 0.0349444 |
| umls:C1720189 | Episodic Ataxia | 18 | 1.816075 | 0.0482247 | 0.0361448 |
| umls:C0278864 | Growth Hormone-Producing Pituitary Gland Neoplasm | 10 | 1.807948 | 0.0482247 | 0.0361448 |
| umls:C0432028 | Split foot | 10 | 1.807657 | 0.0482247 | 0.0361448 |
| umls:C2911647 | Weight Gain Adverse Event | 138 | 1.803999 | 0.0466231 | 0.0349444 |
| umls:C0037773 | Spastic Paraplegia, Hereditary | 62 | 1.782308 | 0.0466231 | 0.0349444 |
| umls:C0162670 | Mitochondrial Myopathies | 48 | 1.748064 | 0.0471197 | 0.0353166 |
| umls:C0085584 | Encephalopathies | 120 | 1.734605 | 0.0466231 | 0.0349444 |
| umls:C0242422 | Parkinsonian Disorders | 173 | 1.710886 | 0.0466231 | 0.0349444 |
| umls:C1263846 | Attention deficit hyperactivity disorder | 365 | 1.705684 | 0.0466231 | 0.0349444 |
| umls:C0004936 | Mental disorders | 384 | 1.687791 | 0.0466231 | 0.0349444 |
| umls:C0424551 | Impaired exercise tolerance | 27 | 1.685058 | 0.0481819 | 0.0361127 |
| umls:C0009952 | Febrile Convulsions | 60 | 1.660894 | 0.0495553 | 0.0371421 |
| umls:C0236736 | Cocaine-Related Disorders | 93 | 1.641811 | 0.0466231 | 0.0349444 |
| umls:C0393593 | Dystonia Disorders | 119 | 1.637567 | 0.0466231 | 0.0349444 |
| umls:C0424605 | Developmental delay (disorder) | 170 | 1.617865 | 0.0466231 | 0.0349444 |
| umls:C0007758 | Cerebellar Ataxia | 94 | 1.611195 | 0.0484409 | 0.0363069 |
| umls:C3714756 | Intellectual Disability | 422 | 1.609837 | 0.0466231 | 0.0349444 |
| umls:C0041696 | Unipolar Depression | 366 | 1.606141 | 0.0466231 | 0.0349444 |
| umls:C0018817 | Atrial Septal Defects | 231 | 1.584548 | 0.0466231 | 0.0349444 |
| umls:C0025362 | Mental Retardation | 356 | 1.573522 | 0.0466231 | 0.0349444 |
| umls:C0027765 | nervous system disorder | 388 | 1.567742 | 0.0466231 | 0.0349444 |
| umls:C1269683 | Major Depressive Disorder | 426 | 1.564966 | 0.0466231 | 0.0349444 |
| umls:C0751651 | Mitochondrial Diseases | 123 | 1.537339 | 0.0484409 | 0.0363069 |
| umls:C0338656 | Impaired cognition | 343 | 1.514572 | 0.0466231 | 0.0349444 |
| umls:C0043094 | Weight Gain | 217 | 1.473246 | 0.0482247 | 0.0361448 |
| ID | Description | setSize | NES | p.adjust | qvalues |
|---|---|---|---|---|---|
| umls:C2986658 | Diffuse Intrinsic Pontine Glioma | 19 | 2.664576 | 0.0167243 | 0.0117021 |
| umls:C0278504 | Non-small cell lung cancer stage I | 61 | 2.520511 | 0.0167243 | 0.0117021 |
| umls:C0595936 | Aqueous Humor Disorders | 54 | 2.368952 | 0.0167243 | 0.0117021 |
| umls:C0600518 | Choroidal Neovascularization | 43 | 2.332125 | 0.0167243 | 0.0117021 |
| umls:C0016059 | Fibrosis | 163 | 2.305263 | 0.0167243 | 0.0117021 |
| umls:C0034067 | Pulmonary Emphysema | 153 | 2.305145 | 0.0167243 | 0.0117021 |
| umls:C1800706 | Idiopathic Pulmonary Fibrosis | 276 | 2.296737 | 0.0167243 | 0.0117021 |
| umls:C3714514 | Infection | 464 | 2.287752 | 0.0167243 | 0.0117021 |
| umls:C0240035 | Interstitial fibrosis | 82 | 2.270451 | 0.0167243 | 0.0117021 |
| umls:C0151650 | Renal fibrosis | 143 | 2.268175 | 0.0167243 | 0.0117021 |
| umls:C1306759 | Eosinophilic disorder | 96 | 2.258364 | 0.0167243 | 0.0117021 |
| umls:C0152101 | Hypoplastic Left Heart Syndrome | 18 | 2.252855 | 0.0167243 | 0.0117021 |
| umls:C0162871 | Aortic Aneurysm, Abdominal | 151 | 2.243151 | 0.0167243 | 0.0117021 |
| umls:C1636667 | Disorder characterized by eosinophilia | 95 | 2.235024 | 0.0167243 | 0.0117021 |
| umls:C0042798 | Low Vision | 19 | 2.233750 | 0.0167243 | 0.0117021 |
| umls:C0041956 | Ureteral obstruction | 120 | 2.227728 | 0.0167243 | 0.0117021 |
| umls:C0153676 | Secondary malignant neoplasm of lung | 490 | 2.218196 | 0.0167243 | 0.0117021 |
| umls:C0002962 | Angina Pectoris | 31 | 2.217219 | 0.0167243 | 0.0117021 |
| umls:C0340643 | Dissection of aorta | 31 | 2.201097 | 0.0167243 | 0.0117021 |
| umls:C0019189 | Hepatitis, Chronic | 138 | 2.198963 | 0.0167243 | 0.0117021 |
| umls:C0238288 | Muscular Dystrophy, Facioscapulohumeral | 60 | 2.196008 | 0.0167243 | 0.0117021 |
| umls:C0025568 | Metaplasia | 62 | 2.193596 | 0.0167243 | 0.0117021 |
| umls:C3495559 | Juvenile arthritis | 272 | 2.193496 | 0.0167243 | 0.0117021 |
| umls:C0004623 | Bacterial Infections | 180 | 2.182155 | 0.0167243 | 0.0117021 |
| umls:C3825567 | Tumors in children | 10 | 2.175738 | 0.0167243 | 0.0117021 |
| umls:C0879615 | Stromal Neoplasm | 70 | 2.175153 | 0.0167243 | 0.0117021 |
| umls:C0243038 | Carcinoma, Lewis Lung | 67 | 2.162927 | 0.0167243 | 0.0117021 |
| umls:C1527311 | Brain Edema | 43 | 2.150425 | 0.0167243 | 0.0117021 |
| umls:C0036421 | Systemic Scleroderma | 441 | 2.140162 | 0.0167243 | 0.0117021 |
| umls:C1261287 | Stenosis | 26 | 2.136433 | 0.0167243 | 0.0117021 |
| umls:C0008495 | Chorioamnionitis | 156 | 2.136288 | 0.0167243 | 0.0117021 |
| umls:C0026654 | Moyamoya Disease | 34 | 2.133518 | 0.0167243 | 0.0117021 |
| umls:C0015944 | Fetal Membranes, Premature Rupture | 155 | 2.129837 | 0.0167243 | 0.0117021 |
| umls:C0027613 | Neonatal hepatitis | 12 | 2.110280 | 0.0167243 | 0.0117021 |
| umls:C0029434 | Osteogenesis Imperfecta | 38 | 2.104095 | 0.0167243 | 0.0117021 |
| umls:C0220810 | Congenital defects | 43 | 2.101958 | 0.0167243 | 0.0117021 |
| umls:C0001339 | Acute pancreatitis | 70 | 2.099831 | 0.0167243 | 0.0117021 |
| umls:C3665419 | Intracranial glioma | 34 | 2.098128 | 0.0167243 | 0.0117021 |
| umls:C0003486 | Aortic Aneurysm | 167 | 2.097108 | 0.0167243 | 0.0117021 |
| umls:C2919032 | Infection of amniotic sac and membranes, unspecified, unspecified trimester, not applicable or unspecified | 149 | 2.095887 | 0.0167243 | 0.0117021 |
| umls:C0021345 | Infectious Mononucleosis | 22 | 2.091323 | 0.0167243 | 0.0117021 |
| umls:C0032964 | Pregnancy Complications, Hematologic | 108 | 2.088528 | 0.0167243 | 0.0117021 |
| umls:C0014457 | Eosinophilia | 102 | 2.085527 | 0.0167243 | 0.0117021 |
| umls:C0019061 | Hemolytic-Uremic Syndrome | 49 | 2.084316 | 0.0167243 | 0.0117021 |
| umls:C0019187 | Hepatitis, Alcoholic | 41 | 2.078615 | 0.0167243 | 0.0117021 |
| umls:C0023893 | Liver Cirrhosis, Experimental | 149 | 2.077015 | 0.0167243 | 0.0117021 |
| umls:C0206659 | Embryonal Carcinoma | 128 | 2.074546 | 0.0167243 | 0.0117021 |
| umls:C0038395 | Streptococcal Infections | 35 | 2.071819 | 0.0167243 | 0.0117021 |
| umls:C0032965 | Pregnancy Complications, Infectious | 24 | 2.065497 | 0.0167243 | 0.0117021 |
| umls:C1292758 | Precursor T-cell lymphoblastic lymphoma | 12 | 2.060110 | 0.0167243 | 0.0117021 |
| umls:C0022876 | Premature Obstetric Labor | 163 | 2.057221 | 0.0167243 | 0.0117021 |
| umls:C0242488 | Acute Lung Injury | 57 | 2.056643 | 0.0167243 | 0.0117021 |
| umls:C0011603 | Dermatitis | 126 | 2.055413 | 0.0167243 | 0.0117021 |
| umls:C1719672 | Severe Sepsis | 66 | 2.054683 | 0.0167243 | 0.0117021 |
| umls:C0008373 | Cholesteatoma | 33 | 2.053767 | 0.0167243 | 0.0117021 |
| umls:C0162810 | Cicatrix, Hypertrophic | 51 | 2.052398 | 0.0167243 | 0.0117021 |
| umls:C0026857 | Musculoskeletal Diseases | 107 | 2.051981 | 0.0167243 | 0.0117021 |
| umls:C0032285 | Pneumonia | 312 | 2.051294 | 0.0167243 | 0.0117021 |
| umls:C0034069 | Pulmonary Fibrosis | 290 | 2.045027 | 0.0167243 | 0.0117021 |
| umls:C0024291 | Lymphohistiocytosis, Hemophagocytic | 69 | 2.044440 | 0.0167243 | 0.0117021 |
| umls:C0220641 | Lip and Oral Cavity Carcinoma | 344 | 2.041983 | 0.0167243 | 0.0117021 |
| umls:C0042345 | Varicosity | 39 | 2.039254 | 0.0167243 | 0.0117021 |
| umls:C0403447 | Chronic Kidney Insufficiency | 149 | 2.037793 | 0.0167243 | 0.0117021 |
| umls:C0149516 | Chronic sinusitis | 42 | 2.037077 | 0.0167243 | 0.0117021 |
| umls:C0002940 | Aneurysm | 107 | 2.027965 | 0.0167243 | 0.0117021 |
| umls:C0024236 | Lymphedema | 45 | 2.025914 | 0.0167243 | 0.0117021 |
| umls:C0035369 | Retroviridae Infections | 54 | 2.025767 | 0.0167243 | 0.0117021 |
| umls:C0026640 | Mouth Neoplasms | 173 | 2.021292 | 0.0167243 | 0.0117021 |
| umls:C1519670 | Tumor Angiogenesis | 360 | 2.020365 | 0.0167243 | 0.0117021 |
| umls:C0024115 | Lung diseases | 276 | 2.018978 | 0.0167243 | 0.0117021 |
| umls:C0085390 | Li-Fraumeni Syndrome | 37 | 2.017408 | 0.0167243 | 0.0117021 |
| umls:C0085437 | Meningitis, Bacterial | 32 | 2.016302 | 0.0167243 | 0.0117021 |
| umls:C0151526 | Premature Birth | 235 | 2.015831 | 0.0167243 | 0.0117021 |
| umls:C0856825 | Acute GVH disease | 90 | 2.015036 | 0.0167243 | 0.0117021 |
| umls:C0867389 | Chronic graft-versus-host disease | 60 | 2.013438 | 0.0167243 | 0.0117021 |
| umls:C0035455 | Rhinitis | 71 | 2.013250 | 0.0167243 | 0.0117021 |
| umls:C0585362 | Squamous cell carcinoma of mouth | 42 | 2.012994 | 0.0167243 | 0.0117021 |
| umls:C0035222 | Respiratory Distress Syndrome, Adult | 113 | 2.012097 | 0.0167243 | 0.0117021 |
| umls:C0023484 | Leukemia, Plasma Cell | 35 | 2.011566 | 0.0167243 | 0.0117021 |
| umls:C1334274 | Invasive Carcinoma | 134 | 2.010370 | 0.0167243 | 0.0117021 |
| umls:C0340629 | Aortic aneurysm without mention of rupture NOS | 26 | 2.009482 | 0.0167243 | 0.0117021 |
| umls:C0153381 | Malignant neoplasm of mouth | 344 | 2.008563 | 0.0167243 | 0.0117021 |
| umls:C0036920 | Sezary Syndrome | 109 | 2.007829 | 0.0167243 | 0.0117021 |
| umls:C0023646 | Lichen Planus | 16 | 2.007498 | 0.0167243 | 0.0117021 |
| umls:C0007282 | Carotid Stenosis | 95 | 2.005633 | 0.0167243 | 0.0117021 |
| umls:C0162872 | Aortic Aneurysm, Thoracic | 91 | 2.003847 | 0.0167243 | 0.0117021 |
| umls:C1956391 | Temporal Arteritis | 13 | 2.001715 | 0.0167243 | 0.0117021 |
| umls:C0019340 | Herpes NOS | 67 | 2.000683 | 0.0167243 | 0.0117021 |
| umls:C0029172 | Oral Submucous Fibrosis | 45 | 1.998321 | 0.0167243 | 0.0117021 |
| umls:C0339539 | Familial Exudative Vitreoretinopathy | 14 | 1.996388 | 0.0167243 | 0.0117021 |
| umls:C0920646 | Renal ischaemia | 76 | 1.996294 | 0.0167243 | 0.0117021 |
| umls:C0029118 | Opportunistic Infections | 25 | 1.996010 | 0.0167243 | 0.0117021 |
| umls:C0014356 | Enterocolitis | 18 | 1.995200 | 0.0167243 | 0.0117021 |
| umls:C0013537 | Eclampsia | 143 | 1.994462 | 0.0167243 | 0.0117021 |
| umls:C1566590 | Delayed Graft Function | 13 | 1.993396 | 0.0167243 | 0.0117021 |
| umls:C0033687 | Proteinuria | 67 | 1.991694 | 0.0167243 | 0.0117021 |
| umls:C0009447 | Common Variable Immunodeficiency | 91 | 1.989739 | 0.0167243 | 0.0117021 |
| umls:C0037928 | Spinal Cord Diseases | 32 | 1.988874 | 0.0167243 | 0.0117021 |
| umls:C0374997 | Helicobacter pylori (H. pylori) infection in conditions classified elsewhere and of unspecified site | 246 | 1.988762 | 0.0167243 | 0.0117021 |
| umls:C0042131 | Uterine Diseases | 16 | 1.986974 | 0.0167243 | 0.0117021 |
| umls:C0235989 | Renal interstitial fibrosis | 29 | 1.984096 | 0.0167243 | 0.0117021 |
| umls:C0003130 | Anoxia | 306 | 1.983164 | 0.0167243 | 0.0117021 |
| umls:C0030481 | Tropical Spastic Paraparesis | 33 | 1.983160 | 0.0167243 | 0.0117021 |
| umls:C0036117 | Salmonella infections | 23 | 1.982932 | 0.0167243 | 0.0117021 |
| umls:C0034362 | Q Fever | 20 | 1.982387 | 0.0167243 | 0.0117021 |
| umls:C0025295 | Meningitis, Pneumococcal | 28 | 1.981475 | 0.0167243 | 0.0117021 |
| umls:C0971858 | Arthritis, Collagen-Induced | 133 | 1.979505 | 0.0167243 | 0.0117021 |
| umls:C0085090 | Lymphoma, AIDS-Related | 27 | 1.977390 | 0.0167243 | 0.0117021 |
| umls:C0042373 | Vascular Diseases | 328 | 1.976202 | 0.0167243 | 0.0117021 |
| umls:C0035328 | Retinal Vein Occlusion | 24 | 1.974219 | 0.0167243 | 0.0117021 |
| umls:C0079218 | Fibromatosis, Aggressive | 53 | 1.973459 | 0.0167243 | 0.0117021 |
| umls:C0162820 | Dermatitis, Allergic Contact | 83 | 1.972440 | 0.0167243 | 0.0117021 |
| umls:C0017658 | Glomerulonephritis | 161 | 1.972250 | 0.0167243 | 0.0117021 |
| umls:C0887833 | Carcinoma, Pancreatic Ductal | 55 | 1.971403 | 0.0167243 | 0.0117021 |
| umls:C0017411 | Female Genital Diseases | 14 | 1.970766 | 0.0167243 | 0.0117021 |
| umls:C0947751 | Vascular inflammations | 99 | 1.970520 | 0.0167243 | 0.0117021 |
| umls:C0014170 | Endometrial Neoplasms | 220 | 1.968924 | 0.0167243 | 0.0117021 |
| umls:C1318485 | Liver regeneration disorder | 75 | 1.967044 | 0.0167243 | 0.0117021 |
| umls:C0023895 | Liver diseases | 446 | 1.966124 | 0.0167243 | 0.0117021 |
| umls:C0332853 | Anastomosis | 18 | 1.963422 | 0.0252770 | 0.0176865 |
| umls:C0027626 | Neoplasm Invasiveness | 147 | 1.961754 | 0.0167243 | 0.0117021 |
| umls:C0040053 | Thrombosis | 105 | 1.957679 | 0.0167243 | 0.0117021 |
| umls:C0034040 | Puerperal Disorders | 27 | 1.956047 | 0.0167243 | 0.0117021 |
| umls:C0206677 | Adenomatous Polyps | 58 | 1.953494 | 0.0167243 | 0.0117021 |
| umls:C0036202 | Sarcoidosis | 195 | 1.953156 | 0.0167243 | 0.0117021 |
| umls:C2931384 | Moyamoya disease 1 | 25 | 1.953123 | 0.0167243 | 0.0117021 |
| umls:C1176475 | Ductal Carcinoma | 185 | 1.951113 | 0.0167243 | 0.0117021 |
| umls:C1512433 | Cervical high grade squamous intraepithelial lesion | 15 | 1.951104 | 0.0252770 | 0.0176865 |
| umls:C1260959 | Drusen | 38 | 1.949270 | 0.0167243 | 0.0117021 |
| umls:C0015929 | Fetal Diseases | 122 | 1.947972 | 0.0167243 | 0.0117021 |
| umls:C1762616 | Meningioma, benign, no ICD-O subtype | 191 | 1.947949 | 0.0167243 | 0.0117021 |
| umls:C0027697 | Nephritis | 117 | 1.942911 | 0.0167243 | 0.0117021 |
| umls:C0032914 | Pre-Eclampsia | 275 | 1.942371 | 0.0167243 | 0.0117021 |
| umls:C0701807 | Acute anterior uveitis | 33 | 1.941898 | 0.0167243 | 0.0117021 |
| umls:C0007772 | Intracranial Arteriovenous Malformation | 10 | 1.941728 | 0.0167243 | 0.0117021 |
| umls:C0022548 | Keloid | 146 | 1.941089 | 0.0167243 | 0.0117021 |
| umls:C0006274 | Bronchiolitis, Viral | 139 | 1.938986 | 0.0167243 | 0.0117021 |
| umls:C0017612 | Glaucoma, Open-Angle | 77 | 1.935449 | 0.0167243 | 0.0117021 |
| umls:C0036420 | Localized scleroderma | 19 | 1.935438 | 0.0339424 | 0.0237497 |
| umls:C0153690 | Secondary malignant neoplasm of bone | 233 | 1.934874 | 0.0167243 | 0.0117021 |
| umls:C1368683 | Epithelioma | 225 | 1.932421 | 0.0167243 | 0.0117021 |
| umls:C0278996 | Cancer of Head and Neck | 361 | 1.932031 | 0.0167243 | 0.0117021 |
| umls:C1719495 | Aggressive periodontitis, generalized | 29 | 1.929658 | 0.0167243 | 0.0117021 |
| umls:C0346429 | Multiple malignancy | 164 | 1.927884 | 0.0167243 | 0.0117021 |
| umls:C0012236 | DiGeorge Syndrome | 64 | 1.927164 | 0.0167243 | 0.0117021 |
| umls:C0013295 | Duodenal Ulcer | 60 | 1.925079 | 0.0167243 | 0.0117021 |
| umls:C0149939 | Obstructive nephropathy | 33 | 1.924865 | 0.0167243 | 0.0117021 |
| umls:C1851585 | MYELOPROLIFERATIVE DISORDER, CHRONIC, WITH EOSINOPHILIA | 23 | 1.923578 | 0.0167243 | 0.0117021 |
| umls:C0700613 | Anxiety state | 11 | 1.923350 | 0.0167243 | 0.0117021 |
| umls:C0011615 | Dermatitis, Atopic | 333 | 1.919431 | 0.0167243 | 0.0117021 |
| umls:C0333307 | Superficial ulcer | 98 | 1.918153 | 0.0167243 | 0.0117021 |
| umls:C0031106 | Periodontitis, Juvenile | 69 | 1.916850 | 0.0167243 | 0.0117021 |
| umls:C0020541 | Hypertension, Portal | 56 | 1.916834 | 0.0167243 | 0.0117021 |
| umls:C0206708 | Cervical Intraepithelial Neoplasia | 179 | 1.916114 | 0.0167243 | 0.0117021 |
| umls:C0014009 | Empyema | 11 | 1.915612 | 0.0167243 | 0.0117021 |
| umls:C0023241 | Legionnaires’ Disease | 12 | 1.914343 | 0.0167243 | 0.0117021 |
| umls:C0023267 | Fibroid Tumor | 270 | 1.914058 | 0.0167243 | 0.0117021 |
| umls:C0003864 | Arthritis | 427 | 1.913413 | 0.0167243 | 0.0117021 |
| umls:C0020473 | Hyperlipidemia | 174 | 1.912435 | 0.0167243 | 0.0117021 |
| umls:C2004493 | Leukemia, B-Cell | 77 | 1.912346 | 0.0167243 | 0.0117021 |
| umls:C0080233 | Tooth Loss | 14 | 1.912054 | 0.0252770 | 0.0176865 |
| umls:C0018824 | Heart valve disease | 38 | 1.911223 | 0.0167243 | 0.0117021 |
| umls:C0221204 | Lytic lesion | 11 | 1.910914 | 0.0167243 | 0.0117021 |
| umls:C0032787 | Postoperative Complications | 48 | 1.910711 | 0.0167243 | 0.0117021 |
| umls:C0034155 | Purpura, Thrombotic Thrombocytopenic | 32 | 1.910517 | 0.0167243 | 0.0117021 |
| umls:C0236788 | Bipolar II disorder | 11 | 1.909844 | 0.0167243 | 0.0117021 |
| umls:C0019080 | Hemorrhage | 54 | 1.909747 | 0.0167243 | 0.0117021 |
| umls:C0013884 | Filarial Elephantiases | 16 | 1.909328 | 0.0252770 | 0.0176865 |
| umls:C1444680 | Posterior capsule opacification | 12 | 1.907970 | 0.0252770 | 0.0176865 |
| umls:C0004030 | Aspergillosis | 21 | 1.907854 | 0.0167243 | 0.0117021 |
| umls:C0262985 | Psoriasiform eczema | 12 | 1.907710 | 0.0252770 | 0.0176865 |
| umls:C0340543 | Familial primary pulmonary hypertension | 22 | 1.907194 | 0.0167243 | 0.0117021 |
| umls:C0042164 | Uveitis | 100 | 1.907034 | 0.0167243 | 0.0117021 |
| umls:C0032131 | Plasmacytoma | 63 | 1.906024 | 0.0167243 | 0.0117021 |
| umls:C0003507 | Aortic Valve Stenosis | 72 | 1.905072 | 0.0167243 | 0.0117021 |
| umls:C0035235 | Respiratory Syncytial Virus Infections | 217 | 1.903980 | 0.0167243 | 0.0117021 |
| umls:C0024266 | Lymphocytic Choriomeningitis | 42 | 1.903168 | 0.0167243 | 0.0117021 |
| umls:C0265004 | Dilatation of aorta | 14 | 1.902844 | 0.0339424 | 0.0237497 |
| umls:C0263641 | Epithelial hyperplasia of skin | 33 | 1.901061 | 0.0167243 | 0.0117021 |
| umls:C0278701 | Gastric Adenocarcinoma | 216 | 1.900705 | 0.0167243 | 0.0117021 |
| umls:C0014072 | Experimental Autoimmune Encephalomyelitis | 305 | 1.895914 | 0.0167243 | 0.0117021 |
| umls:C1621958 | Glioblastoma Multiforme | 370 | 1.892622 | 0.0167243 | 0.0117021 |
| umls:C0079487 | Helicobacter Infections | 81 | 1.891091 | 0.0167243 | 0.0117021 |
| umls:C0031154 | Peritonitis | 88 | 1.890533 | 0.0167243 | 0.0117021 |
| umls:C0399440 | Hereditary gingival fibromatosis | 17 | 1.890429 | 0.0252770 | 0.0176865 |
| umls:C0002448 | Ameloblastoma | 58 | 1.889633 | 0.0167243 | 0.0117021 |
| umls:C0021831 | Intestinal Diseases | 54 | 1.889080 | 0.0167243 | 0.0117021 |
| umls:C1306889 | Peripheral arterial occlusive disease | 14 | 1.886797 | 0.0339424 | 0.0237497 |
| umls:C0011436 | Dentinogenesis Imperfecta | 11 | 1.885687 | 0.0167243 | 0.0117021 |
| umls:C1861922 | CAMPOMELIC DYSPLASIA | 26 | 1.885473 | 0.0252770 | 0.0176865 |
| umls:C0156181 | Peritoneal adhesion | 12 | 1.884784 | 0.0252770 | 0.0176865 |
| umls:C3495801 | Granulomatosis with polyangiitis | 44 | 1.883371 | 0.0167243 | 0.0117021 |
| umls:C0085083 | Ovarian Hyperstimulation Syndrome | 24 | 1.882728 | 0.0339424 | 0.0237497 |
| umls:C0023055 | Laryngeal neoplasm | 89 | 1.880075 | 0.0167243 | 0.0117021 |
| umls:C0742133 | cervical cancer squamous cell | 12 | 1.879654 | 0.0252770 | 0.0176865 |
| umls:C0409959 | Osteoarthritis, Knee | 94 | 1.879294 | 0.0167243 | 0.0117021 |
| umls:C0398686 | Primary immune deficiency disorder | 59 | 1.878575 | 0.0167243 | 0.0117021 |
| umls:C0019158 | Hepatitis | 196 | 1.878264 | 0.0167243 | 0.0117021 |
| umls:C1449563 | Cardiomyopathy, Familial Idiopathic | 159 | 1.877229 | 0.0167243 | 0.0117021 |
| umls:C0265110 | Cerebral Vasospasm | 13 | 1.875252 | 0.0411477 | 0.0287912 |
| umls:C0268731 | Renal glomerular disease | 81 | 1.874205 | 0.0167243 | 0.0117021 |
| umls:C0019829 | Hodgkin Disease | 306 | 1.874098 | 0.0167243 | 0.0117021 |
| umls:C0007766 | Intracranial Aneurysm | 96 | 1.873716 | 0.0167243 | 0.0117021 |
| umls:C0543697 | Mixed cryoglobulinemia | 24 | 1.873631 | 0.0339424 | 0.0237497 |
| umls:C0278484 | Malignant neoplasm of colon stage IV | 62 | 1.873243 | 0.0167243 | 0.0117021 |
| umls:C0850666 | Helicobacter pylori infection | 225 | 1.872858 | 0.0167243 | 0.0117021 |
| umls:C0345967 | Malignant mesothelioma | 227 | 1.872669 | 0.0167243 | 0.0117021 |
| umls:C0036220 | Kaposi Sarcoma | 147 | 1.871938 | 0.0167243 | 0.0117021 |
| umls:C0153349 | Malignant neoplasm of tongue | 41 | 1.871673 | 0.0167243 | 0.0117021 |
| umls:C0153601 | Malignant neoplasm of penis | 22 | 1.871458 | 0.0252770 | 0.0176865 |
| umls:C0009782 | Connective Tissue Diseases | 159 | 1.870142 | 0.0167243 | 0.0117021 |
| umls:C0085786 | Hamman-Rich syndrome | 29 | 1.869605 | 0.0167243 | 0.0117021 |
| umls:C0268363 | Osteogenesis imperfecta type IV (disorder) | 11 | 1.868969 | 0.0339424 | 0.0237497 |
| umls:C0038358 | Gastric ulcer | 87 | 1.868234 | 0.0167243 | 0.0117021 |
| umls:C0023281 | Leishmaniasis | 45 | 1.867381 | 0.0167243 | 0.0117021 |
| umls:C0009319 | Colitis | 414 | 1.864835 | 0.0167243 | 0.0117021 |
| umls:C0018378 | Guillain-Barre Syndrome | 39 | 1.864703 | 0.0167243 | 0.0117021 |
| umls:C0042344 | Varicose Ulcer | 35 | 1.864204 | 0.0167243 | 0.0117021 |
| umls:C0024143 | Lupus Nephritis | 161 | 1.863456 | 0.0167243 | 0.0117021 |
| umls:C0031099 | Periodontitis | 198 | 1.862201 | 0.0167243 | 0.0117021 |
| umls:C0035439 | Rheumatic Heart Disease | 41 | 1.861155 | 0.0167243 | 0.0117021 |
| umls:C0349566 | Squamous cell carcinoma of tongue | 98 | 1.861022 | 0.0167243 | 0.0117021 |
| umls:C0278488 | Carcinoma breast stage IV | 280 | 1.860954 | 0.0167243 | 0.0117021 |
| umls:C2607914 | Allergic rhinitis (disorder) | 120 | 1.860865 | 0.0167243 | 0.0117021 |
| umls:C0154084 | Stage 0 Breast Carcinoma | 13 | 1.860612 | 0.0411477 | 0.0287912 |
| umls:C0178238 | Intestinal infectious disease (disorder) | 12 | 1.860562 | 0.0339424 | 0.0237497 |
| umls:C0239946 | Fibrosis, Liver | 271 | 1.860536 | 0.0167243 | 0.0117021 |
| umls:C0376620 | Pouchitis | 12 | 1.858472 | 0.0339424 | 0.0237497 |
| umls:C0268351 | Cutis Laxa, Autosomal Recessive, Type I | 14 | 1.857879 | 0.0339424 | 0.0237497 |
| umls:C0039445 | Hereditary hemorrhagic telangiectasia | 17 | 1.856179 | 0.0339424 | 0.0237497 |
| umls:C0026277 | Mixed Salivary Gland Tumor | 92 | 1.854383 | 0.0167243 | 0.0117021 |
| umls:C0017668 | Focal glomerulosclerosis | 85 | 1.852332 | 0.0167243 | 0.0117021 |
| umls:C0018081 | Gonorrhea | 33 | 1.852291 | 0.0252770 | 0.0176865 |
| umls:C0000786 | Spontaneous abortion | 191 | 1.850923 | 0.0167243 | 0.0117021 |
| umls:C0006267 | Bronchiectasis | 33 | 1.849576 | 0.0252770 | 0.0176865 |
| umls:C1367654 | Marginal Zone B-Cell Lymphoma | 38 | 1.849461 | 0.0167243 | 0.0117021 |
| umls:C0334579 | Anaplastic astrocytoma | 125 | 1.847827 | 0.0167243 | 0.0117021 |
| umls:C0022602 | Actinic keratosis | 69 | 1.847822 | 0.0167243 | 0.0117021 |
| umls:C0028064 | Niemann-Pick Diseases | 10 | 1.846400 | 0.0252770 | 0.0176865 |
| umls:C3272363 | Ischemic Cerebrovascular Accident | 271 | 1.845240 | 0.0167243 | 0.0117021 |
| umls:C1290886 | Chronic inflammatory disorder | 59 | 1.845112 | 0.0167243 | 0.0117021 |
| umls:C0263454 | Chloracne | 36 | 1.844147 | 0.0167243 | 0.0117021 |
| umls:C1301355 | Myelodysplastic-Myeloproliferative Diseases | 17 | 1.842531 | 0.0339424 | 0.0237497 |
| umls:C0409651 | Seropositive rheumatoid arthritis | 16 | 1.842431 | 0.0411477 | 0.0287912 |
| umls:C0007873 | Uterine Cervical Neoplasm | 146 | 1.842088 | 0.0167243 | 0.0117021 |
| umls:C0023343 | Leprosy | 105 | 1.841018 | 0.0167243 | 0.0117021 |
| umls:C0020443 | Hypercholesterolemia | 150 | 1.840963 | 0.0167243 | 0.0117021 |
| umls:C0162869 | Aneurysm, Ruptured | 22 | 1.840785 | 0.0339424 | 0.0237497 |
| umls:C0162526 | AIDS-Related Opportunistic Infections | 10 | 1.839548 | 0.0339572 | 0.0237601 |
| umls:C0008497 | Choriocarcinoma | 226 | 1.838158 | 0.0167243 | 0.0117021 |
| umls:C0004626 | Pneumonia, Bacterial | 24 | 1.837186 | 0.0411477 | 0.0287912 |
| umls:C0005411 | Biliary Atresia | 69 | 1.837120 | 0.0167243 | 0.0117021 |
| umls:C0022354 | Jaundice, Obstructive | 12 | 1.836877 | 0.0339424 | 0.0237497 |
| umls:C0019100 | Severe Dengue | 59 | 1.831721 | 0.0167243 | 0.0117021 |
| umls:C0206694 | Mucoepidermoid Carcinoma | 59 | 1.830709 | 0.0167243 | 0.0117021 |
| umls:C0042133 | Uterine Fibroids | 276 | 1.830595 | 0.0167243 | 0.0117021 |
| umls:C0019069 | Hemophilia A | 73 | 1.830296 | 0.0167243 | 0.0117021 |
| umls:C0558353 | Tongue Carcinoma | 44 | 1.829262 | 0.0252770 | 0.0176865 |
| umls:C0282350 | Sexual abuse | 12 | 1.827923 | 0.0339424 | 0.0237497 |
| umls:C0034065 | Pulmonary Embolism | 54 | 1.827452 | 0.0167243 | 0.0117021 |
| umls:C0856053 | Leukemia secondary | 17 | 1.827178 | 0.0339424 | 0.0237497 |
| umls:C0013720 | Ehlers-Danlos Syndrome | 52 | 1.824302 | 0.0167243 | 0.0117021 |
| umls:C0079588 | Ichthyosis, X-Linked | 70 | 1.823989 | 0.0167243 | 0.0117021 |
| umls:C1378703 | Renal carcinoma | 387 | 1.823203 | 0.0167243 | 0.0117021 |
| umls:C1290884 | Inflammatory disorder | 183 | 1.822401 | 0.0167243 | 0.0117021 |
| umls:C1876165 | Copper-Overload Cirrhosis | 11 | 1.819774 | 0.0411477 | 0.0287912 |
| umls:C0149521 | Pancreatitis, Chronic | 214 | 1.819636 | 0.0167243 | 0.0117021 |
| umls:C0333186 | Restenosis | 169 | 1.819625 | 0.0167243 | 0.0117021 |
| umls:C0699949 | airway disease | 64 | 1.819065 | 0.0167243 | 0.0117021 |
| umls:C0006663 | Calcinosis | 82 | 1.817570 | 0.0167243 | 0.0117021 |
| umls:C0206180 | Ki-1+ Anaplastic Large Cell Lymphoma | 214 | 1.817324 | 0.0167243 | 0.0117021 |
| umls:C0002793 | Anaplasia | 191 | 1.816733 | 0.0167243 | 0.0117021 |
| umls:C0008384 | Cholesterol Ester Storage Disease | 11 | 1.816395 | 0.0411477 | 0.0287912 |
| umls:C0015695 | Fatty Liver | 286 | 1.815854 | 0.0167243 | 0.0117021 |
| umls:C0023465 | Acute monocytic leukemia | 64 | 1.814703 | 0.0167243 | 0.0117021 |
| umls:C0035126 | Reperfusion Injury | 271 | 1.814696 | 0.0167243 | 0.0117021 |
| umls:C0013595 | Eczema | 281 | 1.813419 | 0.0167243 | 0.0117021 |
| umls:C0036205 | Sarcoidosis, Pulmonary | 41 | 1.813243 | 0.0167243 | 0.0117021 |
| umls:C0038013 | Ankylosing spondylitis | 187 | 1.812473 | 0.0167243 | 0.0117021 |
| umls:C0011616 | Contact Dermatitis | 62 | 1.811122 | 0.0167243 | 0.0117021 |
| umls:C0013312 | Dupuytren Contracture | 16 | 1.810505 | 0.0471454 | 0.0329879 |
| umls:C1333171 | Primary Cutaneous Follicle Center Lymphoma | 11 | 1.809953 | 0.0411477 | 0.0287912 |
| umls:C0948089 | Acute Coronary Syndrome | 241 | 1.808814 | 0.0167243 | 0.0117021 |
| umls:C0020507 | Hyperplasia | 122 | 1.808539 | 0.0167243 | 0.0117021 |
| umls:C0334520 | Teratoma, Malignant | 17 | 1.808398 | 0.0471454 | 0.0329879 |
| umls:C0521607 | Peritoneal Fibrosis | 29 | 1.807570 | 0.0339424 | 0.0237497 |
| umls:C0010495 | Cutis Laxa | 26 | 1.804516 | 0.0411477 | 0.0287912 |
| umls:C0017152 | Gastritis | 153 | 1.804121 | 0.0167243 | 0.0117021 |
| umls:C0267375 | Chronic colitis | 24 | 1.802578 | 0.0471454 | 0.0329879 |
| umls:C0008312 | Primary biliary cirrhosis | 201 | 1.802572 | 0.0167243 | 0.0117021 |
| umls:C0024232 | Lymphatic Metastasis | 133 | 1.802518 | 0.0167243 | 0.0117021 |
| umls:C0917804 | Arteriovenous Malformations, Cerebral | 15 | 1.802402 | 0.0471454 | 0.0329879 |
| umls:C0235653 | Malignant neoplasm of female breast | 45 | 1.802396 | 0.0252770 | 0.0176865 |
| umls:C0042487 | Venous Thrombosis | 75 | 1.802368 | 0.0167243 | 0.0117021 |
| umls:C0042165 | Anterior uveitis | 28 | 1.802043 | 0.0471454 | 0.0329879 |
| umls:C0021361 | Female infertility | 53 | 1.801870 | 0.0167243 | 0.0117021 |
| umls:C0948008 | Ischemic stroke | 307 | 1.801617 | 0.0167243 | 0.0117021 |
| umls:C0008149 | Chlamydia Infections | 61 | 1.801275 | 0.0167243 | 0.0117021 |
| umls:C3642347 | Basal-Like Breast Carcinoma | 15 | 1.800277 | 0.0471454 | 0.0329879 |
| umls:C0018915 | Hemangioendothelioma | 11 | 1.800217 | 0.0411477 | 0.0287912 |
| umls:C0029458 | Osteoporosis, Postmenopausal | 74 | 1.799164 | 0.0167243 | 0.0117021 |
| umls:C0152018 | Esophageal carcinoma | 445 | 1.798540 | 0.0167243 | 0.0117021 |
| umls:C0033054 | Prenatal Exposure Delayed Effects | 44 | 1.797632 | 0.0252770 | 0.0176865 |
| umls:C0085220 | Cerebral Amyloid Angiopathy | 35 | 1.797443 | 0.0167243 | 0.0117021 |
| umls:C1336527 | Carcinoma of urinary bladder, superficial | 33 | 1.795379 | 0.0252770 | 0.0176865 |
| umls:C0032927 | Precancerous Conditions | 351 | 1.794377 | 0.0167243 | 0.0117021 |
| umls:C0022578 | Keratoconus | 66 | 1.794114 | 0.0167243 | 0.0117021 |
| umls:C1561643 | Chronic Kidney Diseases | 229 | 1.793931 | 0.0167243 | 0.0117021 |
| umls:C0853879 | Invasive breast carcinoma | 321 | 1.792351 | 0.0167243 | 0.0117021 |
| umls:C0007104 | Female Breast Carcinoma | 48 | 1.792038 | 0.0339424 | 0.0237497 |
| umls:C0037286 | Skin Neoplasms | 274 | 1.789932 | 0.0167243 | 0.0117021 |
| umls:C0002351 | Altitude Sickness | 16 | 1.788366 | 0.0471454 | 0.0329879 |
| umls:C0016034 | Breast Fibrocystic Disease | 55 | 1.788150 | 0.0167243 | 0.0117021 |
| umls:C3494652 | Severe dementia | 11 | 1.784819 | 0.0471454 | 0.0329879 |
| umls:C0376628 | Chromosome Breakage | 15 | 1.784685 | 0.0471454 | 0.0329879 |
| umls:C0270726 | Alexander Disease | 16 | 1.784195 | 0.0471454 | 0.0329879 |
| umls:C0031039 | Pericardial effusion | 22 | 1.783537 | 0.0471454 | 0.0329879 |
| umls:C0015393 | Eye Abnormalities | 36 | 1.783211 | 0.0167243 | 0.0117021 |
| umls:C0024282 | Lymphocytosis | 42 | 1.782982 | 0.0167243 | 0.0117021 |
| umls:C3539878 | Triple Negative Breast Neoplasms | 388 | 1.782919 | 0.0167243 | 0.0117021 |
| umls:C0001486 | Adenovirus Infections | 63 | 1.782503 | 0.0167243 | 0.0117021 |
| umls:C0280803 | Primary central nervous system lymphoma | 39 | 1.782132 | 0.0253258 | 0.0177206 |
| umls:C0032231 | Pleurisy | 22 | 1.780922 | 0.0471454 | 0.0329879 |
| umls:C0007789 | Cerebral Palsy | 65 | 1.780762 | 0.0167243 | 0.0117021 |
| umls:C0267941 | Pancreatitis, Acute Necrotizing | 30 | 1.780754 | 0.0411477 | 0.0287912 |
| umls:C0009917 | Contracture | 35 | 1.780570 | 0.0252770 | 0.0176865 |
| umls:C2609414 | Acute kidney injury | 96 | 1.776528 | 0.0167243 | 0.0117021 |
| umls:C0033999 | Pterygium | 53 | 1.775969 | 0.0167243 | 0.0117021 |
| umls:C0010606 | Adenoid Cystic Carcinoma | 185 | 1.775475 | 0.0167243 | 0.0117021 |
| umls:C0265268 | Adams Oliver syndrome | 11 | 1.775360 | 0.0471454 | 0.0329879 |
| umls:C0018798 | Congenital Heart Defects | 210 | 1.773590 | 0.0167243 | 0.0117021 |
| umls:C0038354 | Stomach Diseases | 31 | 1.771818 | 0.0339424 | 0.0237497 |
| umls:C0018133 | Graft-vs-Host Disease | 230 | 1.770887 | 0.0167243 | 0.0117021 |
| umls:C0011644 | Scleroderma | 132 | 1.770086 | 0.0167243 | 0.0117021 |
| umls:C1279420 | Anxiety neurosis (finding) | 10 | 1.769379 | 0.0411477 | 0.0287912 |
| umls:C2986665 | Early-Stage Breast Carcinoma | 57 | 1.768873 | 0.0252770 | 0.0176865 |
| umls:C0034063 | Pulmonary Edema | 66 | 1.768723 | 0.0167243 | 0.0117021 |
| umls:C0278883 | Metastatic melanoma | 272 | 1.768577 | 0.0167243 | 0.0117021 |
| umls:C1333762 | Gastric Cardia Adenocarcinoma | 31 | 1.766686 | 0.0339424 | 0.0237497 |
| umls:C0037199 | Sinusitis | 29 | 1.766470 | 0.0471454 | 0.0329879 |
| umls:C0007114 | Malignant neoplasm of skin | 192 | 1.765509 | 0.0167243 | 0.0117021 |
| umls:C0008626 | Congenital chromosomal disease | 440 | 1.763545 | 0.0167243 | 0.0117021 |
| umls:C0339543 | Epiretinal Membrane | 30 | 1.763514 | 0.0411477 | 0.0287912 |
| umls:C0003838 | Arterial Occlusive Diseases | 37 | 1.762074 | 0.0167243 | 0.0117021 |
| umls:C1096184 | West Nile viral infection | 64 | 1.761705 | 0.0252770 | 0.0176865 |
| umls:C0149678 | Epstein-Barr Virus Infections | 174 | 1.761387 | 0.0167243 | 0.0117021 |
| umls:C0024305 | Lymphoma, Non-Hodgkin | 426 | 1.761370 | 0.0167243 | 0.0117021 |
| umls:C0013238 | Dry Eye Syndromes | 36 | 1.760131 | 0.0167243 | 0.0117021 |
| umls:C0020217 | Hydatidiform Mole | 48 | 1.759795 | 0.0411477 | 0.0287912 |
| umls:C0242706 | Hyperoxia | 42 | 1.759420 | 0.0252770 | 0.0176865 |
| umls:C0013371 | Shigella Infections | 51 | 1.758149 | 0.0339424 | 0.0237497 |
| umls:C0079772 | T-Cell Lymphoma | 239 | 1.758118 | 0.0167243 | 0.0117021 |
| umls:C0008313 | Cholangitis, Sclerosing | 69 | 1.756650 | 0.0167243 | 0.0117021 |
| umls:C0004610 | Bacteremia | 73 | 1.756270 | 0.0167243 | 0.0117021 |
| umls:C0013182 | Drug Allergy | 52 | 1.753839 | 0.0252770 | 0.0176865 |
| umls:C0007103 | Malignant neoplasm of endometrium | 413 | 1.751976 | 0.0167243 | 0.0117021 |
| umls:C1883486 | Uterine Corpus Cancer | 413 | 1.751976 | 0.0167243 | 0.0117021 |
| umls:C0079744 | Diffuse Large B-Cell Lymphoma | 459 | 1.751193 | 0.0167243 | 0.0117021 |
| umls:C0279628 | Adenocarcinoma Of Esophagus | 229 | 1.751174 | 0.0167243 | 0.0117021 |
| umls:C0006272 | Bronchiolitis Obliterans | 40 | 1.750466 | 0.0167243 | 0.0117021 |
| umls:C0002965 | Angina, Unstable | 65 | 1.749311 | 0.0167243 | 0.0117021 |
| umls:C1559271 | Non-Malignant Ascites Adverse Event | 146 | 1.748952 | 0.0167243 | 0.0117021 |
| umls:C3714636 | Pneumonitis | 46 | 1.747471 | 0.0340331 | 0.0238131 |
| umls:C0020474 | Hyperlipidemia, Familial Combined | 67 | 1.746435 | 0.0167243 | 0.0117021 |
| umls:C0546837 | Malignant neoplasm of esophagus | 485 | 1.745507 | 0.0167243 | 0.0117021 |
| umls:C0333997 | Lymphoid hyperplasia | 15 | 1.745000 | 0.0471454 | 0.0329879 |
| umls:C0004997 | Benign Ovarian Neoplasm | 32 | 1.743089 | 0.0411477 | 0.0287912 |
| umls:C0524910 | Hepatitis C, Chronic | 327 | 1.741859 | 0.0167243 | 0.0117021 |
| umls:C0029445 | Bone necrosis | 40 | 1.741560 | 0.0167243 | 0.0117021 |
| umls:C0949690 | Spondylarthritis | 47 | 1.740370 | 0.0411477 | 0.0287912 |
| umls:C0751967 | Multiple Sclerosis, Relapsing-Remitting | 77 | 1.739242 | 0.0167243 | 0.0117021 |
| umls:C1623038 | Cirrhosis | 307 | 1.738872 | 0.0167243 | 0.0117021 |
| umls:C0206139 | Lichen Planus, Oral | 64 | 1.737950 | 0.0252770 | 0.0176865 |
| umls:C0524909 | Hepatitis B, Chronic | 185 | 1.736431 | 0.0167243 | 0.0117021 |
| umls:C1168327 | High-Grade Prostatic Intraepithelial Neoplasia | 80 | 1.734454 | 0.0167243 | 0.0117021 |
| umls:C0600452 | Hepatopulmonary Syndrome | 81 | 1.733940 | 0.0167243 | 0.0117021 |
| umls:C0042384 | Vasculitis | 105 | 1.733712 | 0.0167243 | 0.0117021 |
| umls:C0040592 | Trachoma | 41 | 1.733263 | 0.0252770 | 0.0176865 |
| umls:C0155862 | Streptococcal pneumonia | 25 | 1.733116 | 0.0471454 | 0.0329879 |
| umls:C1335302 | Pancreatic Ductal Adenocarcinoma | 462 | 1.730426 | 0.0167243 | 0.0117021 |
| umls:C0005779 | Blood Coagulation Disorders | 102 | 1.730172 | 0.0167243 | 0.0117021 |
| umls:C0242647 | Mucosa-Associated Lymphoid Tissue Lymphoma | 142 | 1.727809 | 0.0167243 | 0.0117021 |
| umls:C1840264 | IMMUNE SUPPRESSION | 61 | 1.726027 | 0.0252770 | 0.0176865 |
| umls:C0024131 | Lupus Vulgaris | 238 | 1.725299 | 0.0167243 | 0.0117021 |
| umls:C0007787 | Transient Ischemic Attack | 153 | 1.725171 | 0.0167243 | 0.0117021 |
| umls:C0023290 | Leishmaniasis, Visceral | 58 | 1.725145 | 0.0252770 | 0.0176865 |
| umls:C0026850 | Muscular Dystrophy | 182 | 1.725115 | 0.0167243 | 0.0117021 |
| umls:C0206638 | Giant Cell Tumor of Bone | 58 | 1.724844 | 0.0252770 | 0.0176865 |
| umls:C0238190 | Inclusion Body Myositis (disorder) | 58 | 1.723197 | 0.0252770 | 0.0176865 |
| umls:C0206698 | Cholangiocarcinoma | 333 | 1.722673 | 0.0167243 | 0.0117021 |
| umls:C0085110 | Severe Combined Immunodeficiency | 420 | 1.718085 | 0.0167243 | 0.0117021 |
| umls:C1527390 | Neoplasms, Intracranial | 54 | 1.715787 | 0.0339471 | 0.0237530 |
| umls:C0221757 | alpha 1-Antitrypsin Deficiency | 45 | 1.715674 | 0.0339626 | 0.0237638 |
| umls:C0005695 | Bladder Neoplasm | 390 | 1.715393 | 0.0167243 | 0.0117021 |
| umls:C0494165 | Secondary malignant neoplasm of liver | 349 | 1.714033 | 0.0167243 | 0.0117021 |
| umls:C0206734 | Hemangioblastoma | 32 | 1.713130 | 0.0411477 | 0.0287912 |
| umls:C1518171 | Malignant Conversion | 40 | 1.710506 | 0.0167243 | 0.0117021 |
| umls:C0341439 | Chronic liver disease | 108 | 1.709358 | 0.0167243 | 0.0117021 |
| umls:C3539909 | Allergic disposition | 149 | 1.708266 | 0.0167243 | 0.0117021 |
| umls:C0025286 | Meningioma | 381 | 1.707166 | 0.0167243 | 0.0117021 |
| umls:C1519346 | Skin Carcinogenesis | 95 | 1.706870 | 0.0339424 | 0.0237497 |
| umls:C1511789 | Desmoplastic | 68 | 1.706768 | 0.0167243 | 0.0117021 |
| umls:C0269102 | Endometrioma | 55 | 1.706713 | 0.0411477 | 0.0287912 |
| umls:C0238394 | Female Pseudohermaphroditism | 43 | 1.706024 | 0.0339424 | 0.0237497 |
| umls:C1134719 | Invasive Ductal Breast Carcinoma | 205 | 1.704863 | 0.0167243 | 0.0117021 |
| umls:C0027726 | Nephrotic Syndrome | 144 | 1.704760 | 0.0167243 | 0.0117021 |
| umls:C0403592 | Chronic rejection of renal transplant | 35 | 1.704078 | 0.0339424 | 0.0237497 |
| umls:C1333064 | Classical Hodgkin’s Lymphoma | 100 | 1.702394 | 0.0167243 | 0.0117021 |
| umls:C3714757 | Juvenile rheumatoid arthritis | 139 | 1.701053 | 0.0252770 | 0.0176865 |
| umls:C0279702 | Conventional (Clear Cell) Renal Cell Carcinoma | 304 | 1.699252 | 0.0167243 | 0.0117021 |
| umls:C0042029 | Urinary tract infection | 64 | 1.698838 | 0.0252770 | 0.0176865 |
| umls:C2711227 | Steatohepatitis | 179 | 1.696872 | 0.0167243 | 0.0117021 |
| umls:C0030524 | Paratuberculosis | 32 | 1.694411 | 0.0411477 | 0.0287912 |
| umls:C0376545 | Hematologic Neoplasms | 399 | 1.692548 | 0.0167243 | 0.0117021 |
| umls:C0020517 | Hypersensitivity | 121 | 1.692144 | 0.0252770 | 0.0176865 |
| umls:C0851140 | Carcinoma in situ of uterine cervix | 48 | 1.689809 | 0.0471454 | 0.0329879 |
| umls:C0266929 | Chronic Periodontitis | 127 | 1.689439 | 0.0252770 | 0.0176865 |
| umls:C0011311 | Dengue Fever | 140 | 1.689382 | 0.0252770 | 0.0176865 |
| umls:C0341858 | Endometriosis of uterus | 48 | 1.688473 | 0.0471454 | 0.0329879 |
| umls:C0006413 | Burkitt Lymphoma | 167 | 1.687532 | 0.0167243 | 0.0117021 |
| umls:C0007193 | Cardiomyopathy, Dilated | 328 | 1.687212 | 0.0167243 | 0.0117021 |
| umls:C0019159 | Hepatitis A | 188 | 1.686011 | 0.0167243 | 0.0117021 |
| umls:C0334590 | Anaplastic Oligodendroglioma | 121 | 1.684965 | 0.0252770 | 0.0176865 |
| umls:C0392707 | Atopy | 42 | 1.684716 | 0.0341043 | 0.0238629 |
| umls:C0007124 | Noninfiltrating Intraductal Carcinoma | 257 | 1.683990 | 0.0167243 | 0.0117021 |
| umls:C0036983 | Septic Shock | 48 | 1.682822 | 0.0471454 | 0.0329879 |
| umls:C0039103 | Synovitis | 76 | 1.682665 | 0.0167243 | 0.0117021 |
| umls:C0278678 | Metastatic Renal Cell Cancer | 40 | 1.681762 | 0.0252770 | 0.0176865 |
| umls:C0031090 | Periodontal Diseases | 94 | 1.681692 | 0.0339424 | 0.0237497 |
| umls:C0027439 | Nasopharyngeal Neoplasms | 61 | 1.681166 | 0.0411477 | 0.0287912 |
| umls:C0555198 | Malignant Glioma | 356 | 1.681136 | 0.0167243 | 0.0117021 |
| umls:C0280785 | Diffuse Astrocytoma | 37 | 1.680705 | 0.0411477 | 0.0287912 |
| umls:C0242852 | Proliferative vitreoretinopathy | 52 | 1.680549 | 0.0471454 | 0.0329879 |
| umls:C2931852 | Clear-cell metastatic renal cell carcinoma | 92 | 1.680199 | 0.0252770 | 0.0176865 |
| umls:C1292769 | Precursor B-cell lymphoblastic leukemia | 297 | 1.680059 | 0.0167243 | 0.0117021 |
| umls:C0023892 | Biliary cirrhosis | 100 | 1.679717 | 0.0252770 | 0.0176865 |
| umls:C0020542 | Pulmonary Hypertension | 283 | 1.679477 | 0.0167243 | 0.0117021 |
| umls:C0023487 | Acute Promyelocytic Leukemia | 359 | 1.675116 | 0.0167243 | 0.0117021 |
| umls:C0030809 | Pemphigus Vulgaris | 58 | 1.675058 | 0.0252770 | 0.0176865 |
| umls:C0040038 | Thromboembolism | 87 | 1.674121 | 0.0252770 | 0.0176865 |
| umls:C0007570 | Celiac Disease | 268 | 1.674037 | 0.0167243 | 0.0117021 |
| umls:C0010674 | Cystic Fibrosis | 330 | 1.673220 | 0.0167243 | 0.0117021 |
| umls:C0026946 | Mycoses | 193 | 1.673162 | 0.0167243 | 0.0117021 |
| umls:C0339143 | Thyroid associated opthalmopathies | 71 | 1.672860 | 0.0167243 | 0.0117021 |
| umls:C0026896 | Myasthenia Gravis | 139 | 1.672817 | 0.0252770 | 0.0176865 |
| umls:C0029134 | Optic Neuritis | 32 | 1.672727 | 0.0411477 | 0.0287912 |
| umls:C0005967 | Bone neoplasms | 84 | 1.672604 | 0.0252770 | 0.0176865 |
| umls:C0746102 | Chronic lung disease | 47 | 1.672341 | 0.0411477 | 0.0287912 |
| umls:C0860207 | Drug-Induced Liver Injury | 135 | 1.671859 | 0.0252770 | 0.0176865 |
| umls:C0021051 | Immunologic Deficiency Syndromes | 349 | 1.671372 | 0.0167243 | 0.0117021 |
| umls:C0001925 | Albuminuria | 111 | 1.671213 | 0.0167243 | 0.0117021 |
| umls:C0940937 | precancerous lesions | 91 | 1.670272 | 0.0252770 | 0.0176865 |
| umls:C0019621 | Histiocytosis, Langerhans-Cell | 48 | 1.669594 | 0.0471454 | 0.0329879 |
| umls:C0024138 | Lupus Erythematosus, Discoid | 244 | 1.668026 | 0.0167243 | 0.0117021 |
| umls:C0178664 | Glomerulosclerosis (disorder) | 63 | 1.667437 | 0.0411477 | 0.0287912 |
| umls:C0025500 | Mesothelioma | 326 | 1.667059 | 0.0167243 | 0.0117021 |
| umls:C0016781 | Fuchs Endothelial Dystrophy | 35 | 1.666732 | 0.0411477 | 0.0287912 |
| umls:C0993582 | Arthritis, Experimental | 133 | 1.666548 | 0.0252770 | 0.0176865 |
| umls:C0403416 | Idiopathic crescentic glomerulonephritis | 34 | 1.666285 | 0.0411477 | 0.0287912 |
| umls:C0040028 | Thrombocythemia, Essential | 124 | 1.665844 | 0.0252770 | 0.0176865 |
| umls:C0162557 | Liver Failure, Acute | 89 | 1.665768 | 0.0252770 | 0.0176865 |
| umls:C1846064 | Recurrent infections (sinusitis and bacterial pneumonia and meningitis) | 43 | 1.665752 | 0.0339424 | 0.0237497 |
| umls:C0024312 | Lymphopenia | 60 | 1.665304 | 0.0411477 | 0.0287912 |
| umls:C0238463 | Papillary thyroid carcinoma | 379 | 1.665155 | 0.0167243 | 0.0117021 |
| umls:C0345904 | Malignant neoplasm of liver | 481 | 1.664363 | 0.0167243 | 0.0117021 |
| umls:C0745744 | End Stage Liver Disease | 32 | 1.661846 | 0.0471454 | 0.0329879 |
| umls:C0001883 | Airway Obstruction | 37 | 1.660498 | 0.0411477 | 0.0287912 |
| umls:C0011884 | Diabetic Retinopathy | 191 | 1.658249 | 0.0167243 | 0.0117021 |
| umls:C0409974 | Lupus Erythematosus | 284 | 1.657680 | 0.0167243 | 0.0117021 |
| umls:C1318544 | M5b Acute differentiated monocytic leukemia | 73 | 1.657522 | 0.0167243 | 0.0117021 |
| umls:C0008925 | Cleft Palate | 216 | 1.656933 | 0.0167243 | 0.0117021 |
| umls:C0033847 | Pseudoxanthoma Elasticum | 41 | 1.656699 | 0.0411477 | 0.0287912 |
| umls:C0085129 | Bronchial Hyperreactivity | 128 | 1.656006 | 0.0252770 | 0.0176865 |
| umls:C0037299 | Skin Ulcer | 32 | 1.654595 | 0.0471454 | 0.0329879 |
| umls:C0410528 | Skeletal dysplasia | 66 | 1.653604 | 0.0252770 | 0.0176865 |
| umls:C0238301 | Cancer of Nasopharynx | 80 | 1.651272 | 0.0252770 | 0.0176865 |
| umls:C0339573 | Glaucoma, Primary Open Angle | 141 | 1.650596 | 0.0252770 | 0.0176865 |
| umls:C0035412 | Rhabdomyosarcoma | 307 | 1.650114 | 0.0167243 | 0.0117021 |
| umls:C1334177 | Infiltrating Cervical Carcinoma | 50 | 1.649179 | 0.0471454 | 0.0329879 |
| umls:C0340288 | Stable angina | 66 | 1.648267 | 0.0252770 | 0.0176865 |
| umls:C0741923 | cardiac event | 38 | 1.647709 | 0.0411477 | 0.0287912 |
| umls:C0039483 | Giant Cell Arteritis | 97 | 1.646739 | 0.0339424 | 0.0237497 |
| umls:C0023896 | Alcoholic Liver Diseases | 86 | 1.646518 | 0.0252770 | 0.0176865 |
| umls:C0004238 | Atrial Fibrillation | 104 | 1.646495 | 0.0253254 | 0.0177203 |
| umls:C1328840 | Autoimmune Lymphoproliferative Syndrome | 38 | 1.645828 | 0.0411477 | 0.0287912 |
| umls:C0376544 | Hematopoietic Neoplasms | 140 | 1.645069 | 0.0252770 | 0.0176865 |
| umls:C0001175 | Acquired Immunodeficiency Syndrome | 108 | 1.644807 | 0.0252770 | 0.0176865 |
| umls:C0279000 | Liver and Intrahepatic Biliary Tract Carcinoma | 403 | 1.644307 | 0.0167243 | 0.0117021 |
| umls:C3463897 | HYDATIDIFORM MOLE, RECURRENT, 1 | 44 | 1.644252 | 0.0411477 | 0.0287912 |
| umls:C0024796 | Marfan Syndrome | 47 | 1.644043 | 0.0471454 | 0.0329879 |
| umls:C0577631 | Carotid Atherosclerosis | 88 | 1.643938 | 0.0252770 | 0.0176865 |
| umls:C0023493 | Adult T-Cell Lymphoma/Leukemia | 366 | 1.641075 | 0.0167243 | 0.0117021 |
| umls:C0376634 | Craniofacial Abnormalities | 175 | 1.640417 | 0.0167243 | 0.0117021 |
| umls:C0006309 | Brucellosis | 36 | 1.639944 | 0.0471454 | 0.0329879 |
| umls:C0018203 | Chronic granulomatous disease | 60 | 1.638802 | 0.0471454 | 0.0329879 |
| umls:C0011303 | Demyelinating Diseases | 72 | 1.638019 | 0.0167243 | 0.0117021 |
| umls:C0206685 | Acinar Cell Carcinoma | 32 | 1.636366 | 0.0471454 | 0.0329879 |
| umls:C0018995 | Hemochromatosis | 76 | 1.634489 | 0.0252770 | 0.0176865 |
| umls:C0030305 | Pancreatitis | 149 | 1.633939 | 0.0252770 | 0.0176865 |
| umls:C0242383 | Age related macular degeneration | 331 | 1.632937 | 0.0167243 | 0.0117021 |
| umls:C0022408 | Arthropathy | 95 | 1.632616 | 0.0339424 | 0.0237497 |
| umls:C0852949 | Arteriopathic disease | 44 | 1.632289 | 0.0411477 | 0.0287912 |
| umls:C0032962 | Pregnancy Complications | 94 | 1.630460 | 0.0339424 | 0.0237497 |
| umls:C0280141 | Acute Undifferentiated Leukemia | 70 | 1.628983 | 0.0252770 | 0.0176865 |
| umls:C0948192 | Primary infection NOS | 46 | 1.627992 | 0.0411613 | 0.0288007 |
| umls:C0037274 | Dermatologic disorders | 363 | 1.627519 | 0.0167243 | 0.0117021 |
| umls:C0027686 | Pathologic Neovascularization | 62 | 1.626941 | 0.0471454 | 0.0329879 |
| umls:C0584960 | Factor V Leiden mutation | 40 | 1.625852 | 0.0411477 | 0.0287912 |
| umls:C0025007 | Measles | 120 | 1.624298 | 0.0341106 | 0.0238674 |
| umls:C0238790 | bone destruction | 66 | 1.623999 | 0.0339424 | 0.0237497 |
| umls:C0004943 | Behcet Syndrome | 229 | 1.622649 | 0.0167243 | 0.0117021 |
| umls:C0079745 | Lymphoma, Large-Cell, Follicular | 137 | 1.622214 | 0.0252770 | 0.0176865 |
| umls:C0314719 | Dryness of eye | 32 | 1.621884 | 0.0471454 | 0.0329879 |
| umls:C0011065 | Cessation of life | 117 | 1.619749 | 0.0341970 | 0.0239278 |
| umls:C0008924 | Cleft Lip | 173 | 1.619444 | 0.0167243 | 0.0117021 |
| umls:C0017525 | Giant Cell Tumors | 63 | 1.618874 | 0.0471454 | 0.0329879 |
| umls:C0311375 | Arsenic Poisoning | 63 | 1.618215 | 0.0471454 | 0.0329879 |
| umls:C0018213 | Graves Disease | 260 | 1.616571 | 0.0167243 | 0.0117021 |
| umls:C0026691 | Mucocutaneous Lymph Node Syndrome | 145 | 1.615733 | 0.0339424 | 0.0237497 |
| umls:C0006287 | Bronchopulmonary Dysplasia | 174 | 1.615642 | 0.0167243 | 0.0117021 |
| umls:C0595921 | Intraocular pressure disorder | 84 | 1.615596 | 0.0252770 | 0.0176865 |
| umls:C0878500 | Intraepithelial Neoplasia | 106 | 1.615096 | 0.0253263 | 0.0177209 |
| umls:C0151546 | Oral Cavity Carcinoma | 73 | 1.614308 | 0.0252770 | 0.0176865 |
| umls:C0027430 | Nasal Polyps | 141 | 1.613962 | 0.0252770 | 0.0176865 |
| umls:C3665444 | Neutrophilia (disorder) | 40 | 1.613150 | 0.0471454 | 0.0329879 |
| umls:C0598608 | Hyperhomocysteinemia | 98 | 1.610941 | 0.0411477 | 0.0287912 |
| umls:C0740392 | Infarction, Middle Cerebral Artery | 77 | 1.610467 | 0.0252770 | 0.0176865 |
| umls:C0022661 | Kidney Failure, Chronic | 483 | 1.610171 | 0.0167243 | 0.0117021 |
| umls:C0152171 | Idiopathic pulmonary hypertension | 181 | 1.609855 | 0.0167243 | 0.0117021 |
| umls:C0085096 | Peripheral Vascular Diseases | 94 | 1.609822 | 0.0411477 | 0.0287912 |
| umls:C0085278 | Antiphospholipid Syndrome | 45 | 1.609807 | 0.0411477 | 0.0287912 |
| umls:C0333875 | High-Grade Squamous Intraepithelial Lesions | 71 | 1.608227 | 0.0252770 | 0.0176865 |
| umls:C0162309 | Adrenoleukodystrophy | 117 | 1.606103 | 0.0341970 | 0.0239278 |
| umls:C0005940 | Bone Diseases | 137 | 1.605087 | 0.0252770 | 0.0176865 |
| umls:C0220650 | Metastatic malignant neoplasm to brain | 105 | 1.604609 | 0.0253255 | 0.0177204 |
| umls:C0024668 | Mammary Neoplasms, Experimental | 185 | 1.604462 | 0.0252770 | 0.0176865 |
| umls:C0280324 | Laryngeal Squamous Cell Carcinoma | 110 | 1.603225 | 0.0339424 | 0.0237497 |
| umls:C0740457 | Malignant neoplasm of kidney | 337 | 1.600983 | 0.0167243 | 0.0117021 |
| umls:C0008625 | Chromosome Aberrations | 76 | 1.600004 | 0.0252770 | 0.0176865 |
| umls:C0023904 | Liver Neoplasms, Experimental | 78 | 1.597632 | 0.0339424 | 0.0237497 |
| umls:C0007138 | Carcinoma, Transitional Cell | 332 | 1.597320 | 0.0167243 | 0.0117021 |
| umls:C0238198 | Gastrointestinal Stromal Tumors | 279 | 1.596899 | 0.0167243 | 0.0117021 |
| umls:C0085655 | Polymyositis | 80 | 1.596428 | 0.0339424 | 0.0237497 |
| umls:C0007133 | Carcinoma, Papillary | 211 | 1.595170 | 0.0167243 | 0.0117021 |
| umls:C0024301 | Lymphoma, Follicular | 300 | 1.594771 | 0.0167243 | 0.0117021 |
| umls:C0017563 | Gingival Diseases | 74 | 1.594420 | 0.0339424 | 0.0237497 |
| umls:C0017601 | Glaucoma | 180 | 1.591954 | 0.0252770 | 0.0176865 |
| umls:C0027059 | Myocarditis | 83 | 1.590910 | 0.0252770 | 0.0176865 |
| umls:C0400966 | Non-alcoholic Fatty Liver Disease | 243 | 1.589232 | 0.0167243 | 0.0117021 |
| umls:C0206681 | Adenocarcinoma, Clear Cell | 88 | 1.589081 | 0.0339424 | 0.0237497 |
| umls:C0002874 | Aplastic Anemia | 111 | 1.584673 | 0.0339424 | 0.0237497 |
| umls:C0553723 | Squamous cell carcinoma of skin | 126 | 1.580811 | 0.0411477 | 0.0287912 |
| umls:C0035435 | Rheumatism | 86 | 1.580523 | 0.0411477 | 0.0287912 |
| umls:C0027055 | Myocardial Reperfusion Injury | 132 | 1.580072 | 0.0252770 | 0.0176865 |
| umls:C0007115 | Malignant neoplasm of thyroid | 393 | 1.580067 | 0.0167243 | 0.0117021 |
| umls:C0023492 | Leukemia, T-Cell | 270 | 1.579952 | 0.0167243 | 0.0117021 |
| umls:C0020459 | Hyperinsulinism | 211 | 1.577699 | 0.0167243 | 0.0117021 |
| umls:C0014038 | Encephalitis | 106 | 1.575512 | 0.0341970 | 0.0239278 |
| umls:C0019348 | Herpes Simplex Infections | 425 | 1.574852 | 0.0167243 | 0.0117021 |
| umls:C0006012 | Borderline Personality Disorder | 146 | 1.573681 | 0.0339424 | 0.0237497 |
| umls:C0024667 | Animal Mammary Neoplasms | 178 | 1.572727 | 0.0252770 | 0.0176865 |
| umls:C0026846 | Muscular Atrophy | 157 | 1.570307 | 0.0252770 | 0.0176865 |
| umls:C0346957 | Disseminated Malignant Neoplasm | 132 | 1.570126 | 0.0339572 | 0.0237601 |
| umls:C0017185 | Gastrointestinal Neoplasms | 102 | 1.570089 | 0.0411477 | 0.0287912 |
| umls:C0016057 | Fibrosarcoma | 224 | 1.567713 | 0.0167243 | 0.0117021 |
| umls:C0041327 | Tuberculosis, Pulmonary | 170 | 1.566847 | 0.0252770 | 0.0176865 |
| umls:C0021053 | Immune System Diseases | 142 | 1.563548 | 0.0411477 | 0.0287912 |
| umls:C0278601 | Inflammatory Breast Carcinoma | 73 | 1.563244 | 0.0339424 | 0.0237497 |
| umls:C0021655 | Insulin Resistance | 249 | 1.558897 | 0.0167243 | 0.0117021 |
| umls:C0035372 | Rett Syndrome | 111 | 1.556926 | 0.0411477 | 0.0287912 |
| umls:C0007117 | Basal cell carcinoma | 86 | 1.556102 | 0.0411477 | 0.0287912 |
| umls:C0279671 | Cervical Squamous Cell Carcinoma | 110 | 1.553358 | 0.0411477 | 0.0287912 |
| umls:C1512409 | Hepatocarcinogenesis | 399 | 1.553262 | 0.0167243 | 0.0117021 |
| umls:C1527336 | Sjogren’s Syndrome | 88 | 1.550936 | 0.0471454 | 0.0329879 |
| umls:C0022660 | Kidney Failure, Acute | 151 | 1.550136 | 0.0471454 | 0.0329879 |
| umls:C1961099 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 287 | 1.548878 | 0.0167243 | 0.0117021 |
| umls:C0338106 | Adenocarcinoma of colon | 193 | 1.546866 | 0.0252770 | 0.0176865 |
| umls:C0151779 | Cutaneous Melanoma | 217 | 1.544101 | 0.0167243 | 0.0117021 |
| umls:C0220633 | Uveal melanoma | 165 | 1.542561 | 0.0252770 | 0.0176865 |
| umls:C0011633 | Dermatomyositis | 88 | 1.542280 | 0.0471454 | 0.0329879 |
| umls:C0566602 | Primary sclerosing cholangitis | 81 | 1.539694 | 0.0471454 | 0.0329879 |
| umls:C0007785 | Cerebral Infarction | 248 | 1.536002 | 0.0167243 | 0.0117021 |
| umls:C0008479 | Chondrosarcoma | 194 | 1.535331 | 0.0252770 | 0.0176865 |
| umls:C0281361 | Adenocarcinoma of pancreas | 252 | 1.534429 | 0.0167243 | 0.0117021 |
| umls:C0020445 | Hypercholesterolemia, Familial | 132 | 1.534149 | 0.0471454 | 0.0329879 |
| umls:C0005699 | Blast Phase | 183 | 1.533777 | 0.0252770 | 0.0176865 |
| umls:C0030354 | Papilloma | 133 | 1.531579 | 0.0411477 | 0.0287912 |
| umls:C0751396 | Well Differentiated Oligodendroglioma | 152 | 1.530093 | 0.0411477 | 0.0287912 |
| umls:C0521158 | Recurrent tumor | 251 | 1.526603 | 0.0167243 | 0.0117021 |
| umls:C0028945 | oligodendroglioma | 170 | 1.522911 | 0.0252770 | 0.0176865 |
| umls:C1519680 | Tumor Immunity | 74 | 1.518855 | 0.0471454 | 0.0329879 |
| umls:C0020456 | Hyperglycemia | 380 | 1.517361 | 0.0167243 | 0.0117021 |
| umls:C3203102 | Idiopathic pulmonary arterial hypertension | 76 | 1.517151 | 0.0411477 | 0.0287912 |
| umls:C0677932 | Progressive Neoplastic Disease | 124 | 1.516668 | 0.0471454 | 0.0329879 |
| umls:C3539781 | Progressive cGVHD | 124 | 1.516668 | 0.0471454 | 0.0329879 |
| umls:C0010823 | Cytomegalovirus Infections | 133 | 1.516011 | 0.0471454 | 0.0329879 |
| umls:C0029456 | Osteoporosis | 368 | 1.515713 | 0.0167243 | 0.0117021 |
| umls:C1861172 | Venous Thromboembolism | 108 | 1.514747 | 0.0471454 | 0.0329879 |
| umls:C1519689 | Tumor Promotion | 79 | 1.513661 | 0.0471454 | 0.0329879 |
| umls:C0023470 | Myeloid Leukemia | 430 | 1.511598 | 0.0167243 | 0.0117021 |
| umls:C0242339 | Dyslipidemias | 187 | 1.511420 | 0.0252770 | 0.0176865 |
| umls:C0033860 | Psoriasis | 481 | 1.510789 | 0.0167243 | 0.0117021 |
| umls:C0007786 | Brain Ischemia | 357 | 1.509625 | 0.0167243 | 0.0117021 |
| umls:C0333983 | Hyperplastic Polyp | 78 | 1.509326 | 0.0471454 | 0.0329879 |
| umls:C0035078 | Kidney Failure | 268 | 1.509212 | 0.0167243 | 0.0117021 |
| umls:C0151744 | Myocardial Ischemia | 412 | 1.507206 | 0.0167243 | 0.0117021 |
| umls:C0243026 | Sepsis | 440 | 1.507135 | 0.0167243 | 0.0117021 |
| umls:C0271650 | Impaired glucose tolerance | 235 | 1.505848 | 0.0167243 | 0.0117021 |
| umls:C0023448 | Lymphoid leukemia | 195 | 1.505600 | 0.0252770 | 0.0176865 |
| umls:C0086692 | Benign Neoplasm | 170 | 1.504205 | 0.0411477 | 0.0287912 |
| umls:C0002871 | Anemia | 247 | 1.497204 | 0.0167243 | 0.0117021 |
| umls:C1709246 | Non-Neoplastic Disorder | 374 | 1.491041 | 0.0167243 | 0.0117021 |
| umls:C0856169 | Endothelial dysfunction | 182 | 1.487779 | 0.0471454 | 0.0329879 |
| umls:C0029928 | Ovarian Diseases | 180 | 1.483842 | 0.0471454 | 0.0329879 |
| umls:C0032580 | Adenomatous Polyposis Coli | 324 | 1.481725 | 0.0167243 | 0.0117021 |
| umls:C0206624 | Hepatoblastoma | 178 | 1.478142 | 0.0471454 | 0.0329879 |
| umls:C0685938 | Malignant neoplasm of gastrointestinal tract | 182 | 1.477487 | 0.0471454 | 0.0329879 |
| umls:C1516170 | Cancer Cell Growth | 277 | 1.473205 | 0.0252770 | 0.0176865 |
| umls:C0025149 | Medulloblastoma | 462 | 1.470612 | 0.0167243 | 0.0117021 |
| umls:C0018671 | Head and Neck Neoplasms | 292 | 1.470018 | 0.0167243 | 0.0117021 |
| umls:C0079773 | Lymphoma, T-Cell, Cutaneous | 185 | 1.463852 | 0.0471454 | 0.0329879 |
| umls:C0812413 | Malignant Pleural Mesothelioma | 200 | 1.461323 | 0.0252770 | 0.0176865 |
| umls:C0007113 | Rectal Carcinoma | 221 | 1.458939 | 0.0252770 | 0.0176865 |
| umls:C0023452 | Leukemia, Lymphocytic, Acute, L1 | 306 | 1.457041 | 0.0167243 | 0.0117021 |
| umls:C0027022 | Myeloproliferative disease | 216 | 1.454890 | 0.0167243 | 0.0117021 |
| umls:C0155626 | Acute myocardial infarction | 186 | 1.453952 | 0.0471454 | 0.0329879 |
| umls:C1704272 | Benign Prostatic Hyperplasia | 301 | 1.452728 | 0.0167243 | 0.0117021 |
| umls:C2145472 | Urothelial Carcinoma | 175 | 1.452684 | 0.0471454 | 0.0329879 |
| umls:C0375023 | Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site | 194 | 1.447951 | 0.0252770 | 0.0176865 |
| umls:C0040136 | Thyroid Neoplasm | 397 | 1.446689 | 0.0252770 | 0.0176865 |
| umls:C0027708 | Nephroblastoma | 265 | 1.444237 | 0.0167243 | 0.0117021 |
| umls:C0334634 | Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse | 261 | 1.441078 | 0.0167243 | 0.0117021 |
| umls:C3469521 | FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder) | 189 | 1.438611 | 0.0471454 | 0.0329879 |
| umls:C0032019 | Pituitary Neoplasms | 237 | 1.433424 | 0.0252770 | 0.0176865 |
| umls:C0032584 | polyps | 206 | 1.429628 | 0.0252770 | 0.0176865 |
| umls:C0035309 | Retinal Diseases | 289 | 1.423465 | 0.0167243 | 0.0117021 |
| umls:C0022665 | Kidney Neoplasm | 258 | 1.420942 | 0.0167243 | 0.0117021 |
| umls:C1520166 | Xenograft Model | 440 | 1.413595 | 0.0252770 | 0.0176865 |
| umls:C1302401 | Adenoma of large intestine | 207 | 1.410496 | 0.0339297 | 0.0237407 |
| umls:C0011853 | Diabetes Mellitus, Experimental | 422 | 1.403252 | 0.0252770 | 0.0176865 |
| umls:C0085669 | Acute leukemia | 398 | 1.391983 | 0.0398840 | 0.0279070 |
| umls:C2937358 | Cerebral Hemorrhage | 207 | 1.375771 | 0.0470951 | 0.0329527 |
| umls:C0041296 | Tuberculosis | 427 | 1.372973 | 0.0252770 | 0.0176865 |
| umls:C0036690 | Septicemia | 304 | 1.362101 | 0.0252770 | 0.0176865 |
| umls:C0035335 | Retinoblastoma | 388 | 1.341589 | 0.0465136 | 0.0325458 |
| ID | Description | setSize | NES | p.adjust | qvalues |
|---|---|---|---|---|---|
| umls:C2986658 | Diffuse Intrinsic Pontine Glioma | 19 | 2.477416 | 0.0213829 | 0.0157834 |
| umls:C3495559 | Juvenile arthritis | 272 | 2.378926 | 0.0213200 | 0.0157370 |
| umls:C0595936 | Aqueous Humor Disorders | 54 | 2.334878 | 0.0213200 | 0.0157370 |
| umls:C0006274 | Bronchiolitis, Viral | 139 | 2.289616 | 0.0213200 | 0.0157370 |
| umls:C0004623 | Bacterial Infections | 180 | 2.272615 | 0.0213200 | 0.0157370 |
| umls:C0151650 | Renal fibrosis | 143 | 2.231256 | 0.0213200 | 0.0157370 |
| umls:C1527311 | Brain Edema | 43 | 2.191929 | 0.0213200 | 0.0157370 |
| umls:C3714514 | Infection | 464 | 2.190516 | 0.0213200 | 0.0157370 |
| umls:C0856825 | Acute GVH disease | 90 | 2.164842 | 0.0213200 | 0.0157370 |
| umls:C0036202 | Sarcoidosis | 195 | 2.148506 | 0.0213200 | 0.0157370 |
| umls:C0015944 | Fetal Membranes, Premature Rupture | 155 | 2.147448 | 0.0213200 | 0.0157370 |
| umls:C0238288 | Muscular Dystrophy, Facioscapulohumeral | 60 | 2.143640 | 0.0213200 | 0.0157370 |
| umls:C0240035 | Interstitial fibrosis | 82 | 2.132722 | 0.0213200 | 0.0157370 |
| umls:C0008495 | Chorioamnionitis | 156 | 2.131669 | 0.0213200 | 0.0157370 |
| umls:C0027697 | Nephritis | 117 | 2.126371 | 0.0213200 | 0.0157370 |
| umls:C0085437 | Meningitis, Bacterial | 32 | 2.123222 | 0.0213200 | 0.0157370 |
| umls:C0278504 | Non-small cell lung cancer stage I | 61 | 2.122751 | 0.0213200 | 0.0157370 |
| umls:C2004493 | Leukemia, B-Cell | 77 | 2.122223 | 0.0213200 | 0.0157370 |
| umls:C0041956 | Ureteral obstruction | 120 | 2.121561 | 0.0213200 | 0.0157370 |
| umls:C0031099 | Periodontitis | 198 | 2.106942 | 0.0213200 | 0.0157370 |
| umls:C0036421 | Systemic Scleroderma | 441 | 2.102414 | 0.0213200 | 0.0157370 |
| umls:C2919032 | Infection of amniotic sac and membranes, unspecified, unspecified trimester, not applicable or unspecified | 149 | 2.101503 | 0.0213200 | 0.0157370 |
| umls:C0032964 | Pregnancy Complications, Hematologic | 108 | 2.101098 | 0.0213200 | 0.0157370 |
| umls:C0038395 | Streptococcal Infections | 35 | 2.095752 | 0.0213200 | 0.0157370 |
| umls:C0036117 | Salmonella infections | 23 | 2.091344 | 0.0213200 | 0.0157370 |
| umls:C0026857 | Musculoskeletal Diseases | 107 | 2.090082 | 0.0213200 | 0.0157370 |
| umls:C0016059 | Fibrosis | 163 | 2.089532 | 0.0213200 | 0.0157370 |
| umls:C0333307 | Superficial ulcer | 98 | 2.087237 | 0.0213200 | 0.0157370 |
| umls:C0035235 | Respiratory Syncytial Virus Infections | 217 | 2.076661 | 0.0213200 | 0.0157370 |
| umls:C0015929 | Fetal Diseases | 122 | 2.075651 | 0.0213200 | 0.0157370 |
| umls:C1800706 | Idiopathic Pulmonary Fibrosis | 276 | 2.070348 | 0.0213200 | 0.0157370 |
| umls:C0025568 | Metaplasia | 62 | 2.064722 | 0.0213200 | 0.0157370 |
| umls:C0035455 | Rhinitis | 71 | 2.059612 | 0.0213200 | 0.0157370 |
| umls:C0020517 | Hypersensitivity | 121 | 2.056660 | 0.0213200 | 0.0157370 |
| umls:C0333186 | Restenosis | 169 | 2.056332 | 0.0213200 | 0.0157370 |
| umls:C0039128 | Syphilis | 18 | 2.055331 | 0.0213200 | 0.0157370 |
| umls:C0034067 | Pulmonary Emphysema | 153 | 2.048690 | 0.0213200 | 0.0157370 |
| umls:C1636667 | Disorder characterized by eosinophilia | 95 | 2.048537 | 0.0213200 | 0.0157370 |
| umls:C0014457 | Eosinophilia | 102 | 2.046762 | 0.0213200 | 0.0157370 |
| umls:C0242488 | Acute Lung Injury | 57 | 2.043495 | 0.0311509 | 0.0229935 |
| umls:C0162810 | Cicatrix, Hypertrophic | 51 | 2.041923 | 0.0213200 | 0.0157370 |
| umls:C0850639 | premalignant lesion | 19 | 2.041144 | 0.0213829 | 0.0157834 |
| umls:C0032285 | Pneumonia | 312 | 2.040063 | 0.0213200 | 0.0157370 |
| umls:C0022876 | Premature Obstetric Labor | 163 | 2.039189 | 0.0213200 | 0.0157370 |
| umls:C0332853 | Anastomosis | 18 | 2.037882 | 0.0213200 | 0.0157370 |
| umls:C3714757 | Juvenile rheumatoid arthritis | 139 | 2.036202 | 0.0213200 | 0.0157370 |
| umls:C1306759 | Eosinophilic disorder | 96 | 2.035730 | 0.0213200 | 0.0157370 |
| umls:C0024291 | Lymphohistiocytosis, Hemophagocytic | 69 | 2.029287 | 0.0213200 | 0.0157370 |
| umls:C0600518 | Choroidal Neovascularization | 43 | 2.027076 | 0.0213200 | 0.0157370 |
| umls:C1292758 | Precursor T-cell lymphoblastic lymphoma | 12 | 2.021305 | 0.0216080 | 0.0159496 |
| umls:C0009319 | Colitis | 414 | 2.019691 | 0.0213200 | 0.0157370 |
| umls:C0023241 | Legionnaires’ Disease | 12 | 2.007745 | 0.0216080 | 0.0159496 |
| umls:C0374997 | Helicobacter pylori (H. pylori) infection in conditions classified elsewhere and of unspecified site | 246 | 2.004850 | 0.0213200 | 0.0157370 |
| umls:C0162871 | Aortic Aneurysm, Abdominal | 151 | 2.004158 | 0.0213200 | 0.0157370 |
| umls:C0206659 | Embryonal Carcinoma | 128 | 2.004111 | 0.0213200 | 0.0157370 |
| umls:C0024115 | Lung diseases | 276 | 2.000453 | 0.0213200 | 0.0157370 |
| umls:C0001339 | Acute pancreatitis | 70 | 1.995536 | 0.0213200 | 0.0157370 |
| umls:C1719672 | Severe Sepsis | 66 | 1.994544 | 0.0213200 | 0.0157370 |
| umls:C0032914 | Pre-Eclampsia | 275 | 1.989170 | 0.0213200 | 0.0157370 |
| umls:C0029410 | Osteoarthritis of hip | 53 | 1.988582 | 0.0213200 | 0.0157370 |
| umls:C0085129 | Bronchial Hyperreactivity | 128 | 1.988006 | 0.0213200 | 0.0157370 |
| umls:C0879615 | Stromal Neoplasm | 70 | 1.987804 | 0.0213200 | 0.0157370 |
| umls:C0079218 | Fibromatosis, Aggressive | 53 | 1.987539 | 0.0213200 | 0.0157370 |
| umls:C0153690 | Secondary malignant neoplasm of bone | 233 | 1.982889 | 0.0213200 | 0.0157370 |
| umls:C0019829 | Hodgkin Disease | 306 | 1.982287 | 0.0213200 | 0.0157370 |
| umls:C0079588 | Ichthyosis, X-Linked | 70 | 1.978848 | 0.0213200 | 0.0157370 |
| umls:C0023343 | Leprosy | 105 | 1.978436 | 0.0213200 | 0.0157370 |
| umls:C0235989 | Renal interstitial fibrosis | 29 | 1.976910 | 0.0311509 | 0.0229935 |
| umls:C0151526 | Premature Birth | 235 | 1.972550 | 0.0213200 | 0.0157370 |
| umls:C0011603 | Dermatitis | 126 | 1.968657 | 0.0213200 | 0.0157370 |
| umls:C2607914 | Allergic rhinitis (disorder) | 120 | 1.966879 | 0.0213200 | 0.0157370 |
| umls:C0149939 | Obstructive nephropathy | 33 | 1.964525 | 0.0213200 | 0.0157370 |
| umls:C0018824 | Heart valve disease | 38 | 1.964080 | 0.0213200 | 0.0157370 |
| umls:C0035222 | Respiratory Distress Syndrome, Adult | 113 | 1.963345 | 0.0213200 | 0.0157370 |
| umls:C0263454 | Chloracne | 36 | 1.959919 | 0.0213200 | 0.0157370 |
| umls:C0013537 | Eclampsia | 143 | 1.957980 | 0.0213200 | 0.0157370 |
| umls:C0477474 | Dermatitis and eczema | 23 | 1.952579 | 0.0213200 | 0.0157370 |
| umls:C0026654 | Moyamoya Disease | 34 | 1.952175 | 0.0311509 | 0.0229935 |
| umls:C0042165 | Anterior uveitis | 28 | 1.951839 | 0.0213200 | 0.0157370 |
| umls:C0032965 | Pregnancy Complications, Infectious | 24 | 1.950603 | 0.0213200 | 0.0157370 |
| umls:C0494261 | Combined immunodeficiency | 22 | 1.948691 | 0.0213829 | 0.0157834 |
| umls:C0398686 | Primary immune deficiency disorder | 59 | 1.948441 | 0.0311509 | 0.0229935 |
| umls:C0043144 | Wheezing | 50 | 1.947701 | 0.0311509 | 0.0229935 |
| umls:C0024143 | Lupus Nephritis | 161 | 1.939364 | 0.0213200 | 0.0157370 |
| umls:C0017658 | Glomerulonephritis | 161 | 1.935815 | 0.0213200 | 0.0157370 |
| umls:C0019189 | Hepatitis, Chronic | 138 | 1.935481 | 0.0213200 | 0.0157370 |
| umls:C0340629 | Aortic aneurysm without mention of rupture NOS | 26 | 1.929815 | 0.0213200 | 0.0157370 |
| umls:C1261287 | Stenosis | 26 | 1.928441 | 0.0213200 | 0.0157370 |
| umls:C0003507 | Aortic Valve Stenosis | 72 | 1.927683 | 0.0213200 | 0.0157370 |
| umls:C1333064 | Classical Hodgkin’s Lymphoma | 100 | 1.925577 | 0.0213200 | 0.0157370 |
| umls:C0024305 | Lymphoma, Non-Hodgkin | 426 | 1.923015 | 0.0213200 | 0.0157370 |
| umls:C1290884 | Inflammatory disorder | 183 | 1.922539 | 0.0213200 | 0.0157370 |
| umls:C0003864 | Arthritis | 427 | 1.921011 | 0.0213200 | 0.0157370 |
| umls:C0019340 | Herpes NOS | 67 | 1.920709 | 0.0213200 | 0.0157370 |
| umls:C0034040 | Puerperal Disorders | 27 | 1.918742 | 0.0311509 | 0.0229935 |
| umls:C0262655 | Recurrent urinary tract infection | 10 | 1.918535 | 0.0218867 | 0.0161553 |
| umls:C0018133 | Graft-vs-Host Disease | 230 | 1.917069 | 0.0213200 | 0.0157370 |
| umls:C0079487 | Helicobacter Infections | 81 | 1.916418 | 0.0213200 | 0.0157370 |
| umls:C0030848 | Peyronie Disease | 14 | 1.913279 | 0.0214913 | 0.0158635 |
| umls:C0042373 | Vascular Diseases | 328 | 1.910150 | 0.0213200 | 0.0157370 |
| umls:C0206180 | Ki-1+ Anaplastic Large Cell Lymphoma | 214 | 1.909894 | 0.0213200 | 0.0157370 |
| umls:C1290886 | Chronic inflammatory disorder | 59 | 1.906638 | 0.0311509 | 0.0229935 |
| umls:C0034069 | Pulmonary Fibrosis | 290 | 1.904873 | 0.0213200 | 0.0157370 |
| umls:C0014356 | Enterocolitis | 18 | 1.896437 | 0.0213200 | 0.0157370 |
| umls:C0007282 | Carotid Stenosis | 95 | 1.895396 | 0.0213200 | 0.0157370 |
| umls:C0004030 | Aspergillosis | 21 | 1.894287 | 0.0315451 | 0.0232845 |
| umls:C0035457 | Rhinitis, Allergic, Perennial | 26 | 1.891891 | 0.0314450 | 0.0232106 |
| umls:C0042487 | Venous Thrombosis | 75 | 1.891424 | 0.0213200 | 0.0157370 |
| umls:C0392707 | Atopy | 42 | 1.891269 | 0.0311509 | 0.0229935 |
| umls:C0085655 | Polymyositis | 80 | 1.888914 | 0.0213200 | 0.0157370 |
| umls:C0009447 | Common Variable Immunodeficiency | 91 | 1.887062 | 0.0213200 | 0.0157370 |
| umls:C1368683 | Epithelioma | 225 | 1.885352 | 0.0213200 | 0.0157370 |
| umls:C0003486 | Aortic Aneurysm | 167 | 1.885293 | 0.0213200 | 0.0157370 |
| umls:C0162820 | Dermatitis, Allergic Contact | 83 | 1.885115 | 0.0213200 | 0.0157370 |
| umls:C0266929 | Chronic Periodontitis | 127 | 1.882263 | 0.0213200 | 0.0157370 |
| umls:C0006272 | Bronchiolitis Obliterans | 40 | 1.881308 | 0.0311509 | 0.0229935 |
| umls:C0751967 | Multiple Sclerosis, Relapsing-Remitting | 77 | 1.880040 | 0.0213200 | 0.0157370 |
| umls:C0031090 | Periodontal Diseases | 94 | 1.879043 | 0.0213200 | 0.0157370 |
| umls:C0019100 | Severe Dengue | 59 | 1.875929 | 0.0311509 | 0.0229935 |
| umls:C1527336 | Sjogren’s Syndrome | 88 | 1.875917 | 0.0213200 | 0.0157370 |
| umls:C0022548 | Keloid | 146 | 1.875774 | 0.0213200 | 0.0157370 |
| umls:C0740903 | allergic symptom | 12 | 1.875239 | 0.0216080 | 0.0159496 |
| umls:C0920646 | Renal ischaemia | 76 | 1.874924 | 0.0213200 | 0.0157370 |
| umls:C0019061 | Hemolytic-Uremic Syndrome | 49 | 1.874393 | 0.0311509 | 0.0229935 |
| umls:C0340288 | Stable angina | 66 | 1.873044 | 0.0213200 | 0.0157370 |
| umls:C0011615 | Dermatitis, Atopic | 333 | 1.867401 | 0.0213200 | 0.0157370 |
| umls:C0153252 | Systemic candidiasis | 33 | 1.866710 | 0.0405803 | 0.0299536 |
| umls:C0019187 | Hepatitis, Alcoholic | 41 | 1.865726 | 0.0405803 | 0.0299536 |
| umls:C3539909 | Allergic disposition | 149 | 1.865306 | 0.0213200 | 0.0157370 |
| umls:C0014170 | Endometrial Neoplasms | 220 | 1.864897 | 0.0213200 | 0.0157370 |
| umls:C0035369 | Retroviridae Infections | 54 | 1.864806 | 0.0405803 | 0.0299536 |
| umls:C0021345 | Infectious Mononucleosis | 22 | 1.863938 | 0.0315692 | 0.0233023 |
| umls:C0014072 | Experimental Autoimmune Encephalomyelitis | 305 | 1.862708 | 0.0213200 | 0.0157370 |
| umls:C0206139 | Lichen Planus, Oral | 64 | 1.861166 | 0.0311509 | 0.0229935 |
| umls:C0017411 | Female Genital Diseases | 14 | 1.859859 | 0.0318390 | 0.0235014 |
| umls:C0004943 | Behcet Syndrome | 229 | 1.859711 | 0.0213200 | 0.0157370 |
| umls:C1561535 | Creatinine finding | 74 | 1.858689 | 0.0311509 | 0.0229935 |
| umls:C1801959 | Histiocytic medullary reticulosis (disorder) | 12 | 1.858365 | 0.0216080 | 0.0159496 |
| umls:C0020523 | Immediate hypersensitivity | 87 | 1.857445 | 0.0213200 | 0.0157370 |
| umls:C0079773 | Lymphoma, T-Cell, Cutaneous | 185 | 1.857153 | 0.0213200 | 0.0157370 |
| umls:C0024232 | Lymphatic Metastasis | 133 | 1.853178 | 0.0213200 | 0.0157370 |
| umls:C0993582 | Arthritis, Experimental | 133 | 1.852319 | 0.0213200 | 0.0157370 |
| umls:C0007570 | Celiac Disease | 268 | 1.852155 | 0.0213200 | 0.0157370 |
| umls:C0023465 | Acute monocytic leukemia | 64 | 1.851873 | 0.0311509 | 0.0229935 |
| umls:C0042798 | Low Vision | 19 | 1.850846 | 0.0317037 | 0.0234016 |
| umls:C0026946 | Mycoses | 193 | 1.849987 | 0.0213200 | 0.0157370 |
| umls:C0376545 | Hematologic Neoplasms | 399 | 1.846868 | 0.0213200 | 0.0157370 |
| umls:C0034065 | Pulmonary Embolism | 54 | 1.846421 | 0.0405803 | 0.0299536 |
| umls:C0037199 | Sinusitis | 29 | 1.846386 | 0.0405803 | 0.0299536 |
| umls:C0002382 | Alveolar Bone Loss | 26 | 1.845689 | 0.0314450 | 0.0232106 |
| umls:C0020608 | Hypodontia | 18 | 1.845416 | 0.0315216 | 0.0232671 |
| umls:C0153676 | Secondary malignant neoplasm of lung | 490 | 1.842982 | 0.0213200 | 0.0157370 |
| umls:C0031106 | Periodontitis, Juvenile | 69 | 1.841787 | 0.0213200 | 0.0157370 |
| umls:C0029883 | Otitis Media with Effusion | 17 | 1.841379 | 0.0413542 | 0.0305249 |
| umls:C0085435 | Arthritis, Reactive | 38 | 1.841341 | 0.0405803 | 0.0299536 |
| umls:C1096184 | West Nile viral infection | 64 | 1.841339 | 0.0405803 | 0.0299536 |
| umls:C0242647 | Mucosa-Associated Lymphoid Tissue Lymphoma | 142 | 1.840017 | 0.0213200 | 0.0157370 |
| umls:C0206677 | Adenomatous Polyps | 58 | 1.836225 | 0.0405803 | 0.0299536 |
| umls:C1306889 | Peripheral arterial occlusive disease | 14 | 1.836155 | 0.0318390 | 0.0235014 |
| umls:C0856053 | Leukemia secondary | 17 | 1.834491 | 0.0413542 | 0.0305249 |
| umls:C0029899 | Otosclerosis | 15 | 1.834298 | 0.0214913 | 0.0158635 |
| umls:C0701807 | Acute anterior uveitis | 33 | 1.832306 | 0.0405803 | 0.0299536 |
| umls:C0019158 | Hepatitis | 196 | 1.831492 | 0.0213200 | 0.0157370 |
| umls:C0175701 | Aarskog syndrome | 12 | 1.831353 | 0.0216080 | 0.0159496 |
| umls:C0029172 | Oral Submucous Fibrosis | 45 | 1.831225 | 0.0311509 | 0.0229935 |
| umls:C1318544 | M5b Acute differentiated monocytic leukemia | 73 | 1.830951 | 0.0213200 | 0.0157370 |
| umls:C0079772 | T-Cell Lymphoma | 239 | 1.830325 | 0.0213200 | 0.0157370 |
| umls:C0273115 | Lung Injury | 26 | 1.830009 | 0.0314450 | 0.0232106 |
| umls:C0007766 | Intracranial Aneurysm | 96 | 1.829716 | 0.0213200 | 0.0157370 |
| umls:C3714636 | Pneumonitis | 46 | 1.829014 | 0.0311509 | 0.0229935 |
| umls:C0409959 | Osteoarthritis, Knee | 94 | 1.828574 | 0.0213200 | 0.0157370 |
| umls:C0025229 | Melioidosis | 23 | 1.828572 | 0.0412888 | 0.0304767 |
| umls:C1511789 | Desmoplastic | 68 | 1.827364 | 0.0213200 | 0.0157370 |
| umls:C0398650 | Immune thrombocytopenic purpura | 68 | 1.825489 | 0.0311509 | 0.0229935 |
| umls:C3272363 | Ischemic Cerebrovascular Accident | 271 | 1.824877 | 0.0213200 | 0.0157370 |
| umls:C1332977 | Childhood Leukemia | 51 | 1.823810 | 0.0405803 | 0.0299536 |
| umls:C0002351 | Altitude Sickness | 16 | 1.823373 | 0.0413542 | 0.0305249 |
| umls:C0206694 | Mucoepidermoid Carcinoma | 59 | 1.822096 | 0.0405803 | 0.0299536 |
| umls:C0085786 | Hamman-Rich syndrome | 29 | 1.816735 | 0.0405803 | 0.0299536 |
| umls:C0023267 | Fibroid Tumor | 270 | 1.815043 | 0.0213200 | 0.0157370 |
| umls:C0006840 | Candidiasis | 66 | 1.813852 | 0.0405803 | 0.0299536 |
| umls:C0001925 | Albuminuria | 111 | 1.813335 | 0.0213200 | 0.0157370 |
| umls:C0524702 | Pulmonary Thromboembolisms | 14 | 1.807108 | 0.0318390 | 0.0235014 |
| umls:C0037274 | Dermatologic disorders | 363 | 1.806392 | 0.0213200 | 0.0157370 |
| umls:C1519680 | Tumor Immunity | 74 | 1.805772 | 0.0311509 | 0.0229935 |
| umls:C0877009 | Muscle fibrosis | 10 | 1.805284 | 0.0430706 | 0.0317919 |
| umls:C0032787 | Postoperative Complications | 48 | 1.804926 | 0.0405803 | 0.0299536 |
| umls:C0006413 | Burkitt Lymphoma | 167 | 1.802105 | 0.0213200 | 0.0157370 |
| umls:C0340708 | Deep vein thrombosis of lower limb | 37 | 1.801789 | 0.0405803 | 0.0299536 |
| umls:C1449563 | Cardiomyopathy, Familial Idiopathic | 159 | 1.800570 | 0.0213200 | 0.0157370 |
| umls:C0019080 | Hemorrhage | 54 | 1.798345 | 0.0483787 | 0.0357099 |
| umls:C0019069 | Hemophilia A | 73 | 1.798157 | 0.0311509 | 0.0229935 |
| umls:C0009782 | Connective Tissue Diseases | 159 | 1.797990 | 0.0213200 | 0.0157370 |
| umls:C1854310 | Hypotrichosis simplex | 15 | 1.797742 | 0.0416191 | 0.0307204 |
| umls:C0431350 | Primary microcephaly | 17 | 1.797715 | 0.0489743 | 0.0361495 |
| umls:C0020875 | Ileal Diseases | 16 | 1.797385 | 0.0489743 | 0.0361495 |
| umls:C0023895 | Liver diseases | 446 | 1.797311 | 0.0213200 | 0.0157370 |
| umls:C0524909 | Hepatitis B, Chronic | 185 | 1.797022 | 0.0213200 | 0.0157370 |
| umls:C0206708 | Cervical Intraepithelial Neoplasia | 179 | 1.796918 | 0.0213200 | 0.0157370 |
| umls:C0238394 | Female Pseudohermaphroditism | 43 | 1.796287 | 0.0482231 | 0.0355951 |
| umls:C0036420 | Localized scleroderma | 19 | 1.795950 | 0.0414729 | 0.0306125 |
| umls:C0035328 | Retinal Vein Occlusion | 24 | 1.795946 | 0.0314450 | 0.0232106 |
| umls:C0013238 | Dry Eye Syndromes | 36 | 1.795804 | 0.0405803 | 0.0299536 |
| umls:C0340643 | Dissection of aorta | 31 | 1.795056 | 0.0405803 | 0.0299536 |
| umls:C0948008 | Ischemic stroke | 307 | 1.794768 | 0.0213200 | 0.0157370 |
| umls:C0154084 | Stage 0 Breast Carcinoma | 13 | 1.794622 | 0.0418166 | 0.0308662 |
| umls:C0008312 | Primary biliary cirrhosis | 201 | 1.794573 | 0.0213200 | 0.0157370 |
| umls:C0030305 | Pancreatitis | 149 | 1.793622 | 0.0213200 | 0.0157370 |
| umls:C0031154 | Peritonitis | 88 | 1.791978 | 0.0213200 | 0.0157370 |
| umls:C0024312 | Lymphopenia | 60 | 1.791713 | 0.0405803 | 0.0299536 |
| umls:C0178238 | Intestinal infectious disease (disorder) | 12 | 1.789844 | 0.0498646 | 0.0368067 |
| umls:C0017152 | Gastritis | 153 | 1.789086 | 0.0213200 | 0.0157370 |
| umls:C0376620 | Pouchitis | 12 | 1.788864 | 0.0498646 | 0.0368067 |
| umls:C0242966 | Systemic Inflammatory Response Syndrome | 54 | 1.787890 | 0.0483787 | 0.0357099 |
| umls:C0021051 | Immunologic Deficiency Syndromes | 349 | 1.787888 | 0.0213200 | 0.0157370 |
| umls:C0029118 | Opportunistic Infections | 25 | 1.787602 | 0.0489743 | 0.0361495 |
| umls:C0156181 | Peritoneal adhesion | 12 | 1.786238 | 0.0498646 | 0.0368067 |
| umls:C0003872 | Arthritis, Psoriatic | 140 | 1.785486 | 0.0213200 | 0.0157370 |
| umls:C0585362 | Squamous cell carcinoma of mouth | 42 | 1.784861 | 0.0405803 | 0.0299536 |
| umls:C0013884 | Filarial Elephantiases | 16 | 1.784540 | 0.0489743 | 0.0361495 |
| umls:C0162872 | Aortic Aneurysm, Thoracic | 91 | 1.784278 | 0.0213200 | 0.0157370 |
| umls:C0023892 | Biliary cirrhosis | 100 | 1.782895 | 0.0213200 | 0.0157370 |
| umls:C0017563 | Gingival Diseases | 74 | 1.782359 | 0.0311509 | 0.0229935 |
| umls:C0029458 | Osteoporosis, Postmenopausal | 74 | 1.781473 | 0.0311509 | 0.0229935 |
| umls:C1719495 | Aggressive periodontitis, generalized | 29 | 1.781152 | 0.0405803 | 0.0299536 |
| umls:C0345967 | Malignant mesothelioma | 227 | 1.778173 | 0.0213200 | 0.0157370 |
| umls:C0013312 | Dupuytren Contracture | 16 | 1.777424 | 0.0489743 | 0.0361495 |
| umls:C0085390 | Li-Fraumeni Syndrome | 37 | 1.777215 | 0.0483787 | 0.0357099 |
| umls:C0020217 | Hydatidiform Mole | 48 | 1.776973 | 0.0405803 | 0.0299536 |
| umls:C0038013 | Ankylosing spondylitis | 187 | 1.776612 | 0.0213200 | 0.0157370 |
| umls:C0007114 | Malignant neoplasm of skin | 192 | 1.776078 | 0.0213200 | 0.0157370 |
| umls:C0850666 | Helicobacter pylori infection | 225 | 1.774730 | 0.0213200 | 0.0157370 |
| umls:C0035126 | Reperfusion Injury | 271 | 1.774648 | 0.0213200 | 0.0157370 |
| umls:C0040053 | Thrombosis | 105 | 1.773576 | 0.0213200 | 0.0157370 |
| umls:C0010606 | Adenoid Cystic Carcinoma | 185 | 1.773300 | 0.0213200 | 0.0157370 |
| umls:C0008149 | Chlamydia Infections | 61 | 1.772866 | 0.0405803 | 0.0299536 |
| umls:C0080233 | Tooth Loss | 14 | 1.772439 | 0.0495858 | 0.0366009 |
| umls:C3662483 | Allergic sensitization | 29 | 1.771174 | 0.0405803 | 0.0299536 |
| umls:C1402294 | Primary Lesion | 30 | 1.771110 | 0.0405803 | 0.0299536 |
| umls:C0699949 | airway disease | 64 | 1.769208 | 0.0405803 | 0.0299536 |
| umls:C0278996 | Cancer of Head and Neck | 361 | 1.766759 | 0.0213200 | 0.0157370 |
| umls:C0008497 | Choriocarcinoma | 226 | 1.764559 | 0.0213200 | 0.0157370 |
| umls:C1848411 | XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP E | 13 | 1.764103 | 0.0495858 | 0.0366009 |
| umls:C0149516 | Chronic sinusitis | 42 | 1.760737 | 0.0482231 | 0.0355951 |
| umls:C3150911 | GASTRIC CANCER, INTESTINAL | 12 | 1.759898 | 0.0498646 | 0.0368067 |
| umls:C0001486 | Adenovirus Infections | 63 | 1.759357 | 0.0405803 | 0.0299536 |
| umls:C0079744 | Diffuse Large B-Cell Lymphoma | 459 | 1.757885 | 0.0213200 | 0.0157370 |
| umls:C0971858 | Arthritis, Collagen-Induced | 133 | 1.756517 | 0.0213200 | 0.0157370 |
| umls:C1559271 | Non-Malignant Ascites Adverse Event | 146 | 1.756292 | 0.0213200 | 0.0157370 |
| umls:C1176475 | Ductal Carcinoma | 185 | 1.755945 | 0.0213200 | 0.0157370 |
| umls:C1956391 | Temporal Arteritis | 13 | 1.755570 | 0.0495858 | 0.0366009 |
| umls:C0011119 | Decompression Sickness | 13 | 1.755079 | 0.0495858 | 0.0366009 |
| umls:C0694549 | Community acquired pneumonia | 29 | 1.753912 | 0.0482231 | 0.0355951 |
| umls:C1292769 | Precursor B-cell lymphoblastic leukemia | 297 | 1.753829 | 0.0213200 | 0.0157370 |
| umls:C0013595 | Eczema | 281 | 1.753064 | 0.0213200 | 0.0157370 |
| umls:C0018213 | Graves Disease | 260 | 1.751967 | 0.0213200 | 0.0157370 |
| umls:C0948089 | Acute Coronary Syndrome | 241 | 1.750868 | 0.0213200 | 0.0157370 |
| umls:C0409651 | Seropositive rheumatoid arthritis | 16 | 1.749657 | 0.0489743 | 0.0361495 |
| umls:C0149678 | Epstein-Barr Virus Infections | 174 | 1.749288 | 0.0213200 | 0.0157370 |
| umls:C0278701 | Gastric Adenocarcinoma | 216 | 1.748453 | 0.0213200 | 0.0157370 |
| umls:C0276680 | Infection by Candida albicans | 15 | 1.748193 | 0.0495578 | 0.0365803 |
| umls:C0019159 | Hepatitis A | 188 | 1.747388 | 0.0213200 | 0.0157370 |
| umls:C0017612 | Glaucoma, Open-Angle | 77 | 1.746690 | 0.0311509 | 0.0229935 |
| umls:C0242706 | Hyperoxia | 42 | 1.746291 | 0.0482231 | 0.0355951 |
| umls:C0399440 | Hereditary gingival fibromatosis | 17 | 1.745732 | 0.0489743 | 0.0361495 |
| umls:C0024131 | Lupus Vulgaris | 238 | 1.744443 | 0.0213200 | 0.0157370 |
| umls:C0033687 | Proteinuria | 67 | 1.744372 | 0.0482231 | 0.0355951 |
| umls:C1519670 | Tumor Angiogenesis | 360 | 1.743868 | 0.0213200 | 0.0157370 |
| umls:C0853879 | Invasive breast carcinoma | 321 | 1.742790 | 0.0213200 | 0.0157370 |
| umls:C0023290 | Leishmaniasis, Visceral | 58 | 1.740428 | 0.0482231 | 0.0355951 |
| umls:C1561643 | Chronic Kidney Diseases | 229 | 1.740151 | 0.0213200 | 0.0157370 |
| umls:C0023470 | Myeloid Leukemia | 430 | 1.740125 | 0.0213200 | 0.0157370 |
| umls:C0409974 | Lupus Erythematosus | 284 | 1.739497 | 0.0213200 | 0.0157370 |
| umls:C0011616 | Contact Dermatitis | 62 | 1.739032 | 0.0405803 | 0.0299536 |
| umls:C0023893 | Liver Cirrhosis, Experimental | 149 | 1.737959 | 0.0213200 | 0.0157370 |
| umls:C0376544 | Hematopoietic Neoplasms | 140 | 1.735318 | 0.0213200 | 0.0157370 |
| umls:C1621958 | Glioblastoma Multiforme | 370 | 1.734290 | 0.0213200 | 0.0157370 |
| umls:C0220810 | Congenital defects | 43 | 1.733045 | 0.0482231 | 0.0355951 |
| umls:C0149521 | Pancreatitis, Chronic | 214 | 1.732374 | 0.0213200 | 0.0157370 |
| umls:C0027439 | Nasopharyngeal Neoplasms | 61 | 1.732158 | 0.0405803 | 0.0299536 |
| umls:C0000786 | Spontaneous abortion | 191 | 1.730129 | 0.0213200 | 0.0157370 |
| umls:C0079745 | Lymphoma, Large-Cell, Follicular | 137 | 1.729920 | 0.0213200 | 0.0157370 |
| umls:C0011633 | Dermatomyositis | 88 | 1.728514 | 0.0213200 | 0.0157370 |
| umls:C0002940 | Aneurysm | 107 | 1.728356 | 0.0213200 | 0.0157370 |
| umls:C0005411 | Biliary Atresia | 69 | 1.725914 | 0.0482231 | 0.0355951 |
| umls:C2945695 | Limb ischemia | 57 | 1.725085 | 0.0482231 | 0.0355951 |
| umls:C0017185 | Gastrointestinal Neoplasms | 102 | 1.723935 | 0.0311509 | 0.0229935 |
| umls:C0403447 | Chronic Kidney Insufficiency | 149 | 1.723352 | 0.0213200 | 0.0157370 |
| umls:C1378703 | Renal carcinoma | 387 | 1.721292 | 0.0213200 | 0.0157370 |
| umls:C0018273 | Growth Disorders | 64 | 1.720907 | 0.0405803 | 0.0299536 |
| umls:C0027626 | Neoplasm Invasiveness | 147 | 1.719976 | 0.0213200 | 0.0157370 |
| umls:C0006663 | Calcinosis | 82 | 1.719791 | 0.0311509 | 0.0229935 |
| umls:C0036920 | Sezary Syndrome | 109 | 1.718321 | 0.0213200 | 0.0157370 |
| umls:C0038358 | Gastric ulcer | 87 | 1.717007 | 0.0213200 | 0.0157370 |
| umls:C0002793 | Anaplasia | 191 | 1.716325 | 0.0213200 | 0.0157370 |
| umls:C0003130 | Anoxia | 306 | 1.716101 | 0.0213200 | 0.0157370 |
| umls:C0026896 | Myasthenia Gravis | 139 | 1.714579 | 0.0213200 | 0.0157370 |
| umls:C0346153 | Breast Cancer, Familial | 127 | 1.713297 | 0.0213200 | 0.0157370 |
| umls:C0008313 | Cholangitis, Sclerosing | 69 | 1.711042 | 0.0482231 | 0.0355951 |
| umls:C3542024 | AORTIC VALVE DISEASE 2 | 52 | 1.710445 | 0.0482231 | 0.0355951 |
| umls:C1334274 | Invasive Carcinoma | 134 | 1.709532 | 0.0213200 | 0.0157370 |
| umls:C0023452 | Leukemia, Lymphocytic, Acute, L1 | 306 | 1.709137 | 0.0213200 | 0.0157370 |
| umls:C0029456 | Osteoporosis | 368 | 1.709073 | 0.0213200 | 0.0157370 |
| umls:C0027430 | Nasal Polyps | 141 | 1.707847 | 0.0213200 | 0.0157370 |
| umls:C0278883 | Metastatic melanoma | 272 | 1.707684 | 0.0213200 | 0.0157370 |
| umls:C0042029 | Urinary tract infection | 64 | 1.707610 | 0.0482231 | 0.0355951 |
| umls:C0021053 | Immune System Diseases | 142 | 1.706016 | 0.0213200 | 0.0157370 |
| umls:C0023448 | Lymphoid leukemia | 195 | 1.705062 | 0.0213200 | 0.0157370 |
| umls:C1861172 | Venous Thromboembolism | 108 | 1.703912 | 0.0213200 | 0.0157370 |
| umls:C0220641 | Lip and Oral Cavity Carcinoma | 344 | 1.702619 | 0.0213200 | 0.0157370 |
| umls:C0339573 | Glaucoma, Primary Open Angle | 141 | 1.701075 | 0.0213200 | 0.0157370 |
| umls:C0153381 | Malignant neoplasm of mouth | 344 | 1.700469 | 0.0213200 | 0.0157370 |
| umls:C0243038 | Carcinoma, Lewis Lung | 67 | 1.700457 | 0.0482231 | 0.0355951 |
| umls:C0279628 | Adenocarcinoma Of Esophagus | 229 | 1.698785 | 0.0213200 | 0.0157370 |
| umls:C0018203 | Chronic granulomatous disease | 60 | 1.697427 | 0.0482231 | 0.0355951 |
| umls:C0349566 | Squamous cell carcinoma of tongue | 98 | 1.697011 | 0.0213200 | 0.0157370 |
| umls:C0023485 | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 87 | 1.696231 | 0.0311509 | 0.0229935 |
| umls:C0577631 | Carotid Atherosclerosis | 88 | 1.695058 | 0.0311509 | 0.0229935 |
| umls:C0011644 | Scleroderma | 132 | 1.694061 | 0.0213200 | 0.0157370 |
| umls:C0524910 | Hepatitis C, Chronic | 327 | 1.693594 | 0.0213200 | 0.0157370 |
| umls:C0027726 | Nephrotic Syndrome | 144 | 1.690701 | 0.0213200 | 0.0157370 |
| umls:C0023493 | Adult T-Cell Lymphoma/Leukemia | 366 | 1.689828 | 0.0213200 | 0.0157370 |
| umls:C0039103 | Synovitis | 76 | 1.688400 | 0.0482231 | 0.0355951 |
| umls:C0035435 | Rheumatism | 86 | 1.686457 | 0.0311509 | 0.0229935 |
| umls:C0017525 | Giant Cell Tumors | 63 | 1.686411 | 0.0405803 | 0.0299536 |
| umls:C0042384 | Vasculitis | 105 | 1.684148 | 0.0311509 | 0.0229935 |
| umls:C0085110 | Severe Combined Immunodeficiency | 420 | 1.681789 | 0.0213200 | 0.0157370 |
| umls:C0027055 | Myocardial Reperfusion Injury | 132 | 1.678653 | 0.0213200 | 0.0157370 |
| umls:C1762616 | Meningioma, benign, no ICD-O subtype | 191 | 1.677007 | 0.0213200 | 0.0157370 |
| umls:C0239946 | Fibrosis, Liver | 271 | 1.676727 | 0.0213200 | 0.0157370 |
| umls:C0007124 | Noninfiltrating Intraductal Carcinoma | 257 | 1.676222 | 0.0213200 | 0.0157370 |
| umls:C0042164 | Uveitis | 100 | 1.672861 | 0.0311509 | 0.0229935 |
| umls:C0021841 | Intestinal Neoplasms | 121 | 1.670811 | 0.0213200 | 0.0157370 |
| umls:C0025007 | Measles | 120 | 1.670755 | 0.0213200 | 0.0157370 |
| umls:C1840264 | IMMUNE SUPPRESSION | 61 | 1.669468 | 0.0405803 | 0.0299536 |
| umls:C0031069 | Familial Mediterranean Fever | 59 | 1.666993 | 0.0482231 | 0.0355951 |
| umls:C0949691 | Spondylarthropathies | 65 | 1.664208 | 0.0482231 | 0.0355951 |
| umls:C0024138 | Lupus Erythematosus, Discoid | 244 | 1.659966 | 0.0213200 | 0.0157370 |
| umls:C0346429 | Multiple malignancy | 164 | 1.655313 | 0.0213200 | 0.0157370 |
| umls:C0042133 | Uterine Fibroids | 276 | 1.652778 | 0.0213200 | 0.0157370 |
| umls:C0027686 | Pathologic Neovascularization | 62 | 1.645218 | 0.0482231 | 0.0355951 |
| umls:C0280324 | Laryngeal Squamous Cell Carcinoma | 110 | 1.643851 | 0.0311509 | 0.0229935 |
| umls:C0940937 | precancerous lesions | 91 | 1.643798 | 0.0482231 | 0.0355951 |
| umls:C0022578 | Keratoconus | 66 | 1.640926 | 0.0482231 | 0.0355951 |
| umls:C0206698 | Cholangiocarcinoma | 333 | 1.637698 | 0.0213200 | 0.0157370 |
| umls:C0034063 | Pulmonary Edema | 66 | 1.635592 | 0.0482231 | 0.0355951 |
| umls:C0022680 | Polycystic Kidney Diseases | 100 | 1.635009 | 0.0405803 | 0.0299536 |
| umls:C1333990 | Hereditary Nonpolyposis Colorectal Cancer | 100 | 1.632791 | 0.0405803 | 0.0299536 |
| umls:C0020542 | Pulmonary Hypertension | 283 | 1.629915 | 0.0213200 | 0.0157370 |
| umls:C0008924 | Cleft Lip | 173 | 1.629457 | 0.0213200 | 0.0157370 |
| umls:C0005695 | Bladder Neoplasm | 390 | 1.628503 | 0.0213200 | 0.0157370 |
| umls:C0341439 | Chronic liver disease | 108 | 1.624461 | 0.0311509 | 0.0229935 |
| umls:C0035412 | Rhabdomyosarcoma | 307 | 1.623145 | 0.0213200 | 0.0157370 |
| umls:C0019348 | Herpes Simplex Infections | 425 | 1.619254 | 0.0213200 | 0.0157370 |
| umls:C0023524 | Leukoencephalopathy, Progressive Multifocal | 84 | 1.617181 | 0.0482231 | 0.0355951 |
| umls:C0345904 | Malignant neoplasm of liver | 481 | 1.617168 | 0.0213200 | 0.0157370 |
| umls:C0040028 | Thrombocythemia, Essential | 124 | 1.617080 | 0.0213200 | 0.0157370 |
| umls:C0020473 | Hyperlipidemia | 174 | 1.616695 | 0.0213200 | 0.0157370 |
| umls:C0024667 | Animal Mammary Neoplasms | 178 | 1.616187 | 0.0213200 | 0.0157370 |
| umls:C0026691 | Mucocutaneous Lymph Node Syndrome | 145 | 1.614511 | 0.0213200 | 0.0157370 |
| umls:C0151744 | Myocardial Ischemia | 412 | 1.612866 | 0.0213200 | 0.0157370 |
| umls:C0376634 | Craniofacial Abnormalities | 175 | 1.606935 | 0.0213200 | 0.0157370 |
| umls:C0008925 | Cleft Palate | 216 | 1.605817 | 0.0213200 | 0.0157370 |
| umls:C0152018 | Esophageal carcinoma | 445 | 1.605376 | 0.0213200 | 0.0157370 |
| umls:C0025286 | Meningioma | 381 | 1.604537 | 0.0213200 | 0.0157370 |
| umls:C0041327 | Tuberculosis, Pulmonary | 170 | 1.604424 | 0.0213200 | 0.0157370 |
| umls:C0020443 | Hypercholesterolemia | 150 | 1.602699 | 0.0213200 | 0.0157370 |
| umls:C0008626 | Congenital chromosomal disease | 440 | 1.602318 | 0.0213200 | 0.0157370 |
| umls:C0279000 | Liver and Intrahepatic Biliary Tract Carcinoma | 403 | 1.597942 | 0.0213200 | 0.0157370 |
| umls:C1961099 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 287 | 1.597679 | 0.0213200 | 0.0157370 |
| umls:C0007103 | Malignant neoplasm of endometrium | 413 | 1.595849 | 0.0213200 | 0.0157370 |
| umls:C1883486 | Uterine Corpus Cancer | 413 | 1.595849 | 0.0213200 | 0.0157370 |
| umls:C0011311 | Dengue Fever | 140 | 1.595500 | 0.0311509 | 0.0229935 |
| umls:C0242596 | Neoplasm, Residual | 145 | 1.594286 | 0.0311509 | 0.0229935 |
| umls:C0024314 | Lymphoproliferative Disorders | 167 | 1.594002 | 0.0213200 | 0.0157370 |
| umls:C1623038 | Cirrhosis | 307 | 1.592983 | 0.0213200 | 0.0157370 |
| umls:C0546837 | Malignant neoplasm of esophagus | 485 | 1.592897 | 0.0213200 | 0.0157370 |
| umls:C0281361 | Adenocarcinoma of pancreas | 252 | 1.588880 | 0.0213200 | 0.0157370 |
| umls:C0242383 | Age related macular degeneration | 331 | 1.588860 | 0.0213200 | 0.0157370 |
| umls:C0022661 | Kidney Failure, Chronic | 483 | 1.588260 | 0.0213200 | 0.0157370 |
| umls:C0026640 | Mouth Neoplasms | 173 | 1.588257 | 0.0213200 | 0.0157370 |
| umls:C0334579 | Anaplastic astrocytoma | 125 | 1.588124 | 0.0311509 | 0.0229935 |
| umls:C0005940 | Bone Diseases | 137 | 1.586987 | 0.0405803 | 0.0299536 |
| umls:C0018798 | Congenital Heart Defects | 210 | 1.586787 | 0.0311509 | 0.0229935 |
| umls:C0007621 | Neoplastic Cell Transformation | 109 | 1.584165 | 0.0405803 | 0.0299536 |
| umls:C0023487 | Acute Promyelocytic Leukemia | 359 | 1.581779 | 0.0213200 | 0.0157370 |
| umls:C0598608 | Hyperhomocysteinemia | 98 | 1.576703 | 0.0482231 | 0.0355951 |
| umls:C0007873 | Uterine Cervical Neoplasm | 146 | 1.574003 | 0.0311509 | 0.0229935 |
| umls:C0007786 | Brain Ischemia | 357 | 1.573395 | 0.0213200 | 0.0157370 |
| umls:C0243026 | Sepsis | 440 | 1.571539 | 0.0213200 | 0.0157370 |
| umls:C0375023 | Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site | 194 | 1.568765 | 0.0311509 | 0.0229935 |
| umls:C0036220 | Kaposi Sarcoma | 147 | 1.567461 | 0.0474230 | 0.0350045 |
| umls:C0685938 | Malignant neoplasm of gastrointestinal tract | 182 | 1.567058 | 0.0311509 | 0.0229935 |
| umls:C0085669 | Acute leukemia | 398 | 1.564294 | 0.0213200 | 0.0157370 |
| umls:C0152171 | Idiopathic pulmonary hypertension | 181 | 1.564007 | 0.0311509 | 0.0229935 |
| umls:C2316810 | Chronic kidney disease stage 5 | 161 | 1.561765 | 0.0213200 | 0.0157370 |
| umls:C0010674 | Cystic Fibrosis | 330 | 1.554634 | 0.0213200 | 0.0157370 |
| umls:C0595989 | Carcinoma of larynx | 146 | 1.554064 | 0.0311509 | 0.0229935 |
| umls:C1134719 | Invasive Ductal Breast Carcinoma | 205 | 1.549578 | 0.0402397 | 0.0297023 |
| umls:C0338106 | Adenocarcinoma of colon | 193 | 1.547574 | 0.0311509 | 0.0229935 |
| umls:C0238463 | Papillary thyroid carcinoma | 379 | 1.547233 | 0.0213200 | 0.0157370 |
| umls:C3539878 | Triple Negative Breast Neoplasms | 388 | 1.542960 | 0.0213200 | 0.0157370 |
| umls:C0007785 | Cerebral Infarction | 248 | 1.542908 | 0.0213200 | 0.0157370 |
| umls:C0017601 | Glaucoma | 180 | 1.542728 | 0.0311509 | 0.0229935 |
| umls:C0279702 | Conventional (Clear Cell) Renal Cell Carcinoma | 304 | 1.540463 | 0.0213200 | 0.0157370 |
| umls:C0027708 | Nephroblastoma | 265 | 1.535806 | 0.0311509 | 0.0229935 |
| umls:C1292778 | Chronic myeloproliferative disorder | 139 | 1.534717 | 0.0474230 | 0.0350045 |
| umls:C0037286 | Skin Neoplasms | 274 | 1.534092 | 0.0213200 | 0.0157370 |
| umls:C0024301 | Lymphoma, Follicular | 300 | 1.532711 | 0.0213200 | 0.0157370 |
| umls:C0020445 | Hypercholesterolemia, Familial | 132 | 1.532093 | 0.0474230 | 0.0350045 |
| umls:C1335302 | Pancreatic Ductal Adenocarcinoma | 462 | 1.528290 | 0.0213200 | 0.0157370 |
| umls:C0149782 | Squamous cell carcinoma of lung | 163 | 1.527618 | 0.0311509 | 0.0229935 |
| umls:C1384666 | hearing impairment | 134 | 1.524354 | 0.0475364 | 0.0350882 |
| umls:C0400966 | Non-alcoholic Fatty Liver Disease | 243 | 1.524304 | 0.0311509 | 0.0229935 |
| umls:C0917798 | Cerebral Ischemia | 163 | 1.519668 | 0.0311509 | 0.0229935 |
| umls:C0151779 | Cutaneous Melanoma | 217 | 1.518516 | 0.0311509 | 0.0229935 |
| umls:C0013336 | Dwarfism | 161 | 1.517249 | 0.0403029 | 0.0297489 |
| umls:C0008479 | Chondrosarcoma | 194 | 1.514752 | 0.0402700 | 0.0297247 |
| umls:C1336076 | Sporadic Breast Carcinoma | 126 | 1.514103 | 0.0479176 | 0.0353696 |
| umls:C0008370 | Cholestasis | 127 | 1.513776 | 0.0475774 | 0.0351184 |
| umls:C0278488 | Carcinoma breast stage IV | 280 | 1.508732 | 0.0213200 | 0.0157370 |
| umls:C0023492 | Leukemia, T-Cell | 270 | 1.508727 | 0.0311509 | 0.0229935 |
| umls:C0032927 | Precancerous Conditions | 351 | 1.508117 | 0.0213200 | 0.0157370 |
| umls:C0033860 | Psoriasis | 481 | 1.498909 | 0.0213200 | 0.0157370 |
| umls:C1272641 | Systemic arterial pressure | 380 | 1.498210 | 0.0213200 | 0.0157370 |
| umls:C0011884 | Diabetic Retinopathy | 191 | 1.497532 | 0.0402546 | 0.0297132 |
| umls:C0016057 | Fibrosarcoma | 224 | 1.495819 | 0.0213200 | 0.0157370 |
| umls:C0740457 | Malignant neoplasm of kidney | 337 | 1.492967 | 0.0213200 | 0.0157370 |
| umls:C0025500 | Mesothelioma | 326 | 1.492646 | 0.0213200 | 0.0157370 |
| umls:C0007113 | Rectal Carcinoma | 221 | 1.492276 | 0.0311509 | 0.0229935 |
| umls:C0024668 | Mammary Neoplasms, Experimental | 185 | 1.486728 | 0.0402861 | 0.0297365 |
| umls:C1271104 | Blood pressure finding | 330 | 1.484275 | 0.0213200 | 0.0157370 |
| umls:C0494165 | Secondary malignant neoplasm of liver | 349 | 1.480810 | 0.0213200 | 0.0157370 |
| umls:C0027022 | Myeloproliferative disease | 216 | 1.467439 | 0.0465262 | 0.0343425 |
| umls:C0007138 | Carcinoma, Transitional Cell | 332 | 1.461678 | 0.0213200 | 0.0157370 |
| umls:C0032580 | Adenomatous Polyposis Coli | 324 | 1.456559 | 0.0213200 | 0.0157370 |
| umls:C0032584 | polyps | 206 | 1.450466 | 0.0463533 | 0.0342149 |
| umls:C0021400 | Influenza | 374 | 1.447931 | 0.0213200 | 0.0157370 |
| umls:C0007193 | Cardiomyopathy, Dilated | 328 | 1.436125 | 0.0295915 | 0.0218425 |
| umls:C0040136 | Thyroid Neoplasm | 397 | 1.435965 | 0.0213200 | 0.0157370 |
| umls:C1704272 | Benign Prostatic Hyperplasia | 301 | 1.435475 | 0.0301940 | 0.0222872 |
| umls:C0555198 | Malignant Glioma | 356 | 1.435058 | 0.0294219 | 0.0217173 |
| umls:C1709246 | Non-Neoplastic Disorder | 374 | 1.429963 | 0.0213200 | 0.0157370 |
| umls:C0015695 | Fatty Liver | 286 | 1.428683 | 0.0306953 | 0.0226572 |
| umls:C1512409 | Hepatocarcinogenesis | 399 | 1.423309 | 0.0213200 | 0.0157370 |
| umls:C0035309 | Retinal Diseases | 289 | 1.416967 | 0.0440414 | 0.0325084 |
| umls:C1520166 | Xenograft Model | 440 | 1.408263 | 0.0213200 | 0.0157370 |
| umls:C0035078 | Kidney Failure | 268 | 1.404060 | 0.0458797 | 0.0338653 |
| umls:C0020456 | Hyperglycemia | 380 | 1.397997 | 0.0213200 | 0.0157370 |
| umls:C0041296 | Tuberculosis | 427 | 1.394137 | 0.0213200 | 0.0157370 |
| umls:C0036690 | Septicemia | 304 | 1.393012 | 0.0438335 | 0.0323550 |
| umls:C0007115 | Malignant neoplasm of thyroid | 393 | 1.342035 | 0.0427786 | 0.0315763 |
| umls:C0035335 | Retinoblastoma | 388 | 1.328727 | 0.0489743 | 0.0361495 |
| ID | Description | setSize | NES | p.adjust | qvalues |
|---|---|---|---|---|---|
| umls:C0543888 | Epileptic encephalopathy | 51 | 2.482362 | 0.0356247 | 0.0281029 |
| umls:C0342776 | Nicotinamide adenine dinucleotide coenzyme Q reductase deficiency | 38 | 2.432047 | 0.0356247 | 0.0281029 |
| umls:C1838979 | MITOCHONDRIAL COMPLEX I DEFICIENCY | 29 | 2.429053 | 0.0356247 | 0.0281029 |
| umls:C0037769 | West Syndrome | 58 | 2.325541 | 0.0356247 | 0.0281029 |
| umls:C2936907 | NADH:Q(1) Oxidoreductase deficiency | 20 | 2.180142 | 0.0356247 | 0.0281029 |
| umls:C0014550 | Epilepsies, Myoclonic | 36 | 2.170404 | 0.0356247 | 0.0281029 |
| umls:C0238111 | Lennox-Gastaut syndrome | 11 | 2.136084 | 0.0356247 | 0.0281029 |
| umls:C0751122 | Infantile Severe Myoclonic Epilepsy | 25 | 2.113278 | 0.0356247 | 0.0281029 |
| umls:C0393706 | Early infantile epileptic encephalopathy with suppression bursts | 19 | 2.092171 | 0.0356247 | 0.0281029 |
| umls:C0017926 | Glycogen Storage Disease Type VII | 11 | 2.087134 | 0.0356247 | 0.0281029 |
| umls:C1838951 | LEIGH SYNDROME DUE TO MITOCHONDRIAL COMPLEX I DEFICIENCY | 14 | 2.084908 | 0.0356247 | 0.0281029 |
| umls:C0023264 | Leigh Disease | 77 | 2.058937 | 0.0356247 | 0.0281029 |
| umls:C0085292 | Stiff-Person Syndrome | 19 | 2.057038 | 0.0356247 | 0.0281029 |
| umls:C2931919 | X-linked infantile spasm syndrome | 15 | 2.048455 | 0.0356247 | 0.0281029 |
| umls:C1849156 | Spastic Ataxia | 14 | 2.040328 | 0.0356247 | 0.0281029 |
| umls:C0406810 | Carney Complex | 27 | 2.025996 | 0.0493656 | 0.0389425 |
| umls:C0029124 | Optic Atrophy | 31 | 1.993882 | 0.0356247 | 0.0281029 |
| umls:C0342492 | Adrenal hypertrophy or hyperplasia | 17 | 1.985649 | 0.0356247 | 0.0281029 |
| umls:C1621895 | Adrenal hyperplasia | 17 | 1.985649 | 0.0356247 | 0.0281029 |
| umls:C0162670 | Mitochondrial Myopathies | 48 | 1.982734 | 0.0356247 | 0.0281029 |
| umls:C0014547 | Epilepsies, Partial | 42 | 1.967555 | 0.0356247 | 0.0281029 |
| umls:C0026650 | Movement Disorders | 95 | 1.964739 | 0.0356247 | 0.0281029 |
| umls:C1142166 | Brugada Syndrome (disorder) | 46 | 1.920346 | 0.0356247 | 0.0281029 |
| umls:C0162674 | Chronic progressive external ophthalmoplegia | 19 | 1.911793 | 0.0493656 | 0.0389425 |
| umls:C0004134 | Ataxia | 221 | 1.879095 | 0.0356247 | 0.0281029 |
| umls:C0424551 | Impaired exercise tolerance | 27 | 1.854635 | 0.0493656 | 0.0389425 |
| umls:C0014548 | Epilepsy, Generalized | 44 | 1.788307 | 0.0493656 | 0.0389425 |
| umls:C0162666 | Mitochondrial Encephalomyopathies | 32 | 1.773487 | 0.0493656 | 0.0389425 |
| umls:C0270850 | Idiopathic generalized epilepsy | 45 | 1.768474 | 0.0493656 | 0.0389425 |
| umls:C1096063 | Drug Resistant Epilepsy | 53 | 1.758148 | 0.0356247 | 0.0281029 |
| umls:C1955869 | Malformations of Cortical Development | 45 | 1.748752 | 0.0493656 | 0.0389425 |
| umls:C0270736 | Essential Tremor | 49 | 1.746995 | 0.0493656 | 0.0389425 |
| umls:C0278484 | Malignant neoplasm of colon stage IV | 62 | 1.732129 | 0.0493656 | 0.0389425 |
| umls:C0035372 | Rett Syndrome | 111 | 1.687489 | 0.0493656 | 0.0389425 |
| umls:C0026827 | Muscle hypotonia | 73 | 1.671249 | 0.0493656 | 0.0389425 |
| umls:C0525045 | Mood Disorders | 238 | 1.632827 | 0.0356247 | 0.0281029 |
| umls:C0027765 | nervous system disorder | 388 | 1.457565 | 0.0493656 | 0.0389425 |
rm(df)